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Challenging the Myth of Non-Response to the Ergogenic Effects of Caffeine Ingestion on
Exercise Performance
Reprinted from: Nutrients 2019, 11, 732, doi:10.3390/nu11040732 . . . . . . . . . . . . . . . . . . . 115
Paulo Estevão Franco-Alvarenga, Cayque Brietzke, Raul Canestri, Márcio Fagundes Goethel,
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As expected, 2019 has been a prolific year in terms of new evidence regarding the effects of coffee
and caffeine consumption on diverse aspects of human functioning. A search in PubMed for published
studies in 2019 on the effects of caffeine or coffee on humans, following the Preferred Reporting Items
for Systematic Review and Meta-Analyses (PRISMA) guidelines [1], showed a total of 202 manuscripts
that contained “coffee” (n = 65, which represents 32.2% of the total) or “caffeine” (n = 137, which
represents 67.8% of the total) in the title of the manuscript (Figure 1). In the group of studies that
investigated the effect of coffee intake, 58 (89.2%) were related to the use of this beverage to modify one
or more health outcomes, five (7.7%) were related to the use of coffee to improve human performance
and two (3.1%) assessed regular intake of coffee. In the group of studies that investigated the effect
of caffeine intake (in most cases measured as the sum of all the sources containing caffeine such as
coffee, tea, chocolate, energy drinks, etc.), 79 (57.7%) were associated with the use of caffeine with
health variables, 52 (38.0%) were associated with the use of caffeine with ergogenic purposes, six (4.4%)
were associated with regular caffeine intake. Briefly, this analysis shows the elevated amount of new
information published each year regarding the utility of coffee and caffeine to produce a change in
human functioning while reveals that most of the indications of coffee and caffeine are associated with
producing a benefit on health or with enhancing human performance.
Figure 1. Number of articles published in 2019 that investigated the effects of coffee or caffeine
on humans.
This special edition in Nutrients has brought together a variety of investigation that imitates
the pattern of published manuscripts commented above. This issue entitled “Coffee and Caffeine
Nutrients 2020, 12, 125; doi:10.3390/nu12010125 www.mdpi.com/journal/nutrients1
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Consumption for Human Health” gathered 20 manuscripts; two (10.0%) were associated with coffee
intake and 18 (90%) were associated with caffeine intake. In the manuscripts associated with the use of
coffee, one original investigation was geared to study the perceptions of consumers regarding the health
benefits that they might obtain with the regular consumption of this beverage [2]. Interestingly, 75.2% of
the study sample perceived coffee as negative for their health, while the investigation determined that
coffee users that seek potential health benefits of coffee are more likely to be male, young, and working.
The other investigation associated with coffee intake was a systematic review and meta-analysis of
prospective studies on the effect of this beverage on the risk of colorectal cancer [3]. In this study, a
total of 26 investigations were analyzed while the main finding was a weak but significant protective
effect of habitual coffee intake on the risk of suffering colon cancer. In addition, the regular intake of
decaffeinated coffee exerted a protective effect against colorectal cancer, suggesting that part of the
positive effect of coffee to reduce the risk of suffering colorectal cancer is independent of caffeine. Both
investigations reflect the beliefs and patterns of our society because evidence shows that the regular
intake of coffee can have a positive impact on several health outcomes [4]. Nevertheless, consumers
are still cautious about drinking coffee because of the negative image of coffee-(particularly caffeinated
coffee), which is not based on the latest scientific evidence [2]. More efforts should be made to translate
to our society the new pieces of evidence that support the positive effect of regular coffee consumption
on health, in addition to the caution that should be taken in terms of dose, interactions with other
substances, and prevalence of side-effects (e.g., stimulant-like effects).
The remaining 18 studies of this issue investigated the effect of caffeine. There was a particular
focus on the ergogenic effect of caffeine as 14 (77.8% of the investigations with caffeine in this special
issue) investigations were related to this topic. The amount of caffeine ingested on a regular basis
was associated with two (11.1%), and the remaining two (11.1%) determined the effect of caffeine on
health variables. In the investigations that studied caffeine’s ergogenicity, several shared a common
message because they reflect that the acute intake of caffeine (from ~1 to ~6 mg/kg of body mass) was
effective to improve different aspects of physical and sport performance [5–9], along with enhancement
in reaction times and psychological parameters [6]. In addition, several investigations responded to an
Editorial [10] that fostered investigations to assess the effect of acute caffeine intake in female athletes
because most of the current knowledge about the caffeine’s ergogenicity is based on investigations
carried out with only-male study samples. As an answer to this call, Mielgo-Ayuso et al. [11] presented
an analysis, based on a systematic review, indicating that acute caffeine intake exhibited a similar
ergogenic benefit for aerobic performance in men and women athletes. However, the ergogenic effect
of caffeine was inferior in women than in men in strength- and power-based tests, even when the
same dose of caffeine was being administered. This significant, although low in magnitude, effect
of caffeine to increase muscle power and force in women was confirmed by Romero-Moraleda [12],
but these authors suggested that caffeine’s ergogenicity was similar across the menstrual cycle (by
investigating placebo-caffeine comparisons in the early follicular, late follicular and mid-luteal phases).
All these investigations have contributed to explaining the effect of caffeine on human performance,
which is present in several exercise situations and with several dosages, although further investigations
should be carried out to explain the individual differences in the magnitude of the ergogenic effect of
caffeine [13].
The clear evidence provided by this special issue confirming the ergogenic effect of caffeine
might be behind the slight increase in the use of caffeine in sports since its removal from the list of
banned substances in 2004 [14]. By analyzing the concentration of caffeine in post-competition urine
samples, it has been found that about three out of four athletes consume caffeine or caffeine-containing
products to increase performance [14]. Interestingly, the investigation by Shabir et al. [15], who
used a double-dissociation experimental design where caffeine and a placebo were administered
in situations in which participants were informed or misinformed of the substance that they had
ingested, determined that part of the ergogenic effect of caffeine on human performance is explained
by the psychological impact of the expectancy of ergogenicity that caffeine produces in athletes. Thus,
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believing to have ingested caffeine, or feeling the stimulation that it produces, might be an important
part of the actual ergogenic effect of caffeine [16]. In this regard, caffeine ergogenicity can be obtained by
the synergistic action of the pharmacological effect of this substance on the central nervous system [8]
and in other peripheral tissues [17], together with the psychological effect of this potent stimulant [15].
Nevertheless, habituation to caffeine through the regular intake of this substance might be an
important modifier for the obtaining of caffeine ergogenicity. The ingestion of 6 mg/kg of caffeine did
not improve the time employed to complete an 800 m competition in athletes habituated to caffeine
while it negatively affected sleep quality [18]. Similarly, low-to-moderate doses of caffeine (from 3
to 9 mg/kg), were found to be ergogenic in other situations with individuals who do not consume
caffeine or are low caffeine consumers [19,20] and seemed ineffective in increasing muscle performance
in athletes habituated to caffeine intake [21]. These two investigations [18,21] indicate that the use of
moderate doses of caffeine might not be ergogenic in individuals habituated to caffeine, likely due to
the progressive tolerance to the ergogenic effect of this substance when it is ingested chronically [22].
For athletes habituated to caffeine, the use of high doses (up to 11 mg/kg) might exert a positive effect on
maximal strength values, but may negatively affect muscle endurance while increasing the prevalence
of caffeine-induced drawbacks [23]. All this information taken together suggests that athletes who
are consuming caffeine in a habitual manner should refrain from caffeine intake for several days to
remove/reduce tolerance to the ergogenic effect of this substance. For athletes habituated to caffeine
who seek caffeine’s ergogenicity, the dishabituation to caffeine is recommended instead of using doses
of caffeine higher than the daily habitual intake.
Other contributions to science published in this issue suggest the possibility of using the
measurement of urinary caffeine metabolites as a routine clinical examination for evaluating drug
metabolic phenotypes [24], the harmful effects of the administration of high doses of caffeine on the
adrenal glands of immature rats [25], and the safety of a mean caffeine intake <200 mg/day to avoid
any effect on neonatal weight, length, or head, and chest circumference [26].
The diversity of the articles published in this special issue highlights the extent of the effects of
coffee and caffeine on human functioning while it underpins the positive nature of most of these effects.
More work is necessary to completely understand the complex mechanisms behind each effect of
caffeine on body tissues, although this issue has greatly contributed to unveil how coffee and caffeine
might be used to improve human functioning.
Author Contributions: J.D.C., J.J.S., and B.L. wrote the Editorial. All authors have read and agreed to the
published version of the manuscript.
Funding: This research received no external funding.
Conflicts of Interest: The authors declare no conflict of interest.
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Dear Editor-in-Chief,
Today, there is a significant gap in research on the ergogenicity of caffeine, and on sports nutrition
in general: the benefits/drawbacks for a given substance are typically assumed for the whole population
of athletes when most of the evidence is supported by investigations with only male samples. As a
result of this assumption, acute pre-exercise ingestion of 3–9 mg/kg of caffeine is considered an effective
strategy to increase sports performance [1], while data on urine caffeine concentration indicates that
the use of caffeine in sport is similar in both sexes [2]. A few recent investigations using women as
study samples, have also found that caffeine increases sports performance [3–6]. However, evidence
regarding the overall ergogenicity of caffeine in women is much scarcer than in men, and it seems
unsafe to conclude that the ergogenic effect of a moderate dose of caffeine is of similar magnitude in
men and women.
A search for published studies on the effects of caffeine on physical performance in PubMed
and Scopus, following with the Preferred Reporting Items for Systematic Review and Meta-Analyses
(PRISMA) guidelines [7], showed a total of 362 original investigations that have compared caffeine
to a placebo/control situation, with the measurement of at least one physical performance variable
(Figure 1).
Figure 1. Selection of studies.
After filters were applied to remove duplicates or publications with unsuitable methodology,
the search illustrated that a total of 5321 individuals have been tested to assess caffeine ergogenicity,
Nutrients 2019, 11, 1600; doi:10.3390/nu11071600 www.mdpi.com/journal/nutrients7
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since the seminal investigation by Costill et al. [8]. From this sample, 703 participants were women,
which represents only 13.2% of the total sample.
Although investigations on this topic have a higher tendency to include women, especially since
2013, women still represent only 16.3% of individuals participating in research carried out in 2018
(Figure 2). In addition, there is no investigation that has measured caffeine ergogenicity in women with
doses below 1 mg/kg or above 9 mg/kg, and the number of women in investigations about caffeine
effects on speed and muscle power is very low (Table 1).
Figure 2. Evolution of the number of participants (n = total, males and females) in investigations aimed
at determining the ergogenic effects of caffeine.
Table 1. Number (frequency) of male and female participants in investigations aimed at determining
the ergogenic effects of caffeine depending on dose, type of exercise, and participant’s level.
Males Females
Caffeine dose
< 1 mg/kg 10 (100.0%) 0 (0.0%)
1.0–2.9 mg/kg 608 (90.2%) 66 (9.8%)
3.0–5.9 mg/kg 2295 (85.2%) 400 (14.8%)
6.0–9.0 mg/kg 1590 (87.0%) 237 (13.0%)
>9 mg/kg 115 (100.0%) 0 (0.0%)
Type of exercise
Speed 128 (89.5%) 15 (10.5%)
Strength 527 (83.1%) 107 (16.9%)
Power 98 (83.8%) 19 (16.2%)
Anaerobic-like 587 (88.0%) 80 (12.0%)
Endurance-like 2019 (89.0%) 249 (11.0%)
Team-sport 241 (70.9%) 99 (29.1%)
Other 1018 (88.4%) 134 (11.6%)
Athlete’ level
Trained 2777 (87.8%) 385 (12.2%)
Active 1421 (85.7%) 237 (14.3%)
Untrained 420 (83.8%) 81 (16.2%)
Interestingly, there are no investigations measuring the ergogenic effect of caffeine during the
different phases of the menstrual cycle, despite the interactions between caffeine and female sex
hormones [9]. In fact, it has been found that the effect of caffeine on increasing blood pressure is higher
in the follicular than in the luteal phase in female adolescents [10]. All this information indicates
that it is still too early to establish that women experience the same ergogenic response to caffeine as
men, and further research is needed to describe the optimal conditions of caffeine use in sport and
exercise for women. With this Editorial, we want to encourage authors to provide objective information
about the dose-effect of caffeine on female athletes’ physical performance. We also want to embolden
research focused to determine the magnitude of the ergogenic effect of caffeine during the different
phases of the menstrual cycle. The Nutrients’ Special Issue on “Coffee and Caffeine Consumption for
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Human Health” is open to receive investigations on these topics that hold to “bridge the gap” on the
ergogenicity of caffeine in female athletes.
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Abstract: The ergogenic effect of caffeine is well-established, but the extent of its consumption in
sport is unknown at the present. The use of caffeine was considered “prohibited” until 2004, but this
stimulant was moved from the List of Prohibited Substances to the Monitoring Program of the
World Anti-Doping Agency to control its use by monitoring urinary caffeine concentration after
competition. However, there is no updated information about the change in the use of caffeine as the
result of its inclusion in the Monitoring Program. The aim of this study was to describe the changes
in urine caffeine concentration from 2004 to 2015. A total of 7488 urine samples obtained in official
competitions held in Spain and corresponding to athletes competing in Olympic sports (2788 in 2004,
2543 in 2008, and 2157 in 2015) were analyzed for urine caffeine concentration. The percentage of
samples with detectable caffeine (i.e., >0.1 μg/mL) increased from ~70.1%, in 2004–2008 to 75.7% in
2015. The median urine caffeine concentration in 2015 (0.85 μg/mL) was higher when compared to
the median value obtained in 2004 (0.70 μg/mL; p < 0.05) and in 2008 (0.70 μg/mL; p < 0.05). The urine
caffeine concentration significantly increased from 2004 to 2015 in aquatics, athletics, boxing, judo,
football, weightlifting, and rowing (p < 0.05). However, the sports with the highest urine caffeine
concentration in 2015 were cycling, athletics, and rowing. In summary, the concentration of caffeine in
the urine samples obtained after competition in Olympic sports in Spain increased from 2004 to 2015,
particularly in some disciplines. These data indicate that the use of caffeine has slightly increased
since its removal from the list of banned substances, but urine caffeine concentrations suggest that
the use of caffeine is moderate in most sport specialties. Athletes of individual sports or athletes of
sports with an aerobic-like nature are more prone to using caffeine in competition.
Keywords: pharmacokinetics; energy drink; exercise; elite athlete; performance
1. Introduction
Caffeine (1,3,7-trimethylxanthine) is a stimulant naturally present in a variety of foods and drinks,
although it is also artificially included in dietary and sports supplements, over-the-counter medications,
and beverages. In the sport setting, caffeine is widely utilized because it might have the capacity to
enhance endurance performance [1,2], anaerobic-based performance [3], and strength/power-oriented
performance [4,5] in exercise and sports of different nature [6–8]. There is strong evidence supporting
that caffeine, when ingested prior to exercise, and at a dosage of 3–6 mg per kg of body mass, could
benefit sports performance as it has been recently recognized by the International Olympic Committee
Nutrients 2019, 11, 286; doi:10.3390/nu11020286 www.mdpi.com/journal/nutrients11
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in its consensus statement on dietary supplements [9]. However, the ergogenicity of caffeine might
be affected by the scenario of use and may vary widely among individuals because of several factors
that include genetic variants, the microbiome and habituation to caffeine [10]. Specifically, it has
been recently found that AA homozygotes for a single nucleotide polymorphism in the CYP1A2 gene
(rs762551, also known as −163C>A) might obtain greater ergogenic benefits from acute caffeine intake
(2–6 mg/kg) than C-allele carriers [11–13], although this is not always the case [14–17]. In addition,
previous investigations have suggested that the ergogenic effect of acute caffeine ingestion (3–5 mg/kg)
might be reduced by habitual caffeine intake [18,19], suggesting a progressive tolerance to the ergogenic
effects of this substance when this substance is ingested chronically. However, other investigations
have shown that naïve/low caffeine consumers benefited from the acute intake of 3–6 mg/kg of
caffeine to a similar extent to habitual caffeine consumers [20,21], and, to date, there is not a clear
consensus about time course of tolerance to the performance benefits of caffeine. Although the reasons
to explain tolerance to caffeine require further investigation, it seems clear that the physiological
responses to acute caffeine intake have a great inter-individual variability [22].
The use of caffeine in sports can also have several drawbacks, such as increased ratings of
nervousness and insomnia [23] that might limit its efficacy to enhance performance. In this respect,
the “more is better” philosophy (i.e., >9 mg/kg), when applied to caffeine, may result in a higher
prevalence of side effects [24,25] that outweigh the potential performance benefits of this stimulant.
Likely due to these and other drawbacks, caffeine was considered a banned substance in sport by
the medical commission of the International Olympic Committee and other anti-doping authorities
between 1984 and 2004, and its use was prohibited only in competition. A 12 μg/mL threshold for
urine caffeine concentration was set in 1987 to limit the use of high doses of caffeine and athletes that
surpassed this threshold were penalized for doping misconduct. The World Anti-Doping Agency
(WADA) decided to remove caffeine from the list of banned substances with effect from January 1,
2004, and since then, athletes have been able to consume caffeine-containing products freely. However,
WADA included caffeine in its Monitoring Program; a program designed to monitor and detect
patterns of misuse in substances not included in the prohibited list, but with the possibility of being
harmful in sport [26]. Since 2004, WADA has monitored the proportion of urine samples with a caffeine
concentration of over 6 μg/mL in order to monitor the use of high doses that could be harmful for
athletes, although the data are not public. Interestingly, the concentration of caffeine in the urine
samples used for doping control remained similar between 1993–2002 (i.e., when caffeine was in the
list of banned substances) [27] and 2004–2008 (i.e., when caffeine was removed from the list of banned
substances) [28,29]. These data suggest that the use of caffeine was not substantially modified with the
removal of caffeine from the list of banned substances, likely because the “12-μg/mL-threshold” was
not an effective deterrent to prevent the use of caffeine to increase physical performance. However,
since 2008, there is no investigation that have studied the trends in the use of caffeine sports despite the
evidence that support the ergogenicity of caffeine has greatly increased in the last years [1,2,5,30,31].
Thus, the aim of this study was to describe the changes in urine caffeine concentrations in Olympic
sports using samples obtained in 2004, 2008, and 2015. The ultimate goal of this study was to use the
evolution in urinary caffeine concentration to infer changes in the use of caffeine in sport.
2. Materials and Methods
For this study, we measured the urine caffeine concentration in all samples submitted to the
Madrid Doping Control Laboratory (Spain) in 2004, 2008, and 2015 as part of the WADA Monitoring
Program. The samples measured corresponded to specimens gathered after national and international
competitions held in Spain, since urine specimens collected out-of-competition are not routinely
analyzed for caffeine detection. The current study presents an analysis of the 7488 urine samples that
corresponded to athletes competing in Olympic sports (2788 in 2004, 2543 in 2008, and 2157 in 2015).
In 2004, 25.4% of the samples pertained to women athletes, 26.0% in 2008 and 24.2% in 2015. To obtain
representative data on each sport discipline, a threshold of >25 samples per year was established
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to include any Olympic sport in the analysis. Information about the athlete’s sex (included on the
anti-doping form) was integrated into a database for the analysis. The investigation used anonymized
data obtained for the doping control and thus did not require ethical approval. Participants’ rights and
confidentiality were protected during the whole study, and the data were only used for the purposes
included in this investigation. The study conformed to the Declaration of Helsinki.
2.1. Urine Analysis
All samples were obtained following the Guidelines for Urine Sample Collection described by
WADA [32]. Upon collection, the samples were sent to the Doping Control Laboratory by special
refrigerated transport and arrived at the laboratory with an anonymized format (alpha-numeric code).
After arrival, a portion of the sample was used to measure urine caffeine concentration and the
remaining amount was destined to other anti-doping purposes. Specifically, a portion (5 mL) of each
urine sample was poured into a 15-mL screw-capped glass tube. Then, 50 μL of internal standard
(diphenylamine 100 μg/mL) was added to the sample. After that, 100 μL of sodium hydroxide
10 mol/L and 0.5 g of sodium sulphate were added to increase the transfer of analytes from the
aqueous to the organic phase. Alkaline extraction was performed by adding 5 mL of methyl tert-butyl
ether and centrifuging the sample at 60 rpm for 20 min. After that, the sample was frozen in a cryogenic
bath, and the organic phase (upper phase and not frozen) was transferred to a clean vial. The extract
was concentrated with nitrogen, and 2 μL of the remaining extract was injected into the system for
caffeine quantification.
The methodology to quantify urine caffeine concentration was based on gas chromatography–mass
spectrometry (GC-MS), and was validated according to ISO17025. The measurement of each batch of
urine samples was preceded by a calibration process, using a solution with an established caffeine
concentration (6 μg/mL). GC-MS analysis was performed using a 6890N Gas Chromatograph (Agilent
Technologies, Santa Clara, CA, USA) coupled to a 5973N Mass Selective Detector (Agilent Technologies).
All the chromatograms in the samples analyzed in 2004 and in 2008 were obtained in the scan mode
range. At this time, the GC was equipped with a fused silica capillary column OV-1 (J & W Scientific
Inc., Folsom, CA, USA). In 2015, the chromatograms were obtained in the single ion monitoring (SIM)
mode and the GC was equipped with a capillary column Ultra-1 (J & W Scientific Inc., Folsom, CA,
USA). In all analyses the carrier gas was helium, and they were carried out at a constant pressure of
15 psi. To facilitate separation, the initial column temperature was set at 90 ◦C and the final column
temperature was set at 300 ◦C. The temperature on the injector port was set at 275 ◦C.
2.2. Validation Procedure
The between-days reproducibility was evaluated using 20 measurements of the calibration
solution obtained over two months. The between-days coefficient of variation (at 6 μg/mL) was
7%. Accuracy was calculated in terms of the recovery factor (experimental value/theoretical value,
expressed as a percentage). The value obtained was 105%, and no tendencies were observed. Combined
uncertainty was estimated taking into account the contributions of accuracy and reproducibility and
the value obtained was 11%. The limit of detection (LOD) was 0.1 μg/mL.
2.3. Statistical Analysis
All samples with a urinary caffeine concentration below the LOD were considered to be specimens
without any caffeine content. The remaining samples were categorized into intervals of 1.0 μg/mL,
with a maximal caffeine concentration of 13.0 μg/mL. Most of the samples had a urinary caffeine
concentration between 0.0 and 13.0 μg/mL, but 32 samples had a urinary caffeine concentration
of >13.0 μg/mL (14 in 2004, 11 in 2008, and 7 in 2015). These samples were included in the statistical
analysis, but they were not included in the graphical presentation of the data per 1.0 μg/mL-categories.
The samples were grouped by sport discipline, by year of collection, and by athlete’s sex. Normality
for each year of collection was tested with the Kolmogorov-Smirnov test.
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Data are presented as median ± and interquartile range (25% and 75% percentile) for quantitative
variables (urine caffeine concentration), while qualitative variables (distribution) are presented as
percentages. Urine caffeine concentration had a non-normal distribution and thus, non-parametric
statistics were later employed. The comparison of the urine caffeine concentration among the three
years (2004 vs. 2008 vs. 2015) was tested with the Kruskal-Wallis test. The changes in the evolution of
the urine caffeine concentration within each sport were also identified with the Kruskal-Wallis test.
The differences in distribution of samples among ranges of urine caffeine concentration were tested
with crosstab and Chi Square tests, including adjusted standardized residuals. The comparison among
sport specialties was only performed for the samples obtained in 2015 because a previous publication
provided this comparison for 2004–2008 [29]. Finally, the differences between sexes were analyzed with
the U-Mann Whitney test. The data were analyzed with the statistical package SPSS v 21.0 (SPSS Inc.,
Chicago, IL, USA). The significance level for all these statistical analyses was set at p < 0.05.
3. Results
The median urine caffeine concentration in 2015 (0.9; 0.1–2.4 μg/mL) was higher when compared
to the median value obtained in 2004 (0.7; 0.0–2.4 μg/mL; p < 0.05) and 2008 (0.70; 0.1–2.1 μg/mL;
p < 0.05; Figure 1). The maximal value of caffeine concentration was 21.1, 19.2 and 18.6 μg/mL for
2004, 2008, and 2015, respectively.
Figure 1. Box-and-whisker plot for caffeine concentration in the urine samples of Olympic sports
collected in 2004, 2008, and 2015. The cross depicts the mean value while the lower, middle and upper
lines of the box represent the 25%, 50% and 75% percentile. Whiskers represent 1.5 × interquartile
range. Outlier data have been removed to facilitate the comprehension of the figure. (*) Different from
2004 at p < 0.05; (†) Different from 2008 at p < 0.05.
Figure 2 depicts the distribution of urine samples in each year of analysis according to their urine
caffeine concentration, using 1 μg/mL intervals. The distribution of the samples was slightly different
among these years because in 2015, the percentage of samples below the limit of detection was lower
than expected (p < 0.05) while the percentage of samples between 2 and 4 μg/mL was higher than
expected (p < 0.05). The percentage of samples with detectable caffeine (i.e., > 0.1 μg/mL) was 70.3%,
69.8%, and 75.7% in 2004, 2008, and 2015, respectively. The proportion of samples with urine caffeine
concentrations of >12 μg/mL was 0.79%, 0.87%, and 0.60% in 2004, 2008, and 2015, respectively.
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Figure 2. Distribution of urine samples according to the concentration of caffeine in 2004, 2008, and
2015. (*) Different from the expected value. LOD: limit of detection.
Figure 3 depicts box-and-whisker plots for the changes in urine caffeine concentrations in 2004,
2008, and 2015 in men and women. The median values obtained in 2015 were different from 2004 and
2008 in men (upper panel) and women (lower panel), respectively (p < 0.05), while the median values
were always higher in men than in women (p < 0.05).
Figure 3. Box-and-whisker plot for caffeine concentrations in the urine samples from men and women
collected in 2004, 2008, and 2015. The cross depicts the mean value while the lower, middle and upper
lines of the box represent the 25%, 50%, and 75% percentile. Whiskers represent 1.5 × interquartile
range. Outlier data have been removed to facilitate the comprehension of the figure. (*) Different from
2004 at p < 0.05; (†) Different from 2008 at p < 0.05.
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Figure 4 depicts urine caffeine concentration in Olympic sports in 2015 using box-and-whisker
plots. The sports with the highest concentration of caffeine in urine were cycling, rowing, triathlon,
athletics, weightlifting, and volleyball (all with median values >1.0 μg/mL); the sports with the lowest
urine caffeine concentration were shooting, fencing, hockey, basketball, and golf (all with median
values <0.5 μg/mL). Golf presented urine caffeine concentrations lower than cycling, athletics, rowing,
triathlon, handball, and football (p < 0.05). Table 1 contains information on the changes in the median
urine caffeine concentrations in Olympics sports for the years 2004, 2008, and 2015. Specifically, the
values obtained in 2015 were significantly higher than those obtained in 2004 and 2008 in aquatics,
athletics, boxing, judo, and football. In golf and skiing, the data from 2015 were higher only when
compared to 2008, while in rowing and weightlifting, the values in 2015 were only different to 2004.
Figure 4. Box-and-whisker plot for caffeine concentrations in the urine samples of Olympic sports
collected in 2015. The cross depicts the mean value while the lower, middle, and upper lines of the
box represent the 25%, 50%, and 75% percentile. Whiskers represent 1.5 × interquartile range. Outlier
data have been removed to facilitate the comprehension of the figure. CYC = Cycling; ROW = Rowing;
TRI = Triathlon; ATH = Athletics; WEI = Weightlifting; VOL = Volleyball; HAN = Handball;
FOO = Football; JUD = Judo; BOX = Boxing; AQUA = Aquatics; SKI = Skiing; SHO = Shooting;
FEN = Fencing; HOC = Hockey; BAS = Basketball; GOL = Golf. (*) Different from GOL at p < 0.05.
Table 1. Urine caffeine concentrations (μg/mL) in Olympic sports in 2004, 2008, and 2015. Data are
medians (25% and 75% percentile) for each sport.
Sport 2004 2008 2015 p Value
Aquatics 0.1 (0.0–0.8) 0.1 (0.0–1.2) 0.7 (0.1–2.3) *† <0.01
Athletics 0.7 (0.0–2.6) 0.8 (0.1–2.4) 1.5 (0.1–3.6) *† <0.01
Basketball 0.2 (0.0–0.9) 0.4 (0.0–1.2) 0.3 (0.1–1.0) 0.13
Boxing 0.5 (0.0–0.9) 0.0 (0.0–0.8) 0.8 (0.2–2.2) *† <0.01
Cycling 2.0 (0.5–4.0) 1.7 (0.5–3.6) 1.9 (0.5–3.4) 0.30
Fencing 0.5 (0.0–0.9) 0.1 (0.0–0.8) 0.3 (0.1–1.4) 0.19
Football 0.7 (0.0–2.0) 0.5 (0.1–1.6) 0.9 (0.1–2.2) *† <0.01
Golf 0.0 (0.2–0.4) 0.0 (0.0–0.0) * 0.1 (0.0–0.5) † <0.01
Handball 1.0 (0.2–2.7) 0.9 (0.1–2.1) 1.0 (0.2–2.3) 0.40
Hockey 0.4 (0.0–1.6) 0.9 (0.2–2.2) 0.3 (0.3–0.9) 0.60
Judo 0.2 (0.0–0.8) 0.2 (0.0–0.5) 0.9 (0.1–2.4) *† <0.01
Rowing 0.4 (0.1–1.6) 2.7 (0.1–5.0) * 1.8 (0.1–4.1) * <0.01
Shooting 0.4 (0.0–2.0) 0.1 (0.0–1.7) 0.3 (0.1–1.5) 0.24
Skiing 0.2 (0.0–1.0) 0.3 (0.1–0.9) 0.6 (0.2–2.5) † 0.03
Triathlon 1.2 (0.3–4.2) 3.0 (1.5–6.2) * 1.6 (0.8–2.8) <0.01
Volleyball 0.9 (0.1–2.0) 1.5 (0.2–2.6) 1.3 (0.3–2.2) 0.45
Weightlifting 0.2 (0.0–1.2) 0.6 (0.0–1.8) 1.3 (0.4–2.9) *† 0.01
(*) Different from 2004 at p < 0.05. (†) Different from 2008 at p < 0.05.
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4. Discussion
The purpose of this investigation was to describe the changes in urine caffeine concentration
of samples obtained in competition of Olympic sports for the years 2004, 2008, and 2015. The final
goal was to determine the evolution in the use of caffeine in sports, especially one decade after it was
removed from the banned list. For this purpose, we measured caffeine concentration in 7488 urine
samples received by the WADA-accredited Doping Control Laboratory in Madrid as part of the
Monitoring Program. The main outcomes of this investigation indicate the following: (a) in 2015, there
was a slight but statistically significant increase in urine caffeine concentration when compared to
both 2004 and 2008. This increase is reflected by a lower proportion of athletes with urinary caffeine
concentrations below the limit of detection and a higher proportion of athletes with concentrations
between 2 and 4 μg/mL; (b) the increase in urine caffeine concentration in 2015 was similarly present
in both men and women but it was unequal in all sport disciplines. Sports such as aquatics, athletics,
boxing, judo and weightlifting had a progressive increase in urine caffeine concentration from 2004
to 2015, while the concentration in other Olympic sports remained stable throughout this period;
(c) in 2015, cycling, athletics, and rowing were the sports with the highest urine caffeine concentration,
while shooting, basketball, and golf were the disciplines with the lowest concentrations of urinary
caffeine. All this information suggests that the use of caffeine in sports increased from 2008 to
2015, particularly in some individual sports. However, the magnitude of the change in the urine
caffeine concentrations obtained in competition does not reflect misuse of this substance in most
sport disciplines.
After the removal of caffeine from the list of prohibited substances in 2004, athletes were free
to consume caffeine at any amount before, during or even after competitions without the burden
of being sanctioned by the anti-doping authorities. In the first five years after this administrative
decision, the urinary concentration of caffeine in sport did not significantly change, as was shown
by the comparative values of the reports made before [27] and after 2004 [28,29]. The absence of
change suggested a high but stable utilization of caffeine by athletes, with most of the samples in the
low-to-middle range of urinary caffeine concentrations. However, more than 300 new studies dealing
with the effects of caffeine in sports have appeared since 2008, particularly original investigations
determining the effects of caffeine on team sports, strength- and power-based sports or those with
an intermittent nature. Besides, caffeine-containing products have become more accessible in all
types of markets because of the conception of new supplements that incorporate caffeine in their
formulation (e.g., pre-work-outs, carbohydrate gels, etc.) or the increase in the popularity of caffeinated
drinks. Even so, the use of caffeine in sports competition has not dramatically changed since 2008
although a slight increase in 2015 is suggested by the changes in the distribution of urine caffeine
concentration. First, the percentage of samples with a urine caffeine concentration below the limit
of detection decreased from 31.2 in 2008 to 24.3% in 2015 (Figure 2), indicating that the proportion
of athletes that do not consume caffeine before or during sports competition has slightly shrunk in
the last few years. Furthermore, the proportion of athletes with urine caffeine concentrations in the
range of 2–4 μg/mL increased in 2015. Thus, it can be suggested that caffeine is a recurrent substance
used by ~75% of athletes in competition with a minor but significant evolution towards a higher use in
sports in 2015.
Caffeine is a substance present in a multitude of foods and drinks, but the amount of caffeine
included in most commercially available products with caffeine has not been shown to have a
clear effect on physical performance (a dose of at least 3 mg/kg is usually necessary to increase
performance [4,9]). The omnipresence of caffeine in the diet means that this substance can be consumed
by some athletes without the intention of increasing physical performance (i.e., social use of caffeine).
Although there is no consensus about the urinary caffeine concentration that differentiates the social
use of caffeine from the intentional use of caffeine to enhance performance, previous investigations
have revealed that lower doses of caffeine that increase performance (i.e., 3–6 mg/kg of body mass)
derive in urinary caffeine concentrations of 2–5 μg/mL after simulated and real competitions [33–35] or
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other forms of exercise [36]. Despite this evidence, WADA only considers relevant, in terms of misuse
and abuse of caffeine, those samples with urinary caffeine concentration of above 6 μg/mL [32] despite
the fact that this might be indicative of caffeine dosages of >9 mg/kg [37]. In the current data, the
proportion of samples above 6 μg of caffeine per mL of urine was 5.9%, 5.4%, and 4.8% for 2004, 2008,
and 2015, respectively. By using the cut-off point proposed by WADA, one might assume that caffeine
abuse has remained constant and low in the last decade. However, urinary caffeine concentrations
between 2 and 6 μg/mL might also be indicative of intentional use of caffeine in sports.
Interestingly, the increase in the concentration of caffeine has not been equally present in all sports.
The mean urinary concentration of athletes tested in aquatics, athletics, boxing, judo, and weightlifting
increased from 2004 to 2015, suggesting a rise in the use of this substance among these particular
sports. Other sports such as basketball, cycling, fencing, handball, hockey, shooting, and volleyball
have maintained urine caffeine concentration at relatively stable values, suggestive of a steady-state
use of caffeine in the last decade. Despite the uneven evolution or urinary caffeine concentration from
2004 to 2015 among sports, the individual disciplines with an aerobic-based performance continue
to be the sports with the highest concentrations of caffeine, while team sports and accuracy sports
are the disciplines with the lowest concentrations of caffeine (Figure 4). The higher urinary caffeine
concentrations found in aerobic-based sports might be related to the traditional evidence that supported
the ergogenic effects of caffeine by using laboratory-based research protocols with endurance-like
exercise. However, more recent evidences, obtained in sport-specific situations, have demonstrated
that the beneficial effects of pre-competition caffeine intake is extended to sprint- and power-based
exercise [5,38], team sports [6,39,40], combat sports [8,41] and sports in which accuracy is a key
element for success [42,43]. With these new evidences, it might be expected a higher consumption of
caffeine—and a higher urinary caffeine concentration—in these type of sport disciplines in the next
years that should be investigated in future research.
The urinary concentration of caffeine has significantly increased in both male and female athletes
since 2004 (Figure 2) and median values reached 0.9 (0.1–2.2) and 0.8 (0.1–3.1) μg/mL, respectively,
in 2015. Although the median values for men and women are very comparable, the proportion of
samples from women athletes at high urinary caffeine concentrations is higher than expected in
comparison to the proportion of urine samples from male athletes. For example, ~65.0% of all urine
samples with a concentration >10 μg/mL corresponded to female participants, despite urine samples
from women representing only about 25.3% of all the samples analyzed. In the opinion of these
authors, the higher incidence of women’s samples in the highest ranges of urinary concentrations of
caffeine could be the result of the unintended intake of larger relative doses of caffeine, in terms of
mg per kg of body mass. Caffeine-containing products are equally available in the market for both
men and women, but the habitual lower mean body mass of female athletes might mean that the
same absolute amount of caffeine ingested (for example, 160 mg of caffeine in a 500 mL can of an
energy drink) results in a higher relative dose in mg/kg. This is also supported by the similar urinary
pharmacokinetic parameters found for male and female adults [44], which suggests that the higher
urinary caffeine excretion in women is related to the ingestion of higher relative doses rather than
differences in caffeine metabolism and excretion.
The current analysis presents some limitations that should be discussed to correctly understand
the outcomes of the investigation. First, the analysis included data from urine caffeine concentration in
three selected years (2004, 2008, and 2015). According to WADA’s Monitoring Program specifications,
only urine samples with a urinary caffeine concentration above 6.0 μg/mL had to be reported to
WADA (and those samples with concentrations below this cut-off remained unreported. Thus, due to
the high number of samples analyzed in the Madrid Doping Control Laboratory between 2004 and
2015, we have been only able of obtaining the data of all urine samples, irrespective of their urinary
caffeine concentration, in these three specific years. Second, the urine samples included in the analysis
were exclusively obtained in national and international competitions held in Spain. Although in these
competitions participate athletes of different nationalities, it is expected that a high proportion of the
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samples analyzed pertained to Spanish athletes. Thus, it is still possible that the evolution of urinary
caffeine concentration could have been different in other countries due to social, genetic and lifestyle
factors. In addition, the absence of out-of-competition urine samples impeded us to have a control
to differentiate the use of caffeine on a day-to-day basis vs. the use before sports competition. Third,
absorption, distribution, metabolism, and excretion of caffeine in the human body is affected by a
myriad of genetic and environmental factors [45] that could affect the concentration of caffeine in urine
in individuals taking the same dose before exercise. Post-competition urinary caffeine levels might
be affected by the timing of the urine sample in relation to the caffeine dose [46] or the opportunities
to urinate during or after an event. In this regard, the sport disciplines analyzed in this investigation
have different regulations, particularly different durations or the presence of several competitions
within the same day. Since caffeine is typically consumed before exercise, a longer competition period
might allow more time for metabolism and excretion of the substance, affecting those sports with
longer competition durations. In addition, caffeine could be ingested more than once in long-lasting
events to maintain the effects of the substance on performance. Nevertheless, we believe that the high
number of samples analyzed per year minimizes the effect of these factors on the outcomes of the
investigation, and the authors believe that the data provided by this research reflect the evolution of
the use of caffeine in sports.
5. Conclusions
In summary, the concentration of caffeine in the urine samples obtained after competition in
Olympic sports increased from 2004 to 2015, which might indicate a slightly higher use of this substance
in both men and women athletes. The analysis by disciplines revealed that some, but not all, sports
have shown increases in the concentration of urinary caffeine, suggesting that the popularity of this
substance has grown in some sports. Athletes of individual sports or athletes of sports with an
aerobic-like nature are more prone to using caffeine in competition. Finally, investigations about the
effects of caffeine on female athlete populations should be promoted because women athletes present
slightly higher urinary concentrations than men counterparts.
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Abstract: Background: this study examined the effects of caffeine supplementation on anaerobic
performance, neuromuscular efficiency and upper and lower extremities fatigue in Olympic-level
boxers. Methods: Eight male athletes, members of the Spanish National Olympic Team, were enrolled
in the study. In a randomized double-blind, placebo-controlled, counterbalanced, crossover design,
the athletes completed 2 test sessions after the intake of caffeine (6 mg·kg−1) or placebo. Sessions
involved initial measures of lactate, handgrip and countermovement jump (CMJ) performance,
followed by a 30-seconds Wingate test, and then final measures of the previous variables. During
the sessions, electromiography (EMG) data were recorded on the gluteus maximus, biceps femoris,
vastus lateralis, gastrocnemius lateral head and tibialis anterior. Results: caffeine enhanced peak
power (6.27%, p < 0.01; Effect Size (ES) = 1.26), mean power (5.21%; p < 0.01; ES = 1.29) and reduced
the time needed to reach peak power (−9.91%, p < 0.01; ES = 0.58) in the Wingate test, improved jump
height in the CMJ (+2.4 cm, p < 0.01), and improved neuromuscular efficiency at peak power in the
vastus lateralis (ES = 1.01) and gluteus maximus (ES = 0.89), and mean power in the vastus lateralis
(ES = 0.95) and tibialis anterior (ES = 0.83). Conclusions: in these Olympic-level boxers, caffeine
supplementation improved anaerobic performance without affecting EMG activity and fatigue levels
in the lower limbs. Further benefits observed were enhanced neuromuscular efficiency in some
muscles and improved reaction speed.
Keywords: anaerobic; caffeine; CMJ; ergogenic aids; exercise; nutrition; sport supplement; Wingate;
electromyography; efficiency
1. Introduction
Caffeine is one of the five nutritional supplements considered ergogenic aids (EA) with good
to strong evidence of benefits in specific sports scenarios [1,2], along with other EA such as beetroot
juice, sodium bicarbonate, β-alanine, and creatine. All are included in the classification system for
nutritional supplements of the Australian Institute of Sports (AIS) based on the demonstrated level of
scientific evidence (Level A) [3]. Briefly, the ergogenic effect of caffeine on sports performance can be
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attributed mainly to: 1) central nervous system stimulation (i.e., blockade of adenosine receptors and
release of neurotransmitters such as dopamine, catecholamine and acetylcholine, improving cognitive
processes: surveillance, learning, attention and reaction time) [4–6], and 2) enhancement of muscle
contraction (i.e., improved calcium output from the sarcoplasmic reticulum to the sarcoplasm after the
muscle action potential, and increased recruitment of motor units) [7–9].
There is clear consensus in the literature regarding the effects of caffeine consumption on aerobic
performance [10,11]. While fewer studies have focused on sports modalities inducing a predominantly
anaerobic metabolism than one mostly dependent on oxidative processes, it is now emerging that
caffeine may also have an ergogenic effect on anaerobic efforts [12,13].
The characteristics of combat sports are similar to those of other sports modalities including
intermittent dynamics (i.e., high-intensity efforts interspersed with periods of low-intensity activity) [14].
Therefore, at the energy level, combat sports require an important contribution of both aerobic (i.e.,
oxidative phosphorylation) [15] and anaerobic metabolism (i.e., glycolysis and phosphagen system)
during high-intensity actions [16]. Also, combat sports athletes require high levels of isometric handgrip
strength [17,18] and muscular endurance in the upper and lower extremities [19]. Competition analysis
has revealed that maintenance of power performance during combats is crucial for high-performance
in these athletes [20].
As combats sports are characterized by high-intensity power actions and both aerobic and
anaerobic energy metabolism systems are required, caffeine could be an EA in these sport modalities.
However, the effect of this supplement on combat sport performance or fatigue levels has not yet
been addressed in the literature. The present study was therefore designed to examine the effects of
caffeine supplementation on anaerobic performance, neuromuscular efficiency and neuromuscular
fatigue levels in the upper and lower limbs in Olympic-level boxers. We hypothesized that caffeine
supplementation would improve anaerobic performance in a 30-seconds all-out Wingate test, improving
muscular efficiency without inducing greater mechanical or neuromuscular fatigue.
2. Materials and Methods
2.1. Participants Selection: Inclusion and Exclusion Criteria
Eight young, healthy male athletes, members of the Spanish National Olympic Team for the Tokyo
2020 Olympic Games (age: 22.0 ± 1.778 years, height: 1.69 ± 0.09 m, body-mass: 65.63 ± 10.79 kg, Body
Mass Index (BMI): 22.69 ± 1.31, load Wingate test: 4.91 ± 0.82 kp), were enrolled in the study.
Exclusion criteria were: (1) age younger than 18 years, (2) having consumed any substance
that could affect hormone levels or sport performance in the previous 3 months such as nutrition
complements or steroids, (3) having consumed narcotic and/or psychotropic agents, drugs or stimulants
during the test or supplementation period, and (4) being diagnosed with any cardiovascular, metabolic,
neurologic, pulmonary or orthopedic disorder that could limit performance in the different tests.
At the study outset, participants were informed of the study protocol, schedule and nature of
the exercises and tests to be performed before signing an informed consent form. The study protocol
adhered to the tenets of the Declaration of Helsinki and was approved by the Ethics Committee of the
Alfonso X El Sabio University.
2.2. Experimental Design
A randomized double-blind, placebo-controlled, counterbalanced, crossover design was used in
this study. The participants completed 2 identical assessment sessions (see Figure 1) in the laboratory at
the same time slot (±0.5 hours) to avoid the detrimental effects of performance associated with circadian
rhythm [21]. The test sessions started with initial measures of lactate, handgrip and countermovement
jump (CMJ) performance, followed by a 30-seconds Wingate test, and then final measures of the
previously collected variables (see Figure 1).
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Figure 1. Experimental design. CMJ = countermovement jump test.
The two sessions were separated by 48 hours. Over a period of 48 hours before the start of the first
session until the end of the study, subjects were instructed to follow a series of nutrition requirements
and refrain from any type of physical exercise.
2.3. Supplementation and Diet Control
The authors packaged and prepared the capsules containing caffeine or placebo (sucrose). The
capsules used were no.1 opaque red (Guinama S.L.U, 0044634, La Pobla de Valbona, Spain). For the
encapsulation process, we followed the normalized working procedures described for this purpose [22].
The filling equipment used was a manual semiautomatic Carsunorm 2000 system (Miranda de Ebro,
Spain).
The subjects arrived at the laboratory 75 minutes before the start of the session, when they were
given a capsule containing either a caffeine supplement (6 mg·kg−1) or sucrose (6 mg·kg−1, placebo).
Caffeine dosage selection (6 mg·kg−1) was made to promote the higher ergogenic effects producing the
minimum side-effects possible [1]. The protocol timing was designed considering that caffeine reaches
peak concentrations in blood after 1 hour of intake [23], and the degradation quality control tests its
half-life (13.4 minutes) according to previous description [22].
In addition, participants received dietary guidelines to ensure that they all followed a diet with
the same content of macronutrients (i.e., 60% of energy intake in the form of carbohydrates, 30% lipids
and 10% proteins) in the 48 hours prior to each session. A list of foods rich in caffeine was provided to
all participants (e.g., coffee, tea, mate, tea soft drinks, energy drinks, cola drinks, chocolate drinks and
chocolate) so that they avoided caffeine intake from 24 hours before the study to the end of the study.
2.4. Wingate Test
A 30-seconds all-out Wingate test was performed on a Monark cycloergometer (Ergomedic 828E,
Vansbro, Sweden). Before the test, a warm-up protocol was conducted consisting of 5 minutes pedaling
at low intensity (i.e., subjects chose the load and cadence), followed by another 5 minutes pedaling at
60 revolutions per minute (rpm) with a load of 2 kiloponds (Kp). In the last 5 seconds of each minute,
the subjects performed a maximum intensity sprint. After three minutes, subjects performed three
countermovement jumps (CMJs) at increasing intensity with 10 seconds recovery between jumps.
Then, 2 CMJs were executed on the force platform. After two minutes of recovery, the Wingate test
began. Subjects pedaled as fast as possible for 30 seconds against a constant load (Kp) calculated
according to the 7.5% of each participant body mass [24]. The instructions given to them were: i) reach
maximum rpm in the shortest time and ii) try to keep the highest number of rpm until the end of
the test. During the test, subjects were encouraged by 4 researchers from the beginning until the end.
Power output (W) was analyzed during each second and, later, peak power output (Wpeak), time (s) to
reach Wpeak (TWpeak), mean power output during the 30 seconds sprint (Wmean) and minimum power
output during the last 10 seconds of the test (Wmin) were calculated. In addition to Wmean during the
entire sprint, mean power output was also calculated every 5 seconds of the sprint (Split1-5S, Split6-10S,
Split11-15S, Split16-20S, Split21-25S, Split26-30S).
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2.5. Electromyographic Assessment
Electromiography (EMG) data were recorded from the following muscles: gluteus maximus (GM),
biceps femoris (BF), vastus lateralis (VL), gastrocnemius lateral head (GL), and tibialis anterior (TA)
and the mean of the five muscles analyzed (MED). We used a “Trigno Wireless SystemTM Delsys”
(Delsys Inc. Massachusetts, MA, USA). Briefly, one active electrode was placed on the bellies of each
muscle of the right thigh and leg following the protocol established by the SENIAM Project (Surface
ElectroMyoGraphy for the Non-invasive Assessment of Muscles) [25]. These electrodes recorded the
surface electrical activity corresponding to the underlying muscle, sampled at a frequency of 1024 Hz.
The EMG signal was filtered by a band pass between 20 and 300 Hz, and subsequently the EMG Root
Mean Square signal (rms-EMG) was calculated. The rms-EMG variable obtained from each of the
5 muscles was normalized to the maximum value obtained in the corresponding muscle for 1 second.
In our study, rms-EMG was used as an estimate of “total myoelectric activity” of the exercising muscle
as it has been previously shown that this computation: 1) is an accurate measure of EMG amplitude
and 2) is highly correlated with the number of active motor units (fiber recruitment) [26,27].
To facilitate the analysis of results, the 30 seconds of each Wingate test was divided into groups
of 5 seconds and we calculated the rms-EMG mean in this time period (e.g., EMG0–5s, EMG6–10s,
EMG11–15s). In addition, we calculated the average rms-EMG (EMGmean), the rms-EMG corresponding
to the time where Wpeak was reached (EMGWpeak), the time (s) to reach the rms-EMG peak record
(TEMGpeak) and the rms-EMG corresponding to the time when Wmin was reached (EMGWmin). Data
of rms-EMG is expressed as a base index one where the value 1 is equal to 100% (i.e., the value 0.75 is
equal to 75 %).
Additionally, to analyze neuromuscular efficiency (NME), we used the ratios between Wpeak and
EMGWpeak (NMEWpeak) and between Wmean and EMGWmean (NMEWmean). Neuromuscular efficiency
(NME) was used as an index of neuromuscular fatigue [28] and was estimated from the ratio of power
to non-normalized RMS (raw EMG data in volts). We adapted the methodology described by Hug and
Dorel [28], and we propose a ratio of power output to normalized RMS (EMG data in percent of muscle
activation). Our rationale was that to determine NME, it is better to relate power to percent of motor
units activated than to raw volts, as described in the literature, and more often used as a measure of
fatigue [28].
2.6. Blood Lactate
Before the warm-up period and immediately after the Wingate test, 5 μ·l samples of capillary
blood from the soft part of the index finger of the left hand were obtained and subjected to blood
lactate concentration determination using a Lactate ProTM 2 LT-1710 blood analyzer (Arkray Factory
Inc., KDK Corporation, Shiga, Japan).
2.7. Neuromuscular Fatigue
Neuromuscular fatigue in the lower limbs was measured in a CMJ [29] performed on a force
platform (Quattro Jump model 9290AD; Kistler Instruments, Winterthur, Switzerland). Before the
jump was initiated, participants stood on the platform with legs extended and hands on hips. For the
jump, the legs were first flexed to 90º (eccentric action) and then explosively extended in a coordinated
manner (concentric action) trying to reach maximum height. During the flight stage, the knees were
extended. Contact with the ground was made with the toes first. During the test, subjects were
instructed to keep their hands on their hips and avoid any sideways displacements during the flight
stage. This same protocol was applied for the CMJs performed before and after the Wingate test.
From each CMJ test, jump height, mean (CMJWmean) and peak power produced (CMJWpeak) were
extracted, as indicators of neuromuscular fatigue [30].
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2.8. Handgrip Strength
Isometric handgrip strength (IHS) was measured twice for the dominant hand using a calibrated
handgrip dynamometer (Takei 5101, Tokyo, Japan) with 30 seconds of passive recovery between trials.
Participants sat with 0 of shoulder flexion and elbow flexion, and the forearm and hand in a neutral
position and exerted their maximal strength during 5 seconds [31]. The highest value of the dominant
hand was recorded and used for statistical analysis as the maximum voluntary handgrip strength.
2.9. Statistical Analysis
Results for all parameters are presented as mean ± standard deviation (SD). Data analyses were
carried out using the commercial software “Statistical Package for Social Sciences” SPSS v21.0 software
(SPSS Inc., Chicago, IL, USA). The effects of caffeine supplementation on Wingate test performance,
lactate, CMJ and strength grip performance were assessed through a two-way ANOVA test for condition
(caffeine versus placebo) and time (pre-versus post-Wingate for CMJ handgrip strength measures, and
during each 5 seconds period of the Wingate test). Levene’s test revealed the homogeneity of variances
of the data and the Shapiro-Wilk’s test confirmed their normal distribution. When a significant
main effect was detected, pairwise comparisons were assessed using the Holm-Bonferroni test in
order to ensure protection against multiple comparisons. Additionally, Wpeak, TWpeak, Wmean, Wmin,
EMGWpeak, TEMGmax, EMGmean and EMGWmin and efficiency measures (NMEWpeak, NMEWmean and
NMEWmin) were analyzed using the Student’s t-test. Pairwise comparisons significance was assessed
by calculating Cohen’s d Effect Size (ES) [32]. Effect sizes (d) above 0.8, between 0.8 and 0.5, between 0.5
and 0.2 and lower than 0.2 were considered as large, moderate, small, and trivial, respectively [33,34].
3. Results
3.1. Wingate Test
Compared to placebo, caffeine consumption produced a significant and large effect in Wpeak (10.84
± 0.49 versus 10.20 ± 0.59; p < 0.01; Effect Size (ES) = 1.26) and Wmean (8.68 ± 0.34 versus 8.25 ± 0.37;
p < 0.01; ES = 1.29), a decrease in TWpeak (8.00 ± 1.60 versus 8.88 ± 1.64; p < 0.01; ES = 0.58), while
this improvement after caffeine supplementation in Wmin it was not significantly different (p = 0.123)
(see Table 1). Moreover, there was an effect of the time factor (p < 0.001), verified in the analysis of
power output levels throughout the 6 partial tests, as well as for the supplementation factor (p = 0.006).
Significant differences were observed in Split6–10s (p = 0.026) and Split11–15s (p = 0.009), as well as a
significant trend Split16–20s (p = 0.062) (see Table 2). There was no significant interaction between
factors (supplementation-time).
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3.2. Electromyographic Assessment and Neuromuscular Efficiency
In the analysis of rms-EMG, there were no significant differences (p > 0.05) between
supplementation in EMGWpeak, EMGmean and EMGWmin during the Wingate test (see Table 1).
Also, we observed a higher TEMGmax in the gluteus maximus for the caffeine condition (8.00 ± 6.26
versus 3.63 ± 3.66; p = 0.022; ES = 0.91).
On the other hand, there was a time factor effect in EMGVL, EMGBF, EMGTA, EMGGL
(p < 0.05), in the placebo and caffeine conditions at different Wingate time splits (see Table 2).
There were no significant differences for supplementation conditions or the interaction between factors
(supplementation-time) (p > 0.05), except for EMGTA (time·suplementation: p = 0.033).
In the analysis of neuromuscular efficiency there were no significant differences between caffeine
and placebo conditions, but a large effect was detected for NMEWpeak in the vastus lateralis (ES =
1.01) and gluteus maximus (ES = 0.89), and NMEWmean for vastus lateralis (ES = 0.95) and tibialis
anterior (ES = 0.83). There was also a moderate effect near large values (i.e. ≈ 0.8), in NMEMED at
Wpeak (ES = 0.77), and at Wmean (ES = 0.74) (see Table 3).





M ± SD p-Value ES M ± SD p-Value ES
NMEVL
Placebo 13.29 ± 1.63
0.115 1.01
11.34 ± 1.98
0.105 0.95Caffeine 16.71 ± 4.87 13.99 ± 3.71
NMEBF
Placebo 16.75 ± 5.87
0.785 0.12
16.19 ± 5.00
0.678 0.17Caffeine 16.11 ± 5.28 15.39 ± 5.30
NMEGM
Placebo 15.74 ± 4.01
0.187 0.89
13.14 ± 1.75
0.261 0.61Caffeine 22.18 ± 10.19 14.27 ± 2.19
NMETA
Placebo 15.72 ± 7.59
0.957 0.04
13.43 ± 3.06
0.181 0.83Caffeine 15.93 ± 4.66 18.11 ± 7.94
NMEGL
Placebo 14.47 ± 3.77
0.947 0.04
12.76 ± 2.88
0.556 0.31Caffeine 14.58 ± 2.20 13.82 ± 4.35
NMEMED
Placebo 14.35 ± 1.99
0.184 0.77
12.87 ± 1.41
0.054 0.74Caffeine 15.92 ± 2.34 14.36 ± 2.71
NMEWpeak: ratio between Wpeak and EMGWpeak; NMEWmean: ratio between Wmean and EMGWmean; NMEVL:
neuromuscular efficiency measured on the vastus lateralis; NMEBF: neuromuscular efficiency measured on the
biceps femoris; NMEGM: neuromuscular efficiency measured on the gluteus maximus; NMEGL: neuromuscular
efficiency measured on the gastrocnemius lateral head; NMETA: neuromuscular efficiency measured on the tibialis
anterior; NMEMED: neuromuscular efficiency measured as the mean values of the five muscles analyzed; * Significant
difference between Placebo and Caffeine condition at p < 0.05.
3.3. Blood Lactate
Blood lactate concentrations increased from rest (placebo 1.86 ± 0.55 mmol·L−1 versus caffeine
1.53 ± 0.56 mmol·L−1 ) to exhaustion after the Wingate test (placebo 11.88 ± 1.55 mmol·L−1 versus
caffeine 15.36 ± 1.57 mmol·L−1 ), with significant differences in the placebo (p < 0.001) and caffeine
conditions (p < 0.001), but not between conditions (p > 0.05) (see Figure 2).
3.4. Neuromuscular Fatigue (CMJ) and Handgrip Strength
Before the Wingate test, caffeine consumption increased jump height (Placebo versus Caffeine,
43.1 ± 3.7 versus 45.4 ± 4.2 cm; p = 0.006), but not CMJWmean (Placebo versus Caffeine, 28.8 ± 3.0 versus
29.1 ± 4.9 W; p > 0.05) or CMJWpeak (Placebo versus Caffeine, 51.3 ± 3.4 versus 51.6 ± 5.7 W; p > 0.05).
The analysis of the CMJs performed before and after the Wingate test revealed a significant decrease
in jump height, CMJWmean and CMJWpeak after caffeine and placebo ingestion (ANOVA time effect,
p = 0.001). Although compared to placebo, caffeine promoted a less pronounced decrease in jump
height, CMJWmean and CMJWpeak (−2.5%, −1.3% and −2.0%, respectively) only jump height showed a
difference between conditions (ANOVA effect, p = 0.020). In the analysis of handgrip strength, there
were no differences detected for supplementation, time or time·supplementation (p > 0.05).
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Figure 2. Blood lactate concentrations pre-post Wingate. * p < 0.05, significant differences compared to
pre-Wingate values (PRE).
4. Discussion
Our results show that the ingestion of caffeine in Olympic-level boxers significantly improves
anaerobic performance and has a positive effect on neuromuscular efficiency. Caffeine was also found
to reduce lower limbs fatigue levels after an anaerobic test. To our knowledge, this is the first study
that has examined the effects of caffeine in Olympic-level boxers.
The main findings of the present study were that caffeine supplementation (6 mg·kg−1) enhanced
Wpeak (6.27%, p < 0.01; ES = 1.26) and Wmean (5.21%; p < 0.01; ES = 1,29) and reduced TWpeak (−9.91%,
p < 0.01; ES = 0.58) in the Wingate test, improved jump height in the CMJ (+2.4 cm, p < 0.01) and showed
a large effect on neuromuscular efficiency, improving NMEWpeak in the vastus lateralis (ES = 1.01) and
gluteus maximus (ES = 0.89) and NMEWmean for the vastus lateralis (ES = 0.95) and tibialis anterior
(ES = 0.83). Thereby, these results are in accordance with the 21 meta-analysis review conducted by
Grgic et al. [35], who stated that ingestion of caffeine enhanced a large span of exercise performance
variables (e.g., muscle endurance and strength, anaerobic power).
Our results with caffeine ingestion seem to improve the most important physical capacities for elite
level boxers [36] (e.g., maximal strength and power output, muscle resistance). We observed significant
improvements in peak power (6.27%) and mean power (5.21%) in the Wingate test, and in CMJ jump
height (5.1%). These findings are consistent with a meta-analysis that have found similar results for
peak and mean power [12] and power production [13]. Also, these results are competitively relevant
because improvements around 0.6% are enough to make a difference in elite-level sports [37,38].
During the Wingate test, boxers in both conditions, generated the highest power during the second
split (6–10 seconds) and then power production decreased progressively until the end of the test. In a
Wingate test, Wpeak is commonly reached during the first 6 seconds of the sprint where free adenosine
triphosphate (ATP) and phosphocreatine (PCr) stores are essential energy sources [24,39]. Accordingly,
during the 5–10 seconds of the sprint the critical reduction of PCr pools in the muscle promotes
adenosine diphosphate (ADP) accumulation which causes the end of the exercise [40]. Given the
physiological characteristic of boxing, the delayed time to reach Wpeak in elite boxers may be explained
by an increased capacity to store PCr in their muscles. Further, the caffeine condition showed a higher
mean power output in all the splits (differences in splits ranged from +0.27 to +0.56 W·kg−1). These
data support the conclusion reached in two caffeine meta-analyses [12,13] where the ergogenic effect of
this supplement was attributed to the capacity to improve the production of power by skeletal muscle.
Another main result observed in the present study is the higher neuromuscular efficiency (NME)
measured by superficial EMG during the Wingate test in the caffeine condition. To our knowledge,
this is the first attempt to asses this question in Olympic level boxers. Mean EMG recordings were
similar between both conditions (p > 0.05). However, as we described before, the caffeine condition
showed a significantly improved power released (i.e., peak power (+0.64 W·kg−1) and time to achieve
peak power (−0.88 seconds), and mean power (+0.43 W·kg−1)), so the boxers in the caffeine condition
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developed higher power with the same muscle activation (i.e., greater NME). Moreover, we observed a
moderate effect near to large values (i.e., ES > 0.8) for the five muscles measured together NMEMED
peak (ES = 0.77) and mean (ES = 0.74), and large effect for neuromuscular efficiency (ES > 0.80) for
some muscles (i.e., vastus lateralis, gluteus maximus, tibialis anterior). This improved neuromuscular
efficiency may be due to the caffeine-enhanced intra- and inter-muscle coordination [41]. Moreover, the
vastus lateralis and the gluteus maximum are two of the main muscles involved in pedaling, mostly in
the down-stroke phase [42]. Further, in vitro findings observed the increase in calcium release from
the sarcoplasmic reticulum after an action potential that could explain these ergogenic effects [43].
In parallel, the significantly longer time (>4 seconds) to achieve EMG peak in the gluteus maximum
(TEMGpeak GM) in the caffeine condition, also supports this improved neuromuscular efficiency. Then,
during the Wingate test, we observed a greater mean power released in the caffeine condition in each
5 seconds split, with global maintained fiber recruitment (even with a tendency towards lower muscle
activation), and with a delay to achieve peak muscle activity in one of the most important muscles in
cycling, the gluteus maximum. Therefore, it seems that the higher power production and delayed
muscle activity of the gluteus maximum caused by caffeine consumption, facilitated an increased time
to produce higher power output (>4 seconds) at the beginning of the test. Also, the higher NME
of the tibialis anterior, overall an important up-stroke muscle during the Wingate test, may help to
produce this higher power output in the caffeine condition. But further, the NMEMED of the five
muscles contribute to maintain this greater power production during the 30 seconds of the Wingate
test with the same muscle recruitment, resulting in better neuromuscular efficiency. This improved
duration during high-power actions was observed by Coswig et al. [44] after caffeine supplementation,
ten Judo athletes increased the duration of high-intensity actions and decreased the rest duration
during simulated boxing matches. However, Greer, Morales, and Coles [45] studied the effects of
caffeine ingestion on Wingate performance and surface EMG in eighteen active males. They observed
no differences in neuromuscular efficiency (i.e., same power output and EMG amplitude between
conditions). This lack of ergogenic effect may be explained because it could be exclusive to athletes
with high levels of performance, as there are other studies with poorly trained subjects where there
have been no significant differences between caffeine and placebo conditions [46–49]. More deeply,
MacIntosh et al. [50] and Lucia et al. [27] studied this neuromuscular efficiency in cycle ergometry with
active healthy subjects and professional elite cyclists, respectively. Both showed that at high power
outputs (i.e. ≈ 400 W), higher pedaling cadence produced lower rms-EMG amplitude, and then lower
motor unit activation. In the present study, the cycle ergometer was set with the same fixed load for
each boxer in both conditions. In the caffeine condition, they produce higher power output with these
fixed loads, so caffeine permits a higher pedaling cadence to produce this increased power. Then, this
higher cadence may in part explain the better neuromuscular efficiency observed in these elite boxers.
On the other hand, there was a significant EMG fatigue effect in the placebo and caffeine conditions
at different Wingate time splits (ANOVA time effect: EMGVL, EMGBF, EMGTA, EMGGL, p < 0.05;
EMGGM p = 0.094). The data revealed in the five muscles mean EMG differences of −13.9% ± 7.0%
(range −4% to −24%) from the first Wingate split (0–5 seconds) to the last (26–30 seconds). The
rms-EMG used in the present study is an accurate measure of the EMG amplitude and is highly
correlated with the number of active motor units (fiber recruitment) [26,27]. Then, fiber recruitment
decreased progressively during the Wingate test influenced by higher fatigue levels. The same
behavior was described in the Wingate test by Greer, Morales, and Coles [45]. They measured vastus
lateralis and gastrocnemius muscles and observed a significantly decreased EMG amplitude during
the 30-seconds all-out test, with no differences between caffeine and placebo conditions. In combat
sports, Cortez et al. [51] observed the same fatigue effect at the level of the rectus femoris in a dollyo
chagi kick (i.e., Taekwondo technique), before and after a strenuous task, and observed that caffeine
supplementation reduced this fatigue effect compared to the intake of placebo (≈ −5% Caffeine versus
≈ −20% Placebo).
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Caffeine has shown to be effective at improving reaction speed (i.e., reducing the execution time
of the bandal tchagui kick) [52], or reaction time in response to a visual stimulus [53], in combat sports.
Although, the reaction speed of the upper extremities has not been measured, the shorter time to
reach the achieve peak power during the Wingate test (~10%) seems to support this ergogenic effect
of caffeine in boxers. This effect of caffeine intake on reaction speed could be mediated by increased
neurotransmitter delivery, enhancing motor neuron transmission [54–56], and by increased activity of
the sodium-potassium pump, improving the sarcoplasmic availability of calcium [55].
In the present study, caffeine consumption enhanced neuromuscular performance and diminished
neuromuscular fatigue, measured with the countermovement jump test, by significantly increasing
vertical jump height (+2.3 cm) and attenuating the decrease in vertical jump height after the Wingate
test (−2.5%) respectively, and compared to placebo. Fatigue is a very important variable in combat
sports such as Olympic boxing, as the competitions include multiple fights on consecutive days, and
then the maintenance of power levels between fights is considered a valuable performance variable [20].
Our results agree with those of Cortez et al. [51], who observed higher neuromuscular performance
and lower levels of fatigue in a dollyo chagi kick (i.e., Taeckwondo technique) in taekwondo athletes
supplemented with caffeine, before and after a strenuous task compared to placebo intake.
Our data showed that an anaerobic effort such as a Wingate Test results in a significant increase
in blood lactate concentrations in both conditions (time factor for both placebo and caffeine), but
not between conditions (p > 0.05). These findings are in agreement with other data published in
well-trained men [57], Judo athletes [58], and male wrestlers [20]. However, although we did not
find significant differences between conditions, we detected higher lactate concentrations for caffeine
supplementation versus placebo. This large amount of lactate production in the caffeine condition
may be explained by the observed better Wingate performance, that may reflect a higher glycolysis
utilization [12]. Other authors [59,60] observed significantly augmented blood lactate concentrations
in taekwondo and Jiu-Jitsu athletes following caffeine supplementation. As before, this effect could be
explained by the higher energy expenditures related to increased glycolysis utilization with a greater
recruitment of type II motor units [61] (i.e., highly dependent on glycolytic metabolism [62,63]), and by
a reduced effect of adenosine on phosphofructokinase inhibition [43].
In comparison to the placebo condition, no differences were noted in the isometric handgrip
strength (IHS) with caffeine ingestion (−1.34% versus −0.54%). Our results are similar to previous
data with highly resistant training males [64] that reported no differences with caffeine ingestion
versus placebo conditions in IHS (1.88%) after a neuromuscular test battery. However, other studies
have found improvements in handgrip force after caffeine supplementation [9,60,65,66]. The lack
of significant effect of caffeine consumption on isometric strength and the discrepancy observed
in the literature may indicate that this ergogenic aid is more effective on dynamic (eccentric and
concentric) compared to static (isometric) muscular performance. Moreover, it should take into
account that caffeine ingestion stimulates a higher increase in lower body compared to upper body
strength performance [67]. Handgrip is not a specific action for boxing athletes and may not be the
most appropriate test for them. In fact, we can speculate that another explanation of this result may
reside on the differences in muscle recruitment and contraction between the handgrip strength test
and how boxers train their hands. While the handgrip strength test required maximal strength of
the flexor muscle of the hand, in boxing, other muscles of the forearm are implicated and maximal
contraction may not be required. Another explanation may be that the great endurance-strength of
these Olympic-level boxers could overcome the fatigue effect of one Wingate test (i.e., focused overall
on lower limbs performance). In future studies it should be recommended to determine the ergogenic
effects of caffeine on both upper and lower limbs, by subjecting the boxers to several bouts of a specific
test that includes the four extremities. In this sense, Negaresh et al. [68], observed during a simulated
wrestling tournament that an individualized caffeine supplementation protocol should be implemented
when physical performance is expected to be reduced (i.e., usually during the latter combat rounds).
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Limitations
Due to the high quality of the sample, its number is limited and could have masked some of
the known ergogenic effects of caffeine. Moreover, all the enrolled subjects were male. Lastly, blood
samples extraction would help to monitor caffeine presence in plasma in both trials (caffeine and
placebo), a procedure that cannot be performed in the present cohort of elite boxers. Future studies
using a bigger sample with mixed-gender or female population and blood samples are warranted.
5. Conclusions
The present study has demonstrated that caffeine supplementation (6 mg·kg−1) improves anaerobic
performance (i.e., Wingate and CMJ) with a similar electromyographic activity and fatigue levels of
lower limbs (i.e., Wingate and CMJ) and enhanced neuromuscular efficiency in some muscles (i.e., vastus
lateralis, gluteus maximus and tibialis anterior) in Olympic-level boxers. Further, caffeine consumption
enhances reaction speed (i.e., a higher peak power with a lower time to achieve peak power).
Future research should focus on the ergogenic effects of caffeine after repeated bouts of a specific
simulated boxing combat test on both the upper and lower extremities and should also address
cognitive fatigue.
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Abstract: Background: Caffeine ingestion improves athletic performance, but impairs sleep quality.
We aimed to analyze the effect of caffeine intake on 800-m running performance, sleep quality
(SQ), and nocturnal cardiac autonomic activity (CAA) in trained runners. Methods: Fifteen male
middle-distance runners participated in the study (aged 23.7 ± 8.2 years). In a randomized and
comparative crossover study design, the athletes ingested a placebo (PL) or caffeine supplement
(CAF; 6 mg·kg−1) one hour before an 800-m running time-trial test in the evening. During the night,
CAA and SQ were assessed using actigraphy and a sleep questionnaire. A second 800-m running
test was performed 24 h after the first. Time, heart rate, rating of perceived exertion, and blood
lactate concentration were analyzed for each running test. Results: No significant differences in
CAA and performance variables were found between the two conditions. However, CAF impaired
sleep efficiency (p = 0.003), actual wake time (p = 0.001), and the number of awakenings (p = 0.005),
as measured by actigraphy. Also, CAF impaired the questionnaire variables of SQ (p = 0.005), calm
sleep (p = 0.005), ease of falling asleep (p = 0.003), and feeling refreshed after waking (p = 0.006).
Conclusion: The supplementation with caffeine (6 mg·kg−1) did not improve the 800-m running
performance, but did impair the SQ of trained runners.
Keywords: actigraphy; athletic; coffee; ergogenic aid; supplement
1. Introduction
Scientists and coaches are continually looking for techniques to develop more effective and efficient
methods to improve exercise performance [1]. One of the popular methods commonly used by athletes
to maximize their physical performance is the intake of legal ergogenic aids [2]. In this way, caffeine
is frequently used in sport as an ergogenic aid to improve athletic performance and endurance [3].
In fact, it has been reported that 74% of elite athletes may use caffeine as an ergogenic aid prior to or
during a competition [4]. Caffeine is a xanthine alkaloid that increases central nervous activity by the
blockade of central and peripheral adenosine receptors [5]. This stimulant action produces a greater
recruitment of motor units [6], improves the Na+–K+ pump response [7], and increases the rate of
calcium release from the sarcoplasmic reticulum [8] and the mobilization of free fatty acids [9]. Also,
caffeine enhances adrenaline secretion [10] and reduces ratings of perceived exertion [11]. Therefore,
caffeine is administered in order to improve sport performance.
Previous studies that analyzed the effect of caffeine ingestion on runners have shown improvements
in running performance compared to placebo [12,13]. It had previously been reported that compared
to placebo, the intake of 4.5 mg·kg−1 of caffeine increased exercise distance by 2–3 km when running at
85% maximum oxygen uptake until exhaustion [10]. Regarding middle-distance races, compared to
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placebo, 1500-m [13] or one-mile [14] running performances are improved by 1.3–1.9% after 150–200 mg
and 3 mg·kg−1 of caffeine intake, respectively. However, another study found similar 800-m running
performance in amateur runners after placebo or 5.5 mg·kg−1 of caffeine administration [15]. Thus,
there is conflicting evidence in relation to the effectiveness of caffeine as an ergogenic aid to improve
middle-distance race performance in athletes.
On the other hand, caffeine intake can impair sleep [16], which is considered the most important
method for recovery from daily load [17]. Sleep assists in the recovery of the nervous and metabolic
cost imposed by the waking state [18]. However, caffeine typically prolongs sleep latency, reduces
total sleep time and sleep efficiency, and worsens perceived sleep quality (SQ) [16], particularly if it
is administered close to bedtime. Moreover, vigorous-intensity exercise completed close to bedtime
increases the latency time and impairs SQ [19]. Therefore, the use of caffeine as an ergogenic aid in
a competition performed close to bedtime may decrease SQ and the recovery process, which may
decrease athlete performance on the following day. There are some sports modalities, such as athletics,
where the athlete needs to perform in qualification races over consecutive days. Some of these races
are performed at the end of the evening, and the rest time between the first race (e.g., a semi-final)
and the following one (e.g., the final) may be very short. For example, during the Athletics World
Championships of 2019, the qualification and the semi-final race of the 800-m event were separated
by 24 h. Thus, the administration of caffeine before a qualification race performed in the evening
may affect the recovery process and performance in the races on the following day due to sleeping
problems. However, there are no studies that have analyzed the effect of caffeine administration to aid
performance in a race close to bedtime on SQ and on the running performance the following day.
Therefore, the aim of the present study was to analyze the effect of caffeine intake one hour (19:00 h)
before an 800-m race (20:00 h) on actigraphic SQ, subjective SQ, and nocturnal cardiac autonomic
activity (CAA), and on the 800-m performance performed 24 h later in trained middle-distance athletes.
We hypothesized that the pre-exercise ingestion of 6 mg of caffeine per kg of an athletes’s body mass
would impair SQ through subjective and actigraphic impairment, but it would not affect the race
performance on the following day.
2. Methods
2.1. Design
A randomized and comparative crossover study was conducted to test the effects of caffeine
intake or placebo before an 800-m running time trial on actigraphic SQ, the subjective quality of sleep,
nocturnal autonomous cardiac activity, countermovement jump (CMJ), and the 800-m performance of
athletes at international and national levels. Athletes reported to their usual official athletics track four
times over two consecutive weeks. The testing sessions were developed during two consecutive Friday
and Saturday evenings in March. Two weeks before the study, the athletes had finished their winter
season, performing in the National Indoor Championships. Therefore, the study was developed in a
general period training phase.
Upon arrival at the athletics track, runners were given a caffeine or a placebo supplement—placebo
(PL) or caffeine (CAF) in randomized order—in experimental Sessions 1 and 3, while no supplements
were taken in the experimental Sessions 2 and 4. Forty-five minutes (min) after the intake of the
supplements in Sessions 1 and 3, or 45 min after the runners arrived at the athletics track, the participants
started the testing session.
An 800-m running time-trial test was performed in each testing session. Performance (time, CMJ
height), physiological (peak and mean heart rate and blood lactate concentration), and subjective
(rating of perceived exertion) variables were collected during the testing session. The sessions were
carried out at 20:00 h and under similar environmental conditions (20–22 ◦C). In addition, we used
actigraphy to monitor the night after PL or CAF ingestion to assess SQ and a sleep questionnaire and
to analyze the autonomic modulation.
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2.2. Participants
Fifteen male runners in mid-level events participated in the study (age: 23.7 ± 8.2 years; height:
177.4 ± 9.0 cm; weight: 64.6 ± 9.8 kg). Runners performed 9.0 ± 1.8 h per week of training and had
at least six years of middle-distance training experience. They were of national and international
standard at the 800-m level and their best time at that distance ranged between 1:46.72–2:04.10. Eleven
of the runners were of Caucasian race, two were from North Africa (Maghreb race), one was from
South America (Latino race), and another was from Central Africa (Black race). All the subjects gave
their signed and informed consent, and the study was approved (CE031909) by the Ethics Committee
in Institutional Sciences of the University and was in accordance with the Declaration of Helsinki.
The subjects were asked to maintain their usual diet and hydration status and not to ingest caffeine or
alcohol at least 24 h before each test session or to carry out exhaustive training in the 48 h prior the first
and third testing sessions.
2.3. Procedures
Athletes ingested a placebo (sucrose) or caffeine supplement (6 mg·kg−1) in capsules of the same
size, color, and smell in a typical double-blind trial, with a 50% chance of ingesting the actual active or
placebo substance, avoiding any effects of session or time on the results. The blinding efficacy was
checked after the participants had finished their participation. In addition, participants were issued
with nutritional guidelines to ensure that they followed a similar diet in the 48 h before each condition
session. This diet was the same that runners usually used during competition. The last meal was
eaten by runners 3 h before the test. Furthermore, 24 h before each experimental session, caffeine
ingestion was restricted. In addition, a caffeine consumption questionnaire [20] was administered to
the runners, which showed that all the runners were daily consumers of caffeine (between 250–572 mg
of caffeine·day−1) according to classification proposed elsewhere [21]. Also, all the runners were used
to ingesting caffeine (6 mg·kg−1) as an ergogenic aid prior to competition.
2.4. Testing Session
During the first visit, body composition was evaluated using a bioimpedance segmental analyzer
(Tanita BC-601, Tanita Corp, Tokyo, Japan) following previous recommendations [22]. In addition,
45 min after supplement ingestion, participants performed their traditional competitive warm-up of
15 min duration, including running at low intensity, joint mobility, dynamic stretching, and progressive
running sets. After warm-up, a CMJ test was carried out. Two minutes later (~60 min after supplement
ingestion), an 800-m time-trial test was performed. Finally, 2 min after the end of the running test,
a blood lactate concentration analysis and another CMJ test were carried out. The mean and peak heart
rates (Polar RS800, Polar Electro Oy, Kempele, Finland) were recorded during the 800-m running time
trial. In addition, ratings of perceived exertion (RPE) were determined using the 10-point Borg scale [23]
following the 800-m time trial. The 800-m times were recorded using a Geonaute chronometer Onstart
710 (Decathlon, Villeneuve-d’Ascq, France) by two of the researchers, and the mean of these values
was used for analysis. Capillary blood samples (5 μL) were collected by finger prick 2 min after the end
of the running test and analyzed for blood lactate concentration ([La–]) using a Lactate Pro analyzer
(Lactate Pro, Arkay, Inc., Kyoto, Japan). Countermovement jump heights were performed using a
contact platform (Ergotester, Globus, Codogne, Italy). The participants executed two submaximal trials
to ensure proper execution of the jumps with 1-min rest between trials. The CMJ height was measured
before warm-up and prior to the 800-m time trial, and performed at the center of the platform with
the feet placed shoulder-width apart in the standing position. Participants were asked to jump as
high as possible with a rapid self-selected countermovement. The depth of the countermovement was
self-selected, and participants were asked to try to land close to the take-off point. Each individual’s best
performed was used for data analysis. The same testing procedure was applied in each testing session.
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2.5. Actigraphic Quality of Sleep, Subjective Quality of Sleep, and Autonomous Nocturnal Cardiac Activity
Between the end of testing session and the time to go to bed, the athletes had to do their normal
life and record any activity in a diary. Participants were instructed to measure actigraphic sleep
quality and nocturnal cardiac autonomic activity (Heart Rate Variability-HRV) during sleep after
each day with a training session day. Actigraphic sleep quality was recorded using an actiwatch
activity monitoring system (Cambridge Neurotechnology, Cambridge, UK), which measures activity by
means of a piezoelectric accelerometer. The movement of the non-dominant wrist of each participant
was monitored. A low actigraphic sensitivity threshold (80 counts per epoch) was selected, and
the data recorded by the actigraph were analyzed with Actiwatch Sleep Analysis Software. Each
subject received a sleep diary to record bedtime, wake-up time, hours napping, hours without wearing
the actigraph, and the number of nocturnal awakenings. Data analysis started with the onset of
nocturnal rest (bedtime) and ended with the onset of daytime activity (wake time). The following
sleep parameters were measured: (I) sleep efficiency (%): percentage of time spent asleep; (II) time in
bed (min); (III) actual sleep time (min); (IV) actual wake time (min); (V) number of awakenings; (VI)
average time of each awakening(min); and (VII) latency.
Together with the actigraph, during the night, each subject wore an H7 strap Heart monitor (Polar
Electro, Kempele, Finland) to evaluate HRV. Variables of cardiac autonomic activity were analyzed for
the 4-h period of sleep starting 30 min after the reported bedtime [20]. The R–R series were analyzed
using Kubios HRV software (version 2.0, Biosignal Analysis and Medical Imaging Group, University
of Kuopio, Finland). The following HRV variables were assessed: (I) low-frequency (LF) band /
high-frequency (HF) band ratio; (II) total power (TP); (III) percentage of differences between adjacent
normal R–R intervals more than 50 ms (pNN50); (IV) square root of the mean of the sum of the squared
differences between adjacent normal R–R intervals (RMSSD); (V) standard deviation of all normal N–N
intervals (SDNN); (VI) mean heart rate; and (VII) mean R–R intervals.
Participants were also instructed to evaluate their subjective sleep quality in the morning after
awakening using the Karolinska Sleep Diary [24], which analyzes the following questions: (I) sleep
quality (very well [5] to very poorly [1]); (II) calm sleep (very calm [5] to very restless [1]); (III) ease
of falling asleep (very easy [5] to very difficult [1]); (IV) amount of dreaming (much [3] to none [1]);
(V) ease of waking up (very easy [5] to very difficult [1]); (VI) feeling refreshed after awakening
(completely [3] to not at all [1]); (VII) slept throughout the time allotted (yes [5] to woke up much too
early [1]).
2.6. Statistical Analysis
Statistical analysis of data was performed with SPSS 21.0 software (SPSS 21.0, Chicago, IL, USA)
in a Windows environment. Descriptive data are presented as mean ± SD and range. For inferential
analysis, a Shapiro–Wilk W-test was performed to establish the normality of the sampling distribution,
and Mauchly’s W-test analyzed the sphericity between measurements. In addition, analysis of variance
for repeated measures (ANOVA) was calculated (general linear model) to analyze the effects of caffeine
intake on performance over 800 m, and a paired sample T-test or the nonparametric equivalent
(Wilcoxon test) was used to compare the effect of caffeine on heart rate variability and SQ. Effect size
(ES) was calculated using partial eta-squared (η2p) for variance analysis and Cohen’s d to indicate
the standardized difference between two means. Threshold values for ES were ≥0.1 (small), ≥0.3
(moderate), ≥1.2 (large), and ≥2.0 (very large) [25]. The level of significance was set at p ≤ 0.05.
3. Results
Table 1 presents the summary statistics for the changes in performance under each of the measured
conditions (placebo and caffeine). No significant effects were found in performance (Figure 1).
Significant effects were observed in the variable CMJ (F = 4.564; p = 0.008) with a large effect size
(η2p = 0.28); the pair comparison showed a significant difference between the CMJ results (Δ) on days
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1 and 2 when participants took caffeine (mean differences = −6.51, t = −3.14, p = 0.020). However,
no significant effects were found in in any other variable.
Figure 1. Time in 800 m (s). T1: First test 1; T2: second test; PLA: Placebo; CAF: Caffeine.
Table 1. Results of 800-m running time trial test variables.
Placebo Caffeine
ANOVA
Test 1 Test 2 Test 1 Test 2
mean SD mean SD mean SD mean SD F p η2p
Time in 800 m (s) 122.6 5.6 123.8 6.2 122.3 5.1 123.3 5.4 2.317 0.12 0.15
RPE (A.U) 8.4 1.1 8.2 1.0 8.3 0.9 8.1 0.9 0.142 0.934 0.01
mean HR in 800 m (bpm) 170.4 9.8 171.4 10.1 172.7 10.6 173.2 9.2 0.625 0.525 0.06
peak HR in 800 m (bpm) 185.8 9.1 184.5 10.1 188.3 8.2 185.5 10.5 0.889 0.395 0.08
CMJ (Δ cm) −10.2 8.8 −6.8 4.8 −13.3 8.7 −6.8 5.9 4.564 0.008 0.28
Lactate (mmoL/L) 19.1 4.7 19.0 4.2 20.1 4.6 17.8 4.4 0.979 0.413 0.07
RPE: Rate of perceived exertion; CMJ: countermovement jump.
Concerning the SQ results, actigraphic analysis showed significant differences between conditions
(placebo versus caffeine) in sleep efficiency (p = 0.003; ES = 0.71), actual wake time (p = 0.001;
ES = −1.18), and number of awakenings (p = 0.005; ES = −0.96) (Figure 2 and Table 2).
Figure 2. Sleep quality results measured by actigraphy * Significant differences between placebo and
caffeine (p < 0.05).
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Table 2. Sleep quality results.
Placebo Caffeine
Effect Size (ES)
95% CI for ES
Mean SD Mean SD p Lower Upper
Actigraphic sleep quality
Latency (min) 6.15 2.79 6.77 2.32 0.290 −0.31 −0.86 0.25
Sleep efficiency (%) 92.2 3.0 86.4 5.5 0.003 0.71 0.27 0.91
Time in bed (min) 470.2 118.3 461.2 128.2 0.641 0.13 −0.42 0.68
Actual sleep time (min) 434.8 119.7 402.3 136.3 0.091 0.51 −0.08 1.08
Actual wake time (min) 29.2 15.4 52.1 23.2 0.001 −1.18 −1.89 −0.45
Awakenings (n) 13.62 7.05 18.85 7.50 0.005 −0.96 −1.61 −0.28
Average time of each awakening (min) 2.79 1.90 3.18 1.72 0.402 −0.24 −0.79 0.32
Karolinska Sleep Questionnaire
Sleep quality 3.36 0.75 2.21 0.98 0.005 1.11 0.43 1.77
Calm sleep 3.50 1.09 2.36 1.15 0.005 1.11 0.43 1.77
Ease of falling asleep 3.43 1.22 1.57 0.85 0.003 1.38 0.62 2.10
Amount of dreaming 1.43 0.76 1.07 0.48 0.120 0.48 −0.08 1.03
Ease of waking up 3.43 0.76 3.14 0.86 0.395 0.24 −0.30 0.76
Feeling refreshed after awakening 2.07 0.73 1.50 0.65 0.006 1.11 0.43 1.77
Slept throughout the time allotted 3.14 0.86 2.79 1.89 0.389 0.24 −0.30 0.77
In addition, the Karolinska sleep questionnaire showed significant differences between conditions,
favoring placebo in SQ (p = 0.005; ES = 1.11), calm sleep (p = 0.005; ES = 1.11), ease of falling asleep
(p = 0.003; ES = 1.38), and feeling refreshed after waking (p = 0.006; ES = 1.11) (Table 2).
Table 3 shows the summary statistics for heart rate variability during the night. No significant
differences were observed between caffeine and placebo.
Table 3. Heart rate variability results during the night after placebo or caffeine ingestion.
Placebo Caffeine
Effect Size (ES)
95% CI for ES
Mean SD Mean SD p Lower Upper
Mean R-R (ms) 1151.5 114.4 1184.7 131.1 1.000 −0.21 −0.80 0.39
SDNN (ms) 40.4 7.2 36.5 6.7 0.102 0.56 −0.58 0.58
HR (bpm) 52.4 5.7 51.2 6.1 1.000 0.58 −0.01 0.87
RMSSD (ms) 27.1 4.1 26.9 4.0 0.715 0.11 −0.48 0.70
pNN50 (%) 7.1 3.3 7.2 3.1 0.956 −0.02 −0.61 0.58
LF (ms2) 986.3 617.3 814.0 377.4 0.205 0.41 −0.22 1.02
HF (ms2) 192.4 111.1 190.7 77.8 0.953 0.02 −0.57 0.61
TP (ms) 1689.1 1094.3 1371.7 639.8 0.214 0.40 −0.23 1.08
LF/HF 5.6 2.5 4.6 2.0 0.182 0.43 −0.20 1.04
SD: standard deviation; SDNN: standard deviation of all normal N–N intervals; HR: mean heart rate; RMSSD:
square root of the mean of the sum of the squared differences between adjacent normal R–R intervals; pNN50:
percentage of differences between adjacent normal R–R intervals > 50 ms; TP: Total power; LF: low frequency; HF:
high frequency (HF).
4. Discussion
To our knowledge, this is the first study to investigate the effects of caffeine intake 1 h (19:00)
before an 800-m running time trial (20:00) on actigraphic SQ, subjective SQ, and nocturnal CAA, and
on the 800-m performance 24 h later, in trained middle-distance athletes. We found that the ingestion
of 6 mg·kg−1 of caffeine did not improve the 800-m running performance. In addition, caffeine intake
did not modify the 800-m running performance one day after the first 800-m running test. However,
regarding SQ, athletes reported significantly worse subjective SQ, calm sleep, ease of falling asleep,
and feeling refreshed after waking after CAF ingestion in comparison to PL. In addition, caffeine
ingestion impaired the sleep quantity and quality as measured by actigraphy (reducing sleep efficiency,
increasing the number of awakenings, and increasing the actual wake time) in 800-m athletes, but did
not affect the autonomic nervous system during the night.
Caffeine is a supplement with good-to-strong evidence of achieving benefits in athletic performance
when used in specific scenarios across endurance-based situations and in short-term, supramaximal,
and/or repeated sprint tasks [26]. However, our findings revealed no significant differences in 800-m
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times when caffeine ingestion and placebo were compared. These results are in accordance with a
study by Marques et al. [15], who found no performance differences between placebo and caffeine
conditions in 800-m time-trial running performance in overnight-fasting runners. Furthermore, recent
research has shown no positive effect of 5 mg·kg−1 intake on anaerobic capacity in recreationally active
men. Anaerobic capacity is a key factor in performance in middle-distance sports (e.g., 800 m) [27].
In contrast, there are several studies that have found improvements with the use of caffeine as an
ergogenic aid in tests of similar metabolic demands [14,28]. These controversial findings could be due
to the characteristics of the subjects, their daily caffeine intake, and their experience in the use of caffeine
as an ergogenic aid: previous studies have reported that the ergogenic effect of caffeine in habitual
caffeine consumers is diminished [29,30]. In addition, several studies have found significant differences
when intake and testing is carried out in the morning versus the evening, showing benefits when
the protocol was carried out in the morning, and not when it was carried out in the evening [31,32].
Therefore, this must be considered in our study, because the experimental protocol was performed in
the evening, which could diminish the potential effects of caffeine. Finally, the genetic predisposition of
athletes has been shown to have a great influence on the responses to the intake of this ergogenic aid [33].
Some genetic polymorphisms affect the speed of metabolism of caffeine (CYP1A2) and the excitability
of the nervous system (ADORA2A) [33], and this could affect the results obtained in the present study.
Therefore, future studies would assess a genetic test to analyze how these polymorphisms affect 800-m
running performance. Finally, regarding RPE, our results showed no significant differences between
PL and CAF conditions. These findings are in accordance with the above-mentioned 800-m running
study [15]. Moreover, our results agree with a previous meta-analysis that concluded that the intake of
caffeine produces a significant reduction in RPE during exercise, but does not produce any change at
the end of exhausting exercise [34].
Good sleep is vital in the regulation of hormone secretion and in the restoration of metabolic
processes in athletes [35]. However, some factors can impair SQ in athletes before a competition:
about 66% of athletes report that they often experience worse sleep than usual on the night(s) before a
competition [36] for various reasons, including noise, light, anxiety, and nervousness [37]. Moreover,
previous studies report that performing intense exercise close to bedtime impairs SQ [19]. In addition,
caffeine ingestion may have adverse effects on SQ [3,16]. Interestingly, the current study, using trained
male athletes, found that a 6 mg·kg−1 dose of caffeine taken 1 h (19:00) before an 800-m race (20:00)
impairs SQ, with lower sleep efficiency and greater actual wake time and number of awakenings.
These findings can be due to caffeine promoting wakefulness by antagonizing adenosine A1 and A2A
receptors in the brain [38]. These adenosine agonist receptors play a role in arousal and promoting sleep.
In addition, 6-sulphatoxymelatonin excretion plays an essential role in in the biological regulation of
circadian rhythms, including sleep, and previous studies have reported that caffeine interferes with
sleep quantity and quality by the reduction of this substance [39]. Therefore, these physiological
responses can explain the SQ results obtained in the present study. Notably, although poor sleep was
reported after CAF ingestion, no influence on performance was found. This finding is in accordance
with previous studies that reported that disturbed sleep had no influence on sporting performance in
competitions [36,40]. Some possible reasons to explain this unchanged exercise performance following a
night of poor-quality sleep are that metabolic pathways, rating of perceived exertion, and physiological
responses remain largely unaltered [37]. The performance, physiological, and perceptual results of the
present study agree with this finding.
Several studies have analyzed the relationship between HRV and caffeine ingestion [41,42],
reporting that caffeine seems to produce predominantly a parasympathetic rather than a sympathetic
cardiac influence [43]: some studies report that the acute ingestion of caffeine enhances parasympathetic
activity [44], and tends to decrease the LF/HF ratio under resting conditions [43], or increase this variable
during sleep after caffeine administration [45]. However, other studies found no changes in HRV at
rest [46] comparison to placebo. These findings are in accordance with the results of the present study,
where no significant differences were observed in HRV variables during sleep after placebo or caffeine
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ingestion. One possible reason for these findings can be related to the daily caffeine consumption of
the participants. Previous studies have reported that the response of the autonomic nervous system to
caffeine intake is diminished in habitual caffeine consumers [47]. Therefore, the lack of effect on HRV in
the athletes in the present study could be related to the rapid tachyphylaxis of caffeine, as reported [47].
In addition, the effect of caffeine on HRV seems to be time-dependent, resulting in an enhancement of
the activity of autonomic nervous system 2.5 h after caffeine ingestion [46]. Thus, in our study the
participants ingested the caffeine ~3.5–4.5 h before going to sleep, which could be related to the lack of
difference in HRV variables during sleep between the conditions (placebo versus caffeine).
From an application perspective, athletic coaches of middle-distance runners should keep in mind
that if the championship has races on consecutive days, the administration of 6 mg·kg−1 of caffeine
does not improve the 800-m running performance, but can impair sleep quantity and the quality of
trained runners who are habitual caffeine consumers.
The main limitation of the present study was that the number of athletes that took part in the
study was limited. In addition, our results cannot be generalized to other subjects who ingest lower
amounts of caffeine per day (i.e., light caffeine consumers); neither can our findings can be generalized
to other athletes’ modalities (e.g., long distance) or gender (female athletes). Finally, the results of
plasma caffeine concentration were not determined. On the other hand, the main strength of the
present study is the level of the athletes who participated and the practical application of the results
to the real athletic field. Further research into the influence of caffeine supplementation on running
performance and recovery processes (e.g., sleep, using electroencephalography) would be necessary.
Moreover, it would be interesting to increase the number of subjects in a future study also comparing
subjects with regular and non-regular intake of caffeine.
5. Conclusions
In comparison to placebo, the ingestion of 6 mg·kg−1 of caffeine did not improve the 800-m running
performance in daily consumers of caffeine trained athletes, and did not modify the performance of
a subsequent 800-m running test performed one day after the first. However, caffeine impaired the
subjective and actigraphic sleep quantity and quality, but did not affect the autonomic nervous system
during the night after the participants had performed the first 800-m running test.
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Abstract: We aimed to explore the effects of caffeinated gel ingestion on neuromuscular performance
in resistance-trained men. The participants (n = 17; mean ± standard deviation (SD): age 23 ± 2 years,
height 183 ± 5 cm, body mass 83 ± 11 kg) completed two testing conditions that involved ingesting a
caffeinated gel (300 mg of caffeine) or placebo. The testing outcomes included: (1) vertical jump height
in the squat jump (SJ) and countermovement jump (CMJ); (2) knee extension and flexion peak torque
and average power at angular velocities of 60◦·s−1 and 180◦·s−1; (3) barbell velocity in the bench press
with loads corresponding to 50%, 75%, and 90% of one-repetition maximum (1RM); and (4) peak
power output in a test on a rowing ergometer. Compared to the placebo, caffeine improved: (1) SJ
(p = 0.039; Cohen’s d effect size (d) = 0.18; +2.9%) and CMJ height (p = 0.011; d = 0.18; +3.3%); (2) peak
torque and average power in the knee extensors at both angular velocities (d ranged from 0.21 to 0.37;
percent change from +3.5% to +6.9%), peak torque (p = 0.034; d = 0.24; +4.6%), and average power
(p = 0.015; d = 0.32; +6.7%) at 60◦·s−1 in the knee flexors; (3) barbell velocity at 50% 1RM (p = 0.021;
d = 0.33; +3.5%), 75% 1RM (p < 0.001; d = 0.42; +5.4%), and 90% 1RM (p < 0.001; d = 0.59, +12.0%).
We conclude that the ingestion of caffeinated gels may acutely improve vertical jump performance,
strength, and power in resistance-trained men.
Keywords: caffeine; ergogenic aid; resistance training; isokinetic testing
1. Introduction
In the general population, caffeine is a widely consumed food constituent [1]. Caffeine
consumption is also widespread among athletes, likely due to its performance-enhancing effects
on exercise [2]. In most of the studies that examine the effects of caffeine ingestion on exercise
performance, the participants ingest caffeine administered in the form of a capsule and wait 60 min
before starting the exercise session [3,4]. This waiting period is used with the idea that plasma levels of
caffeine reach their peak values ~60 min following the ingestion of a caffeine-containing capsule [5].
In recent years, however, several studies have explored the effects of alternate sources of caffeine
on exercise performance [3]. Some of the alternate sources of caffeine include chewing gums, bars,
gels, mouth rinses, energy drinks, aerosols, and coffee [3,6,7]. These sources attracted the attention
of researchers, given that they may provide rapid absorption of caffeine in the body. For example,
following the consumption of a caffeine-containing gum, increases in caffeine levels in plasma occur
within 5 min [8]. This rapid absorption may lead to a faster ergogenic effect, which subsequently may
be useful in many situations in sport and in exercise settings.
Wickham and Spriet [3] highlighted that only two studies thus far have examined the effects
of caffeinated gels on exercise performance; one reported an ergogenic effect of caffeine on 2000-m
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rowing-ergometer performance [9], while another stated that caffeine ingestion did not enhance
intermittent sprint performance [10]. Due to the scarce and conflicting studies examining the effects of
caffeinated gels on exercise performance, it is evident that further research with this source of caffeine
is warranted.
Two recent meta-analyses reported that caffeine ingestion acutely enhances muscle strength,
as assessed by isokinetic peak torque and jumping performance [11,12]. In both meta-analyses,
all included studies explored the effects of caffeine administered in the form of a capsule or liquid.
In resistance exercise, caffeine ingestion may acutely increase muscle strength, muscle endurance,
and muscle power [13]. However, the effects of caffeine on muscle power in resistance exercise have
been explored the least. Grgic et al. [13] highlighted only four studies [14–17] that have explored the
effect of caffeine on power (as assessed by barbell velocity). Grgic et al. [13] suggest that caffeine may
have a considerable performance-enhancing effect on barbell velocity in resistance exercise; however,
the authors also noted the need for future research on the topic. Given that all four studies that examined
the effects of caffeine on muscle power in resistance exercise used caffeine in the form of a capsule,
it remains unclear if comparable effects may be observed with caffeinated gel as a source of caffeine.
While studies are exploring the effects of caffeine on resistance exercise administered in alternate forms
such as coffee and chewing gums [6,7,18], there is a lack of studies utilizing caffeinated gels.
An additional limitation of the current body of evidence that explored the effects of caffeine on
power is that almost all studies used performance tests that involved a specific body region in isolation
(e.g., upper-body in the bench press exercise). Currently, there is a need for studies that measure
power output during exercise tests that require simultaneous coordinated activity of the upper- and
lower-body musculature.
This study aimed to explore the effects of caffeinated gel ingestion on: (1) jump performance;
(2) isokinetic strength and power of the knee extensor and knee flexor muscles; (3) upper-body power;
and (4) whole-body power, in a sample of resistance-trained men. We hypothesized that ingesting a
caffeinated gel would acutely enhance exercise performance in all of the employed performance tests
compared to the placebo.
2. Materials and Methods
2.1. Study Design
This study employed a randomized, crossover, double-blind, counterbalanced study design.
In the first exercise session, participants were familiarized with the performance tests. Following this
familiarization session, the participants were randomized to two experimental conditions: caffeinated
gel and placebo gel. The dose of caffeinated gel (Smart 1 Energizer Gel, Science in Sport) contained 88 g
of carbohydrates and 300 mg of caffeine. The placebo gel (Go Isotonic Energy Gel, Science in Sport)
contained the same amount of carbohydrates without any caffeine. Therefore, the only difference in
the provided gels was the amount of caffeine.
After ingesting either the placebo or caffeinated gel, the participants were given 10 min to warm-up
before the testing session started. All testing sessions were conducted in the morning hours (between
7:00 and 9:00 a.m.) for all participants. The day before each testing session, the participants were
requested to maintain their general nutritional and sleep habits, and not to perform any vigorous
physical activity. Additionally, the participants were asked to refrain from any caffeine ingestion after
6:00 p.m. on the days before the two experimental conditions. To facilitate this process of caffeine
restriction, the participants were provided with a comprehensive list of the most common food and
drink products containing caffeine. The participants were also instructed not to ingest any food or
drinks (other than plain water) upon waking up; that is, they came to the laboratory in a fasted state.
Adherence to these guidelines was established before the start of each testing session. The testing
sessions were separated by no less than three and no more than six days. The reliability of the outcomes
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analyzed in the exercise protocol was established on a pilot sample of five participants that repeated
the exercise protocol on two occasions, three days apart (Table 1).
Table 1. Test–retest reliability of the exercise protocol; determined on a pilot sample of five participants.
Exercise Test Outcome Average CV
Squat jump (SJ) Jump height (cm) 1.3%
Countermovement jump (CMJ) Jump height (cm) 1.3%
Isokinetic knee extension at 60◦ s−1
Peak torque (Nm) 2.5%
Average power (W) 1.7%
Isokinetic knee flexion at 60◦ s−1
Peak torque (Nm) 5.3%
Average power (W) 4.4%
Isokinetic knee extension at 180◦ s−1
Peak torque (Nm) 2.1%
Average power (W) 2.7%
Isokinetic knee flexion at 180◦ s−1
Peak torque (Nm) 5.9%
Average power (W) 5.0%
Bench press at 50% 1RM Barbell velocity (m·s−1) 1.7%
Bench press at 75% 1RM Barbell velocity (m·s−1) 3.6%
Bench press at 90% 1RM Barbell velocity (m·s−1) 5.1%
Rowing ergometer test Peak power (W) 2.5%
1RM: one-repetition maximum; CV: coefficient of variation.
2.2. Participants
The following inclusion criteria was set for this study: (1) apparently healthy men, aged 18–45
years, without any current muscular injuries or other physical limitations; and (2) resistance-trained,
defined as having at least one year of resistance exercise experience with a minimal weekly training
frequency of two times per week, and by having the ability to successfully lift at least 100% of their
current body mass in the bench press exercise.
A power analysis performed prior to the study initiation using the G*Power software indicated
that the required sample size for this study is 12 participants. The parameters employed in this analysis
were as follows: expected effect f of 0.20 (for barbell velocity in the bench press exercise), alpha of
0.05, statistical power of 0.80, and r of 0.90 [19]. To factor in possible dropouts, we initially recruited a
sample of 18 participants. One participant dropped out due to private reasons; 17 participants (mean
± standard deviation (SD): age 23 ± 2 years, height 183 ± 5 cm, body mass 83 ± 11 kg) successfully
completed all visits and were included in the analysis. Habitual caffeine intake of the participants
was estimated using a validated food frequency questionnaire [20] and amounted to 67 ± 90 mg·day−1
(range: 0 to 357 mg·day−1). Of note here, only one participant had a high habitual caffeine intake of
357 mg·day−1; all remaining participants ingested <180 mg·day−1 with 12 ingesting <100 mg·day−1.
Ethical approval was obtained from the Committee for Scientific Research and Ethics of the Faculty of
Kinesiology at the University of Zagreb. Upon informing the participants about the study requirements,
benefits, and risks, they provided written informed consent.
2.3. Exercise Tests
2.3.1. Vertical Jump
After the warm-up, the testing protocol started with the assessment of jump performance.
The participants performed three squat jumps (SJs) and three countermovement jumps (CMJs) on the
force platform (BP600600, AMTI, Inc., Watertown, MA, USA). The force platform was accompanied
with a custom-developed software for data acquisition and analysis. Vertical jump height for both the
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SJ and the CMJ was automatically calculated by the software from the vertical velocity of the center of
mass at take-off data using the following formula [21]:
vertical jump height = TOV2 / 2g
where TOV is the vertical velocity of the center of mass at take-off, and g is the gravitational acceleration
(9.81 m·sec−2).
The SJ was performed while starting from an initial semi-squat position (knees ~90◦ and trunk/hips
in a flexed position), with participants holding the position for approximately 2 s before jumping
vertically as quickly and as explosively as possible, in order to jump as high as possible in the shortest
possible time using a concentric-only muscle action. Hands remained akimbo for the entire movement
to eliminate any arm-swing influence. The participants were instructed to maintain fully extended
lower limbs throughout the flight period. The CMJ was performed starting from the upright standing
position. On the command of the tester, the participants performed a downward countermovement
by a fast knee flexion. Immediately after, the vertical jump began by an explosive extension of the
legs. The CMJ is characterized by an eccentric–concentric muscle action often referred to as the
stretch-shortening cycle muscle action. The participants were instructed that their lowest position
should be a semi-squat position (knees ~90◦ and trunk/hips in a flexed position), and that the jump
should be performed as quickly and explosively as possible in order to jump as high as possible in the
shortest possible time. One warm-up attempt for both the SJ and CMJ was allowed, during which the
correct execution of the jumps was confirmed. Three official attempts followed, with 1 min of rest
between the attempts; the highest jumps were used for the analysis.
2.3.2. Isokinetic Strength and Power
The isokinetic dynamometer (System 4 Pro, Biodex Medical Systems, Inc., Shirley, NY, USA) was
used for the isokinetic strength and power assessment of the knee extensor and knee flexor muscles.
The assessment was performed unilaterally, involving only the dominant leg. The participants were
placed in a seated position and stabilization straps were applied to the trunk, waist, thigh, and shin.
The lateral femoral epicondyle of the dominant leg was aligned with the dynamometer’s axis of rotation.
The isokinetic dynamometer was calibrated before each testing session, and the range of motion of the
knee joint was set at 80◦. Testing was performed at angular velocities of 60◦·s−1 and 180◦·s−1, in that
order. At each angular velocity, participants first performed three familiarization repetitions to get
accustomed to the speed of the lever arm. Then, following a 30-s rest interval, they performed five
maximal knee extensions and flexions. For this exercise, the participants were instructed to extend and
flex the knee (to “kick” and “pull”) five times as hard and as fast as they could. Peak torque in N·m−1
obtained during knee extension and knee flexion movement patterns was used as the measure of the
knee extensor and knee flexor muscle strength, respectively. Average power over five repetitions at
both angular velocities (i.e., 60◦·s−1 and 180◦·s−1) was also used for the analysis.
2.3.3. Bench Press
The PowerLift mobile phone application was used to measure barbell velocity in the bench press
exercise. The PowerLift application has previously been reported as valid, reliable, and accurate
for measuring barbell velocity during this exercise [22]. The application allowed video recording of
the lift in slow motion. After the recording was complete, the application allowed frame-by-frame
inspection of the recorded video material and manual selection of the beginning and the end of the
concentric part of the movement. The beginning of the movement was considered as the moment
when the barbell left the chest of the participant. The end of the movement was considered as the
moment when the participants fully extended the elbows. This distance (d) between the beginning
and end of the movement was measured with a measuring tape and entered into the application.
The application calculated the time (in ms) between two frames (i.e., the beginning and the end of the
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movement). The outcome of this test was the mean barbell velocity produced during the press. During
each testing session, the participants exercised with loads corresponding to 50%, 75%, and 90% of
their one-repetition maximum (1RM; established during the familiarization session), while completing
two, one, and one repetition, respectively. During each repetition, the participants were instructed to
perform the concentric part of the movement as fast as possible. Three minutes of rest were allowed
between repetitions and/or loads.
2.3.4. Rowing Ergometer Test
A test on a rowing ergometer (Model D, Concept II, Inc., Morrisville, VT, USA) was used to assess
whole-body power. For this test, the resistance control dial of the ergometer was set at 10 (highest
adjustable resistance). First, the participants were given 5 min during which they rowed comfortably
at their own pace. No attempts were made to make any corrections in their rowing technique. Then,
following a 2-min rest, the participants performed six “introductory” strokes, which were followed by
six “all-out” strokes. For the six “all-out” strokes, the participants were instructed to row as hard and
as fast as they could. The outcome of the test was peak power output, defined as the highest power
output produced during the six “all-out” strokes (expressed in Watts), as shown on the performance
monitor of the Concept II ergometer. This test has high test–retest reliability, and was previously
validated by a group of physically active individuals by Metikos et al. [23], where it is explained in
greater detail.
2.4. Side Effects
Immediately following the completion of the exercise testing session and the morning after the
testing, participants completed an eight-item survey regarding their subjective perceptions of side
effects that may have occurred (“yes/no” response scale). This scale has been used in previous research
that examined the effects of caffeine ingestion on exercise performance [14].
2.5. Assessment of Blinding
We tested the effectiveness of the blinding pre- and post-exercise by asking participants to identify
the supplement they had ingested. The question for identification went as follows: “Which supplement
do you think you have ingested?” This question had three possible answers: (a) caffeine; (b) placebo;
(c) do not know [24].
2.6. Statistical Analysis
A Shapiro–Wilk test was used to assess the normality of distribution. Upon confirming the
normality of distribution, a series of one-way repeated measures ANOVAs was used to analyze
the differences between conditions (i.e., placebo and caffeine) for all the performance outcomes.
The statistical significance threshold was set at p < 0.05. Effect sizes (d) were calculated using a Cohen’s
formula, in which the mean difference between the two measurements is divided by the pooled SD.
Trivial, small, moderate, and large effect sizes were considered as <0.20, 0.20–0.49, 0.50–0.79, and ≥0.80,
respectively [25]. Percent changes were also calculated. The effectiveness of the blinding was examined
using Bang’s blinding index (BBI) where -1.0 indicates opposite guessing and 1 complete lack of
blinding. A McNemar test was used to explore the differences in the incidence of side effects between
the placebo and caffeine conditions. All analyses were performed using Statistica software (StatSoft;
Tulsa, OK, USA).
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Compared to placebo, caffeine ingestion improved performance both in the SJ (p = 0.039; d = 0.18;
+2.9%) and in the CMJ (p = 0.011; d = 0.18; +3.3%).
3.1.2. Lower-Body Isokinetic Strength and Power
Caffeine ingestion had a significant effect on peak torque at the angular velocity of 60◦·s−1, both in
the knee extensor (p = 0.002; d = 0.37; +6.9%) and in the knee flexor muscles (p = 0.034; d = 0.24; +4.6%).
At the angular velocity of 180◦·s−1, caffeine ingestion elicited a significant effect on peak torque in the
knee extensor (p = 0.031; d = 0.21; +3.5%), but not in the knee flexor muscles (p = 0.168; d = 0.17; +3.0).
For average power, at the angular velocity of 60◦·s−1, caffeine had a significant effect in increasing
power both in the knee extensor (p = 0.001; d = 0.31; +6.3%) and the knee flexor muscles (p = 0.015;
d = 0.32; +6.7%). At the angular velocity of 180◦·s−1, a significant effect of caffeine on power produced
by the knee extensor muscles was evident (p = 0.025; d = 0.25; +4.5%); however, the same was not the
case for the knee flexor muscles (p = 0.115; d = 0.17; +3.5) (Table 2).
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3.1.3. Bench Press
For barbell velocity in the bench press exercise, a significant effect of caffeine was observed at 50%
of 1RM (p = 0.021; d = 0.33; +3.5%), at 75% of 1RM (p < 0.001; d = 0.42; +5.4%), as well as at 90% of 1RM
(p < 0.001; d = 0.59; +12.0%).
3.1.4. Rowing Ergometer Test
No significant effect of caffeine was observed for peak power output on the rowing ergometer test
(p = 0.647; d = 0.08; +1.4).
3.2. Side Effects
The incidence of side effects is presented in Table 3. Based on the results of the McNemar test,
none of the comparisons between the caffeine and placebo conditions were significant (p > 0.05 for all
comparisons).
Table 3. Incidence of side effects reported immediately after and the morning after ingestion of a
caffeinated gel or a placebo.









Muscle soreness 0 0 0 0
Increased urine
production 0 6 0 6
Tachycardia and heart
palpitations 6 12 0 0
Increased anxiety 0 18 0 0
Headache 0 0 0 0
Abdominal/gut
discomfort 0 6 0 0
Insomnia n/a n/a 0 6
Increased
vigor/activeness 12 41 0 0
Perception of improved
performance 6 35 n/a n/a
Data are frequencies for 17 participants, expressed as the percentage of positive cases; none of the comparisons were
significant based on the McNemar test.
3.3. Assessment of Blinding
The results from the assessment of blinding pre- and post-exercise are presented in Table 4. When
assessed pre-exercise, the BBI for the placebo and caffeine treatments amounted to 0.29 (95% confidence
interval (CI): −0.06, 0.65), and 0.24 (95% CI: −0.07, 0.54), respectively. When assessed post-exercise,
the BBI for the placebo and caffeine conditions amounted to 0.70 (95% CI: 0.49, 0.93) and 0.35 (95% CI:
0.00, 0.72), respectively. Those that correctly identified caffeine generally reported a “better overall
feeling” and “more energy”, as well as increased perspiration.
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(Mean and 95% CI)
Placebo 6 2 9 0.29 (−0.06, 0.65)
Caffeine 3 8 6 0.24 (−0.07, 0.54)
Post-Exercise
Placebo 12 0 5 0.70 (0.49, 0.93)
Caffeine 3 9 5 0.35 (−0.00, 0.72)
CI: confidence interval.
4. Discussion
The present study aimed to explore the effects of caffeinated gel ingestion on exercise performance
of resistance-trained men in tests characterized by a very short duration and maximal exertion.
The results indicate that caffeine ingestion in the form of a caffeinated gel had performance-enhancing
effects on: (1) vertical jump performance in the SJ and CMJ tests; (2) lower-body isokinetic strength and
power; and (3) power of the upper-body musculature. Whole-body power, as assessed on a rowing
ergometer test, did not improve following caffeine ingestion. The blinding of the participants was
generally effective, and the side effects were minimal.
For the vertical jump performance, our results confirm the recent meta-analytical results by
Grgic et al. [11] that caffeine ingestion before exercise may acutely enhance jump height. Indeed, even
the effect size in the SJ and CMJ tests that we observed (d of 0.18 for both tests) were very similar to
the pooled effect size of 0.17 reported in the meta-analysis. Previous studies that reported ergogenic
effects of caffeine on jump performance generally used larger doses of caffeine (e.g., 6 mg·kg−1), as well
as a protocol that included a waiting time of 60 min from ingestion to the initiation of the exercise
testing [11]. Our results highlight that ingesting even a smaller dose of caffeine (300 mg; ~3.6 mg·kg−1)
in the form of a caffeinated gel administered 10 minutes before exercise, may also be ergogenic. These
findings mirror those of Bloms et al. [26] who also used both jump techniques and reported that
ingesting 5 mg·kg−1 of caffeine improved performance both in the SJ and CMJ tests.
A recent meta-analysis [12] reported that caffeine ingestion acutely increases strength, as assessed
by an isokinetic dynamometer. Our results provide further support for these findings, given that we
observed increases in peak torque following the ingestion of caffeine with d across angular velocities
and muscle groups (i.e., knee extensors and knee flexors) ranging from 0.21 to 0.37, and corresponding
percent changes ranging from +3.5% to +6.9%. While the ergogenic effects of caffeine were noted at
both angular velocities for the knee extensor muscles, a significant effect of caffeine on the knee flexor
muscles was observed only at the velocity of 60◦·s−1. This divergent effect between muscle groups
might be due to the lower level of muscle activation during maximal contractions at baseline in the
knee extensor muscles [27]. This naturally occurring lower level of activation may provide a greater
“room for improvement” in contraction force following the ingestion of caffeine in this muscle group.
Smaller muscle groups may have a higher muscle activation level at baseline and, therefore, are less
affected by caffeine ingestion [27]. Caffeine ingestion also improved average power, with a magnitude
of improvement similar to that observed for muscle strength.
The ergogenic effect of caffeine on barbell velocity in the bench press exercise was evident across
all three employed loads with the effects ranging from small (d = 0.33; +3.5%) to moderate (d = 0.59;
+12.0%). These results provide further support to findings of the previous studies that explored the
effects of caffeine on barbell velocity. For example, Mora-Rodriguez et al. [15] reported that caffeine
ingestion in a dosage of 3 mg·kg−1, ingested 60 min before exercise, enhanced barbell velocity in the
bench press when using external loads amounting to 75% 1RM.
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Pallarés et al. [17] suggested that the effects of caffeine on power might be external load- and
caffeine dose-dependent. In that study, caffeine ingested in low and moderate doses (3 and 6 mg·kg−1)
enhanced barbell velocity in the bench press at loads corresponding to 25% and 50% of 1RM. However,
when using loads of 75% of 1RM, only the doses of 6 and 9 mg·kg−1 were effective. At the highest
load of 90% of 1RM, only 9 mg·kg−1 was effective. The findings presented herein are not in full
agreement with the work by Pallarés et al. [17] given that, in the present study, an absolute dose of
300 mg (~3.6 mg·kg−1) was ergogenic for barbell velocity across all three loading schemes (including
90% of 1RM).
In contrast to the work by Pallarés et al. [17], the magnitude of effect in the present study
increased with an increase in the load that the participants lifted (Table 2). The most pronounced effect
across loading schemes, amounting to a +12.0% increase in barbell velocity, was evident for the load
corresponding to 90% of 1RM. Based on these results, it seems that the effects of caffeine are more
noticeable, at least for this exercise, when requirements for the contraction force are the highest. Given
the direct importance of high barbell velocity in the development of power [28], our results suggest
that individuals might consider supplementing with caffeine before exercise to achieve acute increases
in barbell velocity and, subsequently, stronger stimuli for the development of muscle power.
We did not observe any significant differences between placebo and caffeine conditions in the
whole-body power, as assessed by the peak power output produced during the “all-out” rowing
ergometer test. Based on these results, it does not seem that caffeine ingestion is ergogenic for
whole-body peak power output; however, this could be due to large inter-individual variation in
response to caffeine ingestion [29], and therefore needs to be explored in future studies with larger
sample sizes.
4.1. Mechanisms of Caffeine
Caffeine produces its ergogenic effects by binding to adenosine receptors [30]. After binding to
these receptors, caffeine blunts the fatiguing effects of adenosine and subsequently reduces perceived
exertion. Indeed, there is substantial evidence that caffeine’s effect of reducing perceived exertion is one
of the primary mechanisms for its ergogenic effect on aerobic endurance [31]. However, the ergogenic
effect of caffeine on high-intensity, short-duration tests (such as those performed in the current study)
may be related to the release of calcium from the sarcoplasmic reticulum, and the subsequent inhibition
of its reuptake [30]. These actions may be associated with neuromuscular function changes, as well as
increased contractile force in skeletal muscles [32]. For the readers interested, these mechanisms of
caffeine are discussed in greater detail elsewhere [30].
4.2. Limitations
The limitations of this study include the following: (1) the sample consisted of trained young men,
which limited the generalizability of these results to those who are untrained, of older age, or to women;
(2) we did not measure plasma levels of caffeine and, therefore, the amount of caffeine absorbed is not
entirely clear; (3) an absolute dose of caffeine was used, whereas a relative dose might have been more
appropriate (of note here, an absolute dose was given due to the fixed amount of caffeine per 75-mg
gel sachet).
One additional limitation [33] might be that 12 out of 17 participants correctly identified the
placebo condition post-exercise; as determined by the 95% CI of the BBI, this identification was not
solely due to chance. It is likely that correct identification of the placebo condition in the post-exercise
assessment was due to the lack of perceived improvements in performance (only one participant
answered “yes” to the perception of improved performance item following the ingestion of placebo).
This may especially be evident given the small number of individuals that correctly identified placebos
in the pre-exercise evaluation. From that aspect, it is possible that pre-exercise responses are of
greater importance than the answers obtained post-exercise. Additionally, based on the findings by
Tallis et al. [34], an argument can be made that the correct identification of the placebo did not confound
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the results. In that study, the participants experienced similar improvements in isokinetic peak torque
both when they were told that they were given caffeine and received a dose of caffeine, and when they
were told that they ingested the placebo even though the capsule contained caffeine. While the placebo
was identified beyond random chance in the post-exercise assessment, correct identification of caffeine
in the post-exercise assessment can be attributed solely to chance, as there was a 95% CI overlap with
the null value. These results further support an actual ergogenic effect of caffeine.
4.3. Practical Applications
Ingesting a caffeine dose of 300 mg in the form of caffeine gel 10 min before exercise may elicit an
acute ergogenic effect on vertical jump height, muscle strength, and power in an isokinetic strength
assessment, as well as barbell velocity in the bench press exercise. Due to these ergogenic effects, trained
individuals may consider supplementing with caffeinated gels before exercise for acute increases
in performance.
5. Conclusions
The ingestion of caffeinated gels with an absolute dose of caffeine of 300 mg may improve aspects
of short-term, maximal-exertion exercise performance in resistance-trained men. These improvements
are evident in vertical jump performance, strength, and power. These results highlight that individuals
seeking acute performance enhancement in jumping, strength, and power may consider ingesting
caffeinated gels before exercise.
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Abstract: Background: Previously studies confirm ergogenic effects of caffeine (CAF); however there
is no available scientific data regarding the influence of acute CAF intake on power output in athletes
habitually consuming CAF. The main goal of this study was to assess the acute effect of 3, 6, 9 mg/kg/b.m.
doses of CAF intake on power output and bench press bar velocity in athletes habitually consuming
CAF. Methods: The study included 15 healthy strength-trained male athletes (age = 26.8 ± 6.2 years,
body mass = 82.6 ± 9.7 kg; BMI = 24.8 ± 2.7; bench press 1RM = 122.3 ± 24.5 kg). All participants
were habitual caffeine consumers (5.2 ± 1.2 mg/kg/b.m.; 426 ± 102 mg of caffeine per day). This study
had a randomized, crossover, double-blind study design where each participant performed four
different experimental sessions, with one week interval between each trial. In every experimental
session participants performed bench press, three sets of five repetitions at 50% 1RM. The power
output and bar velocity assessments under four different conditions: a placebo (PLAC), and three
doses of caffeine ingestion: 3 mg/kg/b.m. (CAF-3), 6 mg/kg/b.m. (CAF-6) and 9 mg/kg/b.m. (CAF-9).
Results: The statistical significance was set at p < 0.05. The repeated measures ANOVA between
PLAC and CAF-3; CAF-6; CAF-9 revealed no statistically significant differences in power output and
velocity of the bar during the bench press exercise. A large effect size (ES) in mean power-output
was found between PLAC and CAF-9 in Sets 1 and 2. A large ES in peak power-output was found
between PLAC and CAF-6 in Set 2, and between PLAC and CAF-9 in Sets 1 and 2. A large ES in peak
velocity was found between PLAC and CAF-9 in Sets 1–3. Conclusion: The results of the present
study indicate that acute doses of CAF before exercise does not have a significant effect on power
output and bar velocity in a group of habitual caffeine users.
Keywords: supplement; resistance exercise; speed; repetition
1. Introduction
Resistance training is a significant component of conditioning programs in competitive sports. The
ability to generate high values of power output is one of the most significant factors determining success
in numerous sport disciplines [1]. Power output can be described by the relationship between the force
generated by the muscles and movement velocity [2]. Particular attention in studies concerning the
development of power and high speed of movement has been directed at exercise volume with specific
intensity of effort [3,4]. In addition to training, nutrition and supplementation also have a significant
effect on adaptation and post-exercise responses [5–9].
Caffeine (CAF) is among the most often used and widely studied supplements in competitive
sports. Mechanisms responsible for ergogenic effects of CAF are linked to the impact on various
tissues, organs and systems of the human body. In the central nervous system (CNS), CAF acts
through interactions with adenosine receptors that influence the release of noradrenaline, dopamine,
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acetylcholine and serotonin [10–13] and consequently, increase muscle tension [14]. Increased muscle
activation can lead to a greater energy demand during exercise, thus leading to a faster depletion of
energy substrates in muscle cells [15].
Numerous studies have examined the acute performance-enhancing effects of CAF intake on
human physical fitness and exercise performance [16–24]. The most frequently consumed dose of
caffeine ranges from 3 to 9 mg/kg body mass (b.m.), ingested in the form of capsules 30 to 90 minutes
before exercise. However, the optimal dose may differ based on exercise choice, volume, intensity,
and the type of muscle contraction [23,25–28]. Additionally, participants characteristics, such as gender,
age and training experience can affect both, power output and the ergogenic effects of CAF intake.
Although ergogenic effect of CAF is well-established in many aspects, much controversy remains about
the effectiveness of different doses of caffeine on power output of the upper limbs.
Previous studies showed positive acute effects of 3 mg/kg b.m. of CAF on resistance exercise
performance and power output, suggesting that this dose has significant ergogenic properties [25,29,30].
However a dose of 3 mg/kg b.m. is sufficient to increase movement velocity at loads of 25–50%1RM,
whereas a higher caffeine dose (9 mg/kg b.m.) is necessary when submaximal loads (90%1RM), are used
despite the appearance of adverse side effects [25]. Grgic and Mikulic [24] showed an increase in power
output during a medicine ball throw following CAF intake (6 mg/kg b.m.). Pallarés et al. [25] also
showed significantly increased movement velocity and power output at loads of 25–50%1RM after
different doses of CAF ingestion (3, 6, 9 mg/kg b.m.), however, at the load of 75% 1RM, a CAF dose of
3 mg/kg b.m. did not improve power output in the bench press exercise. On the contrary, the study of
Wilk et al. [20] did not show changes in concentric power output and bar velocity during the bench
press to concentric muscle failure, following the intake of 5 mg/kg/b.m. of CAF compared to a placebo.
Furthermore, one should emphasize that most of the previous studies on CAF intake and the
level of power output concerned participants with low daily CAF intake. In competitive athletes
the use of CAF before resistance exercise is particularly common. As a result, research suggesting
75–90% of athletes consume CAF before or during training sessions and competitive events [31,32].
According to Svenningsson et al. [33], Fredholm et al. [34] habitual CAF intake modifies physiological
responses to acute ingestion by the up-regulation of adenosine receptors. Furthermore, constant
exposure to CAF could impact metabolic pathways by inducing cytochrome P450 1A2 and increased
induction speed of that enzyme which may alter the rate of CAF metabolism. However based
on the available evidence, it does not seem that habitual caffeine ingestion reduces the ergogenic
benefits of acute CAF supplementation [35–37]. Evans et al. [38] suggested that non-habitual CAF
(<40 mg/day) users experience a greater magnitude of the ergogenic effect compared with CAF habitual
users (>130 mg/day). However, Gonçalves et al. [36] indicate that habitual CAF intake (low = 58;
moderate = 143; high = 351 mg/day) did not influence exercise performance, suggesting that CAF
habituation has no detrimental impact on CAF ergogenesis. Likewise Dodd et al. [35] also did not show
any differences in time to exhaustion after acute doses of CAF (placebo; 3 mg/kg/b.m.; 5 mg/kg/b.m.),
between a non-habitual user group (<25 mg/day) and habitual CAF consumers (>300 mg/day). The
basic source of variability of results among scientists investigating habitual caffeine use, is the division
of subjects into low, moderate, and high habitual caffeine consumption groups. Some studies have
defined high caffeine use as >100 mg/day [39], while others have defined it as >300 mg/day [35] or even
>750 mg/day [40]. Inconsistency in these caffeine intake reference values makes the interpretation and
cross-comparison of results difficult. Furthermore, daily doses of CAF intake are reported in values of
mg/day [36,38,41], which lacks precision and may be very misleading when athletes with different
body mass are considered. This lack of consistency in caffeine use levels has been noted before, and yet,
to our knowledge, no one has proposed reference values for caffeine use.
Since there is no available scientific data regarding the influence of acute CAF intake on power
output in athletes habitually consuming CAF, with a precisely determined intake of CAF in relation to
body mass (mg/day/kg/b.m.) the main goal of this study was to assess the acute effect of various doses
of CAF on power output and bar velocity in athletes habitually consuming CAF (4–6 mg/day/kg/b.m.).
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2. Materials and Methods
2.1. Study Participants
Fifteen (n = 15) healthy strength-trained male basketball and handball athletes participated in
the study after completing an ethical consent form (age = 26.8 ± 6.2 years, body mass = 82.6 ± 9.7 kg,
BMI = 24.8 ± 2.7, bench press 1RM = 122.3 ± 24.5 kg; data presented as mean ± standard deviation
[SD]) with a minimum 3 years of strength training experience (4.2 ± 1.23 years). All participants were
habitual caffeine consumers (5.2 ± 1.2 mg/kg/b.m., 426 ± 102 mg of caffeine per day). The inclusion
criteria were as follows: (a) free from neuromuscular and musculoskeletal disorders, (b) the participants
were able to perform the bench press exercise with a load of at least 120% of their body mass [42],
(c) habitual caffeine intake in the range of 4–6 mg/kg/b.m., ~300–500 mg of caffeine per day. The
study protocol was approved by the Bioethics Committee for Scientific Research, at the Academy of
Physical Education in Katowice, Poland (10/2018) according to the ethical standards of the Declaration
of Helsinki, 1983.
2.2. Habitual Caffeine Intake Measurement
Habitual caffeine intake was assessed by a specific Food Frequency Questionnaire (FFQ) adapted
from a previously questionnaires [43] under the supervision of a qualified nutritionist. The questionnaire
was employed to assess the habitual consumption of dietary products rich in caffeine. Portions,
in household measures, were used to assess the amount of food consumed according to the following
frequency of consumption: a) more than three times a day, b) two to three times a day, c) once a day,
d) five to six times a week, e) two to four times per week, f) once a week, g) three times per month,
h) rarely or never. The list was composed of dietary products with high caffeine content including
different types of coffees, teas, energy drinks, cocoa’s products, popular beverages, medications and
caffeine supplements. Previously published information and nutritional tables were used for database
construction [17,44,45]. Based on the answers in FFQ, a qualified nutritionist estimated the habitual
caffeine intake.
2.3. Experimental Designed
This study used a randomized, crossover, double-blind design where each participant performed
a familiarization session with a 1RM test on one day, and four different experimental sessions with
one week interval between each trial. The randomization was conducted by a member of the research
team that was not directly involved in the data collection. Participants underwent the power output
and bar velocity assessments under four different conditions: a placebo (PLAC), and three doses
of caffeine ingestion: 3 mg/kg/b.m. (CAF-3), 6 mg/kg/b.m. (CAF-6) and 9 mg/kg/b.m. (CAF-9).
CAF or a PLAC were administered orally 60 minutes before each exercise protocol to allow peak
blood caffeine concentration and at least 2 hours after the last meal to maintain the same time of
absorption. CAF was provided in the form of standard capsules containing 300 mg of CAF, as well
as those specifically prepared for the research, containing 100, 50 and 5 mg doses of CAF. The PLAC
was provided in identical capsules as CAF (all-purpose flour). All CAF and PLAC capsules were
manufactured by Olimp Laboratories. Subjects refrained from physical activity other than that required
by the experimental trials and withdrew from alcohol, tobacco and other drugs and supplements
during the study. The participants were instructed to maintain their usual hydration, dietary habits
including habitual caffeine intake during the entire experiment and keep track of their calorie intake
using the “Myfitness pal” software [46] every 24 hours before the testing procedure. There were no
differences between individually calorie intake between particular sessions. The subjects were also
asked to refrain from heavy exercise for 48 hours and to refrain from caffeine intake 12 hours before
each trial. All testing was performed in the Strength and Power Laboratory at the Jerzy Kukuczka
Academy of Physical Education in Katowice.
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2.4. Familiarization Session and One Repetition Maximum Test
A familiarization session preceded the one repetition maximum testing. The participants arrived
at the laboratory at the same time of day as the upcoming experimental sessions (in the morning
between 9:00 and 10:00 am) and cycled on an ergometer for 5 minutes at an intensity that resulted in
a heart rate of around 130 bpm, followed by a general upper body warm-up. Next, the participants
performed 15, 10, and 5 repetitions of the bench press exercise using 20%, 40%, and 60% of their
estimated 1RM with a 2/0/X/0 tempo of movement [42]. The sequence of digits describing the tempo of
movement (2/0/X/0) represents a 2 second eccentric phase, in which 0 represents a pause during the
transition phase, X represents maximum possible tempo of movement during the concentric phase,
and the last digit represents no pause at the end of movement. The participants then executed single
repetitions with a 5 minutes rest interval between successful trials. The load for each subsequent
attempt was increased by 2.5 kg, and the process was repeated until failure. Hand placement on the
barbell was individually selected with a grip width on the barbell of 150% individual bi-acromial
distance (BAD). BAD was determined by palpating and marking the acromion with a marker, and then
measuring the distance between these points with a standard anthropometric tape. The positioning of
the hands was recorded to ensure consistent hand placement during all testing sessions. No bench
press suits, weightlifting belts, or other supportive garments were permitted. Three spotters were
present during all attempts to ensure safety and technical proficiency.
2.5. Experimental Protocol
Four testing sessions were used for the experimental trials. All testing took place between 9.00
and 11.00 a.m. to avoid circadian variation. The general warm-up for the experimental sessions
was identical to the one used for the familiarization session. After the warm-up, participants started
the main examinations and performed three set of the bench press with 5 repetitions in each set at
50%1RM. The concentric phase of movement was performed at maximal possible velocity, while the
eccentric phase with a 2 second duration (2/0/X/0). All repetitions were performed without bouncing
the barbell off the chest, without intentionally pausing at the transition between the eccentric and
concentric phases, and without raising the lower back off the bench. The time between each session
of the experiment was 7 days. During the experimental trials the participants were encouraged to
perform at maximal engagement according to the recommendations by Brown and Weir [47]. A linear
position transducer system “Tendo Power Analyzer” (Tendo Sport Machines, Trencin, Slovakia) was
used for the evaluation of bar velocity. The Tendo Power Analyzer is a reliable system for measuring
movement velocity and power output [48,49]. The system consists of a velocity sensor connected to
the load by a kevlar cable which, through an interface, instantly transmits the vertical velocity of the
bar to a specific software installed in the computer (Tendo Power Analyzer Software 5.0). The system
measures upward vertical average and peak velocity of the movement. Using a set external load,
the system calculates average peak power and peak velocity in the concentric phase of the movement.
The measurement was made independently for each repetition and automatically converted into the
values of peak power output (PP), mean power output (MP), peak velocity (PV), mean velocity (MV).
All participants completed the described testing protocol.
2.6. Side Effects
Immediately and after 24 hours following each testing procedures participants answered a side
effects questionnaire, included nine items on a yes/no scale of caffeine ingestion [25,50–52].
Statistical Analysis
The Shapiro–Wilk, Levene and Mauchly´s tests were used in order to verify the normality,
homogeneity and sphericity of the sample data variances. Verification of differences between the PLAC
and CAF-3, CAF-6, CAF-9 was performed using ANOVA with repeated measures. Effect sizes (Cohen’s
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d) were reported where appropriate. Parametric effect sizes (ES), were defined as large for d > 0.8,
as moderate between 0.8 and 0.5, and as small for <0.5 [52,53], and was calculated at 95% confidence
intervals. The statistical significance was set at p < 0.05. All statistical analyses were performed using
Statistica 9.1 and Microsoft Office, and were presented as means with standard deviations.
3. Results
The repeated measures ANOVA between PLAC and CAF-3; CAF-6; CAF-9 revealed no statistically
significant differences in MP (Table 1), PP (Table 2), MV (Table 3) as well PV (Table 4). No significant
differences in PP, MP, PV, MV between PLAC and CAF-3; CAF-6; CAF-9 were observed for Sets 1–3.
However, a large effect size (ES) in MP was found between PLAC and CAF-9 in Set 1 and 2 (Table 1).
Similarly, the large ES in PP was found between PLAC and CAF-6 in Set 2, and between PLAC and
CAF-9 in Set 1 and 2 (Table 2). Additionally, the large ES in PV was found between PLAC and CAF-9
in Sets 1–3 (Table 4).
Table 1. Results of mean power output in three successive sets of the bench press exercise in the group
















Set 1 445 ± 98(403; 508)
453 ± 96
(402; 504) 0.99 0.51
462 ± 92
(413; 511) 0.99 0.55
464 ± 98
(411; 516) 0.99 0.93 0.04
Set 2 456 ± 92(407; 505)
465 ± 97
(413; 516) 0.99 0.48
474 ± 98
(422; 526) 0.94 0.47
457 ± 77
(416; 498) 0.99 0.82 0.13
Set 3 463 ± 93(413; 513)
456 ± 93
(407; 506) 0.99 0.42
469 ± 99
(416; 522) 0.99 0.36
473 ± 102
(418; 528) 0.99 0.58 0.08
Notes: mean ± standard deviation [SD]; CI: confidence interval.
Table 2. Results of peak power output in three successive sets of the bench press exercise in the group
















Set 1 831 ± 171(740; 922)
874 ± 202
(767; 982) 0.90 0.59
843 ± 167
(754; 932) 0.99 0.61
848 ± 169
(752; 945) 0.99 0.8 0.16
Set 2 819 ± 172(727; 911)
874 ± 198
(768; 979) 0.81 0.41
879 ± 175
(785; 973) 0.76 0.93
821 ± 136
(752; 899) 0.99 0.81 0.54
Set 3 858 ± 181(728; 921)
846 ± 176
(752; 941) 0.98 0.46
871 ± 173
(779; 963) 0.88 0.62
869 ± 172
(773; 968) 0.99 0.72 0.22
Notes: mean ± standard deviation [SD]; CI: confidence interval.
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Table 3. Results of mean velocity in three successive sets of the bench press exercise in the group that
















Set 1 0.94 ± 0.08(0.90; 0.99)
0.90 ± 0.07
(0.86; 0.94) 0.35 0.53
0.93 ± 0.06
(0.89; 0.96) 0.90 0.51
0.91 ± 0.05
(0.88; 0.94) 0.62 0.73 1.01
Set 2 0.94 ± 0.08(0.90; 0.99)
0.93 ± 0.09
(0.88; 0.98) 0.98 0.50
0.95 ± 0.07
(0.91; 0.99) 0.99 0.51
0.90 ± 0.06
(0.87; 0.94) 0.53 0.77 0.96
Set 3 0.95 ± 0.08(0.91; 1.00)
0.92 ± 0.09
(0.87; 0.97) 0.69 0.44
0.94 ± 0.08
(0.90; 0.99) 0.99 0.52
0.93 ± 0.05
(0.90; 0.96) 0.88 0.61 0.47
Notes: mean ± standard deviation [SD]; CI: confidence interval.
Table 4. Results of peak velocity in three successive sets of the bench press exercise in the group that
















Set 1 1.42 ± 0.16(1.33; 1.51)
1.42 ± 0.16
(1.33; 1.50) 0.99 0.41
1.38 ± 0.12
(1.31; 1.44) 0.81 0.79
1.38 ± 0.11
(1.32; 1.45) 0.89 0.81 0.37
Set 2 1.40 ± 0.16(1.31; 1.49)
1.43 ± 0.16
(1.34; 1.52) 0.96 0.64
1.44 ± 0.16
(1.35; 1.52) 0.93 0.71
1.36 ± 0.14
(1.28; 1.44) 0.88 0.92 0.68
Set 3 1.42 ± 0.16(1.34; 1.51)
1.43 ± 0.20
(1.32; 1.54) 0.99 0.51
1.43 ± 0.14
(1.35; 1.51) 0.99 0.55
1.41 ± 0.13
(1.34; 1.48) 0.99 0.82 0.05
Notes: mean ± standard deviation [SD]; CI: confidence interval.
Caffeine Side Effects
Table 5 details the nine different side effects assessed immediately and 24 hours later. Immediately
after the PLAC trial, subjects reported a very low frequency of side effects (0%–13%; QUEST + 0 hours).
The CAF-3 treatments produced very similar side effects (0%–20%; QUEST+ 0 hours), compared with the
PLAC trial. The CAF-6 treatments produced greater value of side effects (0%–47%; QUEST + 0 hours).
The greatest value of side effect was recorded for perception of performance and increased vigor
(40%–47%; QUEST + 0 hours). Finally, the CAF-9 trial produced a drastic increase in the reported
frequency of side effects (0%–87%; QUEST + 0 hours) (Table 5).
The following morning of each experimental trial (QUEST + 24 hours), very few participants
(0%–7%) reported that PLAC treatment produced residual side effects. The CAF-3 trial produced
very similar side effects to PLAC (0%–13%; QUEST + 24 hours). The CAF-6 trial showed greater
frequency of side effects, with increased urine output and headaches in comparison with the PLAC
and CAF-3 conditions, although with a frequency lower than 33% of the subjects. Finally, CAF-9
increased the frequency of all adverse side effects, with a frequency of appearance from 0 to 73%. In the
group ingesting the highest dose of CAF, 67%–73% of participants reported tachycardia, anxiety or
nervousness, gastrointestinal problems, and 53% had increased urine output (Table 5).
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Table 5. Side effects reported by participants immediately after the testing protocol (QUEST + 0 hours)
and 24 hours later (QUEST + 24 hours).
Side Effects
Doses of CAF Intake During Testing Protocol
PLAC CAF 3 mg/b.m. CAF 6 mg/b.m. CAF 9 mg/b.m.
+0 h +24 h +0 h +24 h +0 h +24 h +0 h +24 h
Muscle soreness 0 0 0 0 0 0 0 0
Increased urine
output 1 (7%) 1 (7%) 3 (20%) 2 (13%) 6 (40%) 5 (33%) 10 (67%) 8 (53%)
Tachycardia and
heart palpitations 2 (13%) 1 (7%) 3 (20%) 2 (13%) 6 (40%) 3 (20%) 12 (80%) 11 (73%)
Anxiety or
nervousness 1 (7%) 1 (7%) 2 (13%) 7 (7%) 3 (20%) 2 (13%) 10 (67%) 3 (20%)
Headache 2 (13%) 1 (7%) 3 (20%) 1 (7%) 2 (13%) 4 (26%) 3 (20%) 6 (40%)
Gastrointestinal




2 (13%) - 3 (20%) - 6 (40%) - 13 (87%) -
Increased
vigor/activeness 2 (13%) 1 (7%) 2 (13%) 1 (7%) 7 (47%) 2 (13%) 13 (87%) 6 (40%)
Insomnia - 0 - 0 - 2 (13%) - 4 (26%)
Data are presented as number of person (n) as well the percentage of prevalence (%).
4. Discussion
The main finding of the study was that acute CAF intake has no significant effect on PP, MP, PV,
MV in habitual users of caffeine. Significant changes in PP, MP, PV, MV were not registered after CAF
intake with doses of 3, 6 or 9 mg/kg/b.m. compared to PLAC. Despite the fact that the results of our
study are inconsistent with previous findings [24–26] it should be emphasized that this is the first
scientific study which considers the acute effect of different doses of CAF intake on power output and
bar velocity changes during the bench press exercise in habitual CAF users.
Previous research showed that acute CAF intake increase power output [24,25]. However, most of
the studies concerned participants with low daily CAF intake. Actually, there are only a few studies
analyzing acute effects of CAF intake in habitual users; however, the results are not conclusive and
mostly refer to aerobic endurance exercises [35,36,41]. To the best of our knowledge, only one study
analyzed power output changes of the upper limbs after different doses of acute CAF intake in group
of habitual users [26]. The study of Sabol et al. [26] showed an increase in medicine ball throwing
distance in subjects ingesting 6 mg/kg/b.m. of CAF compared to a PLAC. However the differences
were non-significant between the intake of PLAC and 2 mg/kg/b.m. as well between PLAC and
4 mg/kg/b.m. It is worth noting that the study of Sabol et al. [26] did not show significant differences in
responses to acute CAF ingestion between the groups of low and moderate-to-high habitual CAF users.
On the contrary, the result of our study did not show any significant changes in power output and bar
velocity after the intake of CAF with a dose of 3, 6 or 9 mg compared to the PLAC. However, it must
be indicated that in the study of Sabol et al. [26] only six participants were classified as those with
moderate-to-high habitual CAF intake. Furthermore, this group had a very wide range of daily CAF
intake (CAF = 358 ± 210 mg/day; range = 135 to 642 mg/day), which limits the reliability of results.
Our study is the first of its kind with a homogeneous research group (n = 15) with study
participants consuming CAF in the range of 4 to 6 mg/kg/b.m. (~300–500 mg/day). Differences related
to the daily CAF intakes limit the possibility to compare our results to those of Sabol et al. [26].
Other previous studies with habitual CAF users, also used different criteria for daily CAF intake.
Gonçalves et al. [36] applied the following reference values for daily CAF intake: low = 58 ± 29 mg/day;
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moderate = 143± 25 mg/day; high = 351± 139 mg/day. On the other hand Sabol et al. [26] considered
high consumers as subjects ingesting >100 mg/day of CAF, however in the study of Dodd et al. [35]
habitual CAF users were defined as subjects that consumed > 300 mg/day. Differences in daily CAF
consumption as well lack of reference values to body mass limits the possibility of comparing previous
research results. Furthermore, our study is the first in which the daily intake of CAF was determined
in relation to body mass.
The physiological effects of acute CAF intake in habitual caffeine consumers is relatively unstudied.
Previous research has suggested that high habitual caffeine intake may reduce the ergogenic effects of
acute CAF supplementation on exercise performance [54], what was confirmed in our study. However
Pickering and Kiely [54] suggested that reductions after acute CAF intake in habitual users can be
modified by using pre-trial doses, substantially greater than habitual intake. While this idea has been
perpetuated in the scientific literature, the results of our study confirmed this statement. The result
of our study did not show significant changes in PP, MP, PV, MV after acute CAF intake compared
to PLAC, even when greater pre-trial doses (CAF-9) were used compared to habitual daily intake
(4–6 mg/kg/b.m./day).
The results of our study showed that the habitual caffeine intake limits physiological responses
to acute CAF doses, in agreement with Svenningsson et al. [33] and Fredholm et al. [34]. Caffeine
is an adenosine receptor antagonist, and when ingested, it binds to adenosine receptors [55]. In
animal models, studies reported that chronic caffeine intake increases adenosine receptor concentration
and this increase attenuates caffeine’s effects [33]. In humans, given that the ergogenic effects of
caffeine are strongly linked to its effects on adenosine receptors, it has been suggested that habitual
caffeine users may experience smaller enhancement in performance following acute CAF intake as
compared to non-users [41]. However, exercise itself may alter the sensitivity of adenosine receptors
and lower the threshold concentration such that a smaller dose provided during or at the beginning
of exercise may be equally or more effective than similar or larger doses provided 1 hour prior to
exercise [56,57]. Likewise, smaller doses provided during warm-up exercise immediately prior to
performance testing [58], or immediately prior to and during exercise [59] can be ergogenic and may
be as effective as a single larger dose ingested 1 hour prior to exercise [60]. However there is no data
available about changes in sensitivity of adenosine receptors in physically active, habitual CAF users.
Despite the fact that our study did not show significant changes in power output and bar velocity
after acute CAF intake compared to PLAC, it should be noted that there was a large ES in MP, PP, PV
between CAF-9 and PLAC which, indicates an acute ergogenic effect. While such changes in power
output and bar velocity might be considered as small in statistical terms, this difference may be of great
significance in training of elite athletes as well as in scientific research. It is known that plasma levels of
caffeine needed to induce tissue changes are significantly higher than those required to affect adenosine
receptors in the brain and peripheral nervous system [61,62], which may explain the occurrence of
side effects using acute intake of CAF-6 and CAF-9 (Table 5), despite the lack of significant changes in
power output and bar velocity. Therefore it can be concluded that acute intake of CAF in habitual
users is to some extent ergogenic.
The variety of methodological approaches and results obtained make meaningful conclusions
and recommendations for athletes difficult. Furthermore, it is hard to isolate the direct effects of CAF
from systematic effects due to the number of potential mechanisms evoked from its wide distribution
within the body. Although there is some controversy in regard to caffeine dose–response relationship,
it is suggested that caffeine intake increases adrenaline release, evokes greater Ca2+ release from the
sarcoplasmic reticulum, improves the function of the Na+/K+ pump, reduces pain perception and
increases plasma fatty acid concentration [63,64]. The present study has several limitations which
should be addressed. There were no genetic assessments related to CAF intolerance in the tested
athletes. However, according to studies of Cornelis et al. [65] genetic variation in the A2A receptor,
the main target of caffeine action in the CNS, is associated with caffeine consumption. Probability of
having the ADORA2A 1083TT genotype associated with caffeine-induced anxiety [66] decreases as
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the caffeine intake increases in a population, and subjects with that genotype are more likely to limit
their caffeine intake. People who were homozygous for the 1083T allele experienced greater anxiety
after consuming 150 mg of caffeine [66]. Furthermore, before the start of our experiment no study
participant reported any side effects after consumption of caffeine within the previous six months.
5. Conclusions
The results of the present study indicate that acute doses of CAF before exercise does not have
a significant effect on power output and bar velocity of the bar during the bench press exercise in
a group of habitual caffeine users. No significant changes in the above mentioned variables were
observed at each of the three doses of CAF administered (3, 6, 9 mg/kg/b.m.). However the results
of our study refer only to power output and bar velocity of the upper limbs during the bench press
exercise with an external load of 50%1RM. These results therefore may not translate to other forms,
volumes, or intensities of exercise.
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Abstract: Recent literature confirms the ergogenic effect of acute caffeine intake to increase muscle
strength and power in men. However, the information about the effect of caffeine on muscle
performance in women is uncertain and it is unknown whether its ergogenicity is similar during the
menstrual cycle. The goal of this investigation was to assess the effect of acute caffeine intake on mean
and peak velocity of half-squat exercise during three different phases of the menstrual cycle. Thirteen
trained eumenorrheic athletes (age = 31 ± 6 years; body mass = 58.6 ± 7.8 kg) participated in a
double-blind, crossover and randomized experimental trial. In the early follicular (EFP), late follicular
(LFP) and mid luteal phases (MLP), participants either ingested a placebo (cellulose) or 3 mg/kg/bm
of caffeine in an opaque and unidentifiable capsule. In each trial, participants performed a half-squat
exercise at maximal velocity with loads equivalent to 20%, 40% 60% and 80% of one repetition
maximum (1RM). In each load, mean and peak velocity were measured during the concentric phase of
the exercise using a rotatory encoder. In comparison to the placebo, a two-way ANOVA showed that
the ingestion of 3 mg/kg/bm of caffeine increased mean velocity at 60% 1RM in EFP (Δ = 1.4 ± 2.7%,
p = 0.04; ES: 0.2 ± 0.2) and LFP (Δ = 5.0 ± 10.4%, p = 0.04; ES: 0.3 ± 0.4). No other statistical differences
were found for the caffeine-placebo comparison for mean velocity, but caffeine induced an ergogenic
effect of small magnitude in all of the menstrual cycle phases. These results suggest that the acute
intake of 3 mg/kg/bm of caffeine induces a small effect to increase movement velocity during resistance
exercise in eumenorrheic female athletes. The positive effect of caffeine was of similar magnitude in
all the three phases of the menstrual cycle.
Keywords: women; resistance exercise; exercise training; velocity; ergogenic aid; muscle function
1. Introduction
Despite the equivocal findings of previous original investigations [1–4], emerging literature using
meta-analysis suggests that acute caffeine intake is able to increase muscle strength and power [5,6].
This new information has given support to consider caffeine as an effective strategy to increase
performance in resistance exercise with a relatively low prevalence of side effects when taken in the
recommended doses (i.e., 3 to 9 mg per kilogram of body mass: mg/kg/bm [7]). However, most of
this body of research has been carried out only on male samples. For example, in the meta-analyses
by Grgic et al., about caffeine ergogenicity on muscle performance [5,6], only 9.7%–22.2% of the total
sample used for these analyses were women. In fact, a detailed analysis of [5] revealed a significant
increase in upper body muscle performance with caffeine in men while this effect was not present in
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women. Thus, caution is needed when assuming that the ergogenicity of caffeine for resistance exercise
is also present in women [7].
Although some investigations have found an ergogenic effect of caffeine on muscle performance
in women [1,8,9], this has not always been the case [10]. In general terms, it seems that the effectiveness
of caffeine in increasing resistance exercise performance is lower in women than in men [11]. Sabblah
et al. (2015) examined the effects of 5 mg/kg/bm of caffeine on the bench press and squat one repetition
maximum (1RM) in both men and women and found there was a tendency towards an ergogenic
effect of caffeine in the weight lifted in males only. Nevertheless, one common limitation of these
investigations is that none of the studies controlled for the potential effects of the menstrual cycle on
muscle performance [12] nor for the possible interaction of caffeine with the fluctuations of female sex
hormones during the menstrual cycle [13,14].
Although the pharmacokinetics of acute caffeine intake are similar in the follicular, ovulatory and
luteal phases [15,16], ethinylestradiol might induce an inhibition of the activity of CYP1A2, an enzyme
responsible for the metabolism of caffeine [17]. In this sense, the administration of low-doses of
estrogen-containing oral contraceptives reduces the rate of plasma clearance of caffeine and increases
the time necessary to reach peak plasma caffeine concentration [18]. Then, the ergogenicity of caffeine
to increase muscle strength might be higher in the days when the concentration of natural estrogens is
higher (i.e., late follicular phase) because the serum caffeine concentration would remain longer than
in the menstrual cycle phases were serum estrogen concentrations are low (i.e., menses and luteal
phase) [19]. In addition, previous investigations have reported higher caffeine-induced effects on
cardiovascular and subjective variables in the follicular phase than in the luteal phase [13,20]. With this
background of knowledge, to date it is difficult to ascertain whether acute caffeine intake could improve
muscle performance in women during resistance exercise. Furthermore, it is unknown if the potential
ergogenic effect of caffeine on muscle performance is present, and of similar magnitude, during all the
different phases of the menstrual cycle. Therefore, the main aim of this investigation was to determine
the effect of caffeine intake on muscle performance during the early follicular, late follicular and
mid-luteal phases of the menstrual cycle in eumenorrheic females.
2. Materials and Methods
2.1. Participants
Thirteen healthy trained women volunteered to participate in this study (age = 31 ± 6 years; body
mass = 58.6 ± 7.8 kg; body height = 1.66 ± 0.06 m; body fat percentage = 14.5 ± 6.5%). All of the
participants were competitive athletes and fulfilled the following inclusion criteria: a) age between 18
and 40 years; b) active training (including a combination of running, cycling and swimming practice)
of ~2 h/day, at least 5 days/week for the previous two months; c) low caffeine consumption (i.e.,
<100 mg/day); and d) steady duration of their menstrual cycle for the previous 4 months. Participants
were excluded if they reported a) any type of injury within the previous six months; b) a positive
smoking status; c) medication usage within the previous month; d) previous history of cardiopulmonary
diseases; e) oral contraceptive use; f) allergy to caffeine; or g) any type of menstrual disorders such as
dysmenorrhea, amenorrhea, or strong symptoms associated with pre-menstrual syndrome. Participants
were included if they had at least six months of resistance training experience (16 ± 8 months of
experience in this sample), and were familiar with the half-squat exercise. All this information was
obtained from a pre-participation screening that included a medical and training history as well as
a food frequency questionnaire. One week before the experiment protocol, participants were fully
informed of the procedures and the risks associated with the experiment. Participants signed their
informed written consent prior to participating in the investigation. The study was approved by the
Camilo José Cela University Research Ethics Committee. All research protocols were in accordance
with the latest version of the Declaration of Helsinki.
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2.2. Experimental Design
A double-blind, placebo-controlled, crossover and randomized experimental design was used
in this investigation. In each of the following three phases of the menstrual cycle: early follicular
(EFP), late follicular (LFP) and the mid-luteal (MLP), each participant completed 2 experimental trials
making a total of 6 identical experimental trials (Figure 1). In each trial, leg muscle performance was
measured using a half-squat exercise at maximal velocity with loads equivalent to 20%, 40% 60%
and 80% of one repetition maximum (1RM). In each load, mean and peak velocity were measured
during the concentric phase of the exercise. During each of these three menstrual cycle phases,
and in a randomized order, participants ingested an opaque and unidentifiable capsule containing
either caffeine (3 mg/kg/bm; 100% purity, Bulk Powders, UK) or an inert substance as a placebo (e.g.,
cellulose; 100% purity, Guinama, Spain). These two trials within each phase were separated by 48 h
to allow recovery, testing reproducibility, and substance elimination. The first menstrual cycle phase
under investigation was randomly assigned, and a similar number of participants started in EFP
(5 participants), LFP (4 participants) and MLP (4 participants). An alphanumeric code was assigned to
each trial by a person independent of the study. This was done in order to double-blind the participants
and researchers to the trial order and substances. Menstrual cycle phase identification was carefully
conducted according to the methodological considerations raised by Janse de Jonge [21] and with the
help of a period tracker application, tympanic temperature, body mass changes and assessment of the
urinary peak of the luteinizing hormone.
Figure 1. Experimental design of the investigation. ad hoc questionnaire; Menses; Body mass
measurement; Tympanic temperature measurement; Caffeine/placebo trials; measurement
of urinary peak of the luteinizing hormone; Protocol of resistance exercise.
This image displays the protocol followed by an athlete with a 28 day menstrual cycle.
After participants had recorded the regularity and length of their menstrual cycles for 4 months,
caffeine (3 mg/kg/bm) or a placebo was administered in three different phases of the menstrual cycle:
early follicular, late follicular and mid-luteal. Muscle performance were measured 60 min after the
assigned capsule was ingested. They then measured their basal tympanic temperature, body mass,
and increases in luteinizing hormone using urine test strips to determine the onset of each menstrual
cycle phase.
2.3. Standardizations, Familiarization and Pre-Experimental Trial
Once participants had fulfilled all the inclusion/exclusion criteria and signed the informed consent,
they were encouraged to avoid nutritional supplements and sympathetic-adrenergic stimulants for
the duration of the study. Participants were explicitly encouraged to avoid any nutritional source
of caffeine (coffee, tea, soft and energy drinks, chocolate), and were informed about the necessity of
maintaining their habitual training routines and a stable state of physical fitness during the experiment.
Two weeks before the onset of the experiment, participants performed two familiarization sessions with
the testing protocol in order to minimize any learning effects during the experiment. One week before
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the experiment, a 1RM test was performed to standardize the loads in the subsequent experimental
sessions. For this 1RM measurement, participants commenced with sets of increasing loads estimated
to be between 20% and 90% of 1RM, as previously described by Banyard et al. [22]. Then, the first
1RM attempt was performed with a maximum of five 1RM attempts permitted. After any successful
1RM attempt, the barbell load was increased between 0.5 and 2.5 kg until the last successful lift with
a correct technique was obtained, which was categorized as 1RM (96.5 ± 17.1 kg). Two minutes of
recovery were taken between 1RM attempts. On this day, participants were nude-weighed (±50 g,
Radwag, Poland) in order to properly calculate caffeine dosage. The day before each trial, participants
performed light, standardized training and a self-selected precompetitive diet/fluid routine was kept
and recorded for replication. Participants were also required to refrain from intaking alcohol and to
maintain a sleep pattern with at least 8 h of sleep the day before each trial.
2.4. Experimental Protocol
Participants performed six identical experimental trials starting with the menstrual cycle phase
that was randomly assigned. Trials were performed in a laboratory, in the morning (between 09:00
and 11:00) and under similar environmental conditions (22–23 ◦C and 60% humidity; OH1001, OH
Haus, Spain). Participants arrived at the laboratory in a fed state (~3 h after their last meal). In each
experimental trial, the participants were nude-weighed after voiding (Tanita BF 350, Tanita Corporation,
Tokyo, Japan), and then ingested the assigned capsule with caffeine or a placebo—and rested supine
for 45 min. They subsequently performed a standardized 15 min warm-up protocol that included
pedaling on a cycle ergometer and a submaximal attempt on the half squat machine. Then, participants
performed two attempts of the half-squat exercise with loads that represented 20%, 40%, 60% and 80%
of their 1RM—measured in the pre-experimental trial. The testing was performed on a Smith Machine
(Technogym, Barcelona, Spain) in which 2 vertical guides regulated the barbell movement. Participants
were encouraged to produce each repetition at their maximal velocity, and they could repeat any attempt
if they considered that this was not maximal. Two minutes of passive rest were allocated between
the attempts with the same load and three minutes of resting between different loads. The complete
range of motion for the half squat exercise consisted of lowering the body by bending the knees to a
90◦ angle until touching a bench with the buttocks. In this position, participants executed a maximal
velocity knee extension and thus, the concentric phase of the exercise was isolated and measured.
Execution technique and motivation were standardized and monitored by 2 experienced researchers
for reliability of the experimental conditions. In each attempt, barbell displacement in the concentric
phase of the movement was recorded with a rotatory encoder and associated software (Isocontrol,
EV-Pro, Spain) and mean and peak velocity (in m/s) were measured. The attempt with the highest
barbell displacement velocity in each load was used for statistical analysis. With this information, the
estimated 1RM was calculated [23] in all phases to ensure that 1RM remained unchanged throughout
the experiment (EFP: 97.0 ± 23.2 kg; LFP: 98.5 ± 18.1 kg; MLP: 98.1 ± 22.2 kg).
2.5. Determination of Menstrual Cycle Phase
The EFP, LFP and MLP phases were selected for investigation because they represent main events
occurring during the menstrual cycle (i.e., menses, pre-ovulation and peak progesterone concentration,
respectively). The duration of the menstrual cycle and the onset of each phase were accurately
determined by using (a) a period tracker application; (b) measurement of basal tympanic temperature
and body mass changes; and (c) assessment of the urinary peak of the luteinizing hormone, following
established recommendations [21]. The duration of each participant’s menstrual cycle was recorded
for a minimum of 4 months prior to the onset of the experiment for a valid characterization of length.
This information was obtained using a mobile application (Mycalendar®, Period-tracker, Hong Kong,
China) together with a menstruation diary, which included the date of menses, length of menses, and
discomfort in the days preceding and during the menses. All participants had a regular menstrual cycle
for the four months previous to the experiment (27 ± 2 days, range = 24–31 days) and were considered
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as eumenorrheic. During the familiarization period, participants were trained on how to measure their
own basal tympanic temperature and to obtain valid body mass measurements. A digital thermometer
(model HDT8208C, Nursal Ear Thermometer, Dongguan, China) and a digital scale (BT200, Daga,
Barcelona, Spain) were provided for each participant to obtain data every morning immediately after
waking up. Participants obtained these data for one complete menstrual cycle, starting with the phase
randomly allocated (tympanic temperature; EFP: 36.34 ± 0.42; LFP: 36.43 ± 0.62; MLP: 36.42 ± 0.47 ◦C,
body mass; EFP: 58.86 ± 9.28; LFP: 58.89 ± 9.14; MLP: 59.03 ± 9.11 kg). In addition, participants were
supplied with 7 reactive test strips (One Step Ovulation LH Test Strip; CVS Health, Woonsocket, RI,
US) to assess any increase in the luteinizing hormone in the first-morning urine sample. With all this
information, the following events were used to determine the onset of each phase, as follows: EFP was
indicated by the onset of menses; LFP was indicated by a positive test for urinary luteinizing hormone;
MLP was determined to be between 70% and 75% of the individual menstrual cycle length (i.e., from
the 20th to 22th day of the menstrual cycle for a regular cycle of 28 days [21]). All these protocols
helped to align the participants’ cycles and therefore, despite different cycle lengths, participants
performed the testing in the same cycle phases.
2.6. Statistical Analysis
Data were collected as previously indicated and the results of each test were blindly introduced
into the statistical package SPSS v 20.0 (IBM company, New York City, NY, US) for later analysis.
Normality was tested for each variable with the Shapiro–Wilk test. All included variables in this
investigation presented a normal distribution (P> 0.05) and parametric statistics were used to determine
the ergogenicity of caffeine. The caffeine-placebo differences in mean and peak velocity were identified
using a two-way ANOVA with repeated measures (treatment × load). After a significant F test,
differences among means were identified using the Bonferroni post hoc procedure. The significance
level was set at P ≤ 0.05. The results are presented as means ± SD. To improve the identification of
meaningful differences, the effect size was also calculated in all caffeine-placebo pairwise comparisons
to allow a magnitude-based inference approach [24]. The effect-size statistic ±90% confidence intervals
(CI) was used on log transformed data to reduce bias due to non-uniformity of error. The smallest
significant standardized effect threshold was set as 0.2. Ranges of likelihood <1% indicated almost
certainly no chances of change; 1% to 5%, very unlikely; 5% to 25%, unlikely; 25% to 75%, possible;
75% to 95%, likely; 95% to 99%, very likely; >99%, most likely. Differences were rated as unclear when
likelihood exceeded >5% in both positive/negative directions. Effect sizes were interpreted according
to the following ranges: <0.2, trivial; 0.2–0.6, small; 0.6–1.2, moderate; 1.2–2.0, large; 2.0–4.0, very large
and; >4.0, extremely large [24].
3. Results
Figure 2 displays mean and peak velocity differences between caffeine and the placebo for all
the loads under investigation. In comparison to the placebo, the two-way ANOVA showed that the
ingestion of 3 mg/kg/bm of caffeine increased mean velocity at 60% 1RM in EFP (Δ = 1.4± 2.7%, P= 0.04)
and LFP (Δ = 5.0 ± 10.4%, P = 0.04). No other differences were identified with the two-way ANOVA in
mean or peak velocity. However, the magnitude-based inference approach showed that, in EFP, mean
velocity was likely higher at 20% 1RM (Δ = 2.9 ± 4.0%, chance% as positive/trivial/negative = 55/45/0%)
with placebo than with caffeine. In EFP, mean velocity was possibly higher at 40% 1RM (Δ = 3.1 ± 5.7%;
55/44/1%) with caffeine than with the placebo (Figure 2, panel A). In LFP, mean velocity was possibly
higher at 40% 1RM with caffeine than with the placebo (Δ = 3.7 ± 8.7%; 63/35/2%). In MLP, mean
velocity was likely higher at 20% (Δ = 5.4 ± 8.7%; 85/14/1%), and 40% 1RM (Δ = 6.1 ± 9.1%, 85/15/0%)
and possibly higher at 60% (Δ = 5.3 ± 12.1%; 70/28/2%), and 80% 1RM (Δ = 4.7 ± 14.7%; 54/43/3%) with
caffeine than with the placebo.
For peak velocity, it was very likely that this variable was higher with placebo at 20% 1RM
(Δ = 3.1 ± 5.7%, 55/44/1%) and possibly higher with caffeine at 40% 1RM (Δ = 3.1 ± 5.7%; 55/44/1%)
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in the EFP (Figure 2, panel B). Caffeine induced possible ergogenic effects on peak velocity at 20%
(Δ = 3.1 ± 4.3%, 53/47/0%), 40% (Δ = 3.9 ± 7.9%, 63/35/1%), and 60% 1RM (Δ = 2.8 ± 7.7%, 60/36/4%) in
the LFP with no trivial or unclear effects in the MLP.
Figure 2. Changes induced with the ingestion of 3 mg/kg/bm of caffeine on mean velocity (A) and
peak velocity (B) during the concentric phase of the Smith machine half-squat exercise of increasing
loads (20%, 40%, 60% and 80% of one repetition maximum; 1RM) in each phase of the menstrual cycle.
Data are mean ± standard deviation from 13 eumenorrheic athletes. The information over the data
corresponds to the caffeine-placebo effect size statistic ±90% confidence intervals and magnitude base
inference of this comparison. (*) Caffeine different from placebo within the same menstrual cycle phase
at P < 0.05.
4. Discussion
The current body of evidence has found that acute caffeine intake (i.e., 5–6 mg/kg/bm) is able to
increase muscle strength and power in women [1,8–10], although the ergogenic effect of this substance
was small in all these investigations. However, previous research protocols on this topic did not
consider the menstrual cycle phase in which the caffeine ergogenicity was found, despite the potential
interaction between female sex hormones and caffeine [13,14]. To the authors’ knowledge, this is the
first study to directly compare the ergogenic response to caffeine on resistance exercise performance
during the different phases of the menstrual cycle. Using a repeated-measures design in which the
onset of the menstrual cycle phase was carefully delimited, caffeine-placebo comparisons were made
in the early follicular, late follicular and mid-luteal phases while muscle performance was measured
during a half squat force-velocity relationship. By using a traditional statistical approach, the two-way
ANOVA revealed only subtle ergogenic effects of caffeine on mean and peak velocity in the half squat
exercise. However, the magnitude-based inference approach indicated that caffeine was able to produce
small ergogenic effects on mean and peak velocity at several loads (Figure 2) with a tendency to move
the force-velocity relationship upwards in all phases of the menstrual cycle. Overall, the magnitude of
these effects was comparable in all the three menstrual cycle phases under investigation. Taken together,
these data suggest that caffeine might have a potential to enhance maximal velocity of movement in
half-squat exercise. Although this effect was equally present during the menstrual cycle, the effect was
catalogued as of small magnitude.
The concentration of the main female sex hormones fluctuates during different phases of the
menstrual cycle provoking changes in physiological functions and performance [25–27]. The ovarian
hormones estrogen and progesterone provoke opposing physiological functions—while estrogen
is a hormone with a purported anabolic function, progesterone has been related to catabolic
pathways [21,28]. For this reason, it has been speculated that muscle performance and muscle
adaptations might be favored when estrogen concentration is high and progesterone is low (i.e., follicular
phase). In fact, although muscle performance seems unaffected during the menstrual cycle [29],
concentrating most of the resistance training in the follicular phase induces greater changes in muscle
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strength and hypertrophy compared to concentrating resistance training in the luteal phase [30].
In addition, the intake of 2 mg/kg/bm of caffeine produces greater caffeine-induced cardiovascular and
mood changes in the follicular vs. the luteal phase [13,20]. Together, these effects might indicate that
acute caffeine intake will produce a higher caffeine ergogenicity in the follicular phase.
Interestingly, this speculation was not confirmed by our data because caffeine presented a similar
ergogenic effect to increase mean velocity in the early follicular, late follicular and mid luteal phases
(Figure 2). Caffeine produced a negative effect on peak velocity at 20% 1RM in the early follicular
phase of the menstrual cycle. However, this negative effect was not found in the remaining loads of
this menstrual cycle phase nor in peak velocity values of the late follicular and mid luteal phases.
In the author’s opinion, this lack of effect of acute caffeine intake at 20% 1RM in the early follicular
phase is anecdotical and does not alter the overall positive effect of caffeine to increase velocity during
half-squat exercise (Figure 2). Caffeine produced this positive effect in the mid-luteal phase despite the
probable high serum concentration of progesterone at this time of the menstrual cycle [15]. Although
we did not assess serum caffeine concentrations, it is presumable that the stable caffeine metabolism
during the menstrual cycle in these women who were not taken oral contraceptives [15,16] produced
comparable serum caffeine concentrations in the early follicular, late follicular and mid luteal phases
that promoted comparable ergogenicity for muscle performance. This finding is novel and reflects
the high potential capacity of acute caffeine intake to produce increases in muscle performance in
women, as previously found in other exercise and sport disciplines [31–33]. In this case, these data are
novel because suggests that the magnitude of the caffeine ergogenic effect is comparable across the
menstrual cycle.
Nevertheless, it is very important to take into account the individual responses during the
menstrual cycle. In the current investigation, eumenorrheic women with no menstrual disorders were
selected as the study sample to avoid the possible effects of these symptoms on the results of the
pairwise caffeine-placebo comparisons. However, there is a high percentage of athletes who report
premenstrual symptoms that might ultimately decrease performance [34]. Unfortunately, the results of
this investigation cannot be used to ascertain whether caffeine might be used to avoid or to reduce
the performance detriments produced by any menstrual disorder and further investigation about
the effects of caffeine in these populations is warranted. The ergogenic effect of caffeine on muscle
performance in women taking oral contraceptives should also be investigated because ethinylestradiol,
one of the substances included in contraceptive pills, decreases caffeine metabolism [17].
There are several limitations to this experiment that should be mentioned and discussed to
understand its scope. Firstly, to determine the onset of the menstrual cycle phases there was no
measure of the concentration and/or quantity of female steroids hormones. However, we used a
menstrual period tracker application, and measured changes in tympanic temperature and body mass.
In addition, we also used luteinizing hormone urine test strips, as previously recommended [12,35].
Secondly, although the participants who underwent this protocol had at least six months of resistance
training experience, they had no experience in velocity-based training. Lastly, we only used a dose
of 3 mg/kg/bm of caffeine which is lower than the 5–6 mg/kg/bm used in previous investigations on
caffeine effects on muscle performance. In addition, we selected low caffeine users while it is possible
that higher doses are necessary to find an ergogenic effect of caffeine in women habituated to caffeine
intake, as this has been demonstrated in male athletes [36]. Thus, it is possible that the magnitude of
the ergogenic effect on mean and peak velocity found in this investigation was affected by the dose
and the lack of tolerance to this drug.
5. Conclusions
In summary, the pre-exercise ingestion of 3 mg/kg/bm of caffeine increased, to a similar extent,
mean and peak velocity in the half squat exercise at increasing loads in the early follicular, late follicular,
and mid luteal phases of eumenorrheic trained athletes. Thus, in eumenorrheic women, caffeine
might have the potential of increasing muscle performance during the menstrual cycle, although
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3 mg/kg/bm would produce an effect of small magnitude. The outcomes of this investigation suggest
that eumenorrheic female athletes might use acute caffeine intake to increase movement velocity
during resistance training routines. The use of caffeine might be used to increase maximal strength
values on different strength-based exercises [37]. In addition, it has been recently found that resistance
training performed at fast movement velocities offers superior muscular strength gains than resistance
training with slow-to-moderate velocities [38]. Thus, the use of caffeine before resistance training might
be effective to enhance muscle adaptation derived from long-term strength training, although such
hypothesis deserves further confirmation. In this sense, caffeine ergogenicity for resistance exercise can
be equally obtained in all phases of the menstrual cycle and then, the supplementation with caffeine can
be used to design strength training programs without any interference with athletes’ menstrual cycle.
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Abstract: Background: The main goal of this study was to assess the acute effects of the intake of
9 and 11 mg/kg/ body mass (b.m.) of caffeine (CAF) on maximal strength and muscle endurance
in athletes habituated to caffeine. Methods: The study included 16 healthy strength-trained male
athletes (age = 24.2 ± 4.2 years, body mass = 79.5 ± 8.5 kg, body mass index (BMI) = 24.5 ± 1.9, bench
press 1RM = 118.3 ± 14.5 kg). All participants were habitual caffeine consumers (4.9 ± 1.1 mg/kg/b.m.,
411 ± 136 mg of caffeine per day). This study had a randomized, crossover, double-blind design,
where each participant performed three experimental sessions after ingesting either a placebo (PLAC)
or 9 mg/kg/b.m. (CAF-9) and 11 mg/kg/b.m. (CAF-11) of caffeine. In each experimental session,
participants underwent a 1RM strength test and a muscle endurance test in the bench press exercise
at 50% 1RM while power output and bar velocity were measured in each test. Results: A one-way
repeated measures ANOVA revealed a significant difference between PLAC, CAF-9, and CAF-11
groups in peak velocity (PV) (p = 0.04). Post-hoc tests showed a significant decrease for PV (p = 0.04)
in the CAF-11 compared to the PLAC group. No other changes were found in the 1RM or muscle
endurance tests with the ingestion of caffeine. Conclusion: The results of the present study indicate
that high acute doses of CAF (9 and 11 mg/kg/b.m.) did not improve muscle strength nor muscle
endurance in athletes habituated to this substance.
Keywords: bench press; upper limb; resistance exercise; ergogenic substances; time under tension;
1RM test
1. Introduction
Caffeine (CAF) is one of the most widely consumed drugs in the world and has become a
popular ergogenic aid for many athletes due to its properties to improve several aspects of physical
performance. The acute intake of CAF has been effective to enhance exercise performance in a wide
range of sport specific tasks [1], muscular endurance [2–4], and strength-power exercise modalities [4,5].
The ergogenic effect of caffeine has been found when consumed at doses ranging from 3 to 9 mg/kg
body mass (b.m.) and ingested in the form of capsules 30 to 90 minutes before exercise [6]. Mechanisms
responsible for ergogenic effect of caffeine are linked to the impact of this substance on various tissues,
organs, and systems of the human body [4,7–10]. However, there is a growing consensus to consider
that caffeine’s ergogenicity lies in its tendency to bind to adenosine A1 and A2A receptors [11].
Although studies have confirmed the ergogenic effects of caffeine in many aspects, much
controversy remains about the effects of acute CAF intake on maximal strength (1-repetition maximum
(1RM)) and local muscle endurance. Several investigations have found that the acute intake of
3–6 mg/kg/b.m. of CAF produces an increase in 1RM test performance [3,12–14], and in the total
number of repetitions performed (T-REP) [12,13,15]. However, other investigations have found that
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the same dosage did not produce such effects [2,3,5,15,16], suggesting that other factors such as the
type of testing, the muscle mass involved, and the athlete’s experience in strength training might affect
the ergogenic effect of caffeine on muscle performance. Furthermore, Wilk et al. [2] observed a positive
effect of CAF intake on time under tension (TUT) in a muscle endurance test, but no significant effect in
the T-REP. According to Wilk et al. [17] and Burd et al. [18], TUT might be the most reliable indicator to
assess exercise volume in resistance exercise regardless of the number of repetitions performed. Based
on literature review, it can be concluded that previous results of studies on the acute effects of CAF
intake on muscle strength and endurance are inconclusive.
Most investigations on the effects of caffeine intake on muscle performance have used participants
unhabituated to caffeine or with low-to-moderate daily consumption of caffeine from 58 to
250 mg/day [3,12,16]. However, caffeine is an ergogenic aid frequently used in training and competition
and it seems that athletes seeking for caffeine ergogenicity are already habituated to caffeine. There
are reports indicating that 75–90% of athletes consume CAF before or during training sessions and
competitive events [19–21], which indicates that studies on the effectiveness of acute CAF intake are
particularly important in habitual caffeine users.
According to Svenningsson et al. [22] and Fredholm et al. [23], habitual caffeine intake modifies
physiological responses to acute ingestion of CAF by the up-regulation of adenosine receptors.
Furthermore, constant exposure to caffeine could impact caffeine metabolism by inducing an accelerated
conversion of caffeine into dimethylxanthines by the cytochrome P450. Therefore, progressive
habituation to the performance benefits of caffeine intake has been recognized in humans when it
is consumed chronically [24]. However, the evidence to certify the existence of habituation to the
ergogenic benefits is still inconclusive because it was found that low caffeine consumers benefited
from the acute intake of 3–6 mg/kg/b.m. of CAF to a similar extent as individuals habituated to
caffeine [25,26]. Lara et al. [27] found that caffeine ergogenicity was lessened when the substance was
ingested daily (3 mg/day/kg/b.m.) for 20 days but it was still ergogenic after this period. In contrast,
Beaumont et al. [28] observed that caffeine’s ergogenicity practically disappeared after 28 days of daily
ingestion (1.5–3 mg/day/kg/b.m.). Interestingly, all these investigations tested tolerance to caffeine’s
ergogenicity using endurance exercise protocols, while only one of them used muscle performance
tests. Wilk et al. [5] showed that neither 3, 6, nor 9 mg/kg/b.m. of CAF intake enhanced power output
and bar velocity during bench press exercise in strength-trained male athletes habituated to caffeine.
However, there are no available data regarding the influence of acute CAF intake on maximal strength
and muscular endurance in athletes habitually consuming caffeine.
Due to the aforementioned contrasting results, the main goal of this study was to assess the acute
effect of high doses of CAF (9 and 11 mg/kg/b.m.) on maximal strength and muscle endurance assessed
on the basis of T-REP and TUT in athletes habituated to CAF (4–6 mg/day/kg/b.m.). We hypothesized
that high doses of caffeine, exceeding athletes’ usual daily consumption of caffeine, would enhance
muscle strength and muscular endurance. Since the value of daily habitual intake of caffeine may
significantly modify the acute ergogenic effects of CAF ingestion, we used doses of CAF significantly
above daily consumption in this investigation.
2. Materials and Methods
2.1. Study Participants
Sixteen healthy strength-trained male athletes (age: 24.2 ± 4.2 years, body mass: 79.5 ± 8.5 kg,
body mass index (BMI): 24.5 ± 1.9, bench press 1RM: 118.3 ± 14.5 kg; mean ± standard deviation)
volunteered to participate in the study after completing an ethical consent form. Participants had
a minimum of 3 years of strength training experience (4.1 ± 1.4 years) and practiced team sports.
All participants were classified as high habitual caffeine consumers according to the classification
recently proposed by Gonçalves et al. [26]. The participants self-reported their daily ingestion of CAF
(4.9 ± 1.1 mg/kg/b.m., 411 ± 136 mg of caffeine per day) based on the Food Frequency Questionnaire
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(FFQ) with their average consumption assessed for four weeks before the start of the experiment.
The inclusion criteria were as follows: (a) Free from neuromuscular and musculoskeletal disorders,
(b) performance of the bench press exercise with a load of at least 120% of body mass, (c) habitual
caffeine intake in the range of 4–6 mg/day/kg/b.m., ~300–500 mg of caffeine per day. Participants
were excluded when they suffered from any pathology or injury. Additionally, they were required to
refrain from alcohol and tobacco consumption and were asked not to take any medications or dietary
supplements as well as other ergogenic substances during and two weeks prior to the experiment. The
study protocol was approved by the Bioethics Committee for Scientific Research at the Academy of
Physical Education in Katowice, Poland, according to the ethical standards of the latest version of the
Declaration of Helsinki, 2013.
2.2. Habitual Caffeine Intake Assessment
Habitual caffeine intake was assessed by an adapted version of the Food Frequency Questionnaire
(FFQ) proposed by Bühler et al. [29]. The FFQ was completed individually with the supervision
of a qualified nutritionist. The FFQ was employed to assess the habitual consumption of dietary
products containing caffeine. Portions, in household measures, were used to assess the amount of
food consumed according to the following frequency of consumption: a) More than three times a
day, b) two to three times a day, c) once a day, d) five to six times a week, e) two to four times per
week, f) once a week, g) three times per month, h) rarely or never. The list was composed of dietary
products with moderate-to-high caffeine content including different types of coffee, tea, energy drinks,
cocoa products, popular beverages, medications, and caffeine supplements. Previously published
information and nutritional tables were used for database construction [1,30,31]. Based on the answers
in the FFQ, a qualified nutritionist estimated the habitual caffeine intake for each participant.
2.3. Experimental Design
This study used a randomized, double-blind, placebo-controlled crossover design where each
participant acted as his own control. Participants performed a familiarization session with a preliminary
1RM test on one day and three different experimental sessions with a one-week interval between
sessions to allow complete recovery and substances wash-out. The blinding and randomization of
the sessions was conducted by a member of the research team that was not directly involved in
data collection.
During the three experimental sessions, participants either ingested a placebo (PLAC), 9 mg/kg/b.m.
of CAF (CAF-9) or 11 mg/kg/b.m. of CAF (CAF-11). After 60 minute of absorbing the substances,
participants underwent a 1RM strength test and a muscle endurance test with the bench press
exercise. During each test, power output and bar velocity were measured. Both CAF and PLAC were
administered orally 60 minute before each exercise protocol to allow peak blood caffeine concentration
and at least 2 hours after the last meal to maintain the same time of absorption. CAF was provided
in the form of capsules containing the individual dose of CAF (Caffeine Kick®, Olimp Laboratories,
Dębica, Poland). The producer also prepared identical PLAC capsules filled out with an inert substance
(all-purpose flour). Participants refrained from physical activity the day before testing and they kept
their habitual training routines during the study period. In addition, participants were instructed to
maintain their usual hydration and dietary habits during the study period including habitual caffeine
intake and register their calorie intake using “Myfitness pal” software [32] every 24 hours before the
testing procedure. The average calorie intake was ~3300 kcal/day and it was similar before the three
experimental trials. Participants were also asked to refrain from caffeine intake 12 hours before each
trial. All testing was performed at the Strength and Power Laboratory at the Jerzy Kukuczka Academy
of Physical Education in Katowice, Poland.
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2.4. Familiarization Session and One Repetition Maximum Test
A familiarization session preceded the preliminary one repetition maximum testing. Participants
arrived at the laboratory at the same time of day as in the upcoming experimental sessions (in the
morning, between 9:00 and 10:00). Upon arrival, participants cycled on an ergometer for 5 minutes at
an intensity that resulted in a heart rate of approximately 130 bpm, followed by a general upper body
warm-up. Next, participants performed 15, 10, 5, and 3 repetitions of the bench press exercise using 20,
40, 60, and 80% of their estimated 1RM with a 2/0/X/0 tempo of movement. The sequence of digits
describing the tempo of movement (2/0/X/0) referred to a 2 seconds eccentric phase, 0 represented a
pause during the transition phase, X referred to the maximum possible tempo of movement during the
concentric phase, and the last digit indicated no pause at the end of movement [33]. Participants then
executed single repetitions of the bench press exercise with a 5 minutes rest interval between successful
trials. The load for each subsequent attempt was increased by 2.5 to 5 kg, and the process was repeated
until failure. Hand placement on the barbell was individually selected with a grip width on the barbell
of 150% individual bi-acromial distance (BAD). BAD was determined by palpating and marking the
acromion with a marker, and then measuring the distance between these points with a standard
anthropometric tape. The positioning of the hands was recorded to ensure consistent hand placement
during all testing sessions. No bench press suits, weightlifting belts, or other supportive garments were
permitted. Three spotters were present during all attempts to ensure safety and technical proficiency.
2.5. Experimental Protocol
Three testing sessions were used for the experimental trials and the protocols were identical.
All testing took place between 9.00 and 11.00 to avoid circadian variation. The general warm-up
for the experimental sessions was identical to the one used for the familiarization session. After
warming up, participants performed the 1RM bench press test to assess upper-body maximal muscle
strength. For the 1RM test, the first warm-up set included eight to ten repetitions with 50% 1RM
determined during the familiarization session. The second set included three to five repetitions with
75% 1RM. Participants then completed one repetition with 95% 1RM. Based on whether the participant
successfully lifted the load or not, the weight was increased or decreased (2.5 to 5 kg) in subsequent
attempts until the 1RM value for the session was obtained. Three- to five–minute rest intervals were
allowed between the 1RM attempts, and all 1RM values were obtained within five attempts. After a
five-minute rest interval, muscle endurance was assessed with one ‘all-out’ set using a load of 50%
of participants’ 1RM measured in the previous 1RM test. The end of the muscle endurance test was
assumed when momentary concentric failure occurred. The concentric phase of the bench press
movement was performed at maximal possible velocity in each repetition, while the eccentric phase
was performed with 2 seconds duration (2/0/X/0). During the muscle endurance test, the following
variables were registered:
• T-REP—total number of repetitions [n];
• TUTCON—time under tension of concentric contractions [s];
• PP—peak concentric power [W];
• MP—mean concentric power [W];
• PV—peak concentric velocity [m/s];
• MV—mean concentric velocity [m/s].
All repetitions were performed without bouncing the barbell off the chest, without intentionally
pausing at the transition between the eccentric and concentric phases, and without raising the lower
back off the bench. During the experimental trials, participants were encouraged to perform at maximal
effort according to the recommendations by Brown and Weir [34]. A linear position transducer system
(Tendo Power Analyzer, Tendo Sport Machines, Trencin, Slovakia) was used for the evaluation of bar
velocity. The Tendo Power Analyzer is a reliable system for measuring movement velocity and to
estimate power output [35,36]. The system consists of a velocity sensor connected to the load by a
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Kevlar cable which, through an interface, instantly transmits the vertical velocity of the bar to specific
software installed in the computer (Tendo Power Analyzer Software 5.0). The system measures upward
vertical mean and peak velocity of the movement. Using a set external load, the system calculates
mean and peak power output in the concentric phase of the movement. The measurement was made
independently in each repetition and automatically converted into the values of power (max, mean)
and concentric velocity (max, mean). All familiarization and experimental sessions were recorded
by means of a Sony camera (Sony FDR191 AX53). Time under tension and the number of performed
repetitions was obtained manually from the recorded data using slow speed playback (1/5 speed).
In order to ensure the reliability of manual data collection, four independent observers performed
data analysis from the Sony camera. There were no significant differences in TUT [s] nor in T-REP [n]
between the data collected by 4 evaluators. All participants completed the described testing protocol
that was carefully replicated in the subsequent experimental sessions.
2.6. Side Effects
Immediately after finishing testing, and after 24 hours, participants answered a side effects
questionnaire (QUEST), which is a nine-item measure with a dichotomous (yes/no) response scale of
caffeine ingestion [20,37,38].
2.7. Statistical Analysis
The Shapiro-Wilk, Levene, and Mauchly´s tests were used in order to verify the normality,
homogeneity and sphericity of the sample data variance. Verification of differences between the PLAC
vs. CAF-9 and CAF-11 groups was performed using one-way ANOVA. In the event of a significant
main effect, post-hoc comparisons were conducted using the Tukey’s test. Percent relative effects
and the 95% confidence intervals were also calculated. Effect Sizes (Cohen’s d) were reported where
appropriate. Parametric effect sizes (ES) were defined as large for d > 0.8, moderate between 0.8 and
0.5, and small for <0.5 [39]. Statistical significance was set at p < 0.05. All statistical analyses were
performed using Statistica 9.1 and were presented as means ± standard deviations.
3. Results
The one-way ANOVA revealed a statistically significant difference in PV (p= 0.04; Table 1) between
PLAC vs. CAF-9 and CAF-11 groups. However, no significant differences in 1RM, T-REP, TUTCON, MP,
PP, nor MV between PLAC, CAF-9, and CAF-11 groups were observed among experimental sessions.
Next, the Tukey’s post-hoc test revealed a significantly lower PV in the CAF-11 when compared to the
PLAC group (p = 0.04; Table 2).
























































(1.16–1.34) 3.43 0.04 *
All data are presented as mean ± standard deviation; CI—confidence interval; * statistically significant difference
p < 0.05; 1RM: One repetition maximum; T-REP: Total number of repetitions; TUTCON: Time under tension during
concentric movement; MP: Mean power output; PP: Peak power output; MV: Mean velocity; PV: Peak velocity.
Table 2. Differences in placebo vs. caffeine conditions between experimental trials.
Variable Comparison p Effect Size (Cohen d) Relative Effects [%]
1RM [kg] Placebo vs CAF-9 0.82 0.26—small 3.3 ± 4.1
Placebo vs CAF-11 0.74 0.45—small 4.7 ± 5.1
T-REP [n] Placebo vs CAF-9 0.99 −0.02—negative effects 0.4 ± 12.1
Placebo vs CAF-11 0.93 0.15—small 2.0 ± 11.2
TUTCON [s]
Placebo vs CAF-9 0.22 0.6—moderate 10.5 ± 15.5
Placebo vs CAF-11 0.99 −0.05—negative effects −6.2 ± 21.5
MP [W] Placebo vs CAF-9 0.85 −0.19—negative effects −1.5 ± 7.6
Placebo vs CAF-11 0.51 −0.38—negative effects −9.4 ± 10.5
PP [W] Placebo vs CAF-9 0.84 −0.21—negative effects −4.2 ± 8.3
Placebo vs CAF-11 0.48 −0.38—negative effects −9.2 ± 11.6
MV [m/s] Placebo vs CAF-9 0.43 −0.44—negative effects −6.0 ± 11.8
Placebo vs CAF-11 0.91 −0.11—negative effects −1.4 ± 6.6
PV [m/s] Placebo vs CAF-9 0.90 −0.12—negative effects −1.5 ± 10.2
Placebo vs CAF-11 0.04 * −0.84—negative effects −11.2 ± 10.7
All data are presented as mean ± standard deviation; * statistically significant difference p < 0.05; 1RM: One repetition
maximum; T-REP: Total number of repetitions; TUTCON: Time under tension during concentric movement; MP:
Mean power output; PP: Peak power output; MV: Mean velocity; PV: Peak velocity.
Side Effects
Table 3 details the occurrence of nine different side effects assessed immediately after and 24 hours
after testing. Immediately after the PLAC trial, participants reported a very low frequency of side
effects (0–13%; QUEST + 0 hour). After CAF-9 ingestion, there were more severe side effects (0–88%;
QUEST + 0 hour) compared to the PLAC trial. The most severe side effects were recorded for increased
urine output, tachycardia and heart palpitations, anxiety or nervousness, perception of performance
improvement, and increased vigor (63–88%; QUEST + 0 hour). Finally, the CAF-11 trial produced a
drastic increase in the intensity and frequency of side effects (0–92%; QUEST + 0 hour; Table 3).
In the morning following testing (QUEST + 24 hours), very few participants (0–13%) reported
side effects with the PLAC. The CAF-9 trial showed greater frequency of side effects (0–69%), with
increased urine output, tachycardia and heart palpitations, gastrointestinal problems, and increased
vigor in comparison with the PLAC trial. Finally, CAF-11 intake increased the frequency and severity
of all adverse side effects, with a frequency of appearance from 0 to 88% (Table 3).
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Table 3. Number (frequency) of participants that reported side effects immediately after the testing
protocol (side effects questionnaire (QUEST) + 0 hour) and 24 hours later (QUEST + 24 hours).
Side Effects
Occurrence of Side Effects in Particular Groups
PLAC CAF-9 CAF-11


































































































Data are presented as the number of participants (frequency) that responded affirmatively to the existence of a
side effect.
4. Discussion
The main finding of the study was that, compared to the ingestion of the PLAC, the acute intake
of high doses of CAF (9 and 11 mg/kg/b.m.) was not effective to produce any statistically measurable
ergogenic effect on the bench press 1RM, T-REP, TUTCON, PP, MP, nor MV in individuals habituated to
CAF intake. In fact, the intake of 11 mg/kg/b.m. significantly decreased PV during bench press testing
performed to concentric muscle failure in these habitual caffeine users. All this information suggests
that even high doses of CAF were ineffective to produce ergogenic effects on maximal strength and
muscular endurance in high-caffeine consumers. This lack of effect was evident despite the fact that the
dosage of caffeine used pre-exercise was well-above their daily intake of this substance. In addition,
these data might be indicative of tolerance to caffeine’s ergogenicity for muscle performance while the
high occurrence of side effects is still maintained with high doses of caffeine.
Previous studies have shown a variety of effects when different doses of CAF were administered
to athletes performing testing to assess maximum strength and muscle endurance. Some of them
indicated a significant increase in 1RM and T-REP performance [12,13], while others did not confirm
such benefits [2,14]. Perhaps differences in the results of previous studies may be attributed to different
doses of CAF consumed by study participants, in addition to the use of participants with an uneven
habituation to caffeine. Since the value of daily habitual intake of caffeine might significantly modify
the acute ergogenic effects of CAF ingestion [40], this investigation was aimed to study the acute effects
of high doses (9 and 11 mg/kg/b.m.) of CAF intake on maximal strength and muscle endurance of the
upper limbs, using athletes clearly habituated to caffeine.
Previous research using well-controlled caffeine treatments has suggested that the habitual intake
of this stimulant might progressively reduce the ergogenic effect of acute CAF supplementation on
exercise performance [27,28,40], reductions after acute CAF intake in habitual users can be modified
using pre-trial doses which should be greater than the daily habitual intake. However, our results do
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not support this statement. Despite the fact that the doses of CAF used in our study were much greater
(9 and 11 mg/kg/b.m.) than the daily intake of studied athletes (4–6 mg/kg/b.m./day), there were no
positive changes in the analyzed strength, endurance, and power variables. In fact, our results indicate
a significant decrease in PV after the intake of CAF-11 compared to the PLAC. Previous studies showed
that acute CAF intake leads to higher activation of motor units [41] and higher MVIC [10,42]. However
in the presented study the supposed effect of increased muscle tension following CAF intake, not only
did not increase the power output generated during the CON phase of the movement, but a decrease
in PV was observed. A decrease in PV after ingestion of CAF-11 undermines the legitimacy of using
high doses of CAF before explosive, high-velocity, low-resistance exercises performed to muscle failure.
According to Pallarés et al. [37], explosive, high-velocity, low-resistance actions require a much lower
CAF dose (3 mg/kg/b.m.) in individuals with none or low habituation to caffeine. However, in the light
of the current results, this statement does not apply to habitual caffeine users. The results of the present
study, and especially the decrease in PV after CAF intake (11 mg/kg/b.m.), are particularly important
for competitive athletes, since research indicates that 75–90% of athletes consume CAF before or during
training sessions and competitive events [19,20]. In this regard, when seeking the benefits of acute
caffeine intake to muscle performance, the dishabituation to caffeine should be recommended instead
of the use of doses above the daily intake of caffeine. For how long habitual caffeine users should
discontinue the intake of caffeine merits further investigation. For now, current evidence suggests that
the dishabituation period should be longer than four days [43].
Furthermore, besides statistically significant change in PV, the results of the study showed negative
effect sizes (ES) and relative (%) decreases in T-REP, TUTCON, MP, PP, PV, and MV after the intake
of CAF-11 compared to the PLAC, as well as relative decreases in MP, PP, PV, MV following the
ingestion of CAF-9 compared to the PLAC. Decreased values of T-REP and TUTCON after acute intake of
CAF-11 may have resulted from the increased muscle tension generated during the movement [10,42].
A supposed increase of muscle activation can lead to a higher energy demand during exercise, thus
leading to a faster depletion of energy substrates in muscle cells [44], which may partially explain a
decline in T-REP and TUTCON after the intake of CAF-11. However, the increased muscle tension
following CAF intake did not improve the power output generated during the CON phase of the
movement. The relative increase in results was observed only in the 1RM test after the intake of CAF-9
and CAF-11 (3.3% and 4.7%, respectively) and in TUTCON after consuming CAF-9 (10.5%). While
such an improvement in results of the 1RM test may be considered small in statistical terms, it can
be of great significance in training and competition of elite athletes, especially in competitions where
success depends on maximal strength production [45]. The relative % increase in results of the 1RM
test after the intake of CAF-9 and CAF-11 compared to the PLAC is partly compatible with Pallarés et
al. [37] who demonstrated that muscle contractions against heavy loads (75–90% 1RM) required a high
CAF dose (9 mg/kg/b.m.) to obtain an ergogenic effect in low caffeine consumers. The results of our
research confirm that, also in habitual consumers, high doses of CAF ingestion might be effective in
improving maximal strength, although this effect is accompanied by a high occurrence of side effects
(Table 3). Additionally, the TUTCON increased by 10.5% after the intake of CAF-9 compared to the
PLAC what may be of great significance in training of elite strength athletes. However, the increase
in TUTCON in the present study is contrary to the results of Wilk et al. [2], who showed a decrease
in TUT during the bench press exercise at 70% 1RM performed to muscle failure after the intake of
CAF (5 mg/kg/b.m.) compared to the PLAC. It should be pointed out that differences in the external
load used in both exercise protocols (50% 1RM vs. 70% 1RM) could have affected the results following
CAF intake [37]. The 10.5% increase in TUTCON in the present study indicates that TUT may be an
additional indicator of training volume during resistance training, compared to the T-REP, where a
0.4% decrease in results was registered after the intake of CAF-9 compared to the PLAC.
Furthermore, the results of our study showed that high doses of CAF in habitual caffeine consumers
may be ineffective or also have a negative effect on physical performance in athletes. The ingestion
of CAF-9 and CAF-11 significantly increased the frequency of self-reported side effects (0–88% for
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CAF-9; 0–92% for CAF-11) compared to the PLAC. It has been empirically established that side effects
of caffeine intake are severe when doses between 9 and 13 mg/kg/b.m. are used [46]. Increased
urine output, tachycardia and heart palpitations, anxiety or nervousness, as well as perception of
performance improvement are among the most common adverse effects experienced by athletes when
they consume caffeine [47]. The current investigation adds some valuable information as it indicates
that these adverse effects are still persistent in individuals habituated to caffeine, at least when they
consume a high dose of CAF to exceed their habitual intake of this substance. However, the occurrence
of these side effects does not always prevent athletes from improving their performance, as was the case
with rowers in Carr et al. [48], who improved their times in a 2000-m ergometer test, or participants in
the study of Pallarés et al. [37], who significantly improved their neuromuscular performance after the
ingestion of 9 mg/kg/b.m. of CAF. On the contrary, Wilk et al. [5] showed an increased frequency of all
adverse side effects after the intake of 9 mg/kg/b.m. of CAF yet with no significant increases in power
output and bar velocity during the bench press exercise compared to the PLAC. All this information
might be indicative of the necessity of evaluating both performance and side effects when planning to
use >9 mg/kg/b.m. of CAF before training or competition.
The duration of adverse effects resulting from CAF intake is another issue to be considered in
research and sports training. The present study showed a drastic increase in the reported frequency of
side effects 24 hours after ingestion (Table 3). The CAF-9 trial showed a frequency of side effects in the
range from 0 to 69%, with increased urine output, tachycardia and heart palpitations, gastrointestinal
problems, as well as increased vigor in comparison with the PLAC group. CAF-11 intake increased
the frequency of all adverse side effects, with a frequency of appearance from 0 to 88%. It should be
stressed that even if caffeine allows for improved physical performance, it can significantly disturb
sleep indices at night, such as sleep efficiency and ability to fall asleep, as well as induce an overall
decrease in sleep itself [49]. Therefore, athletes who consume CAF to enhance their performance
during training and/or competition should take into account its detrimental effects on sleep, especially
if subsequent high-intensity exercise is to be performed on the following day.
The present study has several limitations which should be addressed. The procedure of the
research assumed all participants were similarly habituated to caffeine despite the fact that their daily
intake of caffeine and the duration of this intake presented some inter-individual variation. It has been
recently suggested that all individuals respond to caffeine ingestion when caffeine is compared to a
placebo using multiple and repeated testing sessions [50]. Although two different tests were used to
assess the effect of caffeine intake on muscle performance, the ergogenic effect of CAF was not evident,
suggesting that habituation to caffeine precluded the effect of acute CAF intake. However, it is still
possible that the use of other muscle strength tests can still show ergogenic effects of high doses of CAF
on performance of caffeine-habituated athletes. Furthermore, there were no genetic assessments related
to caffeine metabolism in the tested athletes. According to Cornelis et al. [51], genetic variation in the
A2A receptor (ADORA2A), the main target of caffeine action in the central nervous system, is associated
with caffeine consumption. The probability of having the ADORA2A 1083TT genotype associated
with caffeine-induced anxiety decreases as the caffeine intake increases in a population, and subjects
with that genotype are more likely to limit their caffeine intake. People who were homozygous for the
1083T allele experienced greater anxiety after consuming 150 mg of caffeine [52]. Before the start of our
experiment, no study participant reported any side effects after consumption of CAF within the last six
months suggesting that the side effects found in this investigation were the result of the high doses
used in this study rather than a genetic predisposition.
Practical Applications
The ingesting of high doses of CAF (9 and 11 mg/kg/b.m.) can bring minor benefits during training
with near or maximal external loads. However, if explosive, high-velocity, low-resistance exercises
are performed to muscle failure, the high doses of CAF (9 and 11 mg/kg/b.m.) are not recommended
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as they may hinder performance. These suggestions apply only to habitual strength-trained male
caffeine users.
5. Conclusions
The results of the present study indicate that acute intake of high doses of CAF (9 and 11 mg/kg/b.m.)
before exercise did not produce significant improvements in maximal strength and muscle endurance
during the bench press exercise performed to concentric failure in a group of habitual caffeine users.
However, it should be noted that slight benefits in 1RM and TUTCON after the intake of high doses
of CAF were observed. In addition, the results of this study showed a significant decrease in PV of
the bar after the intake of CAF-11 compared to the PLAC. Overall, this investigation indicates that
the use of high doses of CAF does not improve significant performance during resistance exercises
in high caffeine consumers while it causes a significant increase in the occurrence of side effects.
These outcomes undermine the convenience of using high doses of CAF before resistance training
performed to momentary muscle failure. However, these results may not translate to other forms,
volumes, or intensities of exercise. Future research should compare the inter-subject variation in
response to different doses of caffeine. Additionally, as Chtourou and Souissi [53] mention, it would be
wise to compare the changes in power-output and strength responses to CAF intake between several
time-points following ingestion.
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The authors wish to make a correction to the published version of their paper [1]. We noticed
an error in the statistical analysis that requires correcting, as it may contribute to an incorrect
understanding of our study’s scientific results and conclusions. In the study Section 2.7 (Statistical
Analysis), the identification of differences between the placebo (PLAC) and the two doses of caffeine
under experimentation 9 and 11 mg/kg/b.m.; CAF-9 and CAF-11, respectively) was performed using
a one-way ANOVA. As the 16 participants of this investigation underwent all the experimental
trials and acted as the own controls, the correct statically approach should have included the use
of a one-way repeated measures ANOVA. After running this new statistical analysis, some new
differences have appeared between PLAC and the use of caffeine, in addition to the new p values
for each comparison. The repeated measures ANOVA revealed statistically significant differences in
1RM (p < 0.01), MP (p < 0.01) and PP (p = 0.04) between PLAC vs. CAF-9 and CAF-11, in addition to
the difference in PV (p < 0.01) that was already presented in the previous version of the manuscript
(Table 1). Tukey’s post-hoc tests revealed a significantly higher 1RM in CAF-9 and CAF-11 trials when
compared to PLAC and significantly lower MP, PP and PV in the CAF-11 trial when compared to
PLAC (Table 2).













(116.3 − 135.2) 7.46 0.01 *











(15.1 − 18.8) 2.67 0.08




(276 − 360) 6.07 0.01 *




(632 − 831) 3.27 0.04 *
Nutrients 2019, 11, 2660; doi:10.3390/nu11112660 www.mdpi.com/journal/nutrients99














(0.66 − 0.74) 1.39 0.26




(1.16 − 1.34) 6.09 0.01 *
All data are presented as mean ± standard deviation; CI—Confidence interval; * statistically significant difference
p < 0.05; 1RM: One repetition maximum; T-REP: Total number of repetitions; TUTCON: Time under tension during
concentric movement; MP: Mean power output; PP: Peak power output; MV: Mean velocity; PV: Peak velocity.
Table 2. Differences in placebo vs. caffeine conditions between experimental trials.
Variable Comparison p Effect Size (Cohen d) Relative Effects [%]
1RM [kg]
Placebo vs. CAF-9 0.01 * 0.26—small 3.3 ± 4.1
Placebo vs. CAF-11 0.01 * 0.45—small 4.7 ± 5.1
T-REP [n]
Placebo vs. CAF-9 0.99 −0.02—negative effects 0.4 ± 12.1
Placebo vs. CAF-11 0.90 0.15—small 2.0 ± 11.2
TUTCON [s]
Placebo vs. CAF-9 0.14 0.6—moderate 10.5 ± 15.5
Placebo vs. CAF-11 0.99 −0.05—negative effects −6.2 ± 21.5
MP [W]
Placebo vs. CAF-9 0.21 −0.19—negative effects −1.5 ± 7.6
Placebo vs. CAF-11 0.01 * −0.38—negative effects −9.4 ± 10.5
PP [W]
Placebo vs. CAF-9 0.44 −0.21—negative effects −4.2 ± 8.3
Placebo vs. CAF-11 0.04 * −0.38—negative effects −9.2 ± 11.6
MV [m/s]
Placebo vs. CAF-9 0.25 −0.44—negative effects −6.0 ± 11.8
Placebo vs. CAF-11 0.86 −0.11—negative effects −1.4 ± 6.6
PV [m/s]
Placebo vs. CAF-9 0.84 −0.12—negative effects −1.5 ± 10.2
Placebo vs. CAF-11 0.01 * −0.84—negative effects −11.2 ± 10.7
All data are presented as mean ± standard deviation; * statistically significant difference p < 0.05; 1RM: One repetition
maximum; T-REP: Total number of repetitions; TUTCON: Time under tension during concentric movement; MP:
Mean power output; PP: Peak power output; MV: Mean velocity; PV: Peak velocity.
Although the original experimental results remain unchanged, this new and correct statistical analysis
indicates that the acute intake of high doses of CAF (9 and 11 mg/kg/b.m.) was effective to produce
statistically measurable ergogenic effect on the bench press 1RM in individuals habituated to CAF intake.
In case of muscular endurance, the intake of 11 mg/kg/b.m. significantly decreased MP, PP and PV during
bench press testing performed to concentric muscle failure in these habitual caffeine users.
The authors apologize to the readers for any inconvenience caused by this modification.
The original manuscript will remain online on the article webpage with a reference to this correction.
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Abstract: The current study examined the relationships between the effects of consuming a
caffeine-containing “energy drink” upon (i) short-term maximal performance, (ii) reaction times,
and (iii) psychological factors (i.e., mood state, ratings of perceived exertion (RPE), and affective
load) and on physiological parameters (i.e., blood pressure and blood glucose). A randomized,
double-blind, placebo-controlled, counterbalanced crossover design was implemented in this study.
Nineteen male physical-education students (age: 21.2 ± 1.2 years; height: 1.76 ± 0.08 m; body-mass:
76.6 ± 12.6 kg) performed two test sessions: after drinking the “Red Bull’ beverage (RB) and after
drinking a placebo (PL). One hour after ingestion of each drink, resting blood glucose and blood
pressure were measured and the participants completed the Profile of Mood States questionnaire.
Then, after a 5-min warm-up, simple visual reaction time and handgrip force were measured, and the
30-s Wingate test was performed. Immediately after these tests, the RPE, blood glucose, and blood
pressure were measured, and the affective load was calculated. Differences between treatments were
assessed using two-way repeated measures analyses of variance and paired t-tests, as appropriate.
Relationships between the test variables were assessed using Bland–Altman correlations. Significant (i)
improvements in peak and mean power output, handgrip force, pre- and post-exercise blood glucose,
blood pressure, and vigor and (ii) reductions in reaction times, depression, confusion, fatigue, anger,
anxiety, RPE, and affective load scores were observed after RB compared to PL. There were significant
correlations of (i) physical performances and reaction times with (ii) RPE, affective load, and pre- and
post-exercise blood glucose levels. Gains in peak and mean power were significantly correlated with
reductions in fatigue, anxiety (peak power only), and anger (mean power only). The reduction of
reaction times was significantly correlated with decreases in confusion and anger and with increases
in vigor. Handgrip force and reaction times were significantly correlated with pre- and post-exercise
blood pressures. We conclude that RB ingestion has a positive effect on physical performance and
reaction times. This effect is related to ergogenic responses in both psychological (i.e., RPE, affective
load, and mood state) and physiological (i.e., blood glucose and blood pressure) domains.
Nutrients 2019, 11, 992; doi:10.3390/nu11050992 www.mdpi.com/journal/nutrients101
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1. Introduction
Energy drinks (EDs) are beverages that typically contain a mixture of caffeine, taurine,
herbal extracts (e.g., guarana, yerba mate, ginseng), vitamins (e.g., riboflavin, niacin, vitamin B-6),
glucuronolactone, proprietary blends, and amino acids [1].
They can boost energy, improve alertness and promote wakefulness when performing
high-intensity physical exercise [2], and, for this reason, they have become one of the substances most
commonly consumed by athletes and other practitioners of physical activity. According to Froiland
et al. [3], some 72.9% of U.S. college athletes are ED consumers.
Caffeine-containing EDs have been reported as beneficial in many sporting activities, possibly by
enhancing motor unit recruitment.
Del Coso et al. [4,5] showed that the ingestion of 3 mg/kg of caffeine in the form of a commercially
available ED increased overall running pace and sprint velocities during a rugby sevens competition.
In adolescent basketball players, the same dose increased jump performance with no adverse effect on
basketball shooting precision [6].
Del Coso et al. [7] noted that such an ED enhanced ball velocity in the spike test, the mean height
of squat and countermovement jumps, and performance on the 15-s rebound jump test and the agility
T-test. Furthermore, during a simulated game, players performed successful volleyball actions more
frequently (24.6% ± 14.3% vs. 34.3% ± 16.5%, p < 0.05) with ingestion of the caffeinated ED rather than
the placebo (PL) [7].
Although several studies have investigated the effects of ED on aerobic performance, there is as
yet only limited and inconclusive data about their impact on short-term maximal performance [8].
Fukuda et al. [9] reported that the ingestion of supplements containing creatine, or caffeine plus amino
acids improved the anaerobic running capacity by 10.8%.
In contrast, Hahn et al. [8] saw no beneficial effects of caffeine-containing ED on vertical jumping
and repeated sprinting (i.e., measures of mean and peak anaerobic power). Likewise, Gwacham and
Wagner [10] observed no ergogenic effect of caffeine-taurine ED on repeated sprinting (i.e., 6 × 35-s
with 10-s rest intervals).
Studies of relationships between caffeine-containing EDs and psychological variables are also
inconclusive to date; however, some studies have reported positive effects on subjective alertness,
mental focus, energy, and fatigue tolerance [8,11–14].
Alford et al. [11] saw a positive effect on reaction time (a decrease of 88.7 msec). Likewise,
Hoffman et al. [12] reported significant improvements in focus (+0.5 arbitrary units, AU) and energy
(+0.4 AU) after ingestion of caffeine-containing EDs compared to placebo (PL). Hahn et al. [8] also
described a significant reduction of perceived fatigue during repeated sprinting, and Wesnes et al. [15]
demonstrated significant improvement in the attentional capacity, vigilance, and numeric and spatial
working memory of healthy young adults after ingesting caffeine-containing ED.
However, no significant changes in mood state were seen. In contrast, Petrelli et al. [16] reported
significant reductions of anxiety and depression after ingestion of caffeine-containing ED consumption
compared to PL.
Physiological responses may also be affected by EDs. Del Coso et al. [17] found that
caffeine-containing EDs increased systolic and diastolic blood pressures, although Wesnes et al. [15]
did not show any significant change in blood glucose after drinking caffeine-containing EDs.
As yet, it remains unclear whether changes in mood state, blood pressures, and blood glucose
levels are related to these ergogenic effects. Thus, the purpose of the present study was to examine
relationships between the effects of caffeine-containing ED on (i) short-term maximal performance,
(ii) reaction times, and (iii) psychological variables (mood state, rating of perceived exertion (RPE),
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and affective load) and changes in physiological parameters (i.e., blood pressures and blood glucose
levels).
We hypothesized that the ergogenic effects of caffeine-containing EDs on short-term maximal
performance and reaction times would be related to positive changes in both psychological factors
(mood state, RPE, and affective load) and physiological parameters (blood pressures and blood glucose).
2. Materials and Methods
2.1. Participants Selection: Inclusion and Exclusion Criteria
The sample size was calculated a priori, using procedures suggested by Beck [18] and the software
G*Power [19]. Based on the results of Del Coso et al. [4,5], effect sizes were estimated to be 0.62
(medium effect). To reach the desired statistical power and in order to attribute observed differences to
factors other than chance alone, a minimum sample of 18 participants was required. To accommodate
a possible drop-out of some participants, we recruited a total of 22 healthy and regularly active
physical-education male students from various sports disciplines.
Potential participants were initially screened through telephone interviews based on the following
inclusion criteria: (i) 18–40 years of age, (ii) body mass index (BMI) less than 25 kg/m2, and iii) being
low (<1.5 g/month [20]) and not regular caffeine users.
Exclusion criteria included: i) diagnosis of any chronic metabolic disease such as type 2 diabetes
or cardiovascular disease, ii) diagnosis of an auto-immune disease such as rheumatoid arthritis, lupus,
or type 1 diabetes, liver disease and iii) the intake of any medications or dietary supplements known to
influence blood glucose concentrations or blood pressures.
The study was conducted according to the declaration of Helsinki and the protocol was fully
approved (identification code: 8/16) by the review board “Local Committee of the Laboratory of
Biochemistry, CHU Habib Bourguiba, Sfax, Tunisia.”
After a thorough explanation of the protocol with responses to all questions, participants signed a
written informed consent form.
Subjects were instructed to avoid nicotine, alcohol, dietary supplements, medications, and all
other stimulants and to maintain their normal dietary, sleep and physical activity patterns before
test sessions.
Caffeine and other caffeinated products (e.g., chocolate, caffeinated gums, caffeine-containing
beverages) were avoided for 48 h and food for at least 4 h before testing.
2.2. Experimental Design
A randomized double-blind, placebo-controlled, counterbalanced, crossover design was adopted
for this study. The randomized order of testing was determined using free online software
(www.randomization.com).
Neither staff nor participants were informed about the names of the two drinks, and blinding was
strictly maintained by emphasizing to both staff and participants that both drinks adhered to healthy
principles and that each drink was advocated by certain sports medicine experts.
Two familiarization sessions were completed before definitive test sessions in order to eliminate
any learning effects on physical performance and reaction time measurements. During the second
familiarization session, body mass, and height were recorded.
The experimental design of the present study is pictorially presented in Figure 1.
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Figure 1. Experimental design. PL = placebo; RB = Red Bull; POMS = profile of mood states;
RPE = rating of perceived exertion; HG = handgrip; RT = reaction time.
Each participant visited the laboratory for two formal test sessions, drinking a caffeine-containing
ED (RB) and a caffeine and taurine-free beverage drink (PL). All sessions were arranged in the early
evening hours to avoid any time of day effects, as suggested by Ammar et al. [21–23]. The two definitive
test sessions were separated by an interval of seven days to allow sufficient recovery between tests and
to ensure caffeine washout. To avoid identification, two opaque and unmarked cans [24–26] of RB or
PL were ingested by each participant (i.e., 500 mL) in the presence of a researcher. The two drinks
were similar in volume, texture, and appearance. One can of RB drink (i.e., 250 mL) contained 80 mg
of caffeine, 1 g of taurine, 27 g of carbohydrates, 0.6 g of protein, 5 mg of vitamin B6, and 487 kJ of
energy. The PL drink was prepared by an agri-food engineer; it did not contain any caffeine or taurine,
but comprised carbonated water, carbohydrates, citric acid lemon juice reconstituted from concentrate
(1%), supplemented by flavorings of sodium citrate, acesulfame K, sucralose, potassium sorbate and
RB flavoring that contains propylene glycol E1520 (0.23 mL). Of note, both the PL and RB drinks
were isocaloric.
Beverages were prepared, shaken and chilled in a refrigerator at 14h00 by an investigator who
took no part in the test sessions or data analysis, but prepared the alphanumeric code identifying
the tested drink. At 17h00, the cooled beverages were served in sealed plastic opaque water bottles
and consumed using an opaque straw. Participants were instructed to drink the fluid quickly (within
1 ± 0.5 min) 60 min before their test session and not to discuss or compare tastes or to make any
assumption about what they had ingested. The interval of 60 min was chosen as being optimal for a
complete caffeine absorption [27] and thus enabling the peaking of caffeine concentration [28].
Subjects were supervised by staff to ensure that they drank the entire quantity of fluid, and no
exchange of bottles was allowed. The last standardized meal (i.e., lunch) before the beginning of the
test session was taken at 13h00. Temperature and relative humidity of the laboratory were similar
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over the test sessions, with a temperature of around 22 ◦C and a relative humidity between 45 and
55%. During each test session (from 18h00), resting blood glucose and blood pressures were measured,
and the participants completed the POMS questionnaire.
In order to increase body temperature and thus improve the efficiency of the neuromuscular
system [22,29,30], a 5-min treadmill warm-up was performed [20] (Figure 1). After that, the reaction
time, the handgrip force and the 30-s Wingate tests were performed. RPE scores, blood glucose, and
blood pressures were then measured, and the affective load was calculated. To investigate the effects of
RB on the acute physiological and psychological responses to exercise, blood glucose and pressure and
RPE measures were collected immediately pre- and post-exercise (Figure 1).
2.3. Blood Glucose and Blood Pressure Measurements
Blood glucose was measured using the electrochemical sensor Rightest GM260 Blood Glucose
Monitoring System (Bionime Corporation, Taichung City, Taiwan). The fingertip was pricked
with a lancing device, and a specific test strip was soaked with blood and was inserted into the
measuring apparatus, with an estimate appearing within 5 s. Systolic blood pressure was measured
by the same physician using a stethoscope (Spengler, Germany) and sphygmomanometer (Spengler,
Germany). The intra-class correlation coefficient (ICC) and the standard error of the measurement (SEM)
showed good reliability for blood glucose pre- (ICC > 0.72, absolute SEM < 0.03) and post-exercise
(ICC > 0.71, absolute SEM < 0.04). Similar results were computed for blood pressure pre- (ICC > 0.72,
absolute SEM < 0.32) and post-exercise (ICC > 0.67, absolute SEM < 0.38).
2.4. Profile of Mood States (POMS)
The evaluation of mood states was performed using the French language version of the POMS
questionnaire. Responses to 65 adjectives (ranging from “Zero” (i.e., not at all) to “Four” (i.e., extremely)
assessed immediate mood states in seven dimensions: tension, depression, anger, vigor, fatigue,
confusion, and interpersonal relationships. As previous studies (e.g., [31]) utilized only six parameters of
the POMS questionnaire due to large variations affecting the dimension of “interpersonal relationships,”
this parameter was not included in the analysis. The ICC and SEM showed good reliability for depression
(ICC > 0.67, absolute SEM < 1.38), confusion (ICC > 0.68, absolute SEM < 1.39), fatigue (ICC>0.71,
absolute SEM < 1.04), vigor (ICC > 0.67, absolute SEM < 1.42), anger (ICC > 0.66, absolute SEM < 1.37),
and tension (ICC > 0.68, absolute SEM < 1.26), The ICC and SEM showed, instead, poor reliability for
interpersonal relationships (ICC > 0.1, absolute SEM < 1.95).
2.5. Rating of Perceived Exertion (RPE) and Affective Load
The original Borg RPE scale rates exertion subjectively during or after physical exercise on a
15-point scale ranging from six (extremely light) to twenty (extremely hard). It was used to calculate
the affective load; as suggested by Baron et al. [32], the affective load was obtained as the difference
between the perceived exertion (negative affective response) and pleasure scores (positive affective
response). For example, with an RPE score of six, the negative affective response is zero and the
positive affective response is −14. However, if the RPE score rises to 20, the negative affective response
is +14 and the positive affective response is zero. The potential affective load thus ranges from −14
to +14. A negative affective load score indicates the dominance of pleasant affective responses and a
positive affective load represents the dominance of unpleasant affective responses [33]. RPE and AL.
The ICC and the SEM showed good reliability for RPE and AL (ICC > 0.71, absolute SEM < 0.21).
2.6. Reaction Times and Handgrip Strength
A simple visual reaction time test assessed alertness and motor reaction-speed. Subjects responded
as quickly as possible to the presentation of a stimulus (the image of a black box) on a computer
screen (15” LCD). When this appears, the participant should press the index finger on a computer key.
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The signal appeared in random order within 1–10-s time intervals. Each participant was allowed ten
attempts and the mean reaction time was calculated, using React! V0.9 software.
Handgrip strength was recorded by a dynamometer (T.K.K. 5401; Takei, Tokyo, Japan).
The maximal handgrip force was determined for the dominant hand. Participants exerted their
maximal strength for 4–5-s. With the hand hanging downwards, the dynamometer was held freely
and without support. Three attempts were allowed with 1-min rest intervals, and the largest value
was recorded. The ICC and the SEM showed excellent reliability for both reaction time (ICC > 0.89,
absolute SEM < 0.14) and handgrip strength (ICC > 0.92, absolute SEM < 0.67) measurements.
2.7. Wingate Test
A calibrated mechanically-braked cycle ergometer (Monark 894; Stockholm, Sweden) interfaced
with a microcomputer was utilized for the 30-s Wingate test. Subjects pedaled as fast as possible
for 30-s against a constant load calculated according to the participant’s body mass (i.e., 8.7%).
After maintaining a constant ~60 rpm speed for 4–6-s against minimal resistance, the selected load
was applied. The participant sat on the cycle throughout and was strongly encouraged to maximize
pedaling rates and to maintain a high speed. Peak and mean power (i.e., the average power output
after 30-s) were recorded. The fatigue index was calculated as follows:
Fatigue index (%) = (peak power −minimal power)/peak power × 100 (1)
The ICC and the SEM showed excellent reliability for peak power (ICC> 0.98, absolute SEM< 0.21),
mean power (ICC > 0.98, absolute SEM < 0.23) and fatigue index (ICC > 0.76, absolute SEM < 1.99).
2.8. Statistical Analysis
Results for all parameters are presented as mean ± standard deviation (SD). Data analyses were
carried out using the commercial software “Statistical Package for Social Sciences” SPSS v21.0 software
(SPSS Inc., Chicago, IL) and Microsoft Excel 2010 (Microsoft Corp., Redmont, WA, USA).
To determine whether two familiarization sessions had been sufficient to remove any learning
effects, the intra-class correlation coefficient (ICC) and the standard error of the measurement (SEM)
were calculated for all parameters. ICC values over 0.75 were considered as evidence of excellent
reproducibility, ICC values between 0.4 and 0.75 were considered as good reproducibility and ICC
values less than 0.4 were considered as poor reproducibility.
All parameters met parametric assumptions on the basis of the Shapiro-Wilk’s test. Student’s
t-test was used to compare RB and PL and RB with the exception of blood glucose and blood pressures.
The effect size (ES) was calculated according to the formula of Glass and magnitudes were interpreted
using the Cohen scale: ES < 0.2 was considered as small, ES around 0.5 was considered as medium
and ES > 0.8 was considered as large. The mean confidence interval (CI) was determined at 95%.
For blood glucose and blood pressure, a two-way analysis of variance (ANOVA) (2 (Drink)
× 2 (Exercise)) was utilized. When a significant main effect or interaction was detected, pair-wise
comparisons were assessed using the Bonferroni test in order to ensure protection against multiple
comparisons. The Δ-change induced by the drinks (i.e., the difference between PL and RB) was
calculated as follow:
Δ-change drink = RB - PL (2)
The Δ-change associated with the exercise bout (i.e., the difference between pre- and post-Wingate)
was calculated as follow:
Δ-change exercise = POST - PRE (3)
To assess the relationships between (i) physical and performance and (ii) psychological,
physiological, and reaction time parameters, Bland–Altman correlations were used. The significant
difference was set at an alpha level of p ≤ 0.05 throughout, except in those cases in which multiple
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comparisons were performed. Exact p-values have been reported and results indicated as “0.000” have
been expressed as “<0.0005”.
3. Results
3.1. Participant Characteristics
Over the study, three participants were unable to complete all test sessions due to muscle pain
or injury (Figure 2). Thus, 19 participants (age: 21.2 ± 1.2 years; height: 1.76 ± 0.8 m; body-mass:
76.6 ± 12.6 kg) completed all test sessions (Figure 2).
Figure 2. CONSORT flow chart-trial of the study protocol.
3.2. Physical Performance and Reaction Times
Physical parameters and reaction time recorded during the RB and PL conditions are presented in
Table 1.
Table 1. Confidence intervals (CI), Δ-change and mean and standard deviations (SD) of peak and mean
power and the fatigue index registered during the Wingate test, handgrip force, and reaction times




Mean ± SD CI Mean ± SD CI
Peak power (W·kg−1) 10.5 ± 1.5 9.8–11.2 11.4 ± 0.9 11.0–11.9 0.93 *
Mean power (W·kg−1) 8.1 ± 1.0 7.65–8.63 9.01 ± 0.92 8.56–9.46 0.87 **
Fatigue index (%) 47.9 ± 8.1 44.0–51.8 49.1 ± 4.8 46.8–51.4 1.21
Hand grip force (kg) 55.5 ± 2.7 54.18–57.03 58.2 ± 2.4 56.8–59.4 2.69 **
Reaction time (s) 0.36 ± 0.05 0.34–0.39 0.28 ± 0.02 0.27-0.29 −0.08 ***
*, **, ***: Significant difference between RB and PL at p < 0.05, p < 0.01 and p < 0.001 respectively.
Statistical analysis showed a significant improvement for peak power (t = −2.33; p = 0.0250),
mean power (t = −2.74; p = 0.0093), and hand grip force (t = −3.21; p = 0.0027) between PL and RB
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and there was a significant reduction in the reaction time (t = 5.94; p < 0.0005) with RB ingestion
as compared to PL, but there was no significant difference of fatigue index between the two drink
conditions (t = −0.56; p = 0.5775).
3.3. Blood Glucose and Blood Pressures
Blood glucose levels recorded pre- and post-exercise are presented in Figure 3.
Figure 3. Evolution of blood glucose levels (mean ± SD) from pre- to post-exercise during the placebo
(PL) and the Red Bull (RB) sessions. ***: Significant differences compared to PL at p < 0.001. +, +++:
Significant difference compared to pre-exercise at p < 0.05 and p < 0.001 respectively.
There were significant main effects for Drink (F = 36.75; ηp2 = 0.67; p < 0.0005) and Exercise
(F = 76.94; ηp2 = 0.81; p < 0.0005), and the interaction Drink × Exercise was also significant (F = 8.96;
ηp
2 = 0.33; p = 0.0077). Post-hoc testing showed that blood glucose was significantly lower after
rather than before exercise in both conditions (p < 0.0005 for PL and for RB), with a greater reduction
during RB than in the PL condition (Δ-change: −0.29 g/L vs. −0.20 g/L). However, post-hoc testing
revealed significant increases of blood glucose with RB in comparison to PL, both pre- (p < 0.0005) and
post-exercise (p = 0.0105), with greater gains before rather than after exercise (Δ-change: 0.17 g/L vs.
0.08 g/L).
Blood pressures before and after exercise are presented in Figure 4.
Figure 4. Evolution of blood pressure (Mean ± SD) between pre- and post-exercise during the placebo
(PL) and the red bull (RB) sessions. *, **: Significant difference compare to PL at p < 0.05 and p < 0.01
respectively. +++: Significant difference compared to pre-exercise at p < 0.001.
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There were significant main effects for Drink (F = 34.30; ηp2 = 0.65; p < 0.0005) and Exercise
(F = 216.49; ηp2 = 0.92; p < 0.0005), but the interaction Drink × Exercise was not significant (F = 0.02;
ηp
2 = 0.001; p = 0.9005). Post-hoc testing showed significantly higher values of blood pressure after than
before exercise in both conditions (p < 0.0005). Moreover, post-hoc tests revealed significant greater
blood pressure with RB in comparison to PL at both pre- (p = 0.0120) and post-exercise (p = 0.0080).
3.4. Ratings of Perceived Exertion (RPE), Affective Load and Profile of Mood States (POMS)
POMS parameters, affective load and RPE during PL and RB conditions are presented in Table 2.
Table 2. Confidence interval (CI), Δ-change and mean and standard deviation (SD) for individual
Profile of Mood State parameters (i.e., depression, confusion, fatigue, vigor, anger, and anxiety) and
ratings of perceived exertion (RPE) recorded during the red bull (RB) and placebo (PL) conditions.
POMS
Parameter/RPE
PL BE Δ-Change (AU)
Induced by RB
Mean ± SD CI Mean ± SD CI
Depression (AU) 6.1 ± 5.1 3.6–8.5 4.8 ± 2.2 3.8–5.9 −1.2
Confusion (AU) 7.3 ± 6.0 4.4–10.2 4.2 ± 2.0 3.2–5.1 −3.1 *
Fatigue (AU) 13.8 ± 2.1 12.9–14.8 12.7 ± 2.1 11.7–13.8 −1.1 *
Vigor (AU) 14.7 ± 5.8 12.0–17.5 18.2 ± 4.2 16.1–20.2 3.4 *
Anger (AU) 4.8 ± 3.2 3.2–6.3 3.4 ± 3.2 1.9–5.0 −14.*
Anxiety (AU) 10.8 ± 5.3 8.2–13.3 8.3 ± 2.9 6.9–9.7 −2.5
RPE (AU) 17.5 ± 1.3 16.9–18.2 15.9 ± 1.1 15.4–16.4 −17 ***
Affective load (AU) 9.1 ± 2.6 7.8–10.3 5.8 ± 2.1 4.8–6.8 −3.3 ***
*, ***: Significant difference between RB and PL at p < 0.05 and p < 0.001 respectively.
Although no significant difference between the two drinks conditions was reported for depression
(t = 1.07; p = 0.2952) and anxiety (t = 1.94; p = 0.0675), RB was associated with a significant reduction
in scores for confusion (t = 2.32; p = 0.0322), fatigue (t = 2.34; p = 0.0305), anger (t = 2.43; p = 0.0258),
RPE (t = 4.30; p = 0.0001), and affective load (t = 4.77; p = 0.0001). In contrast, vigor increased
significantly (t = −2.63; p = 0.0167) with RB.
3.5. Correlations between the Recorded Parameters
Peak power was significantly correlated with RPE (r = −0.48; p = 0.0322), affective load (r = −0.48;
p = 0.0322), pre- (r = 0.59; p < 0.01) and post-exercise (r = 0.65; p = 0.0019) levels of blood glucose,
and scores for fatigue (r = −0.50; p = 0.0230) and anxiety (r = −0.50; p = 0.0244). Mean power was
also significantly correlated with RPE (r = −0.64; p = 0.0023), affective load (r = −0.64; p = 0.0023),
pre- (r = 0.68; p = 0.0009) and post-exercise (r = 0.69; p = 0.0007) blood glucose levels, pre-exercise
blood pressure (r = −0.50; p = 0.0233) and scores for fatigue (r = −0.55; p = 0.0113) and anger (r = −0.54;
p = 0.0148). However, no significant correlations were observed between fatigue index and blood
glucose, blood pressure POMS scores, affective load, or RPE. Handgrip force was significantly correlated
with RPE (r = −0.60 p = 0.0049), affective load (r = −0.60; p = 0.0049), pre- (r = 0.78; p < 0.0005) and
post-exercise (r = 0.57; p = 0.0082) blood glucose and pre- (r = 0.62; p = 0.0037) and post-exercise
(r = 0.54; p = 0.0139) blood pressures. Reaction time was significantly correlated with RPE (r = 0.72;
p < 0.0005), affective load (r = 0.72; p < 0.0005), pre- (r = 0.57; p = 0.0080) and post-exercise (r = 0.48;
p = 0.0290) blood glucose, pre- (r = −0.73; p < 0.0005) and post-exercise (r = −0.72; p < 0.0005) blood
pressures and POMS scores for confusion (r = 0.46; p = 0.0387), vigor (r = −0.62; p = 0.0035), and anger
(r = 0.46; p = 0.0393).
4. Discussion
The main findings from the present study were that RB increases peak power (+0.93 W·kg−1) and
mean power (+0.87 W·kg−1) during the 30-s Wingate test, and handgrip force (+2.69 kg), also speeding
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the reaction time (−0.08 s). Additionally, physiological responses to exercise (i.e., blood glucose and
blood pressure) are increased and the RB increases vigor with reduction of ratings for depression,
confusion, fatigue, anger, anxiety, RPE, and affective load.
In agreement with the present results, Alford et al. [11] reported that RB had a positive effect on
short-term maximal performance during the Wingate test. Forbes et al. [34] also found that RB tended
to a positive (but not significant effect) on peak and mean power during three consecutive Wingate
tests. The latter authors also reported significant increases in total repetitions over three sets of bench
press exercises.
In the present study, increases of peak and mean power during the 30-s Wingate test were
significantly correlated with decreases in RPE, affective load, and scores for fatigue, anxiety (for peak
power only), and anger (for mean power only). Increases in handgrip force were also related to
decreases of RPE and affective load. A previous study also reported that the handgrip force was greater
after caffeinated-ED than after PL [7,35]. In agreement with the present study’ results, Hahn et al. [8]
reported significant reductions in fatigue scores when performing a repeated-sprint exercise. However,
they did not show any improvement in performance during the repeated sprinting. From the present
results, the increases in short-term maximal performances induced by RB could be explained by a
reduced perception of exertion and fatigue. Increases are also related to a reduction of affective load,
a change of perceptions in that part of the brain responsible for pacing strategy during physical exercise.
Pacing regulates energy expenditures during exercise. Better short-term maximal performance
after RB ingestion reflects higher energy expenditures, as shown by the higher pre- and post-exercise
blood glucose concentrations during the RB session and by the greater decreases of blood sugar from
before to after exercise (−0.29 g/L vs. −0.20 g/L in PL).
Lim et al. [36] showed that in people who do not normally consume caffeine, taurine ingestion
is detrimental to maximal voluntary muscle power and both maximal isometric and isokinetic peak
torque, whereas taurine ingestion in caffeine-deprived caffeine consumers improves maximal voluntary
muscle power but has no effect on other aspects of contractile performance.
Graham et al. [37] showed that the beneficial effects of caffeine ingestion on short-term maximal
performance were related to muscle fat oxidation and better glycogen sparing capacity. A recent
meta-analysis by Grgic [38] and by Grgic et al. [39] concluded that caffeine ingestion may increase
both peak and mean power output during the Wingate test. In an umbrella review of 21 published
meta-analyses, Grgic et al. [40] concluded that caffeine ingestion improved a broad range of exercise
performance measures such as muscle strength, muscle endurance, anaerobic power, and aerobic
endurance. Mechanisms explaining such findings include an increased Ca2+ release from the
sarcoplasmic reticulum, which may lead to an increase in tetanic tension, and the alterations that
caffeine might have on the neuromuscular transmission [41]. In an animal study, it has been shown
that caffeine may enhance Ca2+ release from the sarcoplasmic reticulum and improve motor unit
recruitment by inhibiting the action of adenosine on the central nervous system [42]. Glucose is an
important metabolic substrate responsible for most of the energy release during anaerobic exercise.
Thus, the pre- and post-exercise increases of blood glucose could, in part, explain the improvement of
short-term maximal performance.
In support of these hypotheses, the present results demonstrated a significant correlation between
peak and mean power during the 30-s Wingate test and the pre- and post-exercise glucose. Also, it has
been reported that glucose increases are related to an improvement in cognitive performance [43]. In this
context, the present study showed significant correlations between pre- and post-exercise blood glucose
and reaction time. Alford et al. [11] also reported significant improvements in choice reaction time,
memory, and concentration (i.e., the number of correct cancellations) after RB ingestion compared to
the PL condition. These authors concluded that RB ingestion improved alertness. This same conclusion
is supported by Mets et al. [44], who showed that RB ingestion improved driving performance and
reduced driver sleepiness. The present study indicated a significant correlation between peak and
mean power during the Wingate test and negative components of mood state (i.e., anxiety and anger).
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Lara et al. [45] also reported a significant improvement in the short-term maximal performance of
swimmers and a significant reduction in anxiety scores after ED consumption.
The present study demonstrated a significant correlation between (i) reaction time and (ii)
positive (i.e., vigor) and negative (i.e., confusion and anger) components of mood state. Therefore,
the enhancement of reaction time could be explained in part by a reduction of confusion and anger
and an improvement of vigor. These findings are supported by Wesnes et al. [15] who suggested
that cognitive performance increased with the improvement of positive and a reduction of negative
components of mood state. On the other hand, as previously reported by Del Coso et al. [4,5] and
Abian-Vicen et al. [6] some subjects do not seem to respond to the ergogenic effects of caffeine-containing
ED. In the present study, four participants could be classified as non- responders in terms of their
performance on the Wingate test; although their performance of the handgrip and reaction time tests
did improve after RB ingestion compared to the PL.
Limitations
One limitation when interpreting this research is that the commercially-prepared ED evaluated
contained several potentially ergogenic ingredients, including compounds such as caffeine,
carbohydrates, and taurine while the PL control drink did not include these substances. Therefore,
it was not possible to identify the specific influence of any one of these several active ingredients on
performance. Future studies should focus on the specific influence of individual active ingredients.
Another limitation inherent to the present study is that the participants were not regular caffeine
users and, then, results could not be generalized to people who do regularly consume caffeine. Also,
the fact that no-baseline (i.e., before RB or PL consumption) measurement was performed represents
another shortcoming of the present investigation.
No immediate adverse effects were seen from the RB, but a more deliberate search for negative
consequences of caffeine ingestion, such as an increase of speed at the expense of skills, would seem
justified. Another limitation of the present study is that enrolled subjects were all male. Future studies
using female or mixed-gender samples are warranted.
Further, the effectiveness of subject blinding was not tested by post-study debriefing. This is of
some importance, because outcomes may be influenced if a participant recognizes that one of the
beverages provided contains caffeine [46]. Tallis et al. [47] underlined that the psychological effects of
“expectancy” and “belief” could have a significant impact on performance. Therefore, future studies
should use a double-blind design and assess the effectiveness of the blinding.
5. Conclusions
The present study has demonstrated that cognitive (i.e., reaction time) and short-term maximal
(i.e., handgrip and Wingate) performances are improved after RB ingestion. Further, ingestion of this
ED increases physiological responses to the 30-s Wingate test, with increases of pre- and post-exercise
blood glucose and blood pressures. Further RB consumption reduces negative effects on mood state
(i.e., decreased scores for depression, confusion, fatigue, anger, and anxiety) and enhances the positive
components of mood state (i.e., vigor), with favorable changes of RPE and affective load, thus leading
to improvements in physical performance.
Gains of physical performance after RB consumption reflect changes in blood glucose and blood
pressure. Cognitive gains (i.e., a speeding of reaction time) are related to both psychological (i.e.,
a reduction of confusion, anger, and RPE and an increase of vigor) and physiological responses (i.e.,
changes in blood glucose and blood pressure) ergogenic changes.
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A.A.; validation, H.C., K.T., and N.L.B.; formal analysis, A.A. and N.L.B.; investigation, H.C., K.T., A.A., and N.L.B.;
resources, N.L.B.; data curation, A.A.; writing—original draft preparation, H.C., K.T., and A.A.; writing—review
and editing, N.L.B. and R.J.S.; visualization, N.L.B.; supervision, H.C.; project administration, N.L.B.; funding
acquisition, N.L.B.
111
Nutrients 2019, 11, 992
Funding: This research received no external funding.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Higgins, J.P.; Babu, K.; Deuster, P.A.; Shearer, J. Energy drinks: A contemporary issues paper. Curr. Sports
Med. Rep. 2018, 17, 65–72. [CrossRef]
2. Jacobson, B.H.; Hester, G.M.; Palmer, T.B.; Williams, K.; Pope, Z.K.; Sellers, J.H.; Conchola, E.C.; Woolsey, C.;
Estrada, C. Effect of energy drink consumption on power and velocity of selected sport performance activities.
J. Strength Cond. Res. 2018, 32, 1613–1618. [CrossRef] [PubMed]
3. Froiland, K.; Koszewski, W.; Hingst, J.; Kopecky, L. Nutritional supplement use among college athletes and
their sources of information. Int. J. Sport. Nutr. Exerc. Metab. 2004, 14, 104–120. [CrossRef]
4. Del Coso, J.; Portillo, J.; Muñoz, G.; Abián-Vicén, J.; Gonzalez-Millán, C.; Muñoz-Guerra, J. Caffeine containing
energy drink improves sprint performance during an international rugby sevens competition. Amino Acids
2013, 44, 1511–1519. [CrossRef] [PubMed]
5. Del Coso, J.; Ramirez, J.A.; Muñoz, G.; Portillo, J.; Gonzalez-Millán, C.; Muñoz, V.; Barbero-Álvarez, J.C.;
Muñoz-Guerra, J. Caffeine containing energy drink improves physical performance of elite rugby players
during a simulated match. Appl. Physiol. Nutr. Metab. 2013, 38, 368–374. [CrossRef]
6. Abian-Vicen, J.; Puente, C.; Salinero, J.J.; González-Millán, C.; Areces, F.; Muñoz, G.; Muñoz-Guerra, J.;
Del Coso, J. A caffeinated energy drink improves jump performance in adolescent basketball players.
Amino Acids 2014, 46, 1333–1341. [CrossRef]
7. Del Coso, J.; Pérez-López, A.; Abian-Vicen, L.; Salinero, J.J.; Lara, B.; Valadés, D. Enhancing physical
performance in male volleyball players with a caffeine-containing energy drink. Int. J. Sports Physiol. Perform.
2014, 9, 1013–1018. [CrossRef]
8. Hahn, C.J.; Jagim, A.R.; Camic, C.L.; Andre, M.J. Acute Effects of a Caffeine-Containing Supplement on
Anaerobic Power and Subjective Measurements of Fatigue in Recreationally Active Men. J. Strength Cond.
Res. 2018, 32, 1029–1035. [CrossRef] [PubMed]
9. Fukuda, D.; Smith, A.; Kendall, K.; Stout, J. The possible combinatory effects of acute consumption of caffeine,
creatine, and amino acids on the improvement of anaerobic running performance in humans. Nutr. Res.
2010, 30, 607–614. [CrossRef]
10. Gwacham, N.; Wagner, D.R. Acute effects of a caffeine-taurine energy drink on repeated sprint performance
of American college football players. Int. J. Sport Nutr. Exerc. Metab. 2012, 22, 109–116. [CrossRef]
11. Alford, C.; Cox, H.; Wescott, R. The effects of red bull energy drink on human performance and mood.
Amino Acids 2001, 21, 139–150. [CrossRef]
12. Hoffman, J.; Kang, J.; Ratamess, N.; Hoffman, M.; Tranchina, C.; Faigenbaum, A. Examination of a pre-exercise,
high energy supplement on exercise performance. J. Int. Soc. Sports Nutr. 2009, 6, 1–8. [CrossRef]
13. Brunyé, T.; Mahoney, C.; Lieberman, H.; Taylor, H. Caffeine modulates attention network function. Brain Cogn.
2010, 72, 181–188. [CrossRef]
14. Jagim, A.; Jones, M.; Wright, G.; Antoine, C.; Kovacs, A.; Oliver, J. The acute effects of multi-ingredient
pre-workout ingestion on strength performance, lower body power, and anaerobic capacity. J. Int. Soc. Sports
Nutr. 2016, 13, 1–10. [CrossRef]
15. Wesnes, K.A.; Brooker, H.; Watson, A.W.; Bal, W.; Okello, E. Effects of the Red Bull energy drink on cognitive
function and mood in healthy young volunteers. J. Psychopharmacol. 2017, 31, 211–221. [CrossRef] [PubMed]
16. Petrelli, F.; Grappasonni, I.; Evangelista, D.; Pompei, P.; Broglia, G.; Cioffi, P.; Kracmarova, L.; Scuri, S.
Mental and physical effects of energy drinks consumption in an Italian young people group: a pilot study.
J. Prev. Med. Hyg. 2018, 59, E80–E87. [PubMed]
17. Del Coso, J.; Salinero, J.J.; González-Millán, C.; Abián-Vicén, J.; Pérez-González, B. Dose response effects of a
caffeine-containing energy drink on muscle performance: a repeated measures design. J. Int. Soc. Sports
Nutr. 2012, 9, 21. [CrossRef]
18. Beck, T.W. The importance of a priori sample size estimation in strength and conditioning research. J. Strength.
Cond. Res. 2013, 27, 2323–2337. [CrossRef]
19. Faul, F.; Erdfelder, E.; Lang, A.G.; Buchner, A.G. Power 3: A flexible statistical power analysis program for
the social, behavioral, and biomedical sciences. Behav. Res. Methods. 2007, 39, 175–191. [CrossRef]
112
Nutrients 2019, 11, 992
20. Prins, P.J.; Goss, F.L.; Nagle, E.F.; Beals, K.; Robertson, R.J.; Lovalekar, M.T.; Welton, G.L. Energy Drinks
Improve Five-Kilometer Running Performance in Recreational Endurance Runners. J. Strength. Cond. Res.
2016, 30, 2979–2990. [CrossRef]
21. Ammar, A.; Chtourou, H.; Hammouda, O.; Trabelsi, K.; Chiboub, J.; Turki, M.; AbdelKarim, O.; El Abed, K.;
Ben Ali, M.; Hoekelmann, A.; Souissi, N. Acute and delayed responses of C-reactive protein, malondialdehyde
and antioxidant markers after resistance training session in elite weightlifters: Effect of Time of day.
Chronobiol. Int. 2015, 32, 1211–1222. [CrossRef]
22. Ammar, A.; Chtourou, H.; Souissi, N. Effect of time-of-day on biochemical markers in response to physical
exercise. J. Strength. Cond. Res. 2017, 31, 272–282. [CrossRef] [PubMed]
23. Ammar, A.; Chtourou, H.; Hammouda, O.; Turki, M.; Ayedi, F.; Kallel, C.; AbdelKarim, O.; Hoekelmann, A.;
Souissi, N. Relationship between biomarkers of muscle damage and redox status in response to a weightlifting
training session: effect of time-of-day. Physiol. Int. 2016, 103, 243–261. [CrossRef]
24. Ammar, A.; Turki, M.; Hammouda, O.; Chtourou, H.; Trabelsi, K.; Bouaziz, M.; Abdelkarim, O.;
Hoekelmann, A.; Ayadi, F.; Souissi, N.; Bailey, S.J.; Driss, T.; Yaich, S. Effects of Pomegranate Juice
Supplementation on Oxidative Stress Biomarkers Following Weightlifting Exercise. Nutrients 2017, 9, 819.
[CrossRef]
25. Ammar, A.; Bailey, S.J.; Chtourou, H.; Trabelsi, K.; Turki, M.; Hökelmann, A.; Souissi, N. Effects of
pomegranate supplementation on exercise performance and post-exercise recovery: A systematic review.
Br. J. Nutr. 2018, 20, 1201–1216. [CrossRef]
26. Ammar, A.; Turki, M.; Chtourou, H.; Hammouda, O.; Trabelsi, K.; Kallel, C.; Abdelkarim, O.; Hoekelmann, A.;
Bouaziz, M.; Ayadi, F.; Driss, T.; Souissi, N. Pomegranate Supplementation Accelerates Recovery of Muscle
Damage and Soreness and Inflammatory Markers after a Weightlifting Training Session. PLoS ONE 2016,
11, e0160305. [CrossRef]
27. Armstrong, L.E. Caffeine, body fluid-electrolyte balance, and exercise performance. Int. J. Sport Nutr. Exerc.
Metab. 2002, 12, 189–206. [CrossRef] [PubMed]
28. Graham, T.E. Caffeine and exercise: metabolism, endurance and performance. Sports Med. 2001, 31, 785–807.
[CrossRef] [PubMed]
29. Joch, W.; Uckert, S. Il riscaldamento ed i suoi effetti. Scuola Dello Sport Italie. 2001, 20, 49–54.
30. Ammar, A.; Chtourou, H.; Trabelsi, K.; Padulo, J.; Turki, M.; El Abed, K.; Hoekelmann, A.; Hakim, A.
Temporal specificity of training: intra-day effects on biochemical responses and Olympic-Weightlifting
performances. J. Sports Sci. 2015, 33, 358–368. [CrossRef]
31. Yeun, E.J.; Shin-Park, K.K. Verification of the profile of mood states-brief: Cross-cultural analysis. J. Clin.
Psychol. 2006, 62, 1173–1180. [CrossRef]
32. Baron, B.; Moullan, F.; Deruelle, F.; Noakes, T.D. The role of emotions on pacing strategies and performance
in middle and long duration sport events. Br. J. Sports Med. 2011, 45, 511–517. [CrossRef] [PubMed]
33. Abel, A.; Baron, B.; Grappe, F.; Francaux, M. Effect of environmental feedbacks on pacing strategy and
affective load during a self-paced 30 min cycling time trial. J. Sports Sci. 2018, 18, 1–7.
34. Forbes, S.C.; Candow, D.G.; Little, J.P.; Magnus, C.; Chilibeck, P.D. Effect of Red Bull energy drink on repeated
Wingate cycle performance and bench-press muscle endurance. Int. J. Sport Nutr. Exerc. Metab. 2007, 17,
433–444. [CrossRef]
35. Astley, C.; Souza, D.B.; Polito, M.D. Acute Specific Effects of Caffeine-containing Energy Drink on Different
Physical Performances in Resistance-trained Men. Int. J. Exerc. Sci. 2018, 11, 260–268.
36. Lim, Z.X.; Singh, A.; Leow, Z.Z.X.; Arthur, P.G.; Fournier, P.A. The Effect of Acute Taurine Ingestion on
Human Maximal Voluntary Muscle Contraction. Med. Sci. Sports Exerc. 2018, 50, 344–352. [CrossRef]
[PubMed]
37. Graham, T.E.; Battram, D.S.; Dela, F.; El-Sohemy, A.; Thong, F.S. Does caffeine alter muscle carbohydrate and
fat metabolism during exercise? Appl. Physiol. Nutr. Metab. 2008, 33, 1311–1318. [CrossRef]
38. Grgic, J. Caffeine ingestion enhances Wingate performance: a meta-analysis. Eur. J. Sport Sci. 2018, 18,
219–225. [CrossRef] [PubMed]
39. Grgic, J.; Trexler, E.T.; Lazinica, B.; Pedisic, Z. Effects of caffeine intake on muscle strength and power:
A systematic review and meta-analysis. J. Int. Soc. Sports Nutr. 2018, 15, 11. [CrossRef]
113
Nutrients 2019, 11, 992
40. Grgic, J.; Grgic, I.; Pickering, C.; Schoenfeld, B.J.; Bishop, D.J.; Pedisic, Z. Wake up and smell the coffee:
Caffeine supplementation and exercise performance—An umbrella review of 21 published meta-analyses.
Br. J. Sports Med. 2019. [CrossRef] [PubMed]
41. Davis, J.K.; Green, J.M. Caffeine and anaerobic performance: Ergogenic value and mechanisms of action.
Sports Med. 2009, 39, 813–832. [CrossRef] [PubMed]
42. Davis, J.M.; Zhao, Z.; Stock, H.S.; Mehl, K.A.; Buggy, J.; Hand, G.A. Central nervous system effects of caffeine
and adenosine on fatigue. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003, 284, R399–R404. [CrossRef]
[PubMed]
43. Benton, D.; Owens, D.S. Blood glucose and human memory. Psychopharmacology 1993, 113, 83–88. [CrossRef]
[PubMed]
44. Mets, M.A.; Ketzer, S.; Blom, C.; van Gerven, M.H.; van Willigenburg, G.M.; Olivier, B.; Verster, J.C.
Positive effects of Red Bull® Energy Drink on driving performance during prolonged driving.
Psychopharmacology 2011, 214, 737–745. [CrossRef] [PubMed]
45. Lara, B.; Gonzalez-Millán, C.; Salinero, J.J.; Abian-Vicen, J.; Areces, F.; Barbero-Alvarez, J.C.; Muñoz, V.;
Portillo, L.J.; Gonzalez-Rave, J.M.; Del Coso, J. Caffeine containing energy drink improves physical
performance in female soccer players. Amino Acids. 2014, 46, 1385–1392. [CrossRef] [PubMed]
46. Saunders, B.; de Oliveira, L.F.; da Silva, R.P.; de Salles Painelli, V.; Gonçalves, L.S.; Yamaguchi, G.; Mutti, T.;
Maciel, E.; Roschel, H.; Artioli, G.G.; Gualano, B. Placebo in sports nutrition: A proof-of-principle study
involving caffeine supplementation. Scand. J. Med. Sci. Sports. 2017, 27, 1240–1247. [CrossRef]
47. Tallis, J.; Muhammad, B.; Islam, M.; Duncan, M.J. Placebo effects of caffeine on maximal voluntary concentric
force of the knee flexors and extensors. Muscle Nerve. 2016, 54, 479–486. [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution




Challenging the Myth of Non-Response to the
Ergogenic Effects of Caffeine Ingestion on
Exercise Performance
Juan Del Coso *, Beatriz Lara, Carlos Ruiz-Moreno and Juan José Salinero
Exercise Physiology Laboratory, Camilo José Cela University, 28692 Madrid, Spain; blara@ucjc.edu (B.L.);
cruizm@ucjc.edu (C.R.-M.); jjsalinero@ucjc.edu (J.J.S.)
* Correspondence: jdelcoso@ucjc.edu; Tel.: +34-918-153-131
Received: 7 March 2019; Accepted: 27 March 2019; Published: 29 March 2019
Abstract: The ergogenicity of caffeine on several exercise and sport situations is well-established.
However, the extent of the ergogenic response to acute caffeine ingestion might greatly vary among
individuals despite using the same dosage and timing. The existence of one or several individuals
that obtained minimal ergogenic effects or even slightly ergolytic effects after caffeine intake (i.e.,
non-responders) has been reported in several previous investigations. Nevertheless, the concept
non-responding to caffeine, in terms of physical performance, relies on investigations based on
the measurement of one performance variable obtained once. Recently it has been suggested that
correct identification of the individual ergogenic effect induced by caffeine intake requires the
repeated measurement of physical performance in identical caffeine–placebo comparisons. In this
communication, we present data from an investigation where the ergogenic effect of acute caffeine
intake (3 mg/kg) was measured eight times over a placebo in the same individuals and under the
same conditions by an incremental cycling test to volitional fatigue and an adapted version of the
Wingate cycling test. The ergogenic response to caffeine varied from 9% to 1% among individuals, but
all participants increased both cycling power in the incremental test and Wingate mean power at least
three to eight times out of eight the caffeine–placebo comparisons. These data expand the suggestion
of a minimal occurrence of caffeine non-responders because it shows that all individuals responded
to caffeine when caffeine is compared to a placebo on multiple and repeated testing sessions.
Keywords: individual responses; responders; exercise performance; ergogenic aids
1. Introduction
2018 has been a prolific year for the publication of manuscripts aimed at explaining the causes of
the interindividual variations for the ergogenic response of caffeine ingestion on exercise performance.
Particularly, we read with interest the reviews by Southward et al. [1] and Fulton et al. [2] and the letter
by Grgic [3], published in Nutrients in 2018, because they offered new insights towards unveiling the
causes of the variability on physiological responses to caffeine. With this communication, we want to
expand the understanding about why some individuals obtain less ergogenic benefits after the ingestion
of a moderate dose of caffeine than others, and perhaps it will help to dispel the myth/concept of
non-responders to caffeine, at least when referring to exercise performance.
2. Individual Responses to Ergogenic Effects of Caffeine Ingestion
The utility of caffeine to increase physical performance in several exercise and sport situations
is well-established and has been recently confirmed by systematic reviews and meta-analyses [4–7].
In addition, the use of caffeine or caffeinated products before competition is high, especially in individual
sports or athletes of sports with an aerobic-like nature [8]. However, a small number of investigations
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have shown that the extent of the ergogenic response(s) to acute caffeine ingestion might greatly vary
among individuals ([9–11] and the analysis of several investigations in [3]). These latter investigations
have used cross-over and randomized experimental designs where the intake of a moderate dose of
caffeine (1–6 mg/kg) is compared to a placebo condition in a group of individuals. Interestingly, these
investigations indicated that, despite caffeine having produced an increase in physical performance as a
group mean, one or several individuals obtained minimal ergogenic effects or even slightly ergolytic
effects after caffeine intake despite being under the same experimental protocol. These individuals are
frequently categorized as non-responders to the ergogenic effects of caffeine [12] and the causes for the
lack of a positive physical response to caffeine have been associated to genetic (CYP1A2 and ADORA2A
polymorphisms) and environmental factors, such as tolerance developed by chronic caffeine use and
inappropriate timing and dose of administration or training status [13,14].
3. The Concept of Non-Responding to Caffeine Based on One Caffeine–Placebo Comparison
Recently, Pickering and Kiely [13] and Grgic [3] have criticized the concept non-responding to
caffeine, in terms of physical performance, because this notion mostly relies on investigations based on
the measurement of one performance variable obtained once. This experimental methodology to assess
individual responses to caffeine ingestion might produce erroneous inferences because an individual
does not always respond to caffeine to the same extent in all forms of exercise testing [9,15]. In addition,
the reliability of the exercise test also needs to be considered when extrapolating conclusions regarding
possible non-responses to the performance-enhancing effects of acute caffeine intake [3]. In fact,
investigations where the ergogenic response to caffeine was explored by using the results of more than
one physical performance test have shown that one participant might be categorized as a responder
and a non-responder to caffeine at the same time due to his/her different outcomes in the different
performance tests [9,15]. Pickering and Kiely [13] and Grgic [3] concur in suggesting that correct
identification of the individual ergogenic effect induced by caffeine intake requires the repeated
measurement of physical performance in identical caffeine–placebo comparisons. As suggested by
Grgic [3], one of the following options can be selected to assess the individual ergogenic effect induced
by caffeine: (1) multiple exercise tests with the same dose of caffeine or, (2) multiple doses of caffeine
with the same exercise test, or (3) using a more complex protocol that combines repeated assessments
of physical performance on different days using the same exercise test and dose of caffeine. If this is
the case, most of the previous investigations on the study of individual responses to ergogenic effects
of caffeine might not be methodologically correct because the categorization has been mainly based on
one caffeine–placebo comparison.
4. Repeated Testing of the Ergogenic Effect of Caffeine Ingestion Measured on Two Exercise Tests
We have recently published an investigation where the ergogenic effect of caffeine (3 mg/kg)
was measured eight times over a placebo in the same individuals by using two physical performance
tests: an incremental cycling test to volitional fatigue (25 W/minutes) and an adapted version of the
Wingate cycling test [16]. The performance measurements were accompanied by the measurement of
resting blood pressure, in addition to other physiological variables. The investigation was aimed at
determining the time course of tolerance to the performance benefits of caffeine, and 11 participants
ingested 3 mg/kg/day of caffeine, or a placebo, for 20 consecutive days. It is important to indicate
that all participants were light caffeine consumers and refrained from all sources of dietary caffeine for
the month before the onset of the experiment to eliminate the effect of habituation to caffeine (which
represents another possible source of error when assessing individual responses). The caffeine–placebo
comparisons were made after 1, 4, 6, 8, 13, 15, 18, and 20 days of consecutive caffeine or placebo
ingestion while the order of the 20-day treatments was randomized. The coefficient of variation of
the exercise tests and of the arterial blood pressure measurement were calculated by using the values
obtained in the 20-day placebo treatment. A complete description of methods and standardizations
can be found in the publication of this experiment [16].
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Because the tolerance to the ergogenic effect of caffeine was not completed after 20 days of
consecutive ingestion, we have performed a sub-analysis for this communication to present the individual
responses to acute caffeine intake in each of the eight identical caffeine–placebo comparisons. Figure 1
presents individual box-and-whisker plots for changes induced by caffeine intake, over the ingestion
of a placebo, on cycling power obtained during the incremental test (Wmax) and mean cycling power
obtained during the 15-second Wingate test. Figure 1 is a clear example of the interindividual variability
in response to caffeine ingestion, with diverse caffeine-induced ergogenicity observed among individuals.
Figure 1 has been organized in a ergogenicity-decrescent manner from left to right, with the participant
showing the highest response to the ergogenic effects of caffeine at the left (subject 1 = 9.0 ± 3.6% and
2.3 ± 1.4% for Wmax and Wingate cycling power, respectively) and the individual with the lowest
response at the right (subject 11 = 0.6 ± 6.3% and 1.6 ± 4.2% for Wmax and Wingate cycling power,
respectively). Furthermore, Figure 1 also shows the intraindividual variability for the ergogenic effects
of caffeine on both exercise performance tests. This figure disputes the notion of non-responding
to the ergogenic effect of caffeine because all of the 11 included participants improved performance
following caffeine ingestion, in either the graded exercise test or the Wingate test, in at least three testing
occasions (with the magnitude of improvements exceeding the coefficient of variation for each test).
These data expand the suggestion of a minimal occurrence of non-responders [3] because it shows that
all individuals responded to caffeine, to an extent above the random error of the performance tests, when
a repeated caffeine–placebo testing protocol was used to assess individual responses to caffeine. Thus,
in the opinion of the authors of this manuscript, the concept of non-responders to the ergogenic effects of
caffeine should be revisited.
Figure 2 offers further insights on this topic because it presents individual data on caffeine-induced
changes on resting systolic and diastolic blood pressure, measured before exercise, which is a variable
also employed to categorize individual responses to acute caffeine ingestion [17]. As it happens
with the ergogenic effect of caffeine, the outcomes of caffeine on blood pressure had great inter- and
intraindividual variability. However, the participants with the highest responses to the cardiovascular
effects of caffeine were the ones with the lowest response to the ergogenic effects of caffeine (with
the exception of subject 5). To further explore this relationship, Figure 3 associates ergogenic and
cardiovascular responses to caffeine ingestion. Interestingly, changes induced by caffeine intake
in both systolic and diastolic blood pressures were negatively related to caffeine ergogenicity in
both cycling performance tests. Briefly, this would mean that the individual with a high response
to the cardiovascular effects of caffeine would be less prone to obtain ergogenic benefits from this
substance. Although the mechanism behind this association is not evident from the current analysis,
the association between high cardiovascular response to caffeine and decreased performance effects
of caffeine has support in the literature. Wardle et al. [18] found that high cardiovascular responders
to a 200-mg dose of caffeine decreased their willingness to exert an effort, a negative outcome that
was not present in low cardiovascular responders to caffeine. This information might suggest that
the cardiovascular and performance effects of caffeine might be incompatible and implies that high
and low responders to the ergogenic effect of caffeine may exhibit divergent blood pressure response
following acute caffeine ingestion. However, given the overall low sample number of the current
study, this is an area that merits future research. If we can pinpoint that simple measurements such
as blood pressure responses to caffeine ingestion are related to the magnitude of improvements in
performance, this information may be of considerable practical importance for coaches and athletes
when determining an optimal approach to caffeine supplementation.
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Figure 1. Box-and-whisker plots for the ergogenic effects of 3 mg/kg of caffeine on cycling power
during a graded exercise test (upper panel) and during a 15-second Wingate test (lower panel). Caffeine
was compared to a placebo on eight different occasions and each plot represents the results of these
eight caffeine–placebo comparisons for each participant. “Average” represents the mean values for
all 11 participants. The cross depicts the mean value for each individual while the lower, middle,
and upper lines of the box represent the 25%, 50%, and 75% percentile for each individual. Whiskers
represent the lowest and highest values (range). The black dashed line represents the natural variation
of the graded exercise test (± 2.4%) and the 15-second Wingate test (± 2.7%) measured during the
placebo treatment.
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Figure 2. Box-and-whisker plots for the effects of 3 mg/kg of caffeine on resting systolic (upper panel)
and diastolic (lower panel) blood pressure (BP). Caffeine was compared to a placebo on eight different
occasions and each plot represents the results of these eight caffeine–placebo comparisons for each
participant. “Average” represents the mean values for all 11 participants. The cross depicts the mean
value for each individual while the lower, middle, and upper lines of the box represent the 25%, 50%,
and 75% percentile for each individual. Whiskers represent the lowest and highest values (range).
The black dashed line represents the natural variation of the systolic (± 3.3%) and diastolic blood
pressure (± 3.8%) measured during the placebo treatment.
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Figure 3. Relationships between the ergogenic effect of caffeine and systolic (upper panel) and diastolic
(lower panel) blood pressure (BP). The ergogenic effect of caffeine was obtained by measuring peak
cycling power during a graded exercise test (Wmax) and during a 15-second Wingate test. Caffeine
was compared to a placebo on eight different occasions and each dot represents an average of these
eight caffeine–placebo comparisons for each participant.
5. Conclusions
In conclusion, the data provided in this communication do not dispute the existence of a great
interindividual variability to the ergogenic effects of caffeine ingestion, nor the genetic, environmental,
or epigenetic causes associated to this variability. However, this analysis suggests that all individuals,
to some extent, positively respond to the acute ingestion of 3 mg/kg of caffeine, while the magnitude of
the ergogenic effect might be the result of the totality of consequences induced by caffeine ingestion on
the human body. In this respect, this communication suggests that the individuals with a high response
to the cardiovascular effects of caffeine would be less prone to obtaining ergogenic benefits from
this stimulant. Caffeine ergogenicity might be subject to genetic influence, but future investigations
on this topic should assess the individual ergogenic response to caffeine by using different forms
of exercise testing and/or by using well-standardized caffeine–placebo comparisons on multiple,
repeated testing sessions. In the point of view of the authors, this repeated measurement of the
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ergogenic effect of caffeine would help to reduce the equivocal findings of previous investigations
on genetic variations [2]. From a practical perspective, the adjustment of appropriate dosage, timing,
and form of administration of caffeine for an athlete might require several examinations in which
physical performance and side-effects of caffeine should be measured and registered over a control
situation. Gathering conclusions about the ergogenic effect of caffeine in one individual solely based
on the results from one performance test might induce erroneous conclusions in both scientific and
sport settings. The use of multiple, repeated comparisons between a potentially active substance vs.
a placebo might also be recommended when investigating the individual ergogenic responses to other
ergogenic substances/supplements.
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Abstract: The central and peripheral effects of caffeine remain debatable. We verified whether
increases in endurance performance after caffeine ingestion occurred together with changes in primary
motor cortex (MC) and prefrontal cortex (PFC) activation, neuromuscular efficiency (NME), and
electroencephalography–electromyography coherence (EEG–EMG coherence). Twelve participants
performed a time-to-task failure isometric contraction at 70% of the maximal voluntary contraction
after ingesting 5 mg/kg of caffeine (CAF) or placebo (PLA), in a crossover and counterbalanced
design. MC (Cz) and PFC (Fp1) EEG alpha wave and vastus lateralis (VL) muscle EMG were recorded
throughout the exercise. EEG–EMG coherence was calculated through the magnitude squared
coherence analysis in MC EEG gamma-wave (CI > 0.0058). Moreover, NME was obtained as the
force–VL EMG ratio. When compared to PLA, CAF improved the time to task failure (p = 0.003,
d = 0.75), but reduced activation in MC and PFC throughout the exercise (p = 0.027, d = 1.01 and
p = 0.045, d = 0.95, respectively). Neither NME (p = 0.802, d = 0.34) nor EEG–EMG coherence
(p = 0.628, d = 0.21) was different between CAF and PLA. The results suggest that CAF improved
muscular performance through a modified central nervous system (CNS) response rather than
through alterations in peripheral muscle or central–peripheral coupling.
Keywords: fatigue; placebo; ergogenic; EEG–EMG coherence
1. Introduction
Caffeine is one of the most widely ergogenic aids traditionally used to improve physical
performance in different exercise scenarios [1,2] such as team sports [3], cycling exercise [4,5], and
muscular function tests [6–8]. However, the underlying mechanism of caffeine ingestion on either
whole-body or muscular endurance exercise performance is still controversial, as it involves central
and peripheral hypotheses such as alterations in central nervous system (CNS) and skeletal muscles,
respectively. It has been well known that caffeine inhibits A1 adenosine receptor and postsynaptic A2a
receptor in CNS [9,10] and muscles [7,8], thereby, improving spinal and supraspinal excitability and
altering cortical and muscular activation during exercise. Nevertheless, it is still debatable whether
caffeine improves endurance performance through coupled or uncoupled alterations in both central
and peripheral sites.
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Results of studies using micromolar doses of caffeine suggest that alterations in CNS are the likely
mechanism of the caffeine effects on endurance performance. Studies have shown an increased spinal
and supraspinal excitability with caffeine [11,12], thus justifying the increased muscular endurance
performance as measured as the time to task failure at a submaximal target force [13]. Interestingly, an
earlier study observed that caffeine ingestion (6 mg·kg−1 of body mass) reduced the motor-related
cortical potential at the vertex during a submaximal isometric knee extension. The authors concluded
that caffeine decreased the magnitude of excitatory inputs from frontal and primary motor cortex
(MC) areas necessary to produce a given force, likely due to an enhanced spinal and supraspinal
excitability [14]. Based on these arguments, one may expect that less activation in MC and frontal cortex
areas would be required to sustain a target force after caffeine ingestion, thus improving the muscular
endurance capacity as measured by time to task failure. Unfortunately, that study used a closed-loop
isometric exercise (i.e., 4 × 10 muscle contractions), so that time-to-task failure measures were not
provided. Moreover, motor-related cortical potential measure may be indicative of readiness (i.e.,
excitability) rather than activation, thus cortical electroencephalography (EEG) measures throughout
a time-to-task failure exercise may be insightful for this proposal. In fact, an earlier study found a
reduced cortical EEG alpha wave after caffeine ingestion at rest [15] so that a study exploring the
cortical EEG alpha wave during exercise is yet to be provided.
On the other hand, studies have suggested that caffeine may also improve endurance exercise
performance through an enhanced muscular function. For example, an earlier study had observed that
caffeine increased tetanic force stimulated at 20 Hz but not at 40 Hz [7]. Additionally, another study
verified that caffeine (6 mg·kg−1 of body mass) increased biceps brachii electromyography (EMG) and
maximal isokinetic force of elbow flexion at different angular velocities [8]. Somehow, caffeine may
have also improved neuromuscular efficiency as caffeine ingestion increased muscle fiber conduction
velocity. Consequently, beyond the reduced cortical activation one may argue that caffeine ingestion
improves muscular endurance capacity through an ameliorated neuromuscular efficiency. However,
evidence that caffeine may improve muscular endurance (i.e., time to task failure) together with a
reduced cortical activation and increased neuromuscular efficiency has yet to be provided in a single
study design.
There is a paucity of studies simultaneously investigating the caffeine effects on both central and
peripheral responses to a muscular endurance performance. For example, an earlier study verified that
the increased maximal voluntary force during maximal knee extensions after caffeine ingestion was
associated with alterations in central more than in peripheral responses [16]. In contrast, a recent study
observed that improved single-leg knee extension performance after caffeine ingestion was associated
with ameliorated central and peripheral fatigue indexes [12]. Therefore, studies simultaneously
investigating central and peripheral responses to caffeine ingestion during muscular endurance
performance are insightful to reveal the importance of central and peripheral effects of caffeine.
In a central vs. peripheral fatigue scenario, it is still unknown whether caffeine improves muscular
endurance performance through a coupled alteration in central and peripheral locations, as one may
argue that caffeine could improve exercise performance through independent effects on cortical and
muscle responses. Analysis of the strength of corticomuscular coupling during a time-to-task failure
protocol may be helpful to understand how caffeine affects the link of information being processed
in these two different locations [17]. In this regard, analysis of the EEG–EMG linear dependency
in time and frequency domains indicates the neuronal synchronicity between cortical and muscle
activation [18], so that EEG–EMG coherence during a time-to-task failure protocol may provide insights
into caffeine effects on corticomuscular coupling and fatigue. Unfortunately, possible caffeine effects
on fatigue and EEG–EMG coherence relationship remain uninvestigated.
The present study verified whether increases in endurance performance after caffeine ingestion
occurred together with changes in cortical activation, neuromuscular efficiency, and EEG–EMG
coherence. Based on independent results, we hypothesized that caffeine ingestion would reduce
cortical activation and increase neuromuscular efficiency, thereby increasing the time to task failure
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during single-leg knee extension protocol. Additionally, a likely improved coherence between central
(i.e., MC EEG) and peripheral sites was expected with caffeine ingestion.
2. Materials and Methods
2.1. Participants
A sample size of 10 participants was determined, having a significance level of 5%, a power
>0.95, and an effect size (ES) >0.8 (G-Power software, version 3.1., Dusseldorf, Germany). However,
we expected a 20% dropout so that 12 participants volunteered to participate in this study. Thus,
recreationally trained cyclists (34.3 ± 6.2 years old; 179.3 ± 5.1 cm; 77.6 ± 6.8 kg), non-smokers and
free from cardiovascular, visual, auditory, and cognitive disorders were recruited. Briefly, three were
non-consumers (≤40 mg of caffeine per day), five were occasional consumers (≤250 mg of caffeine
per day), and four were daily consumers of caffeine (250 < consumption < 572 mg of caffeine per
day), according to classification proposed elsewhere [1,19]. Importantly, caffeine has been suggested
as an ergogenic aid capable of improving endurance performance, regardless of habitual caffeine
consumption [5,20]. They were oriented to avoid consumption of coffee or any stimulant (energy
drink, etc.) and alcoholic beverages, as well as intense exercise for 48 h preceding the sessions.
Experimental procedures, risks, and benefits were explained before collecting their written consent
form signature. The procedures were previously approved by a local Ethics Committee (Process:
63787816.1.0000.5390) from the University of São Paulo and performed according to the Declaration
of Helsinki.
2.2. Study Design
The design of the present study involved five sessions. During the sessions 1 and 2, participants
were familiarized with instruments and procedures of knee isometric extension (IC) and EMG and
EEG measures. Moreover, participants performed three maximal voluntary contractions (MVC) and
a submaximal IC to task failure set at 70% MVC. These procedures were repeated during session 2,
and the force attained in MVC was adopted to determine the IC intensity (i.e., 70% MVC) used in
the following sessions. Session 3, baseline trial (CON): Participants performed a baseline IC to task
failure with no supplementation; sessions 4 and 5, supplementation trials: Participants performed a
submaximal IC exercise ~45 min after caffeine (CAF) or placebo (PLA) ingestion. Sessions 1, 2, and
3 were performed in sequential order, as we were interested in properly familiarizing participants
with procedures before assessing EEG, muscular efficiency, and EEG–EMG coherency in baseline
submaximal IC. Then, we performed sessions 4 and 5 in a double-blinded, counterbalanced order
as we intended to investigate central and peripheral responses to IC exercise after caffeine ingestion.
Therefore, the baseline session was used as a familiarization when assessing physiological responses
to a “natural” non-supplemented IC exercise. The study was finished within 30 days. The sessions
were interspersed by a 3–7 day washout period, being performed at the same time of the day in a
controlled environment (∼24 ◦C and 50%–60% humidity). This experimental setup was part of an
umbrella research project that studied caffeine effects on several psychophysiological responses to
different exercise modes. Importantly, experimental procedures used in other parts of the umbrella
project that have been already published [4] are unlikely to influence the outcomes measured in the
present study [20]. Hence, with the exception of the ingested substance, all experimental trials (CON,
CAF, and PLA) were conducted under identical and controlled conditions, thus ensuring the reliability
of the present study.
2.3. Caffeine and Placebo Ingestion
Participants ingested 5 mg·kg−1 of body mass of caffeine 45 min before the submaximal IC
to task failure. This is in accordance with recommendations of the International Society of Sports
Nutrition (ISSN) for caffeine ingestion [1], suggesting that 3–6 mg·kg−1 of body mass of caffeine
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significantly improves endurance performance when ingested from 45 to 60 min before the exercise
bout [1]. Caffeine and placebo were manipulated in capsules of the same size, color, and smell so that
participants and the researcher directly involved in data sampling were unaware about the substance
ingested. Participants received a capsule containing CAF or PLA (lubricant, magnesium stearate, and
magnesium silicate) in a typical double-blind trial, having 50% chance of ingesting the actual active or
placebo substance. The blinding efficacy was checked after the participants finished their participation.
2.4. MVC and Isometric Contraction to Task Failure
Initially, participants were accommodated in a custom-built single-leg knee extension chair
attached to a cell load (EMG System®, São José dos Campos, Brazil) to measure a force of 2 kHz
frequency, having their hips and knees at 90◦ and 60◦ from the horizontal axis, respectively. Their chest
and hips were carefully fixed in order to avoid accessory movements. After familiarizing with the
MVC and IC protocols in session 1, participants repeated them in session 2. Moreover, in session 2
participants performed three sets of three MVC (interspersed by a 3 min interval) in order to assess the
highest peak force value between them and subsequently determine the submaximal IC workload.
The IC protocol consisted of performing an isometric knee extension to task failure at 70% MVC.
Therefore, after a warm-up consisting of unloaded squats (two sets of 15 repetitions with 1 min interval
between sets), participants sat on the chair which was individually adjusted. They were oriented
to maintain the force corresponding to 70% MVC (±5% variation) by using a visual feedback on a
computer screen. The task failure was identified as the inability to maintain the target force after
three verbal encouragements [21]. Measures of force (expressed as kgf), EEG, and EMG were recorded
throughout the submaximal IC.
2.5. Measures and Instruments
2.5.1. Electroencephalography (EEG)
Activation in MC and PFC was continuously obtained through an EEG unit (Emsa®, EEG BNT 36,
TiEEG, Rio de Janeiro, Brazil) at Cz and Fp1 position, respectively, according to the international EEG
10–20 system [22]. These positions were ensured according to frontal and sagittal planes, referenced
to the mastoid. The EEG was recorded at a 600 Hz sampling frequency, through active electrodes
(Ag–AgCl) with resistance ~5 KΩ. After exfoliation and cleaning, electrodes were fixed with a
conductive gel, adhesive tape, and medical strips. The EEG signal was recorded during a 3 min
baseline before CAF or PLA ingestion (when participants were completely calm) as well as throughout
the submaximal IC. They were oriented to avoid head and trunk movements during baseline and
exercise phases.
An EEG signal with amplitude >100 μV was considered as an artifact (n = 1–2, depending
on the moment of the experimental setup) and removed from analysis [23]. In baseline EEG data,
data recorded during the first and last 30 s of a 180 s time window were removed (to avoid noise
associated with the increased expectation of the start and stop of EEG sampling) and a fast-Fourier
transformation calculated the total power spectral density (tPSD) within 8–13 Hz (alpha wave) over
the most steady (i.e., lowest standard deviation (SD)) 30 s time window. In exercise EEG data,
a fast-Fourier transformation calculated the tPSD within the alpha wave over the last 2 s of every
25% of the submaximal IC duration (i.e., 25%, 50%, 75%, and 100%), thereafter the exercise EEG
data were expressed as a percentage of the baseline. Importantly, we used the EEG alpha wave to
indicate activation as this EEG frequency is suggested to reflect an increased number of neurons
coherently activated [24] as indicated by the increase in inhibited neurons–to–disinhibited neurons
relationship [25]. In this regard, an increased alpha wave may indicate a cooperative-synchronized
behavior of a large number of activated neurons [25]. All EEG analyses were performed through an
algorithm in Matlab® environment.
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2.5.2. Neuromuscular Efficiency (NME)
Initially, participants had their skin shaved, exfoliated, and cleaned with isopropyl alcohol to
reduce the skin impedance. Thereafter, a bipolar electrode was placed over the belly of the vastus
lateralis muscle (VL) according to the probable muscle fiber orientation. The EMG signal was recorded
throughout the submaximal IC through an EMG unit (EMG System, São José dos Campos, Brazil)
at a 2 kHz sample rate (gain 1000) with a recursive fourth-order Butterworth bandpass filter (cutoff
frequencies between 20 and 500 Hz), before calculating the root-mean-square value (RMS) of the
EMG signal. All EEG data collection followed the Surface Electromyography for the Non-Invasive
Assessment of Muscles standards [26].
The neuromuscular efficiency (NME) was obtained as the force–EMG RMS ratio of the EMG burst
over the last 2 s of every 25% of the submaximal IC duration, as proposed elsewhere [27]. Importantly,
as a reduction in NME is expected as fatigue progresses, indicating that more motor units have been
recruited to produce the same force, NME has been suggested as a peripheral fatigue index [27]. Hence,
to obtain the NME, we also filtered force data through a recursive fourth-order Butterworth low-pass
filter, having a cutoff frequency determined by residual analysis at 7 Hz, before normalizing force data
by body mass. Thereafter, the NME index (expressed as arbitrary units) was calculated as the integral
















Initially, we checked through a 95% confidence interval (CI) calculation which EEG spectral wave
from MC (Cz position) revealed coherence with VL EMG signal, as suggested elsewhere [28]:
CL = 1− 0.051/n−1 (2)
where n is the number of windows used for spectral estimation. Given the varied time to task failure,
the number of windows was not the same for all spectral estimates.
Afterward, we computed the power spectral of the rectified EMG and EEG gamma wave (30–50 Hz)
through Welch’s method, having a 50% overlapped Hamming window with 512 samples in each
section. Only active data (i.e., between onset and offset of each trial) were used to calculate the power
spectral, and the magnitude squared coherence between EEG and EMG (expressed as arbitrary units)
was then obtained:
cohc1,c2( f ) =
∣∣∣Sc1c2( f )∣∣∣2
Sc1c1( f )·Sc2c2( f ) (3)
where Sc1c1 and Sc2c2 are the auto-spectra of each signal; Sc1c2 is the cross-spectra. Accordingly,
EEG–EMG coherence data were calculated at each 25% of the submaximal IC duration.
2.5.4. Statistical analyses
Results were reported as mean and standard deviation (±SD). Firstly, one-way ANOVA (Bonferroni
as a post hoc) was used to compare muscle endurance performance (expressed as time to task failure
in submaximal IC) in baseline, CAF, and PLA conditions. Additionally, we also expressed endurance
performance as a percentage of alteration from the baseline session, thus comparing CAF and PLA
trough a paired T-test. Secondly, MC and PFC activation (indicated by EEG alpha wave), NME, and
EEG–EMG coherence responses to submaximal IC between CAF and PLA conditions were compared
at every 25% of the total exercise duration through a 4 × 2 mixed model, having time (25%, 50%, 75%,
and 100%) and ingestion (CAF vs. PLA) as fixed factors and participants as the random one. The AIC
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index (Akaike’s information criterion) determined the covariance matrix that best fitted to the dataset
(homogeneous and heterogeneous compound symmetric, first-order auto-regressive, auto-regressive
moving average, and Toeplitz), while Bonferroni test was used in multiple comparisons.
We reported the post hoc ES analysis (expressed as d-Cohen) as a qualitative analysis approach,
so that ES was interpreted as small (<0.2), moderate (0.2–0.6), large (0.6–1.2), very large (1.2–2.0), and
extremely large (>2.0), as suggested elsewhere [29]. Results were significant when p < 0.05.
3. Results
3.1. Baseline Session and Blinding Efficacy
Participants attained a task failure in 28.5± 16.4 s in baseline session. In order to check the blinding
of manipulation, participants were asked to guess which substance they thought they ingested in each
session. In total, nine participants correctly identified CAF (and consequently PLA) ingestion, while
three did not. Participants reported no adverse effects from caffeine ingestion.
3.2. Caffeine Effects on Muscle Performance
A condition main effect was found (F = 8.489; p = 0.002; d = 1.242 very large ES) so that the absolute
time to task failure was greater in CAF than in PLA (0.007) and baseline (0.006). When expressed as a
percentage of alteration from baseline session, CAF (33.5 ± 14.2 s; (95% CI = 23.9, 40.2), 9.1% ± 36.4%
from baseline) further improved muscular endurance performance (t = 3.993, p = 0.003, d = 0.75 large
ES) when compared to PLA ingestion (25.8 ± 10.6 s; (95% CI = 18.6, 30.8), −7.7% ± 25.1% from baseline)
(Figure 1).
Figure 1. Changes in time to task failure during submaximal isometric contraction after caffeine (CAF)
and placebo (PLA) ingestion. * Indicates significantly different from PLA (p = 0.003). Data are reported
as mean ± standard deviation (SD).
3.3. Caffeine Effects on Central and Peripheral Indexes
Regarding MC activation, EEG Cz activity was significantly reduced (F = 5.654, p = 0.027, d = 1.01
large ES) when compared to PLA. Furthermore, a moment main effect was observed as MC activation
increased throughout the exercise (F = 3.767, p = 0.025, d = 0.83 very large ES). In contrast, no ingestion
by moment interaction effects were found (F = 2.462, p = 0.125, d = 0.67 large ES). Accordingly, an
ingestion main effect (F = 4.925, p = 0.045, d = 0.946 large ES) as well as a moment main effect (F = 10.360,
p = 0.001, d = 1.37, very large ES) was observed in PFC activation, as CAF reduced the EEG Fp1
activity when compared to PLA, although PFC activation has increased throughout the submaximal
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IC exercise. Moreover, no ingestion by moment interaction effects was found (F = 1.280, p = 0.343,
d = 0.48, moderate ES). Figure 2 shows these EEG results.
Figure 2. Electroencephalography (EEG) alpha wave recorded at Cz (A) and Fp1 (B) positions during
isometric contraction in CAF (filled square) and PLA (open square) sessions. * Indicates condition main
effect in Cz (p = 0.027) and PFC (p = 0.045). # indicates moment main effect in Cz (p = 0.000) and Fp1
(p = 0.001). Data are reported as mean ± SD.
Regarding the NME results, caffeine ingestion was ineffective in improving VL muscle efficiency
when compared to PLA (F = 0.065, p = 0.802, d = 0.34 moderate ES). However, a moment main effect
was detected as NME changed throughout the exercise (F = 7.97, p < 0.001, d = 1.20 very large ES).
Additionally, no ingestion by moment interaction effect was observed (F = 0.006, p = 1.00, d = 0.02
small ES). Figure 3 depicts these results.
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Figure 3. Changes in neuromuscular efficiency (NME) of vastus lateralis muscle during isometric
contraction in caffeine (CAF) and placebo (PLA) sessions. # Is moment main effect (p = 0.000). Data are
reported as mean ± SD.
Previous analysis revealed that EEG–EMG coherence was significant (CI > 0.0058) in EEG gamma
wave, as shown by spectrograms (Figure 4). We observed that neither CAF session (F = 0.240, p = 0.628,
d = 0.21 moderate ES) nor moment main effect (F = 0.437, p = 0.727, d = 0.28 moderate ES) changed
EEG–EMG coherence. Accordingly, we did not observe ingestion by moment interaction effects
(F = 0.522, p = 0.670, d = 0.35 moderate ES) in EEG–EMG coherence, as shown in Figure 5. Table 1
presents mean (±SD) and 95% confidence interval (95% CI) values of dependent variables.
Figure 4. Spectrogram of EEG gamma wave at Cz position and vastus lateralis electromyography
(EMG).
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Figure 5. EEG–EMG coherence in CAF (filled square) and PLA (open square) sessions. Data are
reported as mean ± SD.
Table 1. Mean (±SD) and 95% confidence interval (95% CI) for dependent variables.
Time of Exercise
Ingestion Dependent Variable 25% 50% 75% 100%
CAF
Prefrontal EEG 40.9 ± 54.0 49.4 ± 43.2 75.7 ± 16.0 86.7 ± 12.9
95% CI (−507.5–245.1) (−60.2–93.6) (−187.8–80.2) (−366.9–274.2)
Motor Cortex EEG −311.8 ± 634.7 −95.6 ± 184.4 −99.9 ± 197.1 33.1 ± 75.2
95% CI (−176.6–62.6) (−216.1–19.1) (−185.7–46.1) (22.2–88.3)
NME 0.03 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 0.03 ± 0.01
95% CI (0.01–0.04) (0.01–0.04) (0.01–0.03) (0.01–0.03)
EEG–EMG Coherence 0.06 ± 0.05 0.04 ± 0.02 0.04 ± 0.02 0.06 ± 0.06
95% CI (0.02–0.06) (0.02–0.05) (0.02–0.03) (0.02–0.06)
PLA
Prefrontal EEG 70.2 ± 22.9 64.9 ± 36.3 80.1 ± 21.1 92.1 ± 11.6
95% CI (45.2–96.8) (2.7–84.3) (33.1–104.3) (81.6–102.3)
Motor Cortex EEG −27.0 ± 148.9 −80.7 ± 191.9 −10.3 ± 150.3 66.2 ± 57.5
95% CI (57.0–88.6) (−165.7–79.6) (−109.1–121.1) (66.4–107.4)
NME 0.03 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 0.02 ± 0.01
95% CI (0.01–0.06) (0.01–0.05) (0.01–0.04) (0.01–0.04)
EEG–EMG Coherence 0.06 ± 0.06 0.04 ± 0.03 0.09 ± 0.09 0.05 ± 0.05
95% CI (0.02–0.06) (0.02–0.06) (0.03–0.08) (0.02–0.06)
NME—neuromuscular efficiency; EEG—electroencephalography; EMG—electromyography;
CAF—caffeine; PLA—placebo.
4. Discussion
The present study aimed to verify whether an increased time to task failure with CAF ingestion
would be followed by changes in cortical activation, neuromuscular efficiency, and EEG–EMG
coherence during a single-leg knee extension exercise. Our findings showed that caffeine improved
endurance performance, despite a reduced activation in both PFC and MC and unaltered neuromuscular
efficiency and EEG–EMG coherence. These results suggested that caffeine ingestion improved muscular
endurance performance through located modifications in the CNS rather than alterations in peripheral
muscle. Importantly, this is the first study showing that caffeine effects on CNS were uncoupled from
peripheral responses.
Different studies have indicated that caffeine effects on A1 adenosine receptor and postsynaptic
A2a receptor in CNS are the most likely mechanism underlying improvements in endurance
performance [9,10,30]. We hypothesized that caffeine may improve muscular endurance performance
in a time to task failure regardless of a reduced activation in PFC and MC as reported elsewhere [15].
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Although the increase in PFC and MC activity was a main exercise effect, there was a reduced PFC and
MC activation throughout the submaximal IC protocol in the CAF session. A likely explanation of this
reduced cortical activation during exercise is an increased CNS excitability with caffeine ingestion,
as suggested [10] and confirmed elsewhere [11]. Caffeine has been suggested to increase both the
corticospinal [31] and spinal excitability [11], thereby, leading to less excitatory input from frontal to
vertex areas as well as from vertex to peripheral muscles, when generating the same force or power
output [14,30]. Although we have not measured CNS excitability responses in the present study, the fact
that participants maintained the same force requiring less PFC and MC activation throughout most of
the submaximal IC exercise may be suggestive of an increased CNS excitability after caffeine ingestion.
Thus, as a result of the lower cortical activation necessary to produce a given force, participants may
have been capable of further increasing the time to task failure in the CAF session. Interestingly, one
may argue that a likely increased spinal and corticospinal excitability promoted by caffeine ingestion
extended the time to reach a “cortical activation limit”, as both PFC and MC activation were lower in
CAF than PLA from the beginning to 50% and 75% of the exercise duration, respectively, matching a
“maximal cortical activation” (as recorded in the PLA session) only at 100% of the IC exercise. However,
this suggestion must be interpreted with caution, as this argument is based on visual more than
statistical analysis.
Despite the decreased NME as a main exercise effect, caffeine was ineffective in improving muscle
efficiency during submaximal IC exercise, so that the improved muscular endurance performance in
the CAF session cannot be related to peripheral responses. Controversial results of caffeine ingestion on
peripheral responses have been reported. For example, some have found positive caffeine effects either
on calcium release from the sarcoplasmic reticulum [32,33] or muscle fiber conduction velocity [8],
thereby supporting the notion of a caffeine ergogenic effect on peripheral muscles. However, others
have failed to find positive caffeine effects on peripheral muscle indexes such as a peripheral silent
period [31] or M-wave [7], suggesting that sarcolemma excitability and tubule T propagation are
unaffected by caffeine. In the present study, we observed that caffeine ingestion was ineffective in
enhancing neuromuscular efficiency calculated as the force–EMG RMS ratio, thus, indirectly suggesting
no caffeine effects on muscle properties. Such an ineffectiveness of caffeine in improving peripheral
responses may be related to the muscle contraction stimulation frequency of the submaximal IC
exercise, as it has been proposed that caffeine changes muscle properties through alterations in calcium
release rather than through potassium accumulation [33]. Thus, assuming that calcium metabolism
is associated with force losses mainly in frequencies <20–30 Hz [7,34,35] and that our submaximal
IC exercise required a muscle contraction frequency mostly higher than 50 Hz [36], perhaps caffeine
ingestion is ineffective in improving key muscular properties enhance muscle endurance performance
during submaximal IC. Somehow, the fact that coherence analysis indicated a significant coupling
between gamma wave EEG (30–50 Hz) and EMG may reinforce this argument.
Despite studies proposing EEG–EMG coherence analysis as a tool to investigate the corticomuscular
coupling between motor cortex and pooled motor units [37–39], only a few have been designed to
investigate the EEG–EMG coherence and fatigue relationship [18,39]. Coherence, defined as a
spectral power covariance between signals from different origins, may provide an estimation of the
corticomuscular coupling [39] signals. In a muscle fatigue scenario, EEG–EMG coherence is expected to
decrease as exercise progresses, thus suggesting a corticomuscular desynchronization with fatigue [18].
Unexpectedly, we found no main exercise effects on EEG–EMG coherence. Perhaps, the fact that we
used a constant rather than an intermittent muscle contraction during submaximal IC can be related
to this unaltered coherence during exercise [38], given the less-complex muscle recruitment strategy
in this mode of contraction [40,41]. Importantly, the present study was the first to provide evidence
that caffeine ingestion maintained the corticomuscular coupling between the motor cortex and pooled
motor units in submaximal IC exercise, despite reductions in MC activation and increased muscle
endurance. Somehow, the likely increase in corticospinal and spinal excitability in the CAF session [30]
may have been associated with a longer sustained force output despite the reduced MC activation, as
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the signal from MC areas remained coupled with the signal at pooled motor units, even though the
progressive fatigue in the CAF session.
5. Methodological Aspects, Strength, and Limitations
Beta and gamma waves have been suggested for EEG–EMG coherence analysis of isometric and
isotonic muscle contractions, respectively [38,40]. An earlier coherence study observed a greater EEG
gamma wave coherence with EMG signal in isometric knee extension, although both EEG beta and
gamma frequencies were significantly coherent with EMG [38]. In the present study, we first verified
which EEG waves from MC would best reveal coherence with peripheral muscle during IC exercise.
In contrast to earlier results [38,40], we found significant coherence in EEG gamma wave during
isometric exercise. Perhaps, the fact that our participants had to sustain a target force throughout the
exercise until the task failure, while fatigue progressed, may have induced an increase in the median
frequency of the motor command to peripheral muscles, thus shifting the coherence toward higher EEG
frequencies such as the gamma wave. Additionally, the fact that our participants had to focus on visual
feedback on the screen (i.e., horizontal lines delimiting the target force) during the submaximal IC
exercise may have also led to a shift toward higher EEG frequencies, as EEG–EMG coherence can occur
at higher EEG frequencies when individuals modulate the target force through visual feedback [41].
Importantly, results of the check of blinding efficacy challenged the use of traditional
placebo-controlled clinical trials, as suggested elsewhere [42]. Agreeing with previous results [43],
we observed that nine out of 12 participants correctly guessed when caffeine was ingested, despite
using a typical double-blind, placebo-controlled design. Therefore, one may argue that some of the
endurance performance improvements in CAF session may have been potentiated by the expectation
of ingesting caffeine, as a recent study verified that placebo perceived as caffeine improved cycling
performance as much as caffeine [44]. As recently recommended, future research must take caffeine
expectancies into account when investigating caffeine effects on performance [42].
Although we have included participants with different caffeine habituation in the present study,
responsiveness and habituation were seemingly not an issue in the present results, as a recent study
by Del Coso et al. [20] observed that different individuals responded to caffeine ingestion improving
aerobic and anaerobic cycling performance from 9% to 1% across multiple testing sessions and
Wilk et al. [45] found ergogenic effects of caffeine ingestion in athletes habitually using caffeine.
Moreover, a well-controlled study by Goncalves et al. [5] verified that habitual caffeine consumption
did not influence its potential ergogenic effect. Therefore, together these studies reinforce the notion
that caffeine consumption habituation had no impact on results of the present study.
Only a few studies have simultaneously investigated central and peripheral effects of caffeine
on exercise performance, mainly in a well-controlled design [12,16]. In this regard, the present study
contributes to the improvement of the available literature as we showed that caffeine potentiated
muscular endurance performance through central rather than through peripheral effects. Importantly,
this is the first study showing that caffeine effects on CNS were uncoupled with muscle responses, as
we found no effects of caffeine ingestion on corticomuscular coupling. This may be of value for exercise
performance and clinical scenarios, as one may want to focus on CNS alterations without altering
CNS–muscle coupling or muscle responses. However, an obvious limitation is that caffeine may play
a role in multiple physiological responses beyond the electrophysiological ones investigated in the
present study, thus caution is needed when inferring caffeine effects on other physiological responses
such as tissue oxygenation and cell metabolism.
6. Conclusions
Results of the present study showed that caffeine improved muscle endurance performance,
regardless of reductions in both PFC and MC activation and unaltered neuromuscular efficiency and
EEG–EMG coherence. These results may suggest that caffeine ingestion improved performance in
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isometric contraction through a modified CNS response rather than through alterations in peripheral
muscle or central–peripheral coupling.
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Abstract: Caffeine (CAF) has been reported to improve various facets associated with successful soccer
play, including gross motor skill performance, endurance capacity and cognition. These benefits are
primarily attributed to pharmacological mechanisms. However, evidence assessing CAF’s overall
effects on soccer performance are sparse with no studies accounting for CAF’s potential psychological
impact. Therefore, the aim of this study was to assess CAF’s psychological vs. pharmacological
influence on various facets of simulated soccer performance. Utilising a double-dissociation design,
eight male recreational soccer players (age: 22 ± 5 years, body mass: 78 ± 16 kg, height: 178 ± 6 cm)
consumed CAF (3 mg/kg/body mass) or placebo (PLA) capsules, 60 min prior to performing the
Loughborough Intermittent Shuttle Test (LIST) interspersed with a collection of ratings of perceived
exertion (RPE), blood glucose and lactate, heart rate and performing the Loughborough Soccer
Passing Test (LSPT). Whole-body dynamic reaction time (DRT) was assessed pre- and post- LIST,
and endurance capacity (TLIM) post, time-matched LIST. Statistical analysis was performed using
IBM SPSS (v24) whilst subjective perceptions were explored using template analysis. Mean TLIM was
greatest (p < 0.001) for synergism (given CAF/told CAF) (672 ± 132 s) vs. placebo (given PLA/told
PLA) (533 ± 79 s). However, when isolated, TLIM was greater (p = 0.012) for CAF psychology (given
PLA/told CAF) (623 ± 117 s) vs. pharmacology (given CAF/told PLA) (578 ± 99 s), potentially,
via reduced RPE. Although DRT performance was greater (p = 0.024) post-ingestion (+5 hits) and
post-exercise (+7 hits) for pharmacology vs. placebo, psychology and synergism appeared to improve
LSPT performance vs. pharmacology. Interestingly, positive perceptions during psychology inhibited
LSPT and DRT performance via potential CAF over-reliance, with the opposite occurring following
negative perceptions. The benefits associated with CAF expectancies may better suit tasks that entail
lesser cognitive-/skill-specific attributes but greater gross motor function and this is likely due to
reduced RPE. In isolation, these effects appear greater vs. CAF pharmacology. However, an additive
benefit may be observed after combining expectancy with CAF pharmacology (i.e., synergism).
Keywords: sport; exercise; expectancy; belief; perceptions; placebo effect
1. Introduction
Caffeine (CAF) is the most frequently used psychoactive substance in sport, and has been observed
to improve various exercise modalities that may benefit soccer performance including: strength and
Nutrients 2019, 11, 2289; doi:10.3390/nu11102289 www.mdpi.com/journal/nutrients137
Nutrients 2019, 11, 2289
power output [1,2] endurance capacity [3–5] and gross motor skill performance [6–8]. Caffeine’s
ergogenic effects are typically observed with oral doses between 3–9 mg/kg/body mass (BM), with its
most commonly associated mechanism ascribed to the blockade of adenosine receptor sites and
subsequent central nervous stimulation [9,10].
Caffeine’s stimulatory properties may improve soccer performance by ameliorating physical
and/or cognitive fatigue, which has been observed to reduce the total distance ran (~5%–10%) and
frequency of sprints (~3%–4%) between the first and second half of games [11–16]. Associatively,
the majority of goals conceded are also within the latter stages of halves [17], specifically, between min
30–45 (18%) and 75–90 (23%) whereby physical and/or cognitive fatigue has likely peaked. In contrast,
the least goals are conceded within min 0–15 (12%) and 45–60 (16%) when physical and/or cognitive
fatigue is at its lowest or has been somewhat replenished during the half-time interval. However,
studies directly assessing CAF’s influence on soccer performance remain scarce and those that have
done so almost exclusively attribute any benefits to pharmacological mechanisms [3,4,6–8].
Shabir et al. [18] indicate the psychological permutations (e.g., changes in motivation, perceptual
exertion, belief, mood states, etc.) associated with expectancy of oral caffeine consumption may
influence sport, exercise and/or cognitive performance comparably or to a greater extent vs. CAF
pharmacology [19,20]. Expectancy effects of varying magnitude were observed across 13/17 studies.
Moreover, studies assessing sport and exercise performance were always influenced by expectancies.
These effects were facilitated by various mechanisms including the perception of mild side effects
and augmented physiological arousal [21–23], changes in mood states [21,24], reductions in perceived
effort [22,25] and changes in motivation [21,26]. Moreover, in contrast to adenosine receptor sensitivity,
expectancies/beliefs may be trained and/or manipulated, further enhancing any ergogenic experience.
However, at present the influence of CAF expectancies remain generally unaccounted for across
sport and exercise performance with no soccer-specific studies accounting for any potential effects.
However, CAF supplementation in recreational sport is commonly achieved via off-the-shelf products
(e.g., coffee, energy drinks etc.) many of which entail low CAF doses (likely lower than 3 mg/kg/BM
in most cases), thus CAF-induced benefits here may already originate from expectancy rather than
pharmacology. Furthermore, expectancies have been found to enhance attributes that may facilitate
improvements in soccer performance, including lower limb strength/power output [19,21,22,25,27],
endurance capacity [19,27–29], concentration [30], memory [31] and attentional focus [32]. Expectancies
could also ameliorate the quality of exercise recovery, training, and preparation for sports competitions
which may be impaired following CAF consumption prior to late evening games due to changes
in melatonin production and molecular oscillations [33]. Moreover, regular CAF dosing (such as
that which might be expected across the course of a season in soccer) may result in a reduced
pharmacological effect due to habituation to CAF’s central effects [34–36] and this may be overcome if
expectancy elicits an effect.
In order to validly compare CAF’s psychological vs. pharmacological influence on sport and
exercise performance, participant beliefs should be intentionally manipulated in accordance with
the experimental purpose. This reduces the discrepancy of individuals guessing which supplement
they have ingested that if uncontrolled might cause overlaps between pharmacology and psychology,
making it difficult to delineate the individual effects of these properties. The double-dissociation design
is considered most suitable here [18] and includes four groups representing a placebo (given placebo
(PLA)/told PLA (GP/TP)) and the pharmacological (given CAF/told PLA (GC/TP)), psychological
(given PLA/told CAF (GP/TC)) and synergistic effect(s) of CAF (given CAF/told CAF (GC/TC)) on the
dependent variable(s) assessed.
Thus, the novelty and purpose of this study was to explore CAF’s psychological vs.
pharmacological impact on measures of simulated soccer performance (e.g., skill proficiency, dynamic
reaction time (DRT), and endurance capacity) and perceptual states, prior to, during and following
intermittent exercise replicating the metabolic demands of a 90-min soccer game [37]. We hypothesised,
in comparison to a placebo (i.e., given placebo/told placebo), CAF’s isolated psychological and/or
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pharmacological impetus would improve all facets of soccer performance to a greater extent. Moreover,
synergism of CAF psychology and pharmacology would instigate the greatest benefit, although CAF
psychology would prove of greater efficacy vs. CAF pharmacology and any improvements would be
driven by enhanced perceptions.
2. Methods
2.1. Participants
After obtaining institutional ethical approval (ethics code—39-1617-ASs), participants were
emailed an information sheet including all relevant study specific information which was confirmed
verbally before informed consent was provided. Participants were required to be healthy, non-smoking,
recreational male soccer players, between 18–40 years old. Subsequently, eight male participants
(age: 22 ± 5 years, body mass: 78 ± 16 kg, height: 178 ± 6 cm) completed this study. This sample
size is similar to previous studies exploring the influence of CAF expectancies on sport and exercise
performance [21]. Recreational participation was defined as involvement in soccer specific activities
(e.g., 5, 8 and/or 11 aside soccer games) at an amateur standard for 1.5 h per week, across at least 6
months. Although habitual CAF consumption was not confirmed, beliefs regarding CAF ergogenicity
were explored at various time points (Section 2.8).
2.2. Pre-Experimental Procedures
Participants completed physical activity readiness (PAR-Q) and blood-screening questionnaires
prior to participation. Participants were required to avoid strenuous exercise and alcohol 24 h, and CAF
12 h, prior to all exercise trials [38–40]. All participants verbally confirmed that they were not using
ergogenic aids at the onset of this study and were prohibited to do so during participation. Participants
attended trials 2 h post-prandial and were asked to maintain the same diet 24 h prior. This was
recorded via self-reported food diaries and checked visually (e.g., food items included within diet logs
were examined and compared to logs obtained during previous trials to ensure replication) whilst
participants also verbally confirmed the aforementioned prior to each session. To avoid the confounding
influence of changes in macronutrient and/or energy availability, significant importance was placed on
consuming the same meal prior to each session. Dependent on the time of trials, an ideal breakfast/lunch
plan was outlined to assist participants replicating their diets. Subsequently, all participants replicated
their diets prior to each experimental trial. Each participants’ trials commenced at the same time of
day to avoid the influence of circadian changes on exercise performance [41].
2.3. VO2MAX and Brief Familiarisation
This study entailed a within-subjects, counterbalanced, double-blind, double-dissociation, mixed
methods design. Participants attended the laboratory on 6 separate occasions, with trials separated
by at least 48 h recovery. Trial one (T1) involved ascertaining an estimate of maximal oxygen uptake
(VO2MAX) via a 20 m progressive shuttle run test [42] similar to that used in Nicholas et al. [37],
and familiarisation of the main experimental protocols adopted. Briefly, after 5 min seated rest, heart
rate (HR; F1 Polar Heart Rate Monitor, Polar, Kempele, Finland) was telemetrically recorded, and
a finger prick capillary blood sample was taken to later assess blood lactate BLa and glucose BG
concentrations (Biosen C_line, EKF Diagnostic, Magdeburg, Germany). Blood was collected into a
20 μL sodium heparinised capillary tube (EKF diagnostics, Cardiff, United Kingdom) which was
then added to a 1 mL Eppendorf tube and mixed well before being placed into the Biosen C-Line for
analysis. The shuttle run test involved 20 m running bouts between two cones at increasingly fast
speeds until volitional exhaustion. This was controlled by auditory beeps (20M Bleep Test; Version 2.1;
developer: Adam Howard, United Kingdon, London, 2016) using a smart phone device connected to
a large portable speaker. Volitional exhaustion was defined as an inability to reach two consecutive
cones in the allotted time, or via voluntary stoppage. To stimulate maximum effort, participants were
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provided consistent verbal encouragement. Upon completion, HR, blood sampling, both as previously
described and ratings of perceived exertion (RPE; 6–20 category scale [43]) were recorded. From this,
running speeds corresponding to 55% and 95% VO2MAX were calculated for subsequent use during
the Loughborough Intermittent Shuttle Test (LIST) [37].
Following a further 45-min seated rest, participants completed familiarisation and a baseline
session measuring DRT (see Section 2.6), before performing the Loughborough Soccer Passing Test
(LSPT) as described in McGregor et al. [44]. Two consecutive 15 min bouts of LIST (e.g., repeated
sequences of: 3 × walking, 1 × sprint, 3 × cruising (55% VO2MAX) and 3 × jogging (95% VO2MAX);
Part A) were then performed, with each bout followed by recording RPE and HR, blood sampling
and completion of the LSPT, prior to 3 min rest (N.B. bouts of LIST across all trials were followed by
similar measurements). All bouts pertaining to part A were controlled using a LIST sequencer software
package (Nottingham Trent University, Nottingham, Clifton, England). Part B (TLIM) (only relevant
to trials 2 to 6, inclusive) was controlled manually using an online tone generator [45] and involved
20 m running bouts at 55% and 95% VO2MAX until volitional exhaustion. Following completion of
both 15 min LIST bouts, a second session measuring DRT was performed before participants left
the laboratory.
2.4. Full Familiarisation and Experimental Trials
An outline of the main methodological practices implemented during full familiarisation (T2) and
experimental trials (T3–T6), can be found in Figure 1. Trials lasted approximately 4 h. Briefly, following
5 min seated rest, HR and a blood sample were taken to measure BLa and BG concentrations. Mood states
were subsequently assessed using the Brunel Mood Scale (BRUMS; Section 2.7) [46]. Individuals then
performed the LSPT, before familiarisation and a baseline session measuring DRT. This was followed
by administration of 1/4 treatments (Section 2.5). Treatments were consumed within 5 min of a 60 min
seated ingestion period [10], where participants rested quietly in a semi-supine position. Following this all
baseline parameters were reassessed. After completing the LSPT, individuals then rested for 3 min before
performing 3 consecutive bouts of the LIST. A 15 min break replicating the half-time interval during soccer
games was implemented prior to bouts 4, and 5, followed by part B of the LIST. All measures following
LIST were recorded for a final time, as were DRT and completion of the BRUMS.
During the full familiarisation session water intake was measured and replicated during
experimental trials. Furthermore, at the start of familiarisation and experimental trials 1 and 3,
participants completed the CAF expectancies questionnaire (Section 2.8) ((CaffEQ): 47) which aimed to
assess habituated expectancies and whether expectancies changed between trials. Additionally, using
a Dictaphone (Section 2.9), individuals recorded a short verbal description of their experiences at the
end of experimental trials 2 and 4.
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2.5. Treatments
Treatments involved oral consumption of visually identical PLA (3 mg/kg/BM cornflower) or CAF
(3 mg/kg/BM) capsules and were always administered by a member of the technical support team who
was otherwise uninvolved during data collection. We adopted the lowest typical ergogenic dose of
CAF [10], as Goldstein et al. [5] observed no differences in sport and exercise performance between low
to moderate (3–6 mg/kg/BM) doses. Furthermore, greater doses may induce debilitative side effects
and, therefore, override CAF ergogenicity, for some individuals [47]. To facilitate expectancies for CAF
ergogenicity a manuscript and brief video [48] highlighting CAF’s benefits on exercise performance
were used for told CAF conditions. Contrastingly, the manuscript used during told PLA conditions
was designed to invoke a neutral effect, whilst the video [49] was standardised to have minimal
impact on perceptual states, or influence information relayed during told CAF conditions. These
manuscripts/videos were re-administered within the first 5 min of the half-time interval. As such
four treatments were administered across experimental trials: (1) placebo (given PLA/told PLA),
(2) pharmacology (given CAF/told PLA), (3) psychology (given PLA/told CAF) and (4) synergism
(given CAF/told CAF).
2.6. Dynamic Reaction Time (DRT)
Whole body dynamic reaction time was measured using the BATAK Pro (Quotronics Limited,
Surrey, UK) and is considered an important component across various soccer skills including tackling
and shooting [51,52]. Individuals were required to hit as many randomly illuminated targets as
possible, within 60 s (s). To our knowledge there is currently no familiarisation data regarding DRT
using the BATAK Pro; therefore, we adopted a comparable protocol to the Sport Vision Trainer which
is validated in assessment of reliability and repeatability pertaining to hand–eye co-ordination [53].
The mean deviation in DRT scores were within ~1–2 hits across all experimental trials, suggesting
participants were appropriately familiarised to this protocol. All experimental data is reported as
the average of 2 × 60 s attempts (defined as one session), with each attempt separated by 1 min of
seated recovery.
2.7. Brunel Mood Scale (BRUMS)
The BRUMS assessed participant mood states. The BRUMS consists of 24 items equally arranged
into six subscales (anger, confusion, depression, fatigue, tension and vigour), and like all other
perceptual measures employed, its purpose was explained, and demonstrated prior to use. Participants
were required to rate each item on a subscale of ‘not at all’ to ‘extremely’ with each rating entailing a
corresponding numerical, arbitrary unit (AU) (0 = not at all, 1 = a little, 2 =moderately, 3 = quite a bit,
4 = extremely). The sum of responses for each subscale was subsequently divided by 4 to provide a
final score. The BRUMS has high reliability and validity, with details of its development and validation
found in Terry et al. [54].
2.8. Caffeine Expectancies Questionnaire (CaffEQ)
The CaffEQ is a 47-item self-report questionnaire which assesses habituated expectancies across a
range of subscales related to caffeine expectancies including: withdrawal/dependence, energy/work
enhancement, social/mood enhancement, appetite suppression, physical performance enhancement,
anxiety/negative physical effects, and sleep disturbances. The CaffEQ involved choosing a vehicle that
best described individuals most commonly used CAF source(s). If participants were naive to CAF use,
they were advised to base responses on their expectancies. Each item was evaluated on a scale of ‘very
unlikely’ to ‘very likely’ with each rating ascribed a numerical value (0 = very unlikely, 1 = unlikely,
2 = a little unlikely, 3 = a little likely, 4 = likely, 5 = very likely) which was later analysed to provide a
score for each corresponding sub scale. The CaffEQ represents good, internal consistency (0.88–0.96)
and construct validity (0.80–0.94) [50].
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2.9. Dictaphone
Using a standardised neutral script, participants were encouraged to record a verbal description
(lasting up to 5 min) comparing their experiences at the end of experimental trials 2 and 4. Information
reminding what perceived treatment participants had consumed was provided within an A4 sheet
of paper which was folded to uphold confidentiality from the lead researcher. Specific importance
was placed on individuals remaining honest and there being no right/wrong answer(s). Participants
were instructed only to commence recording once they understood what was expected from them and
not to share any information with the research team. Participants were then provided an opportunity
to ask any questions before being left alone for recording to commence. A member of the technical
support team later collected the Dictaphone. These recordings were only made available to the lead
researcher following completion of data collection.
2.10. Qualitative Analysis
Following auditory transcription of Dictaphone logs, written data was explored by means of
template analysis [55]. Template analysis provides flexible use of theoretical underpinnings from both
content analysis [56] and grounded theory [57]. To facilitate template analysis, each transcription was
explored thematically, in line with the phases outlined in Braun and Clarke [58]. The subsequent
findings were, therefore, relative to the researcher’s interpretation of subjective quotes. Once a list
of codes had been compiled for each participant, these were linked/and or differentiated to create
themes. Moreover, in line with Jackson [59], the following three practices were implemented to enhance
trustworthiness [60] and credibility [61] during analysis:
(1) An in-depth description of the data collection and analysis procedure.
(2) Involvement of A.H and M.F.H in guiding the qualitative process, by making implicit enquiries to
the lead researcher (A.S) about the data collection/analysis procedure. This assisted in minimising
biases, whilst improving the clarity of interpretations.
(3) Brainstorming of pre-existing ideologies associated with the phenomenon in question to ensure the
researcher was cognisant of their own inherent beliefs and their influence upon the identification
of codes, themes, and/or concepts [59,62].
Participant identity was protected by use of pseudonyms. However, to provide greater meaning
to the qualitative findings, names were used as opposed to numbers.
2.11. Statistical Analysis
Quantitative statistical analysis was completed using IBM SPSS (v25 IBM Corp, Armonk, New
York, NY, USA). For all data, normality (via Shapiro-Wilk’s test) and homogeneity of variance/sphericity
(via Mauchly’s test) was checked. If sphericity was violated or data was non-normally distributed,
degrees of freedom were corrected using Greenhouse–Geisser values or the appropriate non-parametric
test was selected [63]. Confidence intervals were explored using least significant difference (LSD) (none)
over Bonferroni corrections to minimise the potential of missing meaningful effects. The Bonferroni
correction aims to reduce the chance of type 1 errors but subsequently increases the likelihood of
type 2 errors and may be regarded a conservative approach that is better suited to experiments that
have no clear hypothesis [64]. For analysis of variance (ANOVA, i.e., repeated measures) main effects
and interactions, the effect size (ES) is reported as the partial η2 value. Otherwise, the ES (Cohens d)
was calculated using the difference in means divided by the pooled standard deviation (SD) of the
compared values for normally distributed data [65], and Z/
√
n for non-normally distributed data [66].
Data is presented as mean ± standard deviation unless otherwise stated. The statistical threshold was
set at p ≤ 0.05 [67,68].
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3. Results
3.1. Endurance Capacity (TLIM)
There were no order effects for TLIM (p = 0.485). A main effect for treatment was observed
(p < 0.001; F = 23.638; η2 = 0.772). Mean TLIM was greatest (p < 0.001) for synergism (672 ± 132 s)
vs. placebo (533 ± 79 s) (Figure 2). However, when isolated, TLIM was greater (p = 0.012; ES = 0.4)
for psychology (623 ± 117 s) vs. pharmacology (578 ± 99 s) with all participants running longer for
psychology (Figure 2).
 
Figure 2. Endurance capacity (TLIM) scores (s). (A) Mean TLIM (s) across treatments (#, ¥ and + denotes
significantly lower vs. synergism, psychology and pharmacology, respectively); (B) subjective TLIM
across treatments.
Although main effects were observed for RPE, HR, BLa and BG across time (i.e., greater scores
were observed for TLIM vs. time matched exercise (isotime) (bouts of LIST)) with the exception of HR,
no treatment or interaction effects were observed. However, when these measures at post-exercise
were divided by each minute of TLIM, a trend of reduction was observed for synergism followed by
psychology, pharmacology and placebo (Tables 1 and 2).
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Table 2. Post-exercise heart rate (HR), BLa and BG divided by TLIM per min (exercise termination










Heart Rate (HR; bpm−1)
Synergism 147 159 172 185*
Psychology 160 173 187*
Pharmacology 172 186* - -
Placebo 184* - - -
Blood Lactate (BLa; mmol/L)
Synergism 6.8 7.3 7.9 8.5*
Psychology 7.4 7.9 8.6*
Pharmacology 8.4 9.0* - -
Placebo 8.6* - - -
Blood Glucose (BG; mmol/L)
Synergism 3.5 3.8 4.1 4.4*
Psychology 3.4 3.7 4.0* -
Pharmacology 3.8 4.1* - -
Placebo 4.0* - - -
3.2. Dynamic Reaction Time (DRT)
No treatment x time interaction was observed (p = 0.759; F = 0.561; η2 = 0.074) but main effects
were detected for treatment (p = 0.024; F = 3.854; η2 = 0.355) and time (p < 0.001; F = 20.802; η2 = 0.748).
Fatigue appeared to debilitate DRT performance (p < 0.05), with a mean reduction of between 4 to
7 hits following TLIM vs.
Baseline and 5 to 9 hits vs. post-ingestion. However, pharmacology ameliorated this decline by 2
to 4 hits vs. all treatments. Individuals also achieved 5 hits more at post-ingestion (p = 0.05; ES = 0.5)
and 7 hits more following TLIM (p = 0.008; ES = 0.5), for pharmacology vs. placebo (Figure 3).
Figure 3. Mean dynamic reaction time (DRT) across treatments and time (# and ¥ denotes significantly
greater difference vs. placebo).
3.3. Loughborough Soccer Passing Test (LSPT)
No interaction or main effects were observed across any LSPT parameter. However, time taken to
complete LSPT following isotime exercise was fastest for placebo (70 ± 3 s) followed by synergism and
psychology (74 ± 1 s) which were 2 s faster vs. pharmacology (76 ± 2 s) (Figure 4).
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Figure 4. Time taken to complete the Loughborough Soccer Passing Test (LSPT) across treatments
and time.
3.4. Heart Rate
No treatment x time interaction was observed for HR (p = 0.053; F = 1.613; η2 = 0.187), however
main effects for treatment (p = 0.033; F = 5.359; η2 = 0.434) and time (p < 0.001; F = 1495.447; η2 = 0.995)
showed greater overall HR for given PLA vs. CAF conditions and greater HR with increasing time.
3.5. Blood Variables
No treatment x time interaction or main effect for treatment was observed for BLa and BG.
However, a main effect of time was detected for BLa (p < 0.001; F = 147.898; η2 = 0.967) and BG
(p = 0.009; F = 3.281; η2 = 0.396) with BLa greater with increasing time, whilst BG was reduced.
3.6. BRUMS
No treatment x time interaction or main effect for treatment was observed for any BRUMS subscale.
However, a main effect of time was detected for fatigue (p < 0.001; F = 51.501; η2 = 0.880) and vigour
(p = 0.04; F = 14.587; η2 = 0.646). Generally, fatigue was greater with time, whilst vigour was reduced.
3.7. CaffEQ
Participant responses regarding caffeine expectancies entailed six independent modes of CAF
consumption, with only Aobi representing more than one (Table 3).
Table 3. Beverage chosen during caffeine expectancies questionnaire (CaffEQ) responses.
Participant Responses Based on




5-Molineux Other (not specified)
6-Ave Caffeine in general
7-Sam Energy drinks
8-Aobi Coffee, soft drinks and tea
No mean differences were observed between trials 1 and 3 across any CaffEQ subscales irrespective
of the treatment administered. However, following subjective analysis various differences were
observed across trials (Table 4).
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4. Qualitative Findings
Following template analysis, 5 areas of discussion became prominent (general perceptions, DRT,
LSPT, TLIM and LIST; Table 5). Although the success of expectancy manipulation was not explicity
confirmed, no participants correctly guessed the deception employed. Moreover, during Dictaphone
use, Habi, Ren, Ave and Aobi referred to treatments as they were administered (i.e., told CAF/PLA),
whilst Malik, Jack, Sam and Molineux referred to at least 2/4 treatments. Thus, it appeared participants
believed the deception employed.






• Aobi—‘I felt like I needed the lift that day and you could definitely feel like the
caffeine (trial—psychology) had an impact on me’ (greater mood and energy, and
lowered fatigue perception vs. told PLA treatments).
• Ren—‘Compared to the two placebo trials, after the ingestion period (synergism),
I almost immediately felt more alert, more active, more confident, and more
energetic’. Synergism also reduced fatigue perception during LIST, vs. told
PLA treatments.




• Aobi—Told PLA conditions induced neutral expectancies and/or a lack of
‘psychological effect’ and ‘didn’t really do much’
• Ren—‘I didn’t feel it had any effect on the (sic), obviously knowing it’s a placebo,
both placebos (told PLA treatments), I expect what you’re expected to feel’
• Ave, Molineux and Habi indicated no differences between treatments.
Dynamic reaction time (DRT)
Expectancies > told
PLA treatments
• Ren—Expected ‘to feel fatigued and slower’ during told PLA treatments prior to
measurement of post-exercise DRT, whilst feeling quicker during synergism.
• Molineux and Aobi felt ‘more alert’ for psychology vs. placebo
• Aobi—Psychology improved ‘reaction times’ on a day when he ‘wasn’t really
feeling up to it’.
• Ave—Told CAF conditions ‘really helped’, with synergism resulting in ‘a lot less
misses’ and better performance vs. all other treatments
• Aobi—Felt more familiarised to complete DRT, however this was augmented by




• Ave and Ren—Synergism improved LSPT vs. pharmacology Due to increased
speed. Ren also felt he ‘was getting worse, getting a few more mistakes, missing
the targets more’ during pharmacology.
• Aobi and Molineux were able to give more due to reduced fatigue perception for
synergism vs. told PLA treatments, during TLIM.
• Ave—Synergism improved TLIM vs. placebo due to reduced fatigue perception
associated with ‘the caffeine’. However, ‘struggled’ more during psychology.
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• Malik put everything into LIST bout 1, and subsequently felt ‘fatigued’ and a ‘lack
of motivation’ for psychology vs. told placebo treatments
• Ren—perceived greater cardiovascular and leg fatigue during psychology
vs. pharmacology.
• Ave—felt tired during psychology but attributed this to a ‘lack of sleep’ and not
the treatment.
• Ave and Molineux—no ‘improvement’ for psychology vs. placebo.
PLA = placebo; LIST = Loughborough Intermittent Shuttle Test; CAF = caffeine; LSPT = Loughborough Soccer
Passing Test.
5. Discussion
Through implementation of a double-dissociation design, this study is the first to compare CAF’s
pharmacological vs. psychological impact on various facets of simulated soccer performance. Although
all treatments enhanced TLIM vs. placebo, synergism resulted in the greatest improvements. However,
when isolated, psychology improved TLIM by 7% (~45 s) vs. pharmacology with all participants
displaying improvements for psychology. These findings indicate CAF expectancy is an important
contributor to the performance-enhancing benefit(s) of CAF. In relation to tasks involving a greater
cognitive influence, pharmacology improved post-exercise DRT performance vs. all other treatments,
whilst told CAF conditions improved the time taken to complete LSPT vs. pharmacology. Hence,
CAF may be an effective nutritional supplement to evoke improved exercise performance. In some
cases such benefits may occur with only the belief that CAF has been consumed and these effects
may be greater vs. CAF’s pharmacology impetus. However, an additive effect may be observed after
combining expectancy with CAF pharmacology [18].
Irrespective of the ingested treatment, expectancies improved TLIM with psychology and synergism
resulting in 90 and 95 s improvements vs. placebo and pharmacology, respectively. Using a
double-dissociation model, only two other studies have explored the influence of CAF expectancies on
TLIM, albeit during cycle ergometer based maximal incremental tests. Brietzke et al. [28] found synergism
and psychology resulted in ~19% (~75 s) and ~17% (~68 s) improvements in endurance capacity vs.
a control (i.e., no treatment administered; (CON)), whereas Pires et al. [29] observed ~15% (63 s) and ~17%
(71 s) improvements vs. CON. Both studies utilised 6 mg/kg/BM CAF capsules, and recreationally active
participants. Pires et al. [29] showed rectus femoris activation and pre-frontal cortex deoxygenation
were augmented across both CAF treatments, vs. CON. The latter effect is associated with antagonism of
A1 and A2A adenosine receptors, and subsequent corticospinal excitability. Moreover, whilst Brietzke et
al. [28] observed similar RPE for synergism and psychology, magnitude-based inferences indicated 75%
probability of a beneficial effect for both conditions vs. CON. Comparably, we observed similar RPE
across treatments following TLIM. However, when RPE was divided by TLIM, a trend of reduction was
observed for synergism, followed by psychology, pharmacology and placebo. A similar trend was also
observed for HR, BLa and BG. Hence, TLIM performance was likely facilitated by lowered cardiovascular,
hematological and/or perceptual strain, which appeared greater influenced by CAF expectancies vs.
pharmacology. In support, Benedetti et al. [69] advocate that expectancies could influence changes in
physiological processes associated with perceptual, motor, and homeostatic relevance. Furthermore,
the psychobiological model of endurance performance posits that interventions designed to reduce
perceptual exertion and/or enhance motivation may improve exercise tolerance [70,71]. Indeed,
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placebos have been observed to increase frontal alpha asymmetry and associated positive affect
appraisal of effort perception, when described as ergogenic aids [72]. It is also plausible that perceptual
exertion and/or motivation may share an inverse relationship [73], though subjective motivation was
not directly assessed here. In contrast to the current study, the aforementioned studies were performed
single-blind (i.e., potentially influenced by experimenter bias), whilst subjective perceptions were
unexplored which are important in advocating CAF’s mechanisms of action [18].
Pharmacology resulted in five and seven score improvements during measurement of DRT,
at post-ingestion and post-exercise, respectively, vs. placebo. Synergism also improved DRT at
post-ingestion by 5 scores vs. placebo, thus CAF possibly facilitated augmented performance via
central effects [74]. Moreover, the decline in DRT performance observed at post-exercise vs. baseline
and post-ingestion was also ameliorated during pharmacology, with scores 2 to 4 and 2 to 3 hits
greater vs. all other conditions. In contrast, Oei and Hartley [31] detected comparable performance
on a self-designed sustained attention task for given CAF (~143 mg) (2.57 s) and told CAF (2.47 s)
treatments. Moreover, similar findings were observed on the Bakan vigilance task for psychology,
placebo and pharmacology (200 mg) [38]. The difference in results between the present study and the
aforementioned studies may relate to the differences in tasks employed. Caffeine initiates excitability
at the supraspinal level which may improve gross motor function (i.e., agility, reaction time, whole
body movement) before, during and after sports activities [3,75–77]. In contrast, expectancy effects
may be overestimated during the performance of simple reaction tests due to inhibition of fine motor
skills associated with CAF over arousal and impaired cognitions [78].
Although the time taken to complete the LSPT declined over time, psychology and synergism
appeared to mediate this following time matched exercise and TLIM, vs. pharmacology. These results
were likely due to expectancies for CAF ergogenicity as performance was comparable for synergism
and psychology. Gant et al. [62] reported CAF (3.7 mg/kg/BM) improved LSPT performance by 1.5 s
following isotime exercise vs. CON, in 15 amateur male soccer players. Comparatively, Foskett et al. [7]
observed a 2.3 s reduction for CAF (6 mg/kg/BM) vs. CON, across 12 university soccer players.
Although neither study explored CAF’s psychological impact, Foskett et al. [7] found 4 individuals
correctly, and 3 incorrectly, identified CAF trials with 5 declining to comment. Thus, although
disparate, expectancies likely influenced these findings and this issue may be associated with a lack
of double-dissociation design whereby expectancies were uncontrolled [18]. Moreover, expectancy
effects are likely individually (based on belief and concurrent level of motivation), temporally and
experientially modulated further highlighting the need to explore subjective perceptions. These issues
may have also persisted in Gant et al. [79], although were not explored.
The changes in BG and BLa with increasing exercise intensity are likely causal and
concomitant to augmented glucose metabolism associated with greater energy output and metabolite
accumulation [80,81]. Furthermore, similar effects were observed for HR and are likely associated
with a greater cellular requirement for oxygen and nutrients (e.g., glucose) and removal of metabolites
and carbon dioxide [82]. Moreover, the 2 to 4 bpm−1 between-treatment variances in HR were
likely physiologically negligible, especially as HR following isotime exercise was comparable across




The qualitative implications associated with TLIM highlight the individualistic nature of subjective
perceptions. However, told CAF treatments always facilitated greater or comparable TLIM vs.
told PLA and this was irrespective of whether perceptions for CAF ergogenicity were positive or
negative [73]. For example, psychology was considered detrimental for Ren, yet TLIM was comparable
vs. pharmacology. Interestingly, Ren displayed expectancies for negative physical effects/anxiety
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but also performance enhancements on the CaffEQ, hence a relationship between these expectancies
is plausible. Comparably, Ave documented significant fatigue perception across psychology and
pharmacology, nonetheless TLIM for psychology was comparable to synergism but 30 s greater vs.
pharmacology. Molineux perceived minimal differences across treatments, though told CAF conditions
performed comparably but ≥ 30 s vs. pharmacology. In contrast, Malik and Habi displayed limited
expectancies across the CaffEQ, yet Malik felt psychology was the worst trial, whilst Habi indicated
no differences. Interestingly, TLIM was improved (53 s) or comparable vs. pharmacology, for Malik
and Habi respectively. Thus, expectation of CAF consumption appeared to be the greatest mediating
factor here. Furthermore, these findings are likely influenced by neutral expectancies and/or a lack of
perceived effect for told PLA conditions. However, although the aforementioned was not confirmed,
participants referred to treatments as they were administered (i.e., told CAF/PLA) and none guessed
the deception employed.
5.1.2. DRT and LSPT
The themes associated with DRT and LSPT appeared unrelated to performance outcomes. Instead,
our findings indicate negative perceptions associated with CAF may invoke a greater cognitive impetus
associated with alertness, concentration and technique which is otherwise impaired following positive
perceptions due to CAF over reliance [23,26]. For example, for DRT, Aobi indicated psychology
improved ‘reaction times’ on a day when he ‘wasn’t really feeling up to it’; however, 7 and 14 score
reductions were observed vs. placebo at post-ingestion and post-exercise. Moreover, ‘the burst from
the caffeine’ during synergism was also perceived to improve DRT, yet scores were comparable to
placebo and 5 less vs. pharmacology, at post-ingestion. In contrast, Ren perceived greater fatigue for
psychology vs. synergism, yet post-exercise DRT was 8 and 11 hits greater vs. synergism and placebo.
Comparably, time to complete the LSPT was fastest for psychology vs. all other conditions after Malik
felt the treatment impaired concentration, balance, motivation and technique. Opposingly, Aobi felt
psychology was facilitative, yet LSPT performance was 7 to 12 s slower vs. all other conditions. This
notion is supported by Tallis et al. [26] who propose an inverse relationship between expectations
and motivation, with too positive an expectation resulting in reductions in conscious effort due to
over confidence. We speculate similarly low expectancies associated with placebo may have driven
improvements in LSPT due to increased conscious effort. However, greater clarity is required here,
as limited subjective information was ascertained regarding placebo, following template analysis.
Although positive expectancies following psychology enhanced motivation, Harrell and
Juliano [23] observed slower reaction times and less hits on the rapid visual information processing
task vs. told impair conditions. Moreover, pharmacology appeared to improve performance vs. all
treatments, irrespective of expectancies. Thus, much like the inverted U-hypothesis proposed by Yerkes
and Dodson [83], expectations may need to be modulated to an optimal point for the greatest benefits
and this point might differ individually (based on belief and concurrent level of motivation), temporally
and experientially [18]. Given the potential difficulty in achieving this and the multi-faceted demands
of soccer and other team sports activities, CAF expectancies might not be appropriate here given the
potential for over-reliance with respect to cognitive-based tasks. Alternatively, CAF expectancies may
better suit tasks that entail lower cognitive requirements but may benefit from improved gross motor
function associated with reduced RPE (e.g., long-distance running, weightlifting etc.) [3,75,77].
5.2. Broader Applications
Although synergism of CAF psychology and pharmacology generally modulated the greatest
performance benefits within the current study, when isolated, CAF’s psychological impetus appeared
to mediate CAF ergogenicity to a greater extent vs. CAF pharmacology. Therefore, expectancies may
represent an alternative to CAF dosing prior to late evening sports competitions, ameliorating the quality
of exercise recovery, training and preparation which is otherwise impaired due to changes in melatonin
production, molecular oscillations and sleep quality [33]. The aforementioned approach may also
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benefit soccer coaches in planning training sessions after accounting for variances in physical/mental
recovery which would be aided by enhanced sleep quality. Moreover, these findings represent
important implications for soccer players affected by habituation to CAF’s central effects [34–36]
and health concerns (e.g., individuals suffering from heart disease, cardiac arrythmia, anxiety and
depression) and side effects that are exacerbated/instigated by consumption of CAF and potentially
detrimental to exercise performance [10,84–87]. Indeed, CAF expectancies represent minimal health
concerns as the consumption of pharmacologically active CAF is not required. Moreover, during
instances where CAF is consumed, expectancies may be trained and/or manipulated to enhance overall
CAF ergogenicity (as indicated by the treatment ‘synergism’ during the current study). However,
the influence of CAF expectancies has not been compared vs. CAF’s pharmacological effect following
performance of subsequent games (e.g., soccer tournaments which are common across recreational
sport). As such, it is unclear how CAF’s psychological effect would compare vs. CAF’s central effects
here. Further research is required.
The current findings also emphasise the need for future CAF studies to account for any
psychological effects which are at present largely overlooked. To achieve this, we recommend
implementation of the double-dissociation design which involves manipulating beliefs in accord with
the experimental purpose. This decreases the discrepancy of individuals guessing which treatment
they have been administered and reduces overlaps between CAF psychology and pharmacology.
5.3. Limitations
Although no participants correctly guessed the deception employed, and treatments were generally
referred to as they were administered (i.e., told CAF/PLA) we did not explicitly confirm the success
of expectancy manipulation. Future research will benefit from confirming the success (or not) of
expectancy manipulation.
We compared the subjective experiences of individuals via template analysis, however, CAF
associated changes with respect to an individual’s circadian rhythm (i.e., changes in melatonin
production and molecular oscillations) could have influenced these comparisons especially as some
participants performed sessions in the morning, whilst others in the afternoon [33]. Moreover, subjective
references were made to poor sleep quality possibly influencing exercise performance which may have
been exacerbated by the timing of CAF consumption. Thus, future studies may benefit from measuring
sleep quality prior to trials.
Although the notion of greater TLIM associated with lowered RPE is supported by the
psychobiological model of endurance performance [73], we did not measure subjective motivation
which is also considered an important psychosomatic determinant of exercise tolerance. Future studies
should, therefore, explore changes in motivation across treatments.
Although we explored changes in BLa and BG concentrations, CAF may also influence various
other metabolites (e.g., epinephrine, norepinephrine etc.) [88,89] that might contribute to fluctuations
in sport and exercise performance. Moreover, genetic assessments related to caffeine metabolism were
not checked across participants which may have influenced the efficacy of CAF pharmacology [90,91].
Finally, while expectancies were assessed via the CaffEQ, we did not explore habitual CAF
consumption, which has been observed to decrease the pharmacological effect of caffeine due to
reduced adenosine receptor sensitivity, for habitual consumers [36]. Consequently, CAF’s psychological
effect may have been overestimated across the current study. However, the effects of CAF withdrawal
are likely minimal as generally participants did not indicate any withdrawal symptoms/sensations via
template analysis or BRUMS. Moreover, it is unclear why we observed limited findings with respect of
BRUMS, especially as various mentions were made to changes in mood states across all treatments,
following template analysis.
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6. Conclusions
Through implementation of a double-dissociation design, this study is the first to compare CAF’s
pharmacological vs. psychological impact on various components of simulated soccer performance.
Although all treatments enhanced TLIM vs. placebo, synergism resulted in the greatest improvements.
However, when isolated, psychology improved TLIM by 7% (~45 s) vs. pharmacology with all
participants displaying improvements for psychology. These findings appeared relative to enhanced
expectancies and potentially reduced perceptual exertion but not perceptual states. Interestingly, DRT
was impaired for individuals displaying positive CAF perceptions which may be explained by reduced
conscious effort associated with CAF over-reliance. This was also observed during the LSPT with
the opposite occurring during negative perceptions. Thus, the mechanisms by which expectancies
influence exercise performance appear to be dependent on the task performed, with reduced RPE a
potential key mediator during endurance capacity. Subsequently, CAF expectancies may better suit
tasks that require lesser cognitive/skill specific attributes.
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Abstract: Most studies that have shown the positive effects of caffeine supplementation on sports
performance have been carried out on men. However, the differences between sexes are evident
in terms of body size, body composition, and hormonal functioning, which might cause different
outcomes on performance for the same dosage of caffeine intake in men vs. women. The main aim of
this systematic review was to analyze and compare the effects of caffeine intake between men and
women on sports performance to provide a source of knowledge to sports practitioners and coaches,
especially for those working with women athletes, on the use of caffeine as an ergogenic aid. A
structured search was carried out following the Preferred Reporting Items for Systematic Review and
Meta-Analyses (PRISMA) guidelines in the Web of Science, Cochrane Library, and Scopus databases
until 28 July 2019. The search included studies in which the effects of caffeine supplementation
on athletic performance were compared between sexes and to an identical placebo situation (dose,
duration and timing). No filters were applied for participants’ physical fitness level or age. A total of
254 articles were obtained in the initial search. When applying the inclusion and exclusion criteria,
the final sample was 10 articles. The systematic review concluded that four investigations (100%
of the number of investigations on this topic) had not found differences between sexes in terms of
caffeine supplementation on aerobic performance and 3/3 (100%) on the fatigue index. However, four
out of seven articles (57.1%) showed that the ergogenicity of caffeine for anaerobic performance was
higher in men than women. In particular, it seems that men are able to produce more power, greater
total weight lifted and more speed with the same dose of caffeine than women. In summary, caffeine
supplementation produced a similar ergogenic benefit for aerobic performance and the fatigue index
in men and women athletes. Nevertheless, the effects of caffeine to produce more power, total weight
lifted and to improve sprint performance with respect to a placebo was higher in men than women
athletes despite the same dose of caffeine being administered. Thus, the ergogenic effect of acute
caffeine intake on anaerobic performance might be higher in men than in women.
Keywords: recovery; strength; power; sprint performance; menstrual cycle
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1. Introduction
Numerous studies have shown the effectiveness of caffeine supplementation on sports performance
in which aerobic [1], anaerobic [2–4] or mixed [5–7] metabolism is prioritized. Current guidelines
recommend the ingestion of low-to-moderate doses of caffeine, ranging from 3 to 6 mg/kg, approximately
60 min prior to exercise to get these improvements [8,9]. Higher doses of caffeine (9–13 mg/kg) do not
result in an additional improvement in physical performance [10], while these higher doses might
increase the incidence and magnitude of main caffeine-related side effects. In addition, high doses of
caffeine might end in urine caffeine concentrations greater than 15 μg/ml, which is prohibited in the
National Collegiate Athletic Association (NCAA) [11].
In general, several mechanisms have been proposed to explain the effects of caffeine
supplementation on sports performance [3,12]. However, the most well-recognized mechanism
at present is that caffeine acts in the central nervous system (CNS) as a competitor for adenosine in its
receptors, inhibiting the negative effects that adenosine induces on neurotransmission, excitation and
pain perception [13]. In addition, the hypoalgesic effect of caffeine decreases the perception of pain
and effort during exercise and therefore might also be considered as a supplementary mechanism of
action, at least for exercise situations that induce pain [3,12]. As a result, lower pain perception could
maintain or increase the firing rates of the motor units and possibly produce a more sustainable and
forceful muscle contraction, and consequently, allow greater strength production [3,14].
Caffeine can affect the use of energy substrates during exercise. In particular, it has been suggested
that caffeine supplementation acts as a glycogen saver as it increases the mobilization of free fatty
acids by adrenaline (epinephrine) induction [15]. Although this mechanism could favor aerobic
and anaerobic sports that depend on muscle glycogen, it is currently known that there are other
mechanisms by which athletic performance would be favored such as increased calcium mobilization
and phosphodiesterase inhibition [3,9]. In addition, it has been proposed that caffeine supplementation
causes a greater activity of the Na+/K+ pump to enhance excitation contraction coupling [16].
Given that sex has been identified as an important determinant of athletic performance through the
impact of body composition, aerobic capacity or anaerobic thresholds due to hormonal differences [17],
specific recommendations for each sex should be in agreement with these sex differences to achieve
better results in sports performance. In this respect, while there is a position and recommendations
about the use of caffeine supplements in athletes [18,19], there is not enough comparative information
on the effects of caffeine on athletic performance between men and women athletes [20]. For that
reason, caution would be needed in extrapolating the recommendations made for men to women,
since the vast majority of the studies included only male participants [1,2,5,21]. In fact, only ~13% of
participants in investigations aimed to determine the ergogenic effect of caffeine are women, while
the effect of caffeine in women at high (>9 mg/kg) or very low doses (<1 mg/kg) is unexplored [22].
In addition, due to the menstrual cycle, women are subject to hormonal changes that could affect sports
performance [23,24]. For instance, it has been shown that the phase of the menstrual cycle influences
the development of strength [25]. Also, the consumption of oral contraceptives has effects on the
metabolism of caffeine, extending its half-life and prolonging the responses in the human body [26],
although very few studies take these aspects into account [27].
In this respect, studies conducted with the general population have already shown that the
stimulating effects (less drowsiness and greater activation) of caffeine are greater in men than in
women [28]. Still, few studies have shown the differences in the effect of caffeine supplementation on
sports performance between men and women, and their results are controversial [29–37]. While some
studies have shown a comparable ergogenic effect of caffeine between sexes on sports performance,
others have presented a greater effectiveness of caffeine to increase sprint power [29], isolated forehand
stroke peak and average speed [37], total weight lifted [38] and a shorter time to perform a repeated
modified agility test (RMAT) [30] in men compared to women. Unifying the data from these different
studies could provide knowledge regarding the effect that caffeine supplementation has on sports
performance based on the athlete’s sex. This analysis might help to enhance the recommendations for
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caffeine supplementation based on sex and the type of exercise performed. Therefore, it was proposed
to carry out a systematic review of the relevant articles published in the scientific literature.The main
objective of which was to discern the possible effects of caffeine supplementation on sports performance
based on the participant’s sex. Specifically, this systematic review focuses on determining the different
responses between the sexes to the same caffeine supplementation protocol depending on whether the
exercise will be classified as aerobic, anaerobic or when the protocol induced some type of fatigue that
could be evaluated (i.e., index of fatigue).
2. Methodology
2.1. Search Strategy
This article is a systematic review focused on the performance effects of caffeine in men athletes vs.
women athletes. It was carried out following the Preferred Reporting Items for Systematic Review and
Meta-Analyses (PRISMA) guidelines [39]. A structured search was carried out in the Web of Science
(WOS), which includes other databases such as BCI, BIOSIS, CCC, DIIDW, INSPEC, KJD, MEDLINE,
RSCI, SCIELO, and the Cochrane Library and Scopus, sources of high-quality information in the field
of health sciences, thus guaranteeing complete bibliographic support. The search strategy ended on 28
July 2019. The search terms included a mix of medical subject headings (MeSH) and free-text words
for key concepts related to caffeine, the sex of the athletes under investigation and different forms of
exercise and sports performance. The following search equation was used to find the relevant articles:
(“caffeine”[MeSH Terms] OR “caffeine”[All Fields]) AND ((“female”[MeSH Terms] OR “female”[All Fields])
OR (“women”[MeSH Terms] OR “women”[All Fields])) ((“male”[MeSH Terms] OR “male”[All Fields]) OR
(“men”[MeSH Terms] OR “men”[All Fields] OR “woman”[All Fields])) AND ((“exercise”[MeSH Terms] OR
“exercise”[All Fields]) OR (“sports”[MeSH Terms] OR “sports”[All Fields] OR “sport”[All Fields])) AND
performance [All Fields]. No filters were applied to the athlete’s physical fitness level, race, or age to
increase the power of the analysis. The search for published studies was independently performed by
2 different authors (JMA and JCG).
2.2. Inclusion and Exclusion Criteria
The PICOS model was used to determine the inclusion criteria [40]: P (Population): “men and
women athletes”, I (Intervention): “caffeine supplementation”, C (Comparators): “identical conditions
for caffeine and placebo experimental trials”, O (Outcome): “physical and/or sports performance
measurements”, and S (study design): “single- or double-blind and randomized design”.
As a result, the studies included in this systematic bibliographic review had to meet all the
following criteria: (i) populations were elite or amateur athletes or active people, men and women of
any age; (ii) participants performed any form of physical exercise or sport using caffeine as an ergogenic
aid, which could be administered in the form of capsules/pills, energy or sports drinks, commercial
drinks with caffeine content, chewing gum or coffee; (iii) the effects of caffeine were compared on
both sexes to an identical placebo condition and the protocols used were similar for male and female
participants; (iv) articles examined the effects of caffeine supplementation on physical performance
measurements, physiological responses, perceptual measures; (v) study designs were randomized,
single- or double-blind, and placebo-controlled. The following exclusion criteria were applied to
the experimental protocols of the investigation: (i) studies that were conducted only in men or in
women athletes; (ii) studies that were performed for clinical purposes or therapeutic use; (iii) the
absence of a true placebo condition or different experimental protocols used for male and female
participants; (iv) studies carried out using participants with a previous cardiovascular, metabolic, or
musculoskeletal disorder.
161
Nutrients 2019, 11, 2313
2.3. Study Selection
Two authors identified papers through a database search (JMA and JCG). The titles and abstracts
of publications identified by the search strategy were screened for a subsequent full-text review and
were cross-referenced to identify duplicates. All trials assessed for eligibility and classified as relevant
were retrieved and the full text was peer-reviewed (JMA and JCG). Moreover, the reference sections
of all relevant articles were also examined applying the snowball strategy. Based on the information
within the full reports, inclusion and exclusion criteria were used to select the studies eligible for
inclusion in the systematic review. Disagreements were resolved through discussions between the
different authors (JMA and JCG).
2.4. Data Extraction
Once the inclusion/exclusion criteria were applied to each study, the following data were extracted:
study source (author/s and year of publication); population of the sample indicating the level of activity
or sports discipline, age, sex and number of participants; habitual caffeine intake (mg/day); dose of
caffeine intake, source from which it is obtained and its administration protocol; and performance
outcomes in men and women.
2.5. Quality Assessment and Risk of Bias
In order to carefully consider the potential limitations of the included studies to obtain reliable
conclusions, and following Cochrane Collaboration Guidelines [41], two authors independently
assessed the methodological quality and risk of bias (JMA and DMJ) of each investigation, and
disagreements were resolved by third-party evaluation (JCG). In the Cochrane Risk of Bias tool,
the following items are included and divided into different domains: (1) selection bias (items: random
sequence generation, allocation concealment), (2) performance bias (blinding of participants and
personnel), (3) detection bias (blinding of outcome assessment), (4) attrition bias (incomplete outcome
data), (5) reporting bias (selective reporting), and (6) other bias (other sources of bias). The assessment
of the risk of bias was characterized as low risk (plausible bias unlikely to seriously alter the results),
unclear risk (plausible bias that raises some doubt about the results), or high risk (plausible bias that
seriously weakens confidence in the results).
3. Results
3.1. Search Strategy
After applying the search equation, a total of 202 records were identified through database searches
and six studies through reference list searches. From these 208 articles, 45 of them were removed
because they were duplicates. In addition, 33 studies were excluded after screening the abstract. As a
result, 129 studies were assessed for eligibility. From the 129 full-text articles assessed, another 119
papers were removed because they were unrelated to the topic of this systematic review. The topics
and number of studies that were excluded were as follows: those excluded because the subjects were
inappropriate for the inclusion criteria (n = 51; in animals n = 10; and in the general population n = 41),
those that used an unsuitable methodology (n = 33; outcomes in men and women separately, or did
not compare the responses for both sexes), and those with unsuitable outcomes (n = 29; cognitive
function and sleep n = 23; and toxicological and genetic studies n = 5; and bibliographic reviews n = 7).
Consequently, 10 studies met the previously defined inclusion criteria and were included in this final
systematic review (Figure 1).
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Figure 1. Selection of studies (Preferred Reporting Items for Systematic Review and Meta-Analyses
(PRISMA), 2009 Flow Diagram).
3.2. Caffeine Supplementation
The total sample consisted of 221 participants (n = 113 males; n = 108 females) [29–38]. All
studies were performed using adult populations. Healthy active students were selected in three
studies [30,31,37] while the remaining studies included participants catalogued as athletes because
they train for a specific sport. Athletes from endurance sports such as cycling, triathlon [29,32,36],
and from resistance training modalities were used in the investigations [35,38]. Moreover, two trials
were performed with elite collegiate athletes from several disciplines such as tennis, basketball and
soccer [33,34].
The sources of caffeine supplementation were varied, including commercial drinks used by
Jacobson et al. (2018) [37], Tinsley et al. (2017) [35], high chlorogenic coffee (Turkish coffee) used by
Nieman et al. (2017) [32], dry anhydrous caffeine mixed with 300 mL water and a sugar-free peach
squash solution proposed by Sabblah et al. (2015) [38], and caffeine gum used by Paton et al. (2015) [29].
The other authors of this systematic review used capsules to administer the scheduled doses of caffeine
in their studies [31,33,34,36].
In the included studies, caffeine was administered in different doses, based on an individual’s body
mass, or with an absolute dose. The doses based on the participant’s body mass used between 3 and
6 mg/kg of body mass. Skinner et al. (2019) used 3 mg/kg [36], Paton et al. (2015) used 3–4 mg/kg [29],
and Tinsley et al. (2017) provided 4 mg/kg of caffeine for men and 3.6 mg/kg of caffeine for women
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using a caffeinated supplement [35]. Besides, Jebabli et al. (2016) [30] and Sabblah et al. (2015) [38] used
5 mg/kg in the caffeine administration protocol, while Chen et al. (2015) [33], Chen et al., (2019) [34],
and Suvi et al. (2016) [31] used a dose of 6 mg/kg. In relation to studies that provided an absolute dose,
participants in the study by Jacobson et al. (2018) [37] consumed a commercially available energy drink
with 240 mg (≈3.1 mg/kg) of caffeine, and Nieman et al. (2017) [32] used 474 mg (men: ≈6.7 mg/kg and
women: ≈7.5 mg/kg) of caffeine from a cup of coffee in their study.
In general, the time of the ingestion of caffeine was between 30 and 60 min before testing.
Thus, Chen et al. (2015) [33], Chen et al. (2019) [34] and Sabblah et al. (2015) [38] agreed on
administering this type of supplementation 60 min before testing, and Tinsley et al. (2017) [35] and
Jacobson et al. (2018) [37] prescribed caffeine supplementation 30 min before testing. However, 45 min
before [30] and 90 min before [36] testing were also selected as time-points of caffeine supplementation.
Likewise, Suvi et al. (2016) [31] fractionated the dose into two portions: 60 min before (4 mg/kg) and
immediately prior to testing (2 mg/kg). A different strategy for supplementation was chosen by
Nieman et al. (2017) [32], who proposed a protocol of chronic intake of Turkish coffee every morning
for two weeks. In contrast, only one study [29] administered caffeine supplementation during exercise
(after completing one third of a 30 km test), and another one after exercise [34], where participants
ingested caffeine at 24 and 48 h post-exercise.
3.3. Outcome Variables
Studies included in this systematic review measured a large range of variables. Consequently,
studies were clustered by the character of the measurements, such as aerobic performance (Table 1),
anaerobic performance (Table 2) and the fatigue index (Table 3). As a result, the effects of caffeine
supplementation on aerobic performance were analyzed in four studies [29,31,32,36], on anaerobic
performance in seven studies [29–38] and on the fatigue index in three studies [30,33,34].
3.4. Quality Assessment and Risk of Bias
In relation to selection bias, random sequence generation was characterized as low risk only
in three studies [35–37], while in the remaining studies, the bias was unclear [29–34,38]. Allocation
concealment was categorized as low risk in all experiments [29–38]. Regarding performance bias,
the blinding of participants was categorized as low risk in nine studies [29,31–38] and high risk in
one trial [30], whereas the blinding of personnel was categorized as low risk in four studies [33–36],
unclear in five trials [29–32,37], and high risk in one trial [38]. The domain attrition bias, measured by
incomplete outcome data, shows that six studies can be characterized as low risk [29–32,37,38], and
four studies can be considered as unclear risk [33–36]. In relation to reporting bias, evaluated through
selective reporting, five trials were considered to be of low risk [31,33,34,36,37], three to be of unclear
risk [29,35,38] and two to be of high risk [30,32]. Finally, six studies were characterized as low risk of
other bias [29,31,33,34,36,38], two trials as unclear risk [32,35] and two studies as high risk [30,37]. Full
details for all these risks are given in Figures 2 and 3.
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Figure 2. Risk of bias summary: review of authors´ judgements about each risk of bias item presented
as percentages across all included studies.
 
Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item for each
included study.
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4. Discussion
The main aim of this systematic review was to summarize the differences, if any, in the ergogenic
effect of caffeine supplementation between men and women. This systematic review focuses on
different responses between sexes to the same caffeine supplementation protocol when the exercise
was categorized as aerobic, anaerobic or when the protocol induced some kind of fatigue that could be
assessed (i.e., fatigue index). Knowing that caffeine is one of the most popular ergogenic aids with
demonstrated effects on physical performance [6,18,19], it was considered that this systematic review
might show a global vision of the ergogenic effect of caffeine in men and women, gathering all studies
published in this field. Generally, the investigations analyzed reflect that there are no differences
between men and women. However, some investigations showed some subtle differences between
sexes, indicating that males might experience an increased ergogenic effect of caffeine, especially to
produce more power, greater total weight lifted and higher speed with the same dose of caffeine. These
results suggest that, in general, both men and women athletes benefit from caffeine supplementation to
the same extent. Nevertheless, it seems that ergogenicity might be greater in men for exercise activities
with an anaerobic component. Interestingly, none of the investigations depicted a negative effect of
acute caffeine intake on physical performance. All this information indicates that the current guidelines
for caffeine supplementation can be equally valid for men and women athletes.
4.1. Effects of Caffeine on Aerobic Performance
Caffeine has been popularly used in long-lasting sports given that some improvements are
observed over time to exhaustion [8,9], mainly due to a hypothetical glycogen-sparing effect of
caffeine [15] and the stimulation in the CNS of this substance, capable of attenuating pain [42]. In fact,
numerous studies have used the duration of a test and the time to complete it as an indicator of aerobic
endurance performance, in which the effect of a supplement such as caffeine can be measured [29–32,36].
Regarding the differences between men and women, there are more studies in which there are
no significant differences between sexes in time trials. For example, Paton et al., (2015) [29] showed
improvements of a similar magnitude in the aerobic performance of both sexes, but without differences
between them. However, these authors found that men showed significant improvements in anaerobic
performance with respect to women, probably due to the increase in activity of the CNS. One of
the main reasons why they did not find significant differences between sexes could be the great
interindividual variability, which could be associated with individual differences in the metabolism of
caffeine or the absorption rate [43].
Suvi et al. (2016) [31] did not show significant differences between sexes in endurance capacity
in hot environments (42 ◦C, 20% relative humidity) after taking 6 mg/kg of caffeine in two doses
(4 mg/kg 60 min before the test and 2 mg/kg immediately before it). Similarly, Nieman et al. (2017) [32]
did not find sex differences after chronic intake of 474 mg of caffeine for 2 weeks either. Moreover,
Skinner et al. (2019) [36] showed significant and comparable improvements in endurance performance
in both sexes. The performance improvements observed in women were similar to those in men, even
though women showed higher plasma caffeine concentrations. Thus, Skinner et al. (2019) [36] suggested
that current recommendations for caffeine supplementation, which are derived from studies conducted
in men, could also be applied to women, in particular in aerobic endurance events. The results of these
studies suggest that caffeine supplementation is equally effective in terms of improving the aerobic
capacity in both men and women athletes.
4.2. Effects of Caffeine on Anaerobic Performance
Regarding anaerobic actions, it has been demonstrated that caffeine produces positive effects on
performance among others due to the activation of the CNS [3,44]. Caffeine might antagonistically
bind adenosine receptors and decrease adenosine-mediated fatigue [45]. Moreover, a recent study has
also suggested that caffeine in physiological concentrations (~40 μmol/L) may improve calcium release
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from the sarcoplasmic reticulum during muscle contraction [46]. To the best of the authors’ knowledge,
only one study conducted by Jababli et al. (2016) [30] compared the caffeine supplementation effect
on the glycolytic pathway in both sexes. The authors observed that the effect of caffeine to reduce
the total time employed to complete several repetitions of an agility test was higher in men than
women. The authors indicated that one explanation could be the increase in alertness, leading to more
concentration during the execution of this type of test, especially during the changes of direction [30].
However, the effect of caffeine was similar when only the best time in the agility test was taken into
account. The controversies between these results may be due to either the sex selection or the selected
study population. Due to the scarcity of data comparing the effect of caffeine on agility in men and
women, more studies are necessary to confirm these results.
Anaerobic capacity manifests the rapid use of the phosphagen system (adenosine triphosphate
(ATP) and creatine phosphate) in the muscles, with type II fibers providing the greatest contribution.
Anaerobic capacity can be estimated by numerous laboratory and field tests such as anaerobic speed
test, mean power output and peak power output [47]. In addition, there is evidence about the ergogenic
effect of caffeine on anaerobic capacity [3,30,44], but the causes remain unclear [48]. It is now accepted
that caffeine induces higher levels of Ca2+ and K+. The influx of Ca2+ from the sarcoplasmic reticulum
favors the formation of cross bridges and therefore increases muscle power, whereas the serum increase
in K+ causes increases in the Na+ / K+ ATPase activity, so that it can attenuate muscle fatigue [33,49].
Regarding the potential sex differences of caffeine supplementation on muscle power,
Paton et al. (2015) [29] presented similar increases in mean power in the last 10 km between men and
women after 3–4 mg/kg caffeine chewing gum supplementation during a 30 km continuous cycling
exercise with varying intensity. However, the men showed greater sprint power induced by caffeine
than the women, due to the inclusion of aerobic phases of exercise prior to the sprints performed in the
test, as well as the inter-individual variability in the response to caffeine [8]; thus, posing a possible sex
-based difference that affects high intensity anaerobic measurements [50].
Jacobson et al. (2018) [37] found that only women improved forehand stroke velocity after the
intake of 240 mg of caffeine, while the caffeine-induced changes on vertical jump was similar between
sexes. Opposite results were shown in the Warren et al. (2010) meta-analysis [48], where it is stated
that caffeine has more impact on exercise that involves large muscles than small muscles, such as in
the arms. These differences could be, (a) related to the dose of caffeine supplementation because it
could be adequate to improve the performance of small muscle groups, but insufficient to improve the
performance of muscle groups in the legs and (b) the caffeine amount was the same for all participants,
so that the differences in body mass and body composition between sexes could cause the women to
receive more caffeine than the men [37].
Therefore, based on the results included in the studies of this systematic review, there are
differences between the manifestation of variables associated with muscle power and speed between
men and women. However, given the small number of studies, it is difficult to attribute the causes.
Jebabli et al. (2016) [30] indicated that a dose of 5 mg/kg of caffeine 45 min before a repeated agility
test decreased the total time more in men than in women [30]. The authors attributed these results to
the increase in neuromuscular activity that facilitates the neural transmission observed in the men, of
which there is no evidence in the women [51].
Another physical capacity included in anaerobic performance may be strength. In this respect,
strength is based on a combination of morphological and neural factors that include the cross-sectional
area of the muscle and architecture, musculotendinous stiffness, motor unit recruitment, frequency
coding, motor unit synchronization and neuromuscular inhibition [52]. However, the effects of caffeine
supplementation on strength are not so clear. Some studies found an acute effect of caffeine on
increasing strength, while others did not present a response to supplementation with caffeine [48,53].
In any case, few studies have analyzed the potential differences between sexes evaluating the variables
associated with strength.
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Chen et al. (2015) [33] and Chen et al. (2019) [34] showed that 6 mg/kg of caffeine supplementation
improved the maximum voluntary isometric strength (measured by isometric contractions) of the
knee extensors after 60 min of caffeine ingestion, and 24/48 h post-exercise, respectively, but without
significant differences between sexes. According to the authors, one of the main factors that may have
influenced the absence of sex differences was that the women’s sample was homogenized in relation
to the menstrual cycle (all were in the early follicular phase) [33,34]. In this respect, although some
investigators have reported an inotropic effect of estrogens on muscle because of a switching of muscle
cross-bridges from low- to high-force generation [54,55], in general muscle strength does not appear to
fluctuate significantly during an ovulatory menstrual cycle [47].
In the same line of research, Tinsley et al. (2017) [35] did not show significant differences between
sexes in the production of strength after caffeine supplementation (men: 4.0 mg/kg and women:
3.6 mg/kg of caffeine). However, the effect size showed that the caffeine supplement contributed to
small increases (not significant) in the men′s concentric strength (5–20%, d = 0.2–0.4 relative to placebo),
but not in the women′s. In this study, the women′s menstrual cycle phase was not taken into account.
However, women participants were given 75% of the supplement given to men participants to match
the differences in body composition between both sexes [35], which could have impacted the slightly
lower response to caffeine in the women.
Sabblah et al. (2015) [38] found that 5 mg/kg of caffeine had positive effects on 1RM for both
sexes trained in resistance. However, it showed that the women’s reaction was smaller than men’s,
as evidenced by a tendency to improve total weight lifted for men with no such effect in this variable for
women. Besides, the authors showed that the perception of pain in both sexes revealed no differences
after caffeine supplementation. The greater activation that caffeine has shown in men compared to
women could be the potential cause of these differences in the total weight lifted [28].
Therefore, although there are equivocal results, there are more than reasonable doubts to consider
that the effect of caffeine supplementation influences men and women differently as regards strength.
4.3. Effects of Caffeine on the Fatigue Index
The consumption of pre-workout supplements makes it possible to experience physiological
effects, as well as the psychological effects on performance [35]. In this case, caffeine may delay the onset
of fatigue or block the perception of pain or fatigue, using the same mechanisms involved in perception
variables [33]. However, regarding rated perceived exertion there is scarcely any scientific evidence
that could show significant differences between sexes. Three of the studies included in this systematic
review do not show significant differences between men and women in the fatigue index [30,33–35].
Only the study published by Suvi et al. (2016) [31] showed that caffeine supplementation reduced the
perception of fatigue in men, but not in women, when exercising in hot environments. The authors
attributed this result to the greater sensitivity of men to acute caffeine ingestion compared to women,
as shown by previous research [28,56–58].
5. Conclusions
In summary, 10 studies met the previously defined inclusion/exclusion criteria and were included
in this systematic review, aimed to analyze the between-sex differences in the effect of caffeine
supplementation on physical/sports performance. The total sample consisted of 221 participants
(n = 113 males;n = 108 females), while caffeine supplementation was given by using different sources
of caffeine between 30 and 60 min before testing. Studies included in this systematic review measured
a large range of variables such as aerobic and anaerobic performance and the fatigue index. Overall,
the caffeine supplementation produced a similar ergogenic benefit for aerobic performance and the
fatigue index in men and women athletes. However, the effects of caffeine to produce more power, total
weight lifted and to improve sprint performance with respect to a placebo was greater in men than
women athletes despite the same dose of caffeine being administered. Specifically, the men experienced
greater mean power than the women during the final 10-km cycling test after ~3–4 mg/kg caffeine
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supplementation. Likewise, the ergogenic effect of 5 mg/kg of caffeine to increase the total weight
lifted was higher in men than in women, in particular the ergogenic effect of acute caffeine intake on
anaerobic performance.
Strengths, Limitations and Future Lines of Research
The main strength of the present study is its novelty, given that no previous systematic review has
analyzed the effect of caffeine supplementation on performance between sexes. The main limitations
were the scarcity of information and the low sample sizes used in most investigations. Besides,
differences in physical tests and caffeine supplementation protocols make it difficult to generalize
the recommendations. Finally, it is of great importance to continue the work in future research on
supplementation with caffeine in female populations. Specifically, it is necessary to determine whether
women athletes benefit from acute caffeine intake in other forms of exercise or in sports where several
physical fitness variables affect overall performance. In addition, the between-sex difference in the
response to other dietary supplements should also be investigated to ascertain whether the findings of
previous investigations with males are also applicable to women athletes. Lastly, it is necessary to take
into account women’s menstrual cycle when investigating caffeine ergogenicity to determine whether
this substance exerts positive performance effects in all phases of the menstrual cycle.
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Abstract: Soccer is a complex team sport and success in this discipline depends on different factors
such as physical fitness, player technique and team tactics, among others. In the last few years,
several studies have described the impact of caffeine intake on soccer physical performance, but the
results of these investigations have not been properly reviewed and summarized. The main objective
of this review was to evaluate critically the effectiveness of a moderate dose of caffeine on soccer
physical performance. A structured search was carried out following the Preferred Reporting Items
for Systematic Review and Meta-Analyses (PRISMA) guidelines in the Medline/PubMed and Web of
Science databases from January 2007 to November 2018. The search included studies with a cross-over
and randomized experimental design in which the intake of caffeine (either from caffeinated drinks
or pills) was compared to an identical placebo situation. There were no filters applied to the soccer
players’ level, gender or age. This review included 17 articles that investigated the effects of caffeine
on soccer-specific abilities (n = 12) or on muscle damage (n = 5). The review concluded that 5
investigations (100% of the number of investigations on this topic) had found ergogenic effects of
caffeine on jump performance, 4 (100%) on repeated sprint ability and 2 (100%) on running distance
during a simulated soccer game. However, only 1 investigation (25%) found as an effect of caffeine to
increase serum markers of muscle damage, while no investigation reported an effect of caffeine to
reduce perceived fatigue after soccer practice. In conclusion, a single and moderate dose of caffeine,
ingested 5–60 min before a soccer practice, might produce valuable improvements in certain abilities
related to enhanced soccer physical performance. However, caffeine does not seem to cause increased
markers of muscle damage or changes in perceived exertion during soccer practice.
Keywords: football; RPE; DOMS; sport performance; supplementation; ergogenic aids
1. Introduction
Soccer is considered one of the most popular sports worldwide. According to the Fédération
Internationale de Football Association (FIFA) Big Count survey, there are 265 million active soccer
players and the number is progressively increasing, especially in women’s football [1]. In addition,
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soccer attracts millions of television spectators while the socio-economic impact of elite soccer affects
almost every culture worldwide [2]. Thus, the study of soccer and the variables that affect performance
in this complex team sport can have a great impact on sport sciences. Briefly, modern soccer is
characterized by the continuous combination of short sprints, rapid accelerations/decelerations and
changes of direction interspersed with jumping, kicking, tackling and informal times for recovery [3].
In addition to these physical fitness variables, players’ techniques and cognitive capacity, team tactics,
and psychological factors might also have an impact on overall soccer performance [4,5]. Unlike other
team sports, such as basketball or handball, soccer is a low-scoring game and, thus, the margins of
victory are close/reduced, particularly at the elite level. In consequence, the study of the effects of
ergogenic aids on performance have become an important subject for players, coaches and sport
scientists associated with soccer because it has the potential to increase success in the game [6].
Caffeine (1, 3, 7-trimethylxanthine) is one of the most popular supplements among athletes for
its potent stimulant effects and due to its easy availability in the market in different commercial
forms (energy drinks, caffeinated beverages, pills, pre-workout and thermogenic supplements, etc.).
In addition, the ergogenic effects of the acute ingestion of caffeine have been widely reported on
different forms of exercise, although most of the classic studies focused on endurance performance [7,8].
In the last few years, several investigations have found that caffeine can also increase anaerobic and
sprint performance, although the direct application of these research outcomes to the complexity
of soccer is complicated [9–11]. According to the Australian Institute of Sport (AIS), the potential
ergogenicity of caffeine reflects level 1 evidence, which allocates it as a safe supplement to use
in sport [12]. In addition, the International Olympic Committee indicates, in its recent consensus
statement for dietary supplements, that caffeine intake results in performance gains when ingested
before exercise in doses ranging from 3 to 6 mg/kg. Finally, two recent systematic reviews have
concluded that caffeine might be ergogenic in team sport athletes [6,13]. With this background, one
might suppose that caffeine is also ergogenic in soccer although the information regarding this sport
has not been summarized. In the last few years, several studies have investigated the effects of
caffeine intake on soccer physical performance [14–21] and in the opinion of the authors, the results of
these investigations need to be objectively reviewed and summarized. Therefore, the objective of this
systematic review was to critically evaluate the effectiveness of a moderate dose of caffeine on soccer
physical performance, muscle damage and perception of fatigue in order to provide more objective
and comprehensive information about the positive and negative impact of caffeine on soccer players.
2. Methods
2.1. Search Strategies
The present article is a systematic review focusing on the impact of caffeine intake on soccer
physical performance and it was conducted following the Preferred Reporting Items for Systematic
Review and Meta-Analyses (PRISMA) guidelines and the PICOS model for the definition of the
inclusion criteria: P (Population): “soccer players”, I (Intervention): “impact of caffeine on soccer
physical performance, muscle damage and perception of fatigue”, C (Comparators): “same conditions
with placebo”, O (Outcome): “soccer-specific abilities, serum markers of muscle damage and perceived
fatigue (RPE) and heart rate”, and S (study design): “double-blind and randomized cross-over
design” [22].
A structured search was carried out in the Medline (PubMed) database and in the Web of
Science (WOS) which includes other databases such as BCI, BIOSIS, CCC, DIIDW, INSPEC, KJD,
MEDLINE, RSCI, SCIELO, both high quality databases which guarantee good bibliographic support.
The search covered from July 2006, when Hespel et al., [23] suggested the use of caffeine as an effective
supplement for soccer athletic performance, to November 2018. Search terms included a mix of
Medical Subject Headings (MeSH) and free-text words for key concepts related to caffeine and soccer
physical performance, muscle damage or perceived fatigue as follows: (“football”(All Fields) OR
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“soccer”(All Fields)) AND (“caffeine”(All Fields) OR “energy drink”(All Fields)) AND ((“physical
performance”(All Fields) OR performance(All Fields))) OR ((“muscles”(MeSH Terms) OR “muscles”
(All Fields) OR “muscle” (All Fields))) OR damage(All Fields) OR (RPE(All Fields) OR “perceived
fatigue “(All Fields)). Through this search, relevant articles in the field were obtained applying the
snowball strategy. All titles and abstracts from the search were cross-referenced to identify duplicates
and any potential missing studies. Titles and abstracts were then screened for a subsequent full-text
review. The search for published studies was independently performed by two authors (JMA and JCG)
and disagreements about physical parameters were resolved through discussion.
2.2. Inclusion and Exclusion Criteria
For the articles obtained in the search, the following inclusion criteria were applied to select
studies: articles (1) depicting a well-designed experiment that included the ingestion of an acute dose
of caffeine—or a caffeine-containing product—before and/or during exercise in humans; (2) with
an identical experimental situation related to the ingestion of a placebo performed on a different
day; (3) testing the effects of caffeine on soccer-specific tests and/or real or simulated matches;
(4) with a double-blind, and randomized cross-over design; (5) with clear information regarding the
administration of caffeine (relative dose of caffeine per kg of body mass and/or absolute dose of
caffeine with information about body mass; timing of caffeine intake before the onset of performance
measurements, etc.); (6) where caffeine was administered in the form of a beverage, coffee gum or pills;
(7) on soccer players with previous training backgrounds in soccer; (8) the languages were restricted
to English, German, French, Italian, Spanish and Portuguese. The following exclusion criteria were
applied to the experimental protocols of the investigation: (1) the use of caffeine doses below 1 mg/kg
or above 9 mg/kg; (2) the absence of a true placebo condition; (3) the absence of pre-experimental
standardizations such as elimination of dietary sources of caffeine 24 h before testing; (4) carried
out in participants with a previous condition or injury. There were no filters applied to the soccer
players’ level, sex or age to increase the power of the analysis. Moreover, the Physiotherapy Evidence
Database scale (PEDro), the key factors of which assess eligibility criteria, random allocation, baseline
values, success of the blinding procedures, power of the key outcomes, correct statistical analysis
and measurement of participants’ distribution of studies, was used to evaluate whether the selected
randomized controlled trials were scientifically sound: 9–10 = excellent, 6–8 = good, 4–5 = fair, and
<4 = poor) [24]. Papers with a poor PEDro score were excluded (i.e., <4 points).
Once the inclusion/exclusion criteria were applied to each study, data on study source (including
authors and year of publication), study design, caffeine administration (dose and timing), sample
size, characteristics of the participants (level and sex), and final outcomes of the interventions were
extracted independently by two authors (JMA and JCG) using a spreadsheet (Microsoft Inc, Seattle,
WA, USA). Subsequently, disagreements were resolved through discussion until a consensus was
reached. Experiments were clustered by the type of test used to assess the effects of caffeine on soccer
physical performance and groups of experiments were created on the effects of caffeine physical




The literature search provided a total of 135 articles related to the selected descriptors, but only
17 articles met all the inclusion/exclusion criteria (see Figure 1). The number of articles and their
exclusion criteria were: 32 papers were removed because they were duplicated; 4 papers were removed
because they were performed on a non-human population; another 4 papers were removed because
they were narrative or systematic reviews; 13 studies were not carried out during the range of dates
included in the inclusion criteria. From the remaining 40 articles, another 23 papers were removed
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because they were unrelated to the effects of caffeine on soccer physical performance. The topics
and number of studies that were excluded were: 1 because of lack of information on body mass,
1 because the caffeine content was found in nutritional supplements with other drugs, 1 because it
was a suggestion for future research, 1 because the sport investigated was not specified, 4 because
they dealt with recovery or sleep processes, 4 because they investigated other team sports (1 rugby,
1 volleyball, 1 tennis, 1 Gaelic football), and the remaining 11 articles because they studied other
subjects unrelated to the focus of this systematic review. Thus, the current systematic review includes
17 studies.
Records identified through 
database searching 





















Additional records identified 
through other sources 
(n = 0) 
Records after duplicates removed 
(n = 61) 
Records screened 
(n = 61) 
Records excluded 
(n = 21) 
Full-text articles assessed 
for eligibility 
(n = 40) 
Full-text articles excluded, 
with reasons 
(n = 23) 
 
Unsuitable Outcomes = 1 
Unsuitable methodology = 3 
Other sports = 4 
Subjects unrelated =15 
Studies included in 
qualitative synthesis 
(n = 17) 
Figure 1. Selection of studies.
3.2. Caffeine Supplementation
The participants’ samples included players of both genders (241 males and 33 females), who
competed in professional or elite (n = 108), semi-professional (n = 19) and amateur teams (n = 147).
In addition, 70 players were adolescents. Out of the 17 investigations, only 2 studies included female
soccer players. In 12 out of 17 studies, caffeine was administered based on the soccer player’s body
mass, while an absolute dose was provided for all participants in 5 studies. In 2 studies the caffeine
dose employed was less than 3 mg/kg, 3 studies used a caffeine dose of around 3 mg/kg, in 2 studies
it was 4.5 mg/kg, in 3 studies it was around 5 mg/kg, in 4 studies the dose was 6 mg/kg and 2
studies included a dose above 6 mg/kg (i.e., 7.2 mg/kg). In 1 study, soccer players took different
doses (1, 2 and 3 mg/kg). Regarding the form of administration, 9 investigations used capsules filled
with caffeine, 3 investigations used caffeinated energy drinks, 3 investigations used a caffeinated sport
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drink, 1 investigation employed a 20% carbohydrate solution and 1 investigation employed caffeinated
chewing gum.
Most investigations administered caffeine 30–60 min prior to testing, with the exception of the
studies conducted by Andrade-Souza et al. (2015) where the consumption of caffeine was carried
out 3 h after a practice session, 4 h after its effects were evaluated in a simulated match [25]. Also,
Guttierres et al. (2013) used a protocol that included the ingestion of caffeine 1 h before the test and
every 15 min during the protocol [26]. Finally, Ranchordas et al. (2018) employed caffeine 5 min before
the tests because they used caffeinated gums [17]. In summary, different studies examined the effect of
caffeine on soccer physical performance by using a variety of times of ingestion prior to the testing
(5 min–60 min).
3.3. Outcome Measures
Tables 1–3 include information about author/s and year of publication; the sample investigated,
with details of sport level, sex and the number of participants; the study design cites the control
group if the study included one; the supplementation protocol that specifies the type of caffeine used,
the dose and the time that it was administered; the parameters analyzed or main effects either on
sport performance (n = 12; Table 1) and muscle damage (n = 5; Table 2) and finally results or main
conclusions. Additionally, some studies also presented data on the effects of caffeine on perceived
exertion and heart rate (n = 6; Table 3).
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4. Discussion
The purpose of this systematic review was to summarize all scientific evidence for the effect of
acute caffeine ingestion on variables related to soccer physical performance. Due to the differences
of the effects studied among the investigations included in the analysis, the following variables have
been clustered for a more comprehensive scrutiny.
4.1. Impact on Sports Performance
A total of 12 investigations carried out research protocols that studied the effects of caffeine on
one or more variables related to soccer-specific abilities. Overall, these investigations showed an
improvement in soccer-related skills with the pre-exercise ingestion of caffeine (Table 1). Specifically,
Foskett et al., [15], with 12 first division football players (age: 23.8 ± 4.5 years), observed that
the consumption of 6 mg/kg of caffeine before exercise increased passing accuracy and accrued
significantly less penalty time during two validated tests to assess soccer skill performance (intermittent
shuttle-running protocol and Loughborough Soccer Passing Test; LSPT). In addition, this investigation
also found that caffeine improved the functional power of the leg measured by a vertical jump. In the
study conducted by Jordan et al., 17 soccer players from the elite youth category (age: 14.1 ± 0.5 years)
performed an agility test (reactive agility test) validated for football [34]. These authors indicated,
based on the results of their investigation, the intake of 6 mg/kg of caffeine 60 min before the test
significantly improved the reaction time of the players in their non-dominant leg [16]. In another study
conducted with 15 elite young players (age: 16 ± 1 years) that were administered low doses of caffeine
(1, 2 and 3 mg/kg), Ellis et al., [21] observed that improvements in physical performance depended on
the dose and the type of task. Specifically, they concluded that 3 mg/kg of caffeine seems to be the
optimal dose to obtain positive effects on soccer-specific tests (20 m sprint, arrowhead agility and CMJ).
However, the authors also suggested that even higher doses of caffeine might be required to improve
endurance performance, as measured by the Yo-Yo intermittent recovery test level 1 (Yo-Yo IR1).
In this line, Apostolidis et al., [19] showed that 6 mg/kg of caffeine ingested 60 min previous to a
battery of tests improved aerobic endurance (time to fatigue) and neuromuscular performance (CMJ)
in 20 well-trained soccer players (age: 21.5 ± 4 years). Since these authors did not find any change in
substrate oxidation with caffeine, measured by indirect calorimetry during the testing, they commented
that performance improvements could only be attributed to positive effects on the central nervous
system and/or neuromuscular function, although the precise mechanism of caffeine ergogenicity was
not indicated in this investigation. Finally, Guerra et al., [18] investigated the addition of caffeine
(5 mg/kg) to a post-activation potentiation protocol that included plyometrics and sled towing. These
authors found that, in a group of 12 male professional soccer players (age: 23 ± 5 years), caffeine
augmented the effects of the post-activation potentiation, as measured by CMJ. These investigations,
taken together, suggest that caffeine might be effective to improve performance in players’ abilities
and soccer-specific skills (jumps, sprint, agility, aerobic endurance, accuracy of passes and ball control).
Caffeinated energy drinks are considered as one of the most common ways to provide caffeine
before exercise [14], and the effect of this type of beverages have been also investigated in soccer players.
Del Coso et al., [16] chose 19 semi-professional players (age: 21 ± 2 years) in order to determine if
the caffeine, provided via a commercially-available energy drink (3 mg/kg), improved performance
during several soccer-specific tests (single and repeated jump tests and repeated sprint ability test)
and during a simulated soccer match. For this investigation, players ingested either an energy drink
without sugar but with caffeine (i.e., sugar-free Redbull), or a sugar-free soda (Pepsi diet without
caffeine) 60 min prior to testing. The results showed that the consumption of the caffeinated energy
drink increased the ability to jump, to repeat sprints, and it affected positively total running distance
and the running distance at >13 km/h covered during the simulated game. In another similar study
carried out with 18 semi-professional women soccer players (age: 21 ± 2 years), Lara et al., [34]
demonstrated that the consumption of an energy drink containing 3 mg/kg of caffeine improved
jump height, the ability to perform sprints, the total running distance and the distance covered at high
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running intensity (i.e., >18 km/h). These two investigations together suggest that caffeine in the form
of an energy drink, can improve the physical demands associated with high performance in soccer,
such as sprints, rapid accelerations/decelerations and constant changes of direction [35,36].
Thanks to the collaboration of 18 junior soccer players (age: 16.1 ± 0.7 years), Guttierres et al., [29]
evaluated whether the physical performance of these players increased with the consumption of
a caffeinated sports drink (250 mg/L ≈ 7.2 mg/kg) compared to a commercial carbonated drink.
They concluded that the caffeine-based sport drink significantly increased jump height and improved
the power in the lower limbs, another determinant factor in soccer physical performance [37]. However,
positive effects were not demonstrated in the “Illinois Agility Test”, a validated routine to assess agility
in team sports players [38]. This lack of positive effects was possibly due to the fact that players’ agility
is a complex process that depends on the coordination of factors such as decision making and speed in
the changes of direction, both aspects of which are trained and constantly improved in training [39].
Gant et al., [28] used a caffeine-containing carbonated drink in 15 professional soccer players (age: 21.3
± 3 years) and were able to evidence that the addition of caffeine to a carbonated drink, in a dose of
3.7 mg/kg (60 min before starting and every 15 min during the test), improved sprint performance
and the vertical jump in soccer players. Andrade-Souza et al., [25] proposed a very interesting study
where the aim was to investigate the effect of a carbohydrate-based drink, with (6 mg/kg) and without
caffeine, and they compared these trials to the isolated ingestion of caffeine. The study was carried
out with 11 college football players (age: 25.4 ± 2.3 years) with the ingestion of the drinks after the
morning training session to see the effects of the 20% carbohydrate solutions on the afternoon training
session of the same day. The main finding of Andrade-Souza’s study was that none of the drinks was
able to increase performance. This fact could be related to reduction of the glycogen levels from the
morning to the afternoon training sessions, a factor that was either not considered or measured in
the study. According to Jacobs [40], a reduction in the content of muscle glycogen below a critical
threshold can affect anaerobic strength and performance. In the Andrade-Souza’s study, the recovery
time between the two practice sessions was very short (4 h) and the nutritional strategies chosen were
not optimal to replenish muscle glycogen [25]. Thus, it is likely that the reduction of glycogen stores
might have precluded the ergogenic effect of caffeine in this experimental design.
Chewing gum provides an alternative mode of caffeine administration that is more rapidly
absorbed (via the buccal mucosa) than capsules and drinks (i.e., 5 min vs. 45 min, respectively) and
less likely to cause gastrointestinal distress [41]. Along these lines, Ranchordas et al., reported that
caffeinated chewing gum, containing 200 mg of caffeine, can enhance aerobic capacity (Yo-Yo IR1) by
2% and increase CMJ performance by 2.2% in 10 male university soccer players (age: 19 ± 1 years) [17].
Therefore, chewing gum could be beneficial for soccer players where the time between ingestion and
performance is short, (e.g., for substitutes that would come on when called upon by the coach and
for players who cannot tolerate caffeinated beverages or capsules because of gastrointestinal distress
before kick-off [17]).
4.2. Impact on Muscle Damage
A total of 5 investigations studied the effect of caffeine on the levels of muscle damage after
a soccer practice (Table 2). In soccer, muscle damage is a very important physiological variable
because all the high-intensity exercises produced in this sport (sprints, accelerations/decelerations,
changes of directions and even tackles) may be associated with myofibril damage [42]. In this way,
Machado et al. carried out three studies on this specific topic: one with 20 healthy soccer players
(age: 18.8 ± 1 years) [31]; another one with 15 male soccer players (age: 19 ± 1 years) [32] and the last
one with 15 male soccer athletes (age: 18.4 ± 0.8 years) [30]. The main goal of these three investigations
was to determine whether consumption of caffeine in single and acute doses (4.5–5.5 mg/kg) negatively
affected blood markers typically used to assess the level of muscle damage. The authors concluded
that these markers (creatine kinase, lactate dehydrogenase, aspartate aminotransferase and alanine
aminotransferase) increased with exercise, but they did not find that this increase was exacerbated
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with the consumption of caffeine. On the other hand, a study conducted by Bassini-Cameron et al., [33]
which measured hematological variables, muscle proteins and liver enzymes in 22 professional soccer
players (age: 26.0 ± 1.6 years), concluded that 5 mg/kg of caffeine ingested 60 min before the start of a
game increased the risk of muscle damage in players because there was an increase in the white blood
cell count. However, the serum concentration of white blood cells is not a definitive marker of muscle
damage level during exercise, as other factors can increase the count of leukocytes during exercise.
In summary, although most of studies found an absence of effect of caffeine on exercise-induced muscle
damage in soccer players, further research is necessary to confirm this notion [43].
Guttierres et al., [26], in an experiment with 20 youth soccer players (age: 16.1 ± 0.7 years),
observed the effect of caffeine (contained in a sport drinks) on free fatty acids mobilization.
Participants consumed the beverage 20 min before a soccer match and every 15 min during the
game with a total caffeine consumption of 7.2 mg/kg. The authors certified that the caffeine did
not increase the mobilization of free fatty acids. Anyway, the caffeinated beverage was also rich
in carbohydrates, increasing blood glucose concentration, promoting more insulin and therefore
inhibiting the mobilization of fatty acids. Graham, et al., [44] showed that caffeine with glucose
increased insulin secretion versus glucose consumption alone. In the Guttierres study, blood
glucose concentrations were higher possibly due to an increase in sympathetic nervous system
activity [26], increasing adrenaline and noradrenaline and glycogenolysis [45,46]. Moreover, blood
lactate concentrations increased with the ingestion of caffeine, likely indicating, in an indirect manner,
that players achieved a greater intensity in the trial with caffeine. These outcomes could suggest that
soccer players exercised at a higher percentage of their maximum heart rate (caffeine: 80.6 % versus
control: 74.7% of maximum heart rate) with the ingestion of caffeine.
4.3. Impact on the Perception of Fatigue
Astorino et al., [20] concluded that the consumption of a serving portion of an energy drink
(Redbull), with 1.3 mg/kg of caffeine, did not alter the perception of fatigue or heart rate in 15
semi-professional soccer players (age: 19.5 ± 1.1 years; Table 3). An important limitation of this study
was that the amount of caffeine consumed was very low (80 mg) and thus, the effects of caffeine
would have been limited due to dosage. On the contrary, Guttierres et al., [26] and Lara et al., [28]
found that caffeine tended to cause an increase in exercise heart rate with a concomitant reduction in
the perception of fatigue. While caffeine has been proven to reduce perception of fatigue in exercise
protocols that used a fixed exercise intensity [47], these investigations [20,26,28] used exercise protocols
more applicable to soccer, where exercise intensity can be freely chosen, as happens during soccer
play. Under these specific conditions, caffeine served to increase exercise intensity (as indicated by
higher running distances and higher average heart rate) while perception of fatigue was unaffected or
tended to be reduced. Thus, it might be speculated that caffeine might have the capacity to enhance
soccer physical performance without producing higher values of fatigue, which can be understood as
a positive property of this stimulant.
4.4. Caffeine Dose and Inter-Individual Responses to Caffeine Administration
The dose of caffeine administered in the experiments ranged from 1.3 to ~7.2 mg/kg and thus,
the ergogenic effects of caffeine on soccer players must be attributed to this range of dosage. However,
it is still possible that dose-response effects exist or even that a caffeine dose threshold is necessary
to obtain benefits from caffeine in soccer, as recently suggested by Chia et al., for ball sports [6].
Based on previous investigations with other different forms of exercise [48–50], or soccer [20,21], it can
be suggested that doses below 2 mg of caffeine per kg of body mass might not be effective to increase
soccer physical performance. All the experiments included in this systematic review reported their
findings as a group mean comparing caffeine vs. placebo trials. Nevertheless, recent investigations
have shown that not all individuals experience enhanced physical performance after the ingestion
of moderate doses of caffeine [51–54]. These studies have identified the presence of athletes who
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obtain minimal ergogenic effects or only slight ergolytic effects after acute administration of caffeine,
and such participants have been catalogued as “non-responders to caffeine” [55]. To date, there is
still no clear explanation for the lack of ergogenic effects after the acute administration of caffeine in
some individuals, although factors such as training status, habitual daily caffeine intake, tolerance to
caffeine, and genotype variation have been proposed as possible modifying factors for the ergogenicity
of caffeine [55]. Whilst this systematic review suggests that the ingestion of 3–6 mg/kg of caffeine is
ergogenic for soccer players, it might not be optimal for everyone. The inter-individual variability in
the ergogenic response to acute caffeine ingestion suggests that caffeine should be recommended in a
customized manner. The development of more precise and individualized guidelines would seem
necessary for soccer players.
4.5. Strengths, Limitations and Future Lines of Research
The current systematic review presents some limitations related to the different research protocols
and performance tests used in the investigations included. Although we selected investigations
in which caffeine was compared to an identical situation without caffeine administration, in some
investigations, caffeine was co-ingested with other ingredients (e.g., carbohydrates). It is still possible
that some of these ingredients produced a synergistic or antagonistic effect on performance. In addition,
the dose of caffeine and posology were not uniform among investigations, which could influence some
of the outcomes of the research included in the review. In addition, in the investigations included in
the analysis there were different competitive levels and age categories while the low number of articles
impeded us from knowing if the effect of caffeine on soccer physical performance depends on level or
players’ age. Despite these limitations, this review suggests a positive effect of caffeine in increasing
soccer players’ physical performance with no or little effect on the levels of muscle damage, perceived
effort, or exercising heart rate. Because soccer is a complex sport in which the variables investigated
in this systematic review represent only a small proportion of the factors necessary for succeeding,
further investigations are necessary to determine the effects of caffeine on more complex and ecological
soccer-specific tests, especially involving decision-making situations. In the same way, studies should
be undertaken into whether the effect of caffeine is different according to the competitive level or
soccer player’s age.
5. Conclusions
In summary, acute caffeine intake of a moderate dose of caffeine before exercise has the capacity
to improve several soccer-related abilities and skills such as vertical jump height, repeated sprint
ability, running distances during a game and passing accuracy. Likewise, so far, it has been shown
that a single and acute dose of caffeine does not have a negative impact on the increase of variables
related to muscle damage during official matches. However, more studies are needed to assess whether
chronic caffeine consumption could alter muscle damage markers. Moreover, caffeine supplementation
does not cause changes in either the perception of effort or heart rate during regular high-intensity
intermittent soccer exercises.
Despite this investigation suggesting several benefits of caffeine in soccer, the use of this stimulant
should only be recommended after a careful evaluation of the drawbacks typically associated with the
use of caffeine [56]. With this aim, the minimal dose with a positive impact would be recommended
(i.e., 3 mg/kg), while it can be consumed in either powder (capsules) or liquid (energy drink or sport
drink) forms. Caffeine should only be recommended to athletes who are willing to use ergogenic aids
to increase performance and it should be recommended only on an individual basis under careful
supervision, in order to avoid the use of this substance in non-responders or athletes who report
negative side-effects. Experimenting with caffeine while training, before use in any competition,
and avoiding caffeine tolerance may also be further recommendations when using this substance to
increase soccer physical performance.
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Abstract: Exercise has beneficial effects on our health by stimulating metabolic activation of skeletal
muscle contraction. Caffeine is a powerful metabolic stimulant in the skeletal muscle that has ergogenic
effects, including enhanced muscle power output and endurance capacity. In the present study,
we aim to characterize the metabolic signatures of contracting muscles with or without caffeine
stimulation using liquid chromatography-mass spectrometry and capillary electrophoresis coupled to
mass spectrometry. Isolated rat epitrochlearis muscle was incubated in the presence or absence or of
3 mM caffeine for 30 min. Electrical stimulation (ES) was used to induce tetanic contractions during
the final 10 min of incubation. Principal component analysis and hierarchical clustering analysis
detected 184 distinct metabolites across three experimental groups—basal, ES, and ES with caffeine
(ES + C). Significance Analysis of Microarray identified a total of 50 metabolites with significant
changes in expression, and 23 metabolites significantly changed between the ES and ES + C groups.
Changes were observed in metabolite levels of various metabolic pathways, including the pentose
phosphate, nucleotide synthesis, β-oxidation, tricarboxylic acid cycle, and amino acid metabolism.
In particular, D-ribose 5-phosphate, IMP, O-acetylcarnitine, butyrylcarnitine, L-leucine, L-valine, and
L-aspartate levels were higher in the ES + C group than in the ES group. These metabolic alterations
induced by caffeine suggest that caffeine accelerates contraction-induced metabolic activations,
thereby contributing to muscle endurance performance and exercise benefits to our health.
Keywords: metabolome; skeletal muscle; exercise; muscle contraction; ergogenic effect
1. Introduction
Exercise contributes to health benefits by reducing the risk of several chronic diseases. These effects
are partly attributed to metabolic alterations that occur in contracting skeletal muscles. Exercise enhances
muscle insulin sensitivity and mitochondrial function by stimulating master metabolic regulators,
such as 5′-AMP-activated protein kinase (AMPK), sirtuin 1, and peroxisome proliferator-activated
receptor-γ co-activator 1α [1,2]. Recent evidence has suggested that secreted myokines from contracting
skeletal muscles have positive effects on metabolic disorders [3]. Therefore, it is accepted that muscle
contraction-induced metabolic activation is a key factor for maintaining normal physical function.
Caffeine is a powerful metabolic stimulant in the skeletal muscle. In vitro caffeine treatment of the
skeletal muscle promotes insulin-independent glucose transport [4–8], fatty acid oxidation [8,9], Ca2+
release from the sarcoplasmic reticulum [10,11], and mitochondrial biogenesis [12]. We have recently
demonstrated that caffeine increases the maximal capacity of contraction-stimulated AMPK activation
and glucose transport in rat skeletal muscles [6]. Additionally, caffeine is thought to be an important
contributor to ergogenic effects in humans. Meta-analyses have shown that caffeine intake has positive
effects on muscle power output and endurance performance [13–15]. These findings suggest that
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caffeine accelerates muscle contraction-induced metabolic activation, thereby contributing to exercise
benefits toward health promotion. However, there are no observations investigating the overall effects
of caffeine on muscle contraction-induced metabolic activation in the skeletal muscle.
Metabolomic techniques are useful tools for the investigation of complex metabolic responses
to muscle contraction [16,17]. In the present study, we aim to characterize the metabolic signatures
of contracting muscles with or without caffeine stimulation, using liquid chromatography-mass
spectrometry (LC-MS) and capillary electrophoresis coupled to mass spectrometry (CE-MS) analysis.
2. Materials and Methods
2.1. Animals
Male Sprague–Dawley rats (150–160 g) were purchased from Shimizu Breeding Laboratories
(Kyoto, Japan). Rats were fed a standard diet (Certified Diet MF; Oriental Koubo, Tokyo, Japan) with
ad libitum water and were subjected to overnight fasting before the experiments. All animal-related
protocols were performed in accordance with the Guide for the Care and Use of Laboratory Animals
as adopted and promulgated by the National Institutes of Health (Bethesda, MD, USA) and were
approved by the Animal Use Committee at Kyoto University Graduate School of Human and
Environmental Studies.
2.2. Muscle Treatment
Muscles were treated as previously described [6]. Rats were killed by cervical dislocation without
anesthesia, and the epitrochlearis muscles were removed and mounted on to an incubation apparatus
with the tension set to 0.5 g. The epitrochlearis muscle is composed predominantly of fast-twitch
glycolytic fibers (60–65% fast-twitch white, 20% fast-twitch red, 15% slow-twitch red) [18], but also has
higher oxidative potential than the other fast-twitch muscle [19]. Moreover, it is a small and thin muscle
that is suitable for in vitro incubation study. The muscles were pre-incubated in alpha-minimum
essential medium (21444-05, nacalai tesque, Kyoto, Japan) containing 1.0 g/L glucose supplemented
with 1% penicillin/streptomycin for 40 min and then incubated in fresh medium in the presence or
absence of 3 mM caffeine for 30 min. For tetanic contractions, the muscles were stimulated using an
electric stimulator (SEN-3401; Nihon Koden, Tokyo, Japan) during the final 10 min of the incubation
period (train rate, 1/min; train duration, 10 s; pulse rate, 100 Hz; pulse duration, 0.1 ms; voltage; 10 V).
Basal muscles were pre-incubated and incubated without contraction and caffeine treatment. All media
were continuously gassed with 95% O2/5% CO2 and maintained at 37 ◦C.
2.3. Metabolomic Analysis
Metabolomic analysis was performed by LSI Medience Corporation (Tokyo, Japan). In brief, the
muscle samples (≥50 mg) were homogenized using beads and suspended into 1 mL distilled water.
They were then mixed with methanol (2 mL) and chloroform (2 mL) for 10 min at room temperature.
After centrifugation at 1000× g for 15 min, the supernatant was evaporated using nitrogen gas and
dissolved with 10% acetonitrile aqueous solution (200 μL). After adding internal standards, the samples
were subjected to both LC-MS and CE-MS. All peak positions (retention time and m/z) and areas
were calculated using Markeranalysis (LSI Medience, Tokyo, Japan). All peak areas were aligned
into one data sheet, and the errors of peak intensities were corrected using internal standards. Noise
peaks were deleted after comparison with the peaks detected in blank samples. The metabolites were
identified by comparing the retention times and m/z values with a standard dataset provided by LSI
Medience Corporation.
2.4. Data Analysis
After applying autoscaling (mean-centered and divided by standard deviation of each variable),
principal component analysis (PCA), significance analysis of microarray (SAM), hierarchical clustering
analysis (HCA), and one-way ANOVA with Tukey’s multiple comparison test were performed using
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the web-based metabolomic data processing tool MetaboAnalyst 4.0 (http://www.metaboanalyst.ca,
Xia Lab, McGill University, Montreal, Canada). In PCA, a score plot of the first and second principal
components was generated. HCA was performed to exhibit simultaneous clustering of metabolites
and samples by Euclidean distance using Ward’s method. Heat maps were generated by coloring the
values of all data across their value ranges. False discovery rates (FDR) were calculated to reduce the
risk of false positives by adjusted p values. FDR < 0.05 was defined as statistically significant.
3. Results and Discussion
3.1. Pattern Recognition of Metabolites
Metabolomic analysis detected 184 metabolites by LC-MS and CE-MS (Table S1). PCA is a statistical
procedure that is used for feature extraction. Using PCA on the detected 184 metabolites, three groups,
i.e., basal, electrical stimulation (ES), and ES with caffeine (ES + C), were clearly distinguished on
the principal component (PC) 2, although they were overlapped on PC1 (Figure 1). We previously
demonstrated that ES in isolated rat skeletal muscles induces metabolic activation [20]. Likewise, the
PCA results in this study indicated that ES-induced muscle contraction influences the metabolomic
profile of the skeletal muscle. Furthermore, PCA plots in the ES +C group were more distant from basal
than in the ES group (Figure 1), suggesting that caffeine accelerates ES-induced metabolic responses.
Figure 1. Principal component analysis (PCA) plot of the identified metabolites of the skeletal muscle of
three groups, basal (B), electrical stimulation (ES), and electrical stimulation + caffeine (ESC). Principal
components (PC1 and PC2) capture 53.0% of the variation in the dataset. The elliptic areas represent
the 95% confidence regions.
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3.2. Discovery of Differentiating Metabolites
To identify differentially expressed metabolites among the three groups, SAM, a popular method
employed in microarray data analysis [21], was used. SAM identified a total of 50 metabolites with
FDR = 0.007 (Figure 2). Table 1 lists the identified compounds. HCA of the 50 metabolites showed that
each group was tightly clustered and that the caffeine influenced the metabolite profiles of ES toward
a high level of contents (Figure 3). Figures 4–7 show the 23 metabolites that significantly changed
between the ES and ES + C groups.
Figure 2. Identification of metabolites with significant changes in expression by significance analysis
of microarray (SAM) among the three groups. The SAM plot is a scatter plot of the observed relative
difference versus the expected relative difference. The solid diagonal line indicates where these
two measures are the same. The dotted lines are drawn at a distance of delta from the solid line.
The significant variables are highlighted in green and the details are shown in Table 1.
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Table 1. Significant features identified by SAM.
Name d Value SD p Value q Value
1 Theobromine 5.7247 0.031023 0.0 0.0
2 Butyrylcarnitine (C4) 5.4855 0.055814 0.0 0.0
3 IMP 5.0676 0.10169 0.0 0.0
4 β-Aminoisobutyric acid 4.7254 0.14193 0.0 0.0
5 L-Lactic acid 4.6827 0.14713 0.0 0.0
6 Cytosine 4.4855 0.1717 5.4348 × 10−5 1.1445 × 10−4
7 D-Ribose 5-phosphate 4.4111 0.1812 5.4348 × 10−5 1.1445 × 10−4
8 D-Glyceraldehyde 4.3854 0.18452 5.4348 × 10−5 1.1445 × 10−4
9 Hypoxanthine 4.3489 0.18926 5.4348 × 10−5 1.1445 × 10−4
10 Maltotriose 4.2295 0.205 5.4348 × 10−5 1.1445 × 10−4
11 D-Glucosamine 6-phosphate 4.1269 0.21883 1.087 × 10−4 1.7607 × 10−4
12 Choline 4.1237 0.21927 1.087 × 10−4 1.7607 × 10−4
13 Succinic acid 4.0087 0.2351 1.087 × 10−4 1.7607 × 10−4
14 N4-Acetylcytidine 3.8995 0.25048 1.6304 × 10−4 2.4524 × 10−4
15 L-Glutamate 3.6907 0.28084 3.2609 × 10−4 4.2917 × 10−4
16 Acetylenedicarboxylate 3.6613 0.28523 3.2609 × 10−4 4.2917 × 10−4
17 L-Leucine 3.5719 0.29872 4.8913 × 10−4 5.7223 × 10−4
18 1-Myristoylglycerophosphocholine 3.5708 0.29889 4.8913 × 10−4 5.7223 × 10−4
19 L-Hexanoyl-carnitine (C6) 3.4897 0.31135 5.4348 × 10−4 6.0234 × 10−4
20 Serotonin 3.4538 0.31693 5.9783 × 10−4 6.2945 × 10−4
21 Threonate 3.4109 0.32367 7.0652 × 10−4 7.0847 × 10−4
22 Glycerol-3-phosphate 3.2018 0.35736 0.001413 0.0012937
23 2-Oxobutanoate 3.1997 0.35772 0.001413 0.0012937
24 ATP 3.009 0.38981 0.0021739 0.0018047
25 N-Acetyl-L-alanine 3.0039 0.3907 0.0021739 0.0018047
26 L-Alanine 2.9853 0.39391 0.0022283 0.0018047
27 Xanthine 2.9261 0.40421 0.0023913 0.001865
28 Imidazole lactic acid 2.913 0.40651 0.0025543 0.001921
29 N8-Acetylspermidine 2.8766 0.41292 0.002663 0.0019337
30 NADP 2.8527 0.41718 0.0029348 0.0020305
31 Oxypurinol 2.8504 0.41759 0.0029891 0.0020305
32 Taurine 2.7011 0.44464 0.0040761 0.0026823
33 O-Acetylcarnitine (C2) 2.6096 0.46169 0.0052174 0.0032651
34 Isatin 2.5882 0.46572 0.0052717 0.0032651
35 L-Fucose 2.5586 0.47133 0.0057065 0.0034334
36 Spermidine 2.5126 0.48016 0.0064674 0.0037831
37 1-Palmitoleoylglycerophosphocholine 2.4683 0.48872 0.0071739 0.0040357
38 GDP 2.4586 0.49062 0.0072826 0.0040357
39 Iminodiacetate 2.3301 0.51606 0.0096196 0.0051941
40 L-Methionine 2.3125 0.51962 0.010054 0.0052477
41 γ-Glu-leu 2.3104 0.52004 0.010217 0.0052477
42 Maleamate 2.2816 0.52587 0.010761 0.0052964
43 L-Aspartate 2.2673 0.52879 0.010815 0.0052964
44 Guanidinosuccinic acid 2.2214 0.53822 0.011793 0.0056442
45 L-Valine 2.169 0.54911 0.013478 0.0062447
46 CDP 2.1582 0.55136 0.013641 0.0062447
47 EDTA 2.134 0.55645 0.014511 0.0064614
48 2-Hydroxyisobutyric acid 2.126 0.55815 0.014728 0.0064614
49 Creatinine 2.1072 0.56212 0.015163 0.0065164
50 3-Methyl-2-oxobutyric acid 2.0385 0.57683 0.017065 0.0071872
197
Nutrients 2019, 11, 1819
Figure 3. A heat map of hierarchical clustering analysis comparing the 50 different metabolites among
groups. The heat map patterns among groups were distinguishable. The color red demonstrates that
the relative content of metabolites is high and blue demonstrates that they are low.
3.3. Pentose Phosphate Pathway/Nucleotide Synthesis Pathway
The pentose phosphate pathway is an alternative pathway to glycolysis [22]. It does not lead to ATP
formation, but rather, produces ribose 5-phosphate. Intracellular ribose 5-phosphate concentration is an
important determinant of rates of de novo purine synthesis [23]. The synthesis of purine nucleotides
begins with ribose 5-phosphate and produces the first fully formed nucleotide, IMP. IMP is accumulated
in contracted skeletal muscle during exercise and accounted for ATP re-synthesis during recovery
phase from exercise [24]. Therefore, pentose phosphate pathway activation and subsequent nucleotide
synthesis is suggested to be important for maintaining cellular energy during and following exercise.
In the present study, ES increased D-ribose 5-phophate levels, and caffeine further increased this
effect (Figure 4), indicating that caffeine promotes exercise-induced activation of the pentose phosphate
pathway in skeletal muscles. It was also found that caffeine in conjunction with ES increased IMP
levels, as compared to ES alone (Figure 4). Taken together, the stimulation of the pentose phosphate
pathway by caffeine may contribute to recovery from energy depletion following muscle contraction
by promoting ATP re-synthesis from IMP. In our previous study, caffeine alleviated muscle fatigue
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during contraction [6]. Furthermore, it has been suggested that activation of the pentose phosphate
pathway stimulates energy production by enhancing mitochondrial function [25]. These metabolic
responses may contribute to a positive effect of caffeine on endurance performance.
A small proportion of IMP is converted to inosine and further to hypoxanthine, and hypoxanthine
is transformed to xanthine, which is then subsequently converted to uric acid and excreted in the
urine [26]. In the present study, hypoxanthine and xanthine levels were increased by caffeine treatment
in the contracted muscle (Figure 4), supporting the caffeine-induced accumulation of IMP.
Figure 4. Box plots of the concentration variations of significantly altered metabolites in the pentose
phosphate pathway/nucleotide synthesis pathway. Y axes are represented as normalized intensity.
The boxes range from the 25% to the 75% percentiles. Medians are indicated by horizontal lines within
each box. The ends of the whiskers represent the maximum and minimum of the data. * One-way
ANOVA with Tukey’s post hoc test indicates a significant difference (false discovery rates (FDR) < 0.05)
between groups.
3.4. Acylcarnitine/Tricarboxylic Acid (TCA) Cycle
Acylcarnitines, which are esters of L-carnitine and fatty acyl-coenzyme A (CoA), are important
intermediates in the transport of long-chain fatty acyl-CoA into the mitochondria [27]. Intramitochondrial
acylcarnitine is converted back to carnitine and long-chain acyl-CoA by carnitine palmitoyltransferase
2, which then undergoes β-oxidation to produce acetyl-CoA. Acetyl-CoA is an essential intermediate
metabolite that enters the TCA cycle and is oxidized to yield energy. When the production of
short-chain acyl-CoAs exceeds TCA cycle flux, acetyl-CoA is converted to acetylcarnitine by carnitine
acetyltransferase [28]. In the present study, caffeine treatment increased O-acetylcarnitine (C2) during
skeletal muscle contraction (Figure 5), indicating that substrate catabolism during β-oxidation exceeds
the capacity of acetyl-CoA utilization in the TCA cycle.
Muscle contraction-induced AMPK activation inhibits acetyl-CoA carboxylase activity, leading
to a decrease in malonyl CoA content [29]. Malonyl CoA is a potent inhibitor of CPT1, an enzyme
that combines fatty acyl-CoA with carnitine for transport into the mitochondria for β-oxidation, and
the decrease in malonyl CoA during muscle contraction contributes to the increase in absolute lipid
oxidation [30]. In addition, it has been demonstrated that the increase in acetylcarinitine level during
muscle contraction decreases the availability of free carnitine, a substrate of CPT1, results in low CPT1
activity [31]. Thus, the accumulation of acetylcarnitine within the skeletal muscle leads to a diminished
supply of long-chain fatty acyl-CoA to β-oxidation [31]. In fact, an increase in acetylcarnitine was
observed concomitantly with a decrease in long-chain fatty acid oxidation during exercise in humans [31].
In the present study, L-hexanoyl-carnitine (C6) was reduced by caffeine treatment (Figure 5), indicating
that the increase in muscle acetylcarnitine level by caffeine might inhibit β-oxidation of long-chain fatty
acyl-CoA, thereby leading to a decreased supply of short-chain (~C10) fatty acyl-CoA.
However, we found the accumulation of butyrylcarnitine (C4) following caffeine treatment
(Figure 5). In accordance with this result, a previous study has demonstrated that the 10 min of treadmill
exercise increased C4 acylcarnitine level in rat skeletal muscle [32]. The authors have suggested that
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the accumulation of C4 acylcarnitine was attributed to a greater utilization of branched chain amino
acids (BCAA: leucine, isoleucine, and valine) [32]. We also found that caffeine treatment increased
L-leucine and L-valine levels in contracted muscle (Figure 6). Therefore, it is suggested that the increase
in butyrylcarnitine (C4) level originates from the amino acids metabolism.
Succinic acid is a key TCA cycle metabolite, the levels of which can be increased by both long-term
exercise training as well as an individual bout of exercise [17,33]. In the present study, caffeine increased
succinic acid levels in the contracted muscle (Figure 5). This result suggests that the TCA cycle is
activated by caffeine treatment during muscle contraction. However, succinic acid level is reflected
by the activity of succinate dehydrogenase, which catalyze succinic acid into fumarate in the TCA
cycle. Therefore, to determine the effect of caffeine on the activity level of the TCA cycle during muscle
contraction, succinate dehydrogenase level and/or another enzyme activity and metabolite levels need
to be investigated.
Figure 5. Box plots of the concentration variations of significantly altered metabolites in the Acylcarnitine/
TCA cycle. * One-way ANOVA with Tukey’s post hoc test indicates a significant difference (FDR < 0.05)
between groups.
In the present study, glycolysis was not affected by caffeine (Figure 8), suggesting that an increase
in acetylcarnitine following caffeine treatment can be attributed to the acceleration of acetyl-CoA
production from β-oxidation. Maintaining the acetylcarnitine recycling system is critical for muscle
contractile performance and fatigue resistance [34]. Therefore, caffeine may stimulate the acetylcarnitine
recycling system, thereby contributing to enhanced muscle endurance capacity. To assess this possibility,
further study is required to measure the effects of caffeine on carnitine.
3.5. Amino Acid/Amino Acid Metabolism
Protein degradation and subsequent amino acid oxidation contribute slightly to energy supply
during exercise as well as to glucose and fatty acid oxidation [35]. Six amino acids are metabolized in
the skeletal muscle: BCAA (leucine, isoleucine, and valine), asparagine, aspartate, and glutamate [35].
Leucine can be converted to acetyl-CoA and oxidized in the TCA cycle [36]. The catabolic pathway of
valine consists of several enzymatic steps and results in the formation of succinyl-CoA, a member of the
TCA cycle. Disruption of BCAA metabolism in skeletal muscle impairs endurance capacity [37]. Thus,
the supply of BCAA is considered to be an important factor for controlling exercise metabolism and
endurance. In the present study, L-leucine and L-valine were higher in the ES + C group than in the ES
group (Figure 6), indicating that these amino acids contribute to energy production of caffeine-treated
muscle by incorporated into TCA intermediates.
Aspartate has been suggested to have an ergogenic potential [38]. Aspartate is converted to
oxaloacetate by aspartate transaminase, which then enters the TCA cycle. A previous study has
demonstrated that the administration of potassium-magnesium-aspartate increased the capacity for
prolonged exercise in human [39]. This effect has been supported by other studies [38]. In the present
study, caffeine suppressed L-aspartate reduction by ES (Figure 6), indicating that the caffeine-induced
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ergogenic effect may be partly attributed to aspartate preservation during muscle contraction. However,
there are a number of negative findings related to aspartate’s ergogenic potential [38]. For example, in
human volunteers neither the exerted force nor the endurance time increased after oral administration of
potassium-magnesium-aspartate [40]. Therefore, further studies are required to clarify the relationship
between aspartate and caffeine’s ergogenic potential.
Methionine is suggested to be transaminated and is also subjected to transulfuration in the skeletal
muscle [41]. Although caffeine increased L-methionine levels (Figure 6) in the contracted muscle, the
importance of methionine during exercise is poorly understood.
Alanine is formed from pyruvate and glutamate in the alanine aminotransferase reaction. Increase
in skeletal muscle alanine is thought to be due to the enhanced availability of pyruvate and glutamate [42].
Alanine synthesized in the skeletal muscle is released into the blood and taken up by the liver, where it
is reconverted into glucose via gluconeogenesis. In the present study, caffeine treatment increased
L-alanine during muscle contraction (Figure 6). Considering that pyruvate and glutamate were
not changed by caffeine stimulation (Table S1), this caffeine-induced increase in alanine may be
attributed to protein degradation. The increase in alanine production may contribute to the increase in
N-acetyl-L-alanine levels, which is generated from alanine by phenylalanine N-acetyltransferase, in
caffeine and electrically stimulated muscle (Figure 6).
Figure 6. Box plots of the concentration variations of significantly altered metabolites in the amino
acid/amino acid metabolism. * One-way ANOVA with Tukey’s post hoc test indicates a significant
difference (FDR < 0.05) between groups.
3.6. Others
N4-acetylcytidine, choline, cytosine, 2-hydroxyisobutyric acid, isatin, guanidinosuccinic acid,
oxypurinol, ethylenediaminetetraacetic acid (EDTA), and acetylenedicarboxylate levels were significantly
higher in the ES+C group than in the ES group (Figure 7). However, no previous studies have investigated
the association between exercise and these metabolites. The functional significance of increased levels
of these metabolites in the caffeine-stimulated group needs to be further investigated.
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Figure 7. Box plots of the concentration variations of significantly altered metabolites in the other
pathways. * One-way ANOVA with Tukey’s post hoc test indicates a significant difference (FDR < 0.05)
between groups.
3.7. Limitations
Many reactions take place continuously within cells, so concentrations of metabolites are very
dynamic. In the present study, we investigated metabolomic responses only 10 min after muscle
contraction. Therefore, in a case where increased levels of metabolites are observed, two distinct
mechanisms contribute to this observation: either increased production or decreased consumption.
For further understanding of caffeine-mediated effects on metabolic changes during muscle contraction,
time-course experiments should be conducted.
In this study, we used a concentration of caffeine at 3 mM, which would be toxic to humans [43].
Plasma concentration of caffeine after ingestion of 100 mg (1 cup of coffee) reaches approximately 5
to 10 μM [44], with less than 70 μM being the physiological concentrations [45]. Experiments using
isolated skeletal muscle preparation have benefits of eliminating the effects of systemic confounders
such as circulatory, humoral and neural factors, and of intestinal absorption of caffeine. Taking
advantage of this point, a number of studies have unveiled the direct ergogenic properties of caffeine
at the supraphysiological concentrations [10,46–49]. Our previous study have demonstrated that μM
concentrations were enough to activate AMPK in vivo, but mM concentrations of caffeine were needed
to activate AMPK in isolate rat skeletal muscle [5]. Therefore, we should be careful when comparing the
results of in vitro and in vivo studies in terms of caffeine concentrations.
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Caffeine is found in foods, beverages, and pharmaceuticals, and the most frequently consumed
non-prescription drug. To date, many researchers have discussed the effect of caffeine on energy
metabolism and our health [50–52]. However, no study has investigated the caffeine-mediated changes
of metabolomic signatures in skeletal muscle and the other organs. Although the present study
contributes to unveiling the effect of caffeine on metabolomic responses during muscle contraction
condition, the effect of caffeine alone on skeletal muscle metabolism has not been cleared. Further
studies are expected to examine the effect of caffeine on muscle’s non-contracted condition.
4. Conclusions
The present study reveals for the first time that caffeine influences metabolic responses induced by
electrically stimulated muscle contraction in isolated rat skeletal muscles. A schematic representation of
the metabolic changes induced by caffeine is shown in Figure 8. Many of these changes are related to
energy metabolism. First, caffeine promotes contraction-induced activation of the pentose phosphate
pathway and increases IMP production. Second, caffeine stimulates β-oxidation of fatty acyl-CoA,
accompanied by increase in acyl-CoA, butylcarnitine and O-acetylcarnitine; however, it does not
affect the glycolysis metabolites, glycerol-3-phosphate and L-lactic acid. Third, caffeine increases
amino acids levels associated with energy production (L-leucine, L-valine, and L-aspartate). These
metabolic alterations induced by caffeine suggest that caffeine accelerates contraction-induced metabolic
activations and thereby contributes to muscle endurance performance and exercise benefits to health.
Figure 8. Schematic representation of metabolic pathway changes. * One-way ANOVA with Tukey’s
post hoc test indicates a significant difference (FDR < 0.05) between groups.
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Abstract: Coffee is popular worldwide and consumption is increasing, particularly in non-traditional
markets. There is evidence that coffee consumption may have beneficial health effects. Consumers’
beliefs in the health benefits of coffee are unclear. The study aimed at analyzing consumers’
perceptions of coffee health benefits, consumption and purchasing motives of coffee consumers
with positive perceptions of coffee health benefits, and willingness to pay for coffee with associated
health claims. Data were collected through a face-to-face survey with consumers, resulting in
a convenience sample of 250 questionnaires valid for data elaboration. Results were elaborated
with factor analysis and logistic regression analysis. Findings revealed that a relevant minority of
consumers believed that coffee could have positive health effects. The consumer with a positive
perception of coffee health benefits is mostly male, young, works, is familiar with non-espresso-based
coffee, consumes a limited amount of coffee (generally not for breakfast and often in social settings),
and buys coffee at retail outlets. Consumers drink coffee for its energetic and therapeutic effects.
Coffee consumption is still price-driven, but consumers are interested in purchasing coffee with
associated health claims. There is the opportunity to improve the perception of coffee health benefits
in consumers’ minds.
Keywords: consumer; behavior; perception; coffee; health; consumption motives
1. Introduction
Coffee is one of the most consumed beverages worldwide. Global coffee consumption is estimated
to increase, particularly in non-traditional coffee drinking countries in Africa, Asia, and Oceania
(+4.1%). Demand in traditional markets is estimated to grow by 1% in Europe and by 2.5% in North
America [1]. Leading drivers for coffee market growth are innovations in out-of-home consumption,
online commerce opportunities, and innovative brewed coffee beverage types [2]. Consumers are
interested in coffee product quality and origin, as well as social, environmental, and economic
sustainability [3].
Innovative coffee attributes related to the health properties of coffee could be a driver for coffee
consumption [4]. Some researchers suggest that coffee might have the potential of a functional food
thanks to its biochemical properties and the possible health benefits [5,6]. In particular, there is evidence
that coffee consumption may have beneficial effects on non-communicable diseases (NCDs) [7].
This may contribute to the World Health Organization’s objective of reducing the relative risk of
premature mortality from NCDs by 25% by 2025, by improving the modifiable risk factor of an
unhealthy diet [8].
Consumers’ beliefs in the health benefits of coffee are unclear. Only 16% of U.S. consumers
know about coffee’s health benefits, and 66% are prone to limiting their caffeine consumption [9].
Many European consumers are also confused about coffee’s impact on health, with 49% believing coffee
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has negative health effects [10]. On the other hand, consumption of green coffee-based beverages
has become popular in recent years due to the belief in its beneficial antioxidant properties (e.g.,
chlorogenic acids, polyphenols) [5,11,12].
Coffee contributes to the daily intake of dietary antioxidants, more than tea, fruit, and
vegetables [13]. A screening of the most consumed beverages for their bioactive non-nutrient contents
identified instant coffee as the beverage with the highest total biophenol content [14]. Two other
studies observed coffee to be the beverage with the highest total antioxidant capacity as compared to
others like green and black tea and herbal infusions [15,16]. The biochemical composition of a cup of
coffee depends on the degree of roasting, the type of bean (Arabica versus Robusta), and the coffee
brewing method, including grind type [17–19]
There is little scientific knowledge on consumers’ attitude towards coffee health benefits.
The perception of coffee’s health effects in consumers’ minds is unclear and has not been thoroughly
researched. Past research studied consumer preferences and attitudes towards coffee attributes
including sustainability, brands, coffee types, and motives for consumption like taste, energy, pleasure,
socialization [20]. The paper aims to fill this gap in the literature and analyze the link between
consumers’ coffee consumption behavior and their perception of coffee’s health benefits and risks.
The research adds value to existing literature by analyzing what consumers perceive about coffee’s
health effects. If coffee has positive effects on human health it would be important to educate consumers
about the possible health benefits and the correct consumption of coffee. Therefore, it is important to
first study the status of consumers’ perceptions about coffee’s health effects. Furthermore, this will
allow for an exploration into whether there are marketing possibilities for coffee with health benefits
considering the increasing consumption trend of healthy food.
In evaluating the healthiness of a cup of coffee it is important to consider that coffee drinking
is a complex consumption behavior and that preferences and preparation methods are influenced
by culture and tradition. To fully exploit coffee’s capability to impact on consumer food dietary
lifestyle and health, there is need to better understand consumers’ coffee consumption habits, motives,
and perception of coffee’s health benefits. Therefore, the objective of the research is to analyze
consumers’ perception of coffee’s health benefits, consumption and purchasing motives of coffee
consumers with positive perception of coffee health benefits, and willingness to pay for coffee with
associated health claims.
Data was collected through a direct face-to-face survey with consumers using questionnaires with
closed-ended questions. The structure of the paper is as follows. Section 2 provides a literature review
of coffee consumption and purchasing motives and coffee and health, with a detailed review of the
relevant literature on coffee’s effect on single health conditions. Section 3 describes data gathering and
elaboration, and the data sample. Results are presented in Section 4. This section first discusses the
results regarding consumers’ characteristics and perception of health effects of coffee, followed by
insights on consumers’ perception of coffee health effects and motives for coffee consumption and
purchasing, and concludes with analyzing consumers’ willingness to pay a price premium for coffee
with associated health claims. Finally, the paper provides a discussion and conclusions on consumers’
perceptions of coffee’s health effects, profiling consumers according to their attitudes towards health
coffee benefits. Section 6 puts the topic into the broader context of consumers’ increasing interest in
healthy food and eating behavior, and reflects on marketing possibilities for coffee focusing on specific
health benefits.
2. Literature Review
2.1. Coffee Consumption Motives
The scientific knowledge on motives and preferences of coffee consumption and purchasing
behavior is fragmented. Past research focused strongly on a limited number of specific issues,
particularly on aspects of sustainability and fair-trade labelling of coffee. Evidence from a recent
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systematic review of 54 papers on coffee consumer research [20] identified the leading motives for
consumers’ coffee consumption and purchasing behaviors. Results suggest that there are several
leading motives for coffee consumption: functional, taste and pleasure, habit, tradition and culture,
and socialization. The main limiting factors for coffee consumption are a dislike of coffee’s taste and
a belief in its possible negative health effects. The functional and the pleasure motives are the two
leading drivers for coffee consumption and are of similar importance across cultures.
2.2. Coffee Purchasing Motives
Key coffee attributes that impact on consumers’ purchasing decisions are sustainability (including
organic and fair trade), intrinsic quality attributes (e.g., roast degree, country of origin, variety),
extrinsic attributes (packaging, brands), and coffee type (e.g., the espresso type includes black espresso
and macchiato, that is, with a small amount of milk; other types include American long coffee (i.e.,
espresso topped with hot water), cappuccino, decaffeinated coffee, filter coffee, iced coffee, and coffee
powder) [20]. A recent review on coffee purchasing motives did not identify studies that focused
specifically on the relation between coffee price and consumer behavior [20]. There is limited research
on consumer preferences for coffee’s intrinsic qualities. Preference for different intrinsic qualities
depends on expertise and sensory skills of the consumer [21]. The untrained consumer has difficulties
in distinguishing quality levels of coffee compared to an expert. The role of familiarity with the product
is important in the assessment of its quality [22]. There is not much evidence on the role that extrinsic
attributes and marketing play in buying decisions towards coffee; nonetheless, brands and labels
are considered essential for the coffee industry. Research on brands, labels and packaging mainly
concerns the willingness to pay for sustainability labels and the role of packaging and labels for the
communication of sustainability information [23].
2.3. Coffee and Health
Consumers’ beliefs in health benefits or risks of coffee are inconclusive. For some the health
benefit (e.g., anti-migraine effect) is a driver for consumption [24], others avoid coffee consumption for
medical reasons like anxiety and insomnia [25], or because of the belief that coffee is generally bad for
health [10]. Coffee drinking is not considered a health-oriented behavior, even if scientific evidence
indicates that coffee can be part of a healthy diet [26,27]. The main health concerns arise with regard to
the caffeine content of coffee [28]. Consumers see coffee mostly as a stimulant and are not informed
about beneficial components and suggested health benefits [10].
Roasted coffee is a mixture of over 1000 bioactive compounds, with potentially therapeutic
antioxidant, anti-inflammatory, antifibrotic, and anticancer effects [11,29]. Key active compounds are
caffeine, chlorogenic acids, diterpenes, cafestol, and kahweol [7,30]. Coffee is rich in vitamin B3 and
magnesium [6], and brewed coffee maintains the potassium concentration of the original seeds [31].
Caffeine is the most studied coffee component.
Scientific research has studied extensively the associations between coffee and all-cause mortality,
cancer, cardiovascular diseases, neurological and gastrointestinal as well as liver systems, and all
effects on pregnancy, with differing results over the years.
Current research concludes that coffee drinking is safe when consumed by healthy, non-pregnant
women and adult persons in moderate quantity, equivalent to three to four cups per day, providing
300 to 400 mg/d of caffeine [7,26,28,32]. The largest reduction in relative risk of all-cause mortality was
found with a consumption of three cups per day as compared with no consumption. Results suggest
an inverse relationship between coffee drinking and all-cause mortality in men and women [7].
Daily coffee drinkers reduced their risk of dying prematurely compared with non-drinkers by
7–12% [33]. There were beneficial effects of coffee on cancer and cardiovascular diseases, as well
as metabolic and neurological conditions [26]. Adverse effects of coffee drinking were mainly limited
to pregnancy and to women at increased risk of bone fracture. Negative effects are mainly associated
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with caffeine rather than any other components in coffee [7,26]. Table 1 provides details on the studies
focused on the effects of coffee on single health conditions.
Table 1. Effects of coffee on single health conditions.
Cardiovascular
disease
Habitual coffee consumption was consistently associated with a lower risk of
cardiovascular diseases mortality [7,31]. Compared to non-coffee drinkers, risk was
reduced by 19% and the largest reduction in relative risk was found at three cups per day
[7,34,35]. Coffee consumption may have a protective effect on the risk of stroke [36,37],
especially in women [38]. Research found a 30% lower risk of mortality from stroke of
coffee consumers compared to non-drinkers [7]. The reduced risk for cardiovascular
conditions is related to the antioxidant effects of coffee [26,39].
Type-2 Diabetes
Polyphenolic coffee compounds have beneficial effects on insulin and glucose metabolism
[26,31]. Coffee consumption was associated with a lower risk of developing type 2
diabetes [7], with a stronger effect for women [40]. An intake of three to four cups of
coffee/day seems to lower the risk by 25% compared to no coffee or less than two cups a
day [34,41,42]. A meta-analysis concluded that the risk to develop type 2 diabetes
decreased by 6% for each cup-per-day increase in consumed coffee [43].
Liver Conditions
Coffee consumption is related to a lower risk of developing several liver conditions [44,45].
There is an inverse association between coffee consumption and liver cancer [46,47].




Lifelong, regular and moderate coffee consumption might have a beneficial effect on
physiological, age-related cognitive decline/dementia [48,49], Parkinson’s disease [50,51],
and Alzheimer’s disease [52,53]. The potential beneficial effects of coffee on mental health
seem to be related to the neuroprotective effect of caffeine [26,50].
Depression and
anxiety
Caffeine and other polyphenolic compounds of coffee have been associated with positive
effects on mental health, for example behavior, mood, depression, and cognition [7,54].
On the other hand, high caffeine consumption is associated with anxiety and nervousness.
Positive effect on mood is influenced by time of consumption, being highest in the late
morning [55]. Caffeine seems to be more beneficial for habitual consumers [56]. Coffee
consumption had a consistent association with lower risk of depression [26,57] and to
relieve depressive symptoms [58].
Cancer
The International Agency for Research on Cancer (IARC) evaluated in 2016 a database of
1000 observational and experimental studies on coffee and cancer and concluded that there
are no clear associations between coffee drinking and cancer at any body site. Coffee was
classified as an agent “not classifiable as to carcinogenicity to humans”. There is evidence
for a lower risk of cancer in high versus low coffee consumption [7]. Phytochemical
compounds in coffee (diterpenes, melanoidins, polyphenols) may have beneficial effects at
the cellular level, for example inhibiting oxidative stress and damage [26]. There is
evidence that coffee intake is associated with a reduced risk of certain cancers [30,59].
Lung and gastric
cancers
An adverse effect of coffee consumption has been seen in an increased risk of lung and
gastric cancers. In this case, it is important to consider the potentially modifying effect of
associated smoking habits. A subgroup analysis showed that the association was
significant only in studies that did not adjust for smoking behavior [7,26].
Blood pressure
Coffee consumption has been associated with a rise in blood pressure [26]. Coffee intake
raises blood pressure in non-coffee-drinkers, but not in habitual coffee drinkers. On the
other hand it was observed that the antioxidant compounds of coffee might counteract the
effects of caffeine in raising blood pressure [26]. Research results are conflicting and the
association between coffee consumption and blood pressure remains unclear [60].
Pregnancy
Negative associations of coffee and caffeine intake were mostly pregnancy-related (low
birth weight, pregnancy loss, preterm birth, childhood leukemia) [7,26,61,62].
The European Food Safety Authority (EFSA) [32] recommends that a moderate caffeine
intake of 200 mg/day does not increase the risk of any pregnancy-related complication.
Still, the association between coffee/caffeine and reproductive health outcomes needs
further investigation as available data are insufficient and the role of confounding
(e.g., diet, smoking etc.) factors is unclear [61].
Bone fracture
A negative association between coffee consumption and bone fracture was seen in women
[7]. A 14% higher risk was found in high versus low coffee consumption [63].
The increased risk in women seems related to caffeine and its potential influence on
calcium absorption [64] and bone mineral density [65]. The systematic review by
Wikoff et al. [28] concludes that a caffeine intake of 400 mg/day was not associated with
negative effects on fracture, bone mineral density, and calcium metabolism.
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The main limitation in drawing conclusions on coffee health associations is that existing evidence
is observational and of lower quality. More research is needed with data from long-term randomized
controlled trials [7,26,28].
3. Materials and Methods
3.1. Data Gathering
Data gathering was based on a direct face-to-face survey. Data was collected using questionnaires
with closed-ended questions. The first question aimed at filtering interviewees so as to collect responses
only from coffee consumers (i.e., those who generally drink coffee). The questionnaire includes five
sections. Section 1 was on coffee consumption habits: types of coffee drunk (e.g., espresso, long coffee,
cappuccino, decaffeinated, coffee powder, iced coffee, filter coffee); number of cups of coffee per day;
occasions and places of consumption; companionship during consumption; consumption of other
caffeinated drinks; type of coffee preparation; and outlets of coffee purchasing. Section 2 focused
on motives of coffee consumption and purchasing (Table 2). Section 3 focused on the perception
of health benefits of coffee. In particular, the first sub-section included questions aimed at eliciting
the view of the consumers as to whether coffee consumption can bring health benefits, can reduce
diseases, can be a functional beverage for human wellness, and has nutritional properties that can
improve human health. These items are based on coffee health impact literature review, past research
studies exploring consumers’ perception of food healthiness [4,9,66–71], and the European Food Safety
Agency food health and nutrition claims [72]. The second sub-section asked consumers’ opinions on
the effects of moderate coffee consumption on diminishing the risk of diseases and on influencing
a number of physical effects based on scientific-tested studies (Table 1). Then, the third sub-section
asked if consumers thought that there was a gender difference in terms of coffee consumption with
respect to health, and whether decaffeinated coffee had different health impact compared to caffeinated
coffee. These items are based on a coffee health impact literature review. Sections 2 and 3 asked the
respondents to rate each question using a 5-point Likert scale of agreement/disagreement (1: “totally
disagree” to 5: “totally agree”, with scale end values anchored to interpretations), or with other
responses options (e.g., “yes”/”no”) as reported in the Table notes.
In the fourth section respondents were asked to state their willingness to pay (WTP) for the
most common type of coffee product, the coffee brick pack. Only participants that more frequently
bought this type of coffee were considered in the analysis. Participants’ WTP was assessed by
applying the multi price list (MPL) in a hypothetical setting method, widely adopted in experimental
economics [73–75]. This mechanism has the great advantage of being transparent and very simple to
understand for participants. The minor disadvantage is the interval response with a psychological
bias toward the middle of the list [76]. Before eliciting their WTP, participants were provided with
a reference price for the product type that was identified based on current retailer prices. The price
premiums went from €0.10/brick to €1.50/brick, with 15 price premium options with a €0.10 difference.
Section 6 gathered information on the socio-demographic profiles of the respondents.
The questionnaire was tested in trial face-to-face interviews and the items identified as unclear
or not important were revised. Interviewers carried out 272 interviews. Data cleaning led to the
definition of a convenience sample of 250 questionnaires for data elaboration. The places of interviews
were retail outlets, coffee shops, bars, and malls. Interviews were carried out from April to July 2018.
At the beginning the interviewer declared the interview was part of a university study, wore a badge
with name and university affiliation, and proceeded with the interview if the respondent agreed to
participate in the research. The time necessary to carry out each interview was around seven minutes.
No reward or token was awarded. Data were collected with the support of the Qualtrics survey
program by uploading the answers gathered during the face-to-face interviews.
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Table 2. Literature references for studied items in the questionnaire.
Item Literature References
Functional (awakening and attention, physical energy) [24,77–79]
Sensory (taste, smell) [25,77–80]
Pleasure (mood and emotion, comfort, relaxing) [77–79]
To socialize (with family, friends, coworkers) [25,79–82]
To have a break [10,25,77]
Health (digestion, against headache, increase blood pressure) [24,25,77,81]
Family tradition and culture [24,25,82]
Habit [24,81,82]
Price, promotion, value for money [23,83,84]
Coffee roast, coffee recipe, intensity and taste information [2,22,80]
Country of origin [20,80,85,86]
Sustainability (fair-trade, organic) [23,84–86]
Brand knowledge, packaging, advertising [83,87–90]
Expert recommendations [21,91]
3.2. Data Elaboration
Data elaboration followed different phases. First, data elaboration calculated the consumers’
level of perception of coffee health benefits. The level of perception was calculated as mean value
of the first sub-section items belonging to Section 3, that is, whether consumers agreed that coffee
consumption could bring health benefits, reduce diseases, be a functional beverage for human wellness,
and have nutritional properties that can improve human health. The mean values of positively versus
negatively inclined consumers were cross-checked with the analysis of variance (ANOVA). The levels
of perception of positively versus negatively inclined consumers were cross-analyzed with consumers’
socio-economic characteristics and coffee consumption habits, and tested using the chi-squared test.
Second, the research identified the existing latent factors in consumers’ coffee consumption and
purchasing motives, with the support of two factor analyses. Two separate factor analyses were run,
one for coffee consumption motives, and one for the coffee purchasing motives in order to highlight
possible different habits in the consumers’ approaches to coffee. The principal components method
(PCA) and Varimax rotation (Eigenvalue criterion being higher than 1) were applied.
Third, the factors were used in the logistic regression (enter method), carried out to explore the
relationship between consumers’ perceptions of health benefits of coffee and their consumption and
purchasing motives. The factor variables were also checked for the multicollinearity analysis, to verify
the possibility that one variable is a linear function of the other. Multicollinearity has been tested
through tolerance and variable inflation factors (VIFs) [92]. Omnibus tests of model coefficient were
analyzed to test the level-of-fit of the model. Model variance with Nagelkerke was considered. Finally,
the research calculated the WTP and cross-analyzed values with socio-economic characteristics of the
consumers. Data elaboration was carried out with the support of SPSS (version 21).
3.3. Sample
Out of the 250 respondents, the majority were women, and about half had an academic degree
(Table 3). There was a majority of people working, and a generally low or medium family income.
The age was well distributed, as 55.2% of the respondents are aged younger than or equal to the
average age, that is, 40.97 years (maximum age is 85 and minimum age 18).
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No academic degree 51.0
With academic degree 49.0
Total 100.0
AGE
Below or equal to average age 55.2






LEVEL OF FAMILY INCOME
Low and medium income (up to €55,000/year) 87.3
High income (above €55,000/year) 12.7
Total * 100.0
* 39.1% did not respond to this question (“I do not know” or “I do not want to respond”).
4. Results
4.1. Consumers Characteristics and Perception of Health Effects of Coffee
A relevant minority of consumers (25%) thought that drinking coffee could have positive effects
on health (Table 4). The average value of the perception on coffee health benefits of the positively
inclined consumers was fairly high (3.7). The analysis of consumers’ socio-economic characteristics,
coffee consumption, and purchasing habits of the positively versus the negatively inclined consumers
showed interesting elements (Table 4). A higher percentage of men (31%), of younger (30.4%), and of
working (27.2%) consumers had a positive perception of the health effects of coffee consumption
compared to female, older, and not working consumers. The level of education was not an explanatory
characteristic for the perception of health effect of coffee consumption. There were more consumers
that tended to drink non-espresso based coffee (36.2%), that consumed from one to two cups of coffee
per day (32.5%), that never or rarely drank coffee for breakfast (34.3%), and that bought coffee in big
retailer chains (27.9%) that had a positive perception of coffee health benefits. A chi-squared p-value
confirmed the results. Other data support that positively inclined consumers tended to drink coffee
with other people (28.5%), and that they did not to have coffee as a break (29.4%) or after lunch (28.1%).
These results suggest that consumers positively inclined towards coffee health benefits are more
likely to be male, young, and working, tending to appreciate non espresso-based coffee, consume in
limited amounts and in social settings, and not usually consuming in the morning. They are more
likely to purchase it in common outlets, probably with other food items.
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Table 4. Consumers’ perceptions of health effect of coffee consumption and consumers’ characteristics.
Negative Perception % Positive Perception % Total ANOVA p-Value
Total a 75.2 24.8 100
Perception of health effect of coffee
(average) a 2.29 3.70 2.91 0.000 ***
Standard deviations 0.500 0.484 0.762
Socio-economic characteristics
Negative Perception % Positive Perception % Total Pearson’s chi-squared p-Value
Gender
Men 69.0 31.0 100 0.075 *
Women 78.3 21.7 100
Age
Below equal to average age 69.6 30.4 100 0.015 **
Above average age 82.1 17.9 100
Level of education
No academic degree 72.0 28.0 100 0.153
Academic degree 78.4 21.6 100
Working condition
Working 72.8 27.2 100 0.047 **
Not working 85.4 14.6 100
Consumption and purchasing habits
Type of coffee most frequently drunk b
Espresso 77.8 22.2 100 0.038 **
Non espresso-based coffee 63.8 36.2 100
Frequency of consumption
One to two cups of coffee/day 67.5 32.5 100 0.038 **
Three or more cups of coffee/day 78.8 21.3 100
Companionship in consumption
On my own 78.7 21.3 100 0.121
With others 71.5 28.5 100
Place of consumption
At home 75.5 24.5 100 0.527
Out of home 75.0 25.0 100
Method of preparation most frequently
adopted c
Moka pot 76.6 23.4 100 0.409
Capsules 74.4 25.6 100
Consumption of caffeine d
Low/medium caffeine consumption 75.7 24.3 100 0.497
High caffeine consumption 74.8 25.2 100
Coffee Consumption for breakfast
Never/rarely 65.7 34.3 100 0.098 *
Often/always 77.1 22.9 100
Coffee Consumption as a break
Never/rarely 70.6 29.4 100 0.106
Often/always 78.4 21.6 100
Coffee Consumption after lunch
Never/rarely 71.9 28.1 100 0.228
Often/always 77.0 23.0 100
Coffee Consumption after dinner
Never/rarely 76.0 24.0 100 0.382
Often/always 73.2 26.8 100
Place of purchasing
Big retailer 72.1 27.9 100 0.096 *
Small retailer 82.5 17.5 100
Note: *, **, *** Significant at p < 0.10; p < 0.05; p < 0.01; a Based on the average value of coffee health impact perception.
Negative and neutral coffee health impact (below or equal to 3); Positive coffee health impact (above 3). b “Espresso”
type includes black espresso and macchiato, that is, with a small amount of milk; “Other types” include American
long coffee (espresso topped with hot water), cappuccinos, decaffeinated coffee, filter coffee, iced coffee, and coffee
powder. c The moka coffee pot is the most common coffee brewing technique in Italy. This results includes only the
moka coffee pot and capsules as they were the most frequently ticked answers (94%). d Other sources of caffeine
consumption, in addition to coffee, are: tea, energy drinks, coke, other caffeine drinks. Low/medium caffeine
consumption has values of 1, 2, 3. High caffeine consumption has values of 4 and 5 in a 5-point Likert scale where 1
is “never” and 5 is “always”.
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Consumers are better inclined towards a limited number of benefits of coffee consumption
(Figure 1). In particular, almost 80% of consumers believe that drinking coffee increases blood pressure,
more than half think that it decreases depression and headache, one-third that it decreases the risk of
stress and anxiety, one-fourth that it decreases the risk of cardiovascular diseases, and one-fifth that it
impacts on women’s capability to absorb calcium and minerals and stimulates the reduction of body
weight. Consumers do not acknowledge other medically tested effects on pregnant women, diabetes,
liver, cancer, neurodegenerative diseases, and pain.
Figure 1. Consumers’ perception of health effect of coffee consumption (%). Note: Consumers’ response
options were “yes”/”no” for each item. Therefore, the figure shows that around 80% of respondents
thought that drinking coffee increased blood pressure.
Moreover, 61% of consumers believe that the correct number of cups of coffee per day is between
three and four. According to scientific studies, this is the recommended quantity (equivalent to
300–400 milligrams of caffeine per day) [7,26,32]. Therefore, the vast majority has an adequate
knowledge of the daily quantity of coffee to be consumed. Around 35% of consumers think that
between one and two cups is adequate, values lower than the threshold set by scientists, thereby
showing some skepticism towards coffee impact on health. Moreover, 84% of consumers think that
the effect is similar in men and women, and 80% that decaffeinated coffee has a similar impact to
caffeinated coffee on human health. These results support that consumers have adequate knowledge
on the quantity to be consumed, the effects on gender, and the types of coffee, fairly in line with
scientific evidence [7,26,32]. There is no evident misconception of the effects of coffee on health.
4.2. Consumers’ Perception of Coffee Health Effect and Motives for Coffee Consumption and Purchasing
The two factor analyses on consumers’ coffee consumption and purchasing motives identified
seven main components (Tables 5 and 6). Four components derive from the factor analysis on
the initial 12 items on coffee consumption motives, and three components derive from the factor
analysis on the initial 13 items on purchasing motives. The second factor analysis was tested until
all identified components had satisfactory internal consistency values. This lead to delete three
items. In both factor analyses items were loaded into single factors, with factor loadings above
0.585. The Kaiser–Meyer–Olkin measure of sampling adequacy and Bartlett’s test of sphericity were
calculated to assess the appropriateness of the data for factor analysis. The Kaiser–Meyer–Olkin index
was 0.649 in the coffee consumption motives PCA and 0.660 in the coffee purchasing motives PCA.
Bartlett’s tests of sphericity were highly significant (0.000). The cumulated variance values explained
by the factors were respectively 66.2 and 66.3. Elaboration results confirmed the data appropriateness.
The values of the factors were calculated based on the mean of the items loading into the single factors.
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Table 5. Factor analysis on motives for coffee consumption and convergent validity and discriminant
validity for each construct.
Habit and Pleasure Social Therapeutic Energy















Increase blood pressure 0.717
Cronbach’s alpha 0.633
Variance explained (%) 21.97 14.12 13.91 13.90
Mean value of factors 3.1 2.7 1.7 2.7
Convergent validity and discriminant validity
Habit and Pleasure Social Therapeutic Energy
Habit and pleasure 0.510
Social 0.324 0.672
Therapeutic 0.092 0.187 0.525
Energy 0.273 0.194 0.173 0.776
Composite reliability 0.84 0.81 0.77 0.88
Note: Diagonal data (in italics) represent Fornell and Larcker’s average variance extracted (AVE). Subdiagonal
represent the inter-construct correlations.
The internal consistency and convergent and discriminant validity of each component was verified
(Tables 5 and 6). The internal consistency of each set of items was measured using Cronbach’s alpha
and composite reliability (CR). Alpha component values were from 0.633 to 0.771, and CR values
were from 0.77 to 0.88 in the first factor analysis. In the second factor analysis, alpha component
values were from 0.675 to 0.836 and CR values were from 0.81 to 0.94. Values were satisfactory and
acceptable [93,94]. The average variance extracted (AVE) provides a measure of convergent validity,
and ranged from 0.504 to 0.696 in the first factor analysis and from 0.510 and 0.776 in the second factor
analysis. These were satisfactory as above the 0.50 threshold [95]. To confirm discriminant validity,
the square root of each construct’s AVE was calculated to ensure it was greater than its bivariate
correlation with other constructs in the model. This led to adequate outcomes. The results confirm the
reliability and validity of the research components.
The factors were labeled according to coffee consumption and purchasing motives associated
with the statements. Coffee consumption is driven by four main factors. The most important factor
is the habit and pleasure of drinking it (3.1). This connects to the organoleptic characteristics that
are coffee smell and taste, family traditions and habits, and the emotions and moods created by
coffee. The energetic physical and mental awakening power of coffee is as important as its role in
having a break during the day and socializing at work (2.7). The fourth motive for drinking coffee
is its therapeutic impact, that is, the capability of coffee to help digestion, increase blood pressure,
and alleviate headaches (1.7). Coffee purchasing is driven by three main motives. The main driving
216
Nutrients 2019, 11, 653
element is the price, that is promotion and value for money (3.3). Another key aspect is the declared
aroma, recipe, level of roasting, and intensity (3.2). The coffee sustainability (1.8) does not strongly
influence consumers’ coffee purchasing. In synthesis, consumers have a hedonistic approach towards
coffee, focused on its taste, smell, and family habits and culture. Their consumer behavior is also
driven by utilitarian reasoning, focused on price. In addition, coffee is drunk for its relevant socializing
and energetic power.
Table 6. Factor analysis on motives for coffee purchasing and convergent validity and discriminant
validity for each construct.
Price Sustainability Aroma
Price 0.902













Variance explained (%) 24.21 22.02 20.11
Mean value of factors 3.3 1.8 3.2




Aroma 0.017 0.101 0.504
Composite Reliability 0.94 0.88 0.81
Note: Diagonal data (in italics) represent Fornell and Larcker’s average variance extracted (AVE). Subdiagonal
represent the inter-construct correlations.
There is a statistically significant relationship between consumers’ perception of coffee health
benefits and motives for coffee consumption and purchasing (Tables 7 and 8). The VIF values
were between 1.020 and 1.401, and the lowest tolerance value was 0.714. Therefore, there was no
multicollinearity between variables. The significant relation is between the perception that coffee
can have health benefits, and the following motives of coffee experience: habit and pleasure (0.017),
aroma (0.048), and price (0.058). The significant relation is in some cases an unpredicted direction.
If the consumers believe in the coffee health benefits, they tend not to drink it as a habit or for pleasure
or consume coffee for its aroma. Moreover, the positively inclined consumers believe price is a motive
of coffee purchasing. Results are confirmed by p-values.
These results suggest that if consumers drink coffee for the pleasure of it, out of family and
traditional habits, and because of the taste and coffee roasting/recipes, then they are distant from the
idea that coffee may have a positive health impact. If their coffee purchasing experience is influenced
by the product price, then they are sensitive to coffee’s health impact. If coffee purchasing and
consumption are not driven by hedonism and traditional routine and are not emotional, then their
perception is better inclined towards new features of coffee.
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Table 7. Logistic regression on the relationship between consumers’ perception of coffee health benefits
and motives for coffee consumption and purchasing.
B S.E. Wald Sig. Exp(B) Tolerance VIF
Habit/pleasure −1.037 0.433 5.744 0.017 ** 0.355 0.980 1.020
Social −0.359 0.440 0.664 0.415 0.699 0.912 1.097
Energy −0.510 0.838 0.370 0.543 0.601 0.714 1.401
Price 0.706 0.373 3.585 0.058 * 2.027 0.961 1.041
Sustainability −0.627 0.631 0.987 0.320 0.534 0.755 1.325
Aroma −0.816 0.412 3.925 0.048 ** 0.442 0.972 1.028
Constant 2.099 1.403 2.236 0.135 8.155
Dependent variable: level of coffee health benefit perception—(0) negative and neutral (average value below or
equal to 3) vs. (1) positive (average value above 3). Note: *, ** significant at p < 0.10; p < 0.05. Omnibus tests:
0; VIF: between 1.020 and 1.041; Nagelkerke R-square: 0.313. The limited number of consumers with positive
perceptions of coffee’s health benefits and with consumption behavior driven by therapeutic motives (one consumer)
suggests not including the therapeutic component in the regression exercise. VIF: variable inflation factor.
Table 8. Relationship between consumers’ perception of coffee health benefits and motives for coffee
consumption and purchasing, with chi-squared results
Consumers Perception of
Coffee’s Health Benefits (%) Total Chi-Squared
Negative Positive
Habit/pleasure Negative 63.7 85.4 75.9 0.000 ***Positive 36.3 14.6 24.1
Social
Negative 72.2 85.7 76.8
0.022 **Positive 27.3 14.3 23.2
Therapeutic Negative 76.1 91.7 77.0 0.192Positive 23.9 8.3a 23.0
Energy Negative 76.3 72.2 76.0 0.442Positive 23.7 27.8 24.0
Price
Negative 82.2 71.0 76.2
0.031 **Positive 17.8 29.0 23.8
Sustainability Negative 76.5 82.6 77.2 0.361Positive 23.5 17.4 22.8
Aroma
Negative 65.6 87.9 78.5
0.000 ***Positive 34.4 12.1 21.5
Note: **, *** significant at p < 0.05; p < 0.01.
4.3. Consumers’ Willingness to Pay a Price Premium for Coffee Health Benefits
The vast majority of consumers (74%) is willing to pay a price premium for coffee with health
benefits (Table 9). Given that the average price is around €2.75/brick pack, a €1.03 average price
premium is equivalent to +37% (average price is €2.78/250 g brick pack, equivalent to €11/kg) [96].
The price premium is significant. There are variations among the different socio-economic groups
of consumers. The highest price premium (between €1.00 and €1.50) would be paid mostly by older
(62.9%) and higher income consumers (17.5%). A higher percentage of women (70.4%) are favorable
towards fairly high coffee price premiums (between €0.51 and €1.00).
218
Nutrients 2019, 11, 653
Table 9. Willingness to pay a price premium for coffee with associated health claims (%).
Yes, I Am Willing to Pay a Price Premium 73.6%
From €0.10 to €0.50 From €0.51 to €1.00 From €1.01 to €1.50
All consumers (average €1.03) 17.2 28.4 28.0
Men 33.9 29.6 37.1
Women 66.1 70.4 62.9
Total 100.0 100 100
Below equal to average age 62.4 62.0 37.1
Above average age 37.6 38.0 62.9
Total 100 100 100
Low and medium income 91.7 92.1 82.5
High income 8.3 7.9 17.5
Total 100 100 100
5. Discussion
The debate over coffee’s effects on the human body has gone through various stages,
with recommendations aimed at promoting or avoiding coffee consumption. The history of coffee
started in the 15th century [97]. Its consumption first grew in Arabic countries and then expanded
to Persia, Egypt, Syria, and Turkey. It was known as “wine of Araby”, and drunk as a substitute for
alcohol, which was prohibited according to the Islamic religion. In the 17th century coffee arrived
in Europe (e.g., Italy, England, France, Austria). Consumers increasingly drank it in coffee houses
that become competitors for pubs, with coffee becoming a substitute for beer and wine. During
the 18th century it became common in North America, and then, thanks to the optimal weather,
it was cultivated in South America. Brazil is currently the most significant coffee-exporting country.
During its long history, coffee has been criticized for various reasons: because it was considered
to stimulate critical thinking (Mecca), because it was considered Satanic (Italy), because it was
considered as a toxic substance used to bring about death (unsuccessfully) (Sweden), and because it
threatened beer consumption and therefore local agricultural production (Prussia) [97,98]. As history
shows, coffee consumption and the beliefs in its nutritional properties have always been intertwined.
Coffee properties perceptions have often shaped coffee consumption and purchasing habits, including
preparation methods, favorite types of coffee, and places of consumption and purchasing.
The present research paper provides valuable insights on consumers’ perception over coffee health
effects, and profiles coffee consumers’ characteristics based on their positive or negative attitudes
towards coffee health effects. There are a number of results that highlight consumers’ socio-economic
characteristics and coffee consumption habits, consumers’ motives for coffee consumption and
purchasing, and consumers’ interest in coffee with associated health claims.
The present research shows that men are more positively inclined towards coffee health benefits
as compared to women. Women appear more skeptical, whereas a higher percentage of men already
believe that drinking coffee benefits their health. Considering women’s general strong propensity
towards healthy food [99], coffee with certified health claims may lead women to have a more positive
inclination towards it. Moreover, the consumer with a positive attitude towards coffee health benefits
is fairly young, works, and has a habit of drinking coffee in social occasions, in limited quantity,
and in various preparations, not necessarily espresso. This approach to coffee drinking is in line
with the most recent coffee consumption trends. Recent studies support that there is an increasing
number of people drinking coffee, with interest in gourmet coffee, new types of coffee (e.g., frozen
blended coffee drinks, nitro coffee, and cold brew), out-of-home consumption, and lower appreciation
for cafe moka [9]. Moreover consumers believe coffee has some effects on the human body (e.g.,
blood pressure, depression, headache, stress and anxiety, body weight). This suggests that there are
no specific misconceptions over coffee, but consumers are still not fully aware of coffee’s nutritional
potential and health impacts.
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Results on the motives for coffee consumption support that the energy coffee provides is the key
health effect consumers aim for. Coffee drinkers expect improved alertness and higher physical and
mental performance [24,25,77,78]. There are motives for coffee consumption that differ among the
positively and negatively inclined consumers with respect to coffee’s health benefits. The positively
inclined consumer to a certain extent values coffee for its aroma, pleasure, habits, and socialization.
This is a relevant difference compared to past studies that supported taste as the main motive for
coffee drinking [25,77–79]. In consumers, coffee evokes feelings of pleasure and comfort during the
drinking experience [77–79]. The wide audience of coffee consumers gives particular importance
to coffee habit and family traditions that influence preferred occasions, locations, and types of
coffee consumption [24,25,82]
Despite the fact that positively inclined consumers drink coffee with others to have a break,
socialization is not a key motive. This approach brings a distinguishing interpretation with respect
to past studies. These studies suggest that drinking coffee is a way to socialize and be part of a
group [25,77,79,82]. In synthesis, the energizing effect is what the consumer aims for. The consumer
aims for a functional drink with a clear mental- and body-stimulating function. This is the same
consumer objective for soft drinks and energy drinks.
Results on the motives of coffee purchasing support that for the positively inclined
consumer, price is a significant attribute. The consumer is influenced by extrinsic coffee attributes.
Coffee purchasing is to a certain degree driven by aroma, coffee recipe, brand, information,
and emotions, but rather by rational and economic elements. Therefore, for these consumers messages
focused on health claims that give value to the money spent may be important for coffee consumption
and purchasing. Past studies found that the use of texts, brands, and metaphorical images on coffee
packaging moderately influenced product expectations, intrinsic quality perception, and purchase
intention [89]. Brand identification is especially important in the coffeehouse market [87–90]. Drinking
a specific coffee brand (e.g., Starbucks) represents a status symbol and way of life for consumers [87,88].
Sustainability is one of the most studied subjects in consumer purchasing research on coffee [20].
Present and past research results suggest that aroma, price, and promotions are more important factors
as compared to sustainability [85]. Only consumers with a strong attitude towards sustainability gave
more importance to the sustainability claims over hedonic attributes and were willing to pay more for
sustainably produced coffee [84,86,100].
The present research on consumers’ interest in the economic investment over coffee products
with health claims further highlights the importance of price in coffee purchasing. Results show that
price is an important element for all consumers and that coffee is mostly purchased from large retailers.
The importance of price in coffee purchasing shows that coffee is still a rather undifferentiated
commodity. Consumers with positive attitudes towards coffee’s health benefits give particular
importance to price. Moreover, consumers are generally willing to pay higher prices for coffee with
health claims. This is suggested for both positively and negatively coffee health-oriented consumers.
In particular, women and consumers with higher monetary resources are more favorable towards
healthy food. This is consistent with past research results [101–103].
The willingness to pay for coffee with innovative attributes is confirmed by the market expansion
of coffee capsules. Capsules have been successful thanks to the low cost of machines, the ease of use,
the practicality of packaging, and effective marketing communication campaigns [96,104]. This success
was achieved despite the high price, with consumers willing to pay up to five times more than coffee
powder brick (around €55/kg for coffee capsules). This market phenomenon has been disruptive
for the coffee market. It contributed to stopping the price competition that excessively lowered the
price of the powder coffee brick, coffee quality, and the capability for investing in coffee research and
development as well as innovations.
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6. Conclusions
Consumer attitudes toward food products determine consumption behavior more than
knowledge. Attitudes and perceptions influence dietary behavior intentions [105]. Results from
the current study on coffee consumers’ consumption and purchasing habits can contribute to
a better understanding of food lifestyle decisions. The integration of knowledge of nutritional
qualities with knowledge of consumers’ expectations and perceived food qualities allows for
addressing possible misconceptions and more effectively defining food consumption and purchasing
behavior recommendations.
There is an expanding consumers’ interest for healthy food. Consumers are increasingly aware
of the impact food has on body functions [69,71,106]. Coffee consumption has often been negatively
criticized for its health effect. Recent studies show that coffee can have positive health effects,
but consumers are still cautious on drinking coffee. The coffee image is of a drink with a health
impact, but not necessarily positive, and not based on the latest science-based outcomes. Coffee is
used for its energetic and therapeutic effects. Together with other energy drinks, it is increasingly used
as a substitute for soft drinks. Coffee is a drink with some advantages. It is naturally low in calories
if drunk “black”, and it is a drink good for socializing. Coffee chains are expanding. Soft drinks
companies are increasingly interested in developing their business to include coffee shop chains [107].
The coffee market is very dynamic, and consumers are increasingly interested in artisanal coffee
and small coffee breweries. Drinking coffee is already acknowledged as a pleasure. The aspects of
aroma, taste, smell, and occasions of consumption are still crucial. However, there is space to improve
perceptions of scientifically-based health benefits. To increase awareness and improve knowledge
among consumers, coffee marketing strategies could focus more on health benefits and nutritional
values of coffee [4,66,108] in addition to the other positive characteristics consumers already associate
with coffee. As a result, coffee consumption could be marketed as being pleasant and healthy at the
same time.
There are already examples for market trends and innovations focusing on the functional and
health aspects of coffee. Ready-to-drink (RTD) coffee (packaged liquid coffee designed to be consumed
when opened without any additional steps) is interpreted as a clean functional beverage category and
a healthier alternative to soft drinks. The RTD coffee segment is expected to grow due to global trends
in the coffee sector: worldwide coffee culture growth, active on-the-go-lifestyle, and investments by
major players [109]. Some coffee brands already use health focused strategies for coffee marketing
(RTD and ground coffee). RTD cold brew coffee is marketed as a sugar and fat-free alternative to
traditional energy drinks [110] or as a probiotic cold brewed coffee supporting digestive and immune
health [111]. There are examples for a prebiotic fiber-enriched ground coffees with digestive health
benefits [112] and for antioxidant-enriched ground coffees [113].
The discussion whether coffee can be claimed as an actual functional food is ongoing and there
is not enough long-term evidence that coffee can prevent disease. Therefore coffee consumption for
health reasons requires further scientific evidence before being recommended and promoted [7,28,114].
Limitations and Future Research
There are some study limitations. Results come from a convenience sample, focused on Italian
consumers. Future studies may aim for samples with statistical representativeness and compare
perceptions of consumers living in different countries. Coffee consumption behavior is related to
various countries’ consumption traditions and habits, and cross-country analysis may bring a more
comprehensive perspective. Furthermore, considering the fast development in coffee consumption
habits, future studies may focus the analysis on consumers that specifically favor coffee consumption
out-of-home or specific coffee types preparations, such as filter, capsules, and powder. Future studies
may also test consumers’ WTP for different combinations of coffees with associated health claims
such as disease reduction and health-promoting effects. Finally, future studies may explore coffee
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consumption motives within the dietary lifestyle, so as to provide sound information on the food
behavior of coffee consumers for nutritionists and doctors.
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Abstract: Caffeine is a psychoactive substance that may affect the normal course of pregnancy,
therefore its intake during that time should not exceed 200 mg/day. The aim of this study was to
evaluate caffeine intake among pregnant women from the Warsaw region. The study was conducted
among 100 pregnant women who delivered at the Department of Obstetrics, Gynecology and
Oncology, Medical University of Warsaw. Caffeine intake from coffee, tea, and energy drinks was
measured using a questionnaire. Direct interviewing was used, with all interviews conducted by
the same dietitian. Multiple regression analysis was used to investigate the relationship between
caffeine intake and anthropometric measurements of the newborns. Mean caffeine intake among
pregnant women was 68 ± 51 mg/day. Only 2% of the respondents exceeded the safe dose of 200 mg.
Tea (mostly black) was the source of 63% of all caffeine. No relationships were found between caffeine
intake and neonatal weight, length, or head and chest circumference (p > 0.05). Caffeine intake in our
study population was relatively low and did not negatively affect fetal growth.
Keywords: caffeine; coffee; tea; energy drinks; pregnancy; newborn
1. Introduction
Caffeine, being a component of many popular products (tea and coffee), is widely consumed by
pregnant women [1,2]. The half-life of caffeine is significantly prolonged in the body of a pregnant
woman [3,4], due to decreased activity of the liver enzyme that is responsible for caffeine metabolism
(by one-third in the first trimester of pregnancy and by half in the second trimester of pregnancy) [5].
The caffeine-induced increase in catecholamine concentrations (adrenaline, dopamine, and serotonin)
interferes with placental blood flow and hampers transplacental nutrient transport to the fetus [6,7].
Caffeine and its metabolites easily cross the placental barrier [2,3,8], and caffeine excretion is delayed
due to the immaturity of the fetal liver [2,9].
The impact of caffeine on the course of pregnancy and the development of the fetus is largely
dependent on maternal intake and, supposedly, also on the speed of caffeine metabolism in the mother’s
body [3,10]. Until recently, most experts believed that daily maternal intake of caffeine should not
exceed 300 mg [9–11], although recent recommendations of the European Food Safety Authority (EFSA)
and the American Institute of Medicine have limited the amount to 200 mg/day [12,13].
High maternal caffeine intake may lead to a miscarriage, premature birth, or low-birth neonatal
weight but, despite extensive research, the evidence remains inconclusive [2,14]. The results of three
meta-analyses, published between 2014 and 2016, of studies on caffeine intake and the risk for
miscarriage seem to be the most unambiguous so far. According to these sources, a 100–150 mg increase
in daily caffeine intake results in an elevated (by 7–19%) risk for miscarriage [14–16]. The risk increases
by 40% among women who consume large amounts of caffeine (350–699 mg/day) as compared to
small amounts (<50 mg) [14]. Nevertheless, research limitations of the abovementioned studies as
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far as methodology is concerned and lack of randomized trials, which yield the most credible results,
need to be emphasized. As for premature birth, a meta-analysis of the available studies revealed no
relationship between caffeine intake during pregnancy and the duration of pregnancy [11], nor has
such a negative correlation been confirmed by a meta-analysis of studies on the risk for central nervous
system defects in the fetus [17,18]. However, a relationship between maternal coffee intake and the risk
for leukemia in the offspring has been suggested by meta-analyses of clinical case-control trials on the
safety of coffee consumption [18,19].
The effects of maternal caffeine intake on the emotional development of their children remains yet
another matter. While some authors found no evidence for the link between maternal caffeine intake
(even over 300 mg/day) and the development of attention-deficit hyperactivity disorder (ADHD) in
children aged 4–11 years [20–22], other researchers are less optimistic. A study from Denmark found
that maternal consumption of ≥8 cups of coffee/day in the second trimester results in hyperexcitability
in their children [23]. Noteworthy, caffeine citrate remains the gold standard in the treatment of apnea
in premature newborns [24,25]. No adverse side effects have ever been reported [26], and some authors
even observed a positive effect of such therapy on the psychomotor development of the affected
children at the age of 18–22 months [27].
In light of a limited amount of data from Poland on caffeine intake during pregnancy, the aim
of our study was to evaluate the level of maternal caffeine intake and its effect on neonatal
anthropometric parameters.
2. Material and Methods
2.1. Study Design
The study was conducted among 100 pregnant women, who delivered at the Department of
Obstetrics, Gynecology and Oncology, Medical University of Warsaw. The women presented at the
hospital on weekdays (Monday–Friday), in the morning, during four months of 2014 and 2015.
Approximately 20% of the women did not consent to participate in the study. The exclusion criteria
were the following: non-Polish nationality, multiple gestation, advanced stage of the delivery, chronic
maternal diseases before pregnancy, and threatened course of labor. A written informed consent was
obtained from all participants. The local ethics committee approved of the study (no. 10/162/KB/2014).
Maternal characteristics are presented in Table 1.
2.2. Data Collection
Caffeine intake from coffee and tea, which according to the available literature constitute the main
sources of caffeine in the diet of pregnant women [1,3,22,28], were evaluated. Energy drinks were
also included in the analysis, predominantly to investigate maternal attitudes to their consumption
during pregnancy. Dietary caffeine intake from coffee and tea was investigated using a questionnaire,
along with the type of coffee and the way of preparing infusions, since the brewing method is largely
the factor behind caffeine content. Direct interviewing (face-to-face) was used and all interviews
were conducted by the same dietitian (the main author of the manuscript) in order to ensure data
homogeneity. The ‘Photo Album of Meals and Products’ was used to precisely evaluate portion size.
Mean caffeine content values in coffee and tea brews were taken from our earlier analysis (Table 2) [28].
Neonatal data (sex, weight, length, Apgar score at 5 min., head and chest circumference) were obtained
from the hospital medical records. The anthropometric measurements were taken by the midwives
immediately upon delivery. Weight was measured using a physician beam scale. The remaining
measurements were taken with the use of a tape measure. The total neonatal length was measured
from the vertex of the head to the soles (with the feet kept vertical at 90 degrees). The occipital-frontal
head circumference (tape was placed on the maximum protrusion of the occiput and supraorbital
ridges) and the chest circumference (tape was placed horizontally on the sternum and lower tip of the
shoulder blade) were measured.
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2.3. Statistical Analysis
The normal distribution of all studied parameters was checked using the Kolmogorov–Smirnov test.
The Mann–Whitney test was used to compare the distribution of caffeine intake between independent
groups (education, age, place of residence, smoking, gestational diabetes, and pregnancy-induced
hypertension). A multivariate logistic regression model was used to investigate a relationship between
caffeine intake and other factors (calcium intake, use of dietary supplements, pre-pregnancy body mass
index (BMI), weight gain during pregnancy, smoking, gestational diabetes, maternal age and education,
gravidity, professional activity during pregnancy, and sex of the neonate) versus neonatal weight,
length, head and chest circumference lower than the median. Only term deliveries (94 newborns) were
included into the analysis. Using the method of step elimination with 0.1 level for staying in the model,
statistically significant factors were selected at a significance level of 5%. The relation of statistically
significant factors was expressed by the odds ratio (OR) and the 95% confidence interval (95% CI).
Table 1. Maternal and neonatal characteristics.
Maternal Characteristics
Number of Women 100
















premature birth (%) 6
pre-pregnancy BMI (mean) ± SD 22.7 ± 3.8
gestational diabetes (%) 11
pregnancy-induced hypertension (%) 9
smoking during pregnancy (%) 15
professionally active during pregnancy (%) 58
daily calcium consumption—from milk and dairy products
(mg)median (min–max) 598 (69–1872)
supplementation with vitamin/mineral preparations (%) 89
Neonatal Characteristics
number of newborns 94
gestational age (weeks) mean ± SD 39.4 ± 1.0
neonatal weight (g) median (min–max) 3530 (2390–4650)
LBW neonates (<2500 g), n (%) 1 (1.1)
macrosomia (>4000 g), n (%) 19 (20.2)
neonatal length (cm) median (min–max) 56 (50–60)
neonatal head circumference (cm) median (min–max) 35 (32.5–38.0)
neonatal chest circumference (cm) median (min–max) 34 (29–38)
Apgar score (points) mean ± SD 9.9 ± 0.1
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Table 2. Caffeine content in coffee and tea brews used to evaluate caffeine intake by the pregnant women.
Product Portion Size (mL) Caffeine Content (mg)






























Mean caffeine intake among the pregnant women from our study was 68 ± 51 mg/day. A vast
majority of the women (79%) consumed <100 mg of caffeine, while the remaining 19% and 2% of the
respondents consumed 100–200 mg and >200 mg/day, respectively. None of the subjects exceeded the
dose of 300 mg of caffeine/day.
Tea was the source of 63% (43 mg) of total caffeine, and the remaining 37% came from coffee. Only
2 (2%) out of all respondents declared sporadic use of energy drinks, and for this reason these products
were not included in evaluation of total caffeine intake.
Black tea supplied 4-fold more caffeine than green tea (34 ± 33 mg and 9 ± 26 mg, respectively).
No statistically significant differences were found between caffeine intake and maternal age, education,
place of inhabitance, smoking, gestational diabetes mellitus, or pregnancy-induced hypertension.
3.2. Caffeine Exposure and Neonatal Anthropometric Parameters
Maternal caffeine intake was not linked with neonatal anthropometric parameters (weight,
length, head and chest circumference) (p > 0.05). Neonatal characteristics are presented in Table 1.
Maternal weight gain during pregnancy was the parameter that turned out to be related to neonatal
length. Pregnant women with too low weight gain are at a 3-fold higher risk for giving birth to infants
with lower than median length for term neonates as compared to women with either recommended or
excessive weight gain (Table 3).
Table 3. Analysis of the influence of maternal caffeine intake and other factors on the risk for neonatal
length below the median.
N = 94 OR (95% CI) p-Value
Caffeine intake:
>100 mg/day vs. ≤100 mg/day 2.52 (0.86; 7.40) 0.092
Calcium intake:
>611 mg/day vs. ≤611 mg/day >0.1






too low vs. recommended and excessive 3.01 (1.08; 8.3) 0.034
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Table 3. Cont.




>30 vs. ≤30 >0.1
Education:
secondary vs. higher 0.38 (0.15; 1.00) 0.051
Gravidity:
primiparas vs. multiparas >0.1
Professional activity during pregnancy >0.1
Neonatal sex >0.1
BMI: body mass index.
3.3. Coffee, Tea, and Energy Drinks Consumption
Tea and/or coffee brews were very popular in the diet of pregnant women. Only 10% of the
respondents declared complete abstinence. Coffee was consumed by 43% of the women, including 1
subject who consumed only decaffeinated coffee. Instant coffee was the most popular drink (31%),
and only 2% of the respondents consumed coffee from a coffee maker (Table 4). Daily consumption of
coffee was declared by 32% of the women, mostly 1 cup/day (26%), and only 1 subject drank 3 cups of
coffee/day. Mean coffee consumption in the entire study population was 74 ± 117 mL/day. All women
consumed light coffee brews (i.e., 1 teaspoon of coffee per cup).
Tea consumption was reported by 80% of the respondents, including 72% who consumed tea
every day, while the remaining women drank tea several times a week or less (Table 4). The amount
of tea consumption varied between 2 cups (26%), 1 cup (21%), 3 cups (15%), or 4–8 cups (10%) a day.
Mean tea consumption in the entire study population was 346 ± 379 mL/day. The vast majority of
the women consumed only black tea (60%), mainly tea bags (90% of tea drinkers), whereas only 10%
used tea leaves. As for brew strength, 84% of the tea bag drinkers declared that they preferred light- or
medium-intensity brews (up to 1 min), and only 16% brewed the tea longer.
Table 4. Coffee and tea consumption among pregnant women.











3–4 times a week 4
1–2 times a week 8
2–3 times a month 1
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black and green 14
Consumption Frequency
every day 72
3–4 times a week 5
1–2 times a week 2
2–3 times a month 1
4. Discussion
In our study, we detected a small caffeine intake among the investigated population, significantly
below 100 mg/day. Bearing in mind that, according to the literature, coffee and tea are the main sources
of that component in the diet of pregnant women (80–90%) [1,22], it seems possible to conclude that
the amount consumed is at a safe level, even taking into account consumption of other products with
caffeine content.
To the best of our knowledge, only two studies on caffeine intake during pregnancy have been
conducted in Poland so far, and both report optimistic findings. Mean daily caffeine intake was
91 mg/day according to the first study (conducted between 2005–2007) and 50 mg/day according
to the second study (conducted between 2014–2015) [28,29]. The current result (68 mg from coffee,
tea, and energy drinks) confirmed that consumption of caffeinated products by women in Poland
during pregnancy is reasonable and non-excessive. Also, other data revealed that 73% of the Polish
pregnant women declared an awareness of the potentially negative impact of coffee on the developing
fetus [30]. Until recently, the amount of over 300 mg of caffeine/day was considered excessive and such
consumption was reported for 1.6% of the investigated women [28]. Lately however, the so-called
‘safe’ dose of caffeine was significantly lowered (to 200 mg), but still only 2% of our study population
and 1.4% of the subjects in the study of Błaszczyk-Bębenek et al. [29] exceeded the recommended dose.
Mean caffeine intake among pregnant women in the US, Great Britain, and Sweden has been estimated
at 58–125 mg, 159 mg, and 215 mg per day, respectively [9,31,32]. Very high (mean 258 mg/day) caffeine
intake was observed in Japan, where over 67% of pregnant women consume over 200 mg/day [3].
In contrast, a surprisingly low (median 44–62 mg/day) caffeine intake among pregnant women was
reported in Norway [1], whose inhabitants are well-known coffee lovers [2].
A relatively low caffeine intake in our study may be the result of a decision to reduce coffee
consumption during pregnancy. In studies by Jarosz et al. [28], and by Wyka et al. [30], 26% and 19% of
the study population, respectively, chose not to drink coffee during pregnancy. Similar findings have
been reported by authors from other countries, where reduced tea and coffee consumption was the
most common modification in the diet of pregnant women [33]. In our study, 43% of the respondents
declared coffee consumption, which is consistent with the national data (39–52% of women) [28,30,34].
Espresso, which contains more caffeine than other coffee brews [1,35], has seldom been consumed by
pregnant women in Poland, which might also account for the low caffeine intake we detected. Tea,
whose consumption was declared by 80% of the respondents in this study and 93% in another study,
is decidedly more popular and continues to be the main source of caffeine in the diet of pregnant
women from Poland [28]. In Poland, black tea is the most popular drink and the main source of daily
caffeine intake (44–59% according to the earlier studies [28,29] and 50% according to the current study),
and only a small amount is derived from green tea (5–16% according to the earlier studies [28,29]
and 13% according to the current study). Tea is also the main source of caffeine in Great Britain [9]
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and Japan [22], although in Japan, most caffeine in the diet of pregnant women comes from green tea
(75%), and only some from black tea (4%). In contrast, coffee remains the main caffeine source in the
Scandinavian countries, the US, and Canada [1,3,28,36]. In our study, we found that pregnant women
avoid energy drinks, which is consistent with reports from Western European countries, where only
1–2% of total caffeine content in the diet of pregnant women is supplied by energy drinks [9,12,28].
The results of the Care Study Group from Great Britain were the reason why EFSA lowered
the safety threshold (to 200 mg) for daily intake of caffeine during pregnancy. The study revealed
that caffeine intake over 200 mg/day results in a 60–70 g decrease in neonatal weight [9]. In our
study, we found no relationship between neonatal anthropometric parameters and caffeine intake.
Importantly, mean caffeine intake was significantly below the permissible dose (i.e., 200 mg/day).
No relationship between neonatal anthropomorphic parameters and caffeine intake in Poland was
found in our previous study as well, where mean caffeine intake was <100 mg, which is similar to
the findings in the present study [28]. According to the latest reports in the literature, in particular a
study from Norway, daily caffeine intake of <200 mg increases the risk for small-for-gestational-age
infant by 16% [37]. In a study from Ireland, a daily increase in caffeine intake by 100 mg resulted in a
decrease in neonatal weight (by 72 g), length (by 0.3 cm), and head circumference (by 0.12 cm) [38].
On the other hand, a study from Brazil revealed no relationship between high caffeine intake (≥300 mg)
and low-birth-weight (LBW) neonates [39]. In light of the recent meta-analyses, Rhee et al. in their
meta-analysis of eight cohort and four case-control studies concluded that high maternal intake of
caffeine increases the risk for LBW neonate by 38% [7], while Greenwood et al., in their meta-analysis
of 26 cohort and 27 case-control studies, found that increased caffeine intake (by 100 mg) results in
higher risk (by 7%) for LBW neonate [15]. Some experts are of the opinion that neonates born to
non-smoking mothers who consume ≥300 mg of caffeine/day, but only those who metabolize caffeine
fast (i.e., AA genotype), are at higher risk for delivering infants with decreased birth size [40].
Several limitations of the present study might have biased the final results, chief among them
a small sample size, which was the result of the number of deliveries at the clinic, but also the fact
that it was a pilot study. It was a preliminary study to recognize the attitudes of pregnant women
to coffee consumption after the introduction of a coffee cup into the graphic representation of the
nutrition guidelines (food pyramid) in Poland. Also, we collected data on maternal caffeine intake on
the day of the delivery, so the study was retrospective in nature. Nonetheless, drinking coffee and
tea is a common component of many individuals’ eating habits and it should not be problematic to
recall the frequency of their consumption, even from the time perspective. Also, caffeine intake might
have been different throughout the pregnancy, although various studies reported lack of significant
differences between caffeine intake and pregnancy trimesters [9,39]. Furthermore, the questionnaire
did not include information about other sources of caffeine, such as soft drinks, but many authors
have previously reported that coffee and tea are the sources of over 80% of the caffeine in the diets of
pregnant women [1,22,38]. Our data included information on types of coffee (e.g., instant, brewed), as
well as the intensity of tea and coffee brews, which to a large extent is the decisive factor for determining
caffeine content in a drink and allows for a precise evaluation of the intake.
5. Conclusions
Caffeine intake among our study population was relatively low, which resulted from low coffee
consumption. Tea, due to its higher popularity during pregnancy, constituted the main source of caffeine.
No relationship was found between such caffeine intake and neonatal anthropometric parameters.
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Abstract: Caffeine is commonly taken via the daily dietary consumption of caffeine-containing foods.
The absorbed caffeine is metabolized to yield various metabolites by drug-metabolizing enzymes,
and measuring the levels of each caffeine metabolite can provide useful information for evaluating
the phenotypes of those enzymes. In this study, the urinary concentrations of caffeine and its 13
metabolites were determined, and the phenotypes of drug metabolic enzymes were investigated
based on the caffeine metabolite ratios. Human urine samples were pretreated using solid phase
extraction, and caffeine and its metabolites were analyzed using liquid chromatography-tandem mass
spectrometry. Based on the urinary caffeine metabolite concentrations, the caffeine metabolite ratios
were calculated for six human subjects at specified time points after caffeine intake. Variations in
urinary metabolite levels among individuals and time points were reported. In addition, the resultant
enzyme activities showed different patterns, depending on the metabolite ratio equations applied.
However, some data presented a constant metabolite ratio range, irrespective of time points, even
at pre-dose. This suggests the possibility of urinary caffeine metabolite analysis for routine clinical
examination. These findings show that urinary caffeine and the metabolite analysis would be useful
in evaluating metabolic phenotypes for personalized medicine.
Keywords: caffeine; metabolites; phenotyping; CYP450; NAT; xanthine oxidase
1. Introduction
Caffeine, an alkaloid of the methylxanthine class, is the world’s most widely consumed
psychoactive substance. As a naturally occurring substance, caffeine is found in the leaves, fruits, or
seeds of more than 60 plant species. Caffeine is popularly and extensively taken via the daily dietary
consumption of caffeine-containing beverages or foods [1,2].
In the liver, caffeine is subjected to a series of metabolic reactions to yield a mixture of
N-methylated xanthines, uric acids, and an acetylated uracil, as its metabolites [3]. There are
various metabolic enzymes involved in each caffeine metabolic pathway (Figure 1). These enzymes
include N-acetyltransferase 2 (NAT2), xanthine oxidase (XO), and cytochrome P450—particularly 1A2
(CYP1A2) and 2A6 (CYP2A6)—which are of prime interest and must be phenotypically evaluated
because of their roles in metabolizing various xenobiotics [4–6]. These four enzymes involved
in caffeine metabolism display genetic polymorphism, and their metabolizing activities can vary
in individuals [4–6]. Accordingly, inter-individual variability can be observed in caffeine and its
metabolite levels, or their ratios in biological fluids or tissues. In this context, measuring the levels of
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caffeine and each caffeine metabolite can provide useful information for evaluating the phenotypes
of drug-metabolizing enzymes. Furthermore, caffeine is popularly, and even routinely, consumed
worldwide as various types of foods, such that caffeine or its metabolites are likely to be detected
in urine. Due to these aspects, the measurement of urinary caffeine metabolite levels can be an
advantageous marker for the phenotyping of individual drug-metabolizing activities.
Figure 1. The metabolic pathway of caffeine.
Several analytical methods have been reported for measuring caffeine and its metabolites
in urine using high-performance liquid chromatography (HPLC) or high-performance liquid
chromatography-tandem mass spectrometry (LC-MS/MS) [7–16]. Based on such analytical methods, the
phenotyping of CYP1A2, CYP2A6, NAT2, or XO enzyme activity has been investigated by measuring
urinary caffeine and its metabolites in subjects receiving a regulated dietary caffeine intake and in
uncontrolled subjects [7,9,10,12,13,17–20]. However, each study evaluated the enzyme phenotypes
based on different metabolite ratio equations for a limited population, and information on the feasibility
of those methods is still insufficient for general, practical application.
In this study, the urinary concentrations of caffeine and its metabolites were determined using
LC-MS/MS analysis. The resulting concentration data was applied to various caffeine metabolite ratio
equations to determine the phenotypes of each drug metabolic enzyme. The feasibility of phenotyping
the drug-metabolizing enzyme based on urinary caffeine metabolite ratios was examined.
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2. Materials and Methods
2.1. Chemicals and Reagents
Chemicals including, 1-methylxanthine (1X), 3-methylxanthine (3X), 7-methylxanthine
(7X), 1,3-dimethylxanthine (theophylline, 13X), 1,7-dimethylxanthine (paraxanthine, 17X),
3,7-dimethylxanthine (theobromine, 37X), 1,3,7-trimethylxanthine (caffeine, 137X), 1-methyluric
acid (1U), 1,3-dimethyluric acid (13U), 1,7-dimethyluric acid (17U), 3,7-dimethyluric acid (37U),
and 1,3,7-trimethyluric acid (137U), and acetic acid were provided by Sigma-Aldrich (St.
Louis, MO, USA). The following chemicals were procured from Santa Cruz (Dallas, TX,
USA): 5-acetylamino-6-amino-3-methyluracil (AAMU), 5-acetylamino-6-formylamino-3-methyluracil
(AFMU) and internal standards (IS) including 1-methylxanthine-2,4,5,6-13C4 (1X*), 1,3,9-15N3, and
1-methyluricacid-2,4,5,6-13C4,1,3,9-15N3 (1U*). HPLC-grade acetonitrile was purchased from J. T.
Baker (Philipsburg, NJ, USA). Water was prepared using a Milli-Q purification system (Millipore,
Bedford, MA, USA). All other chemicals used were of analytical grade and used as received. All the
standard solutions and mobile phases were passed through a 0.22-μm membrane filter before use.
2.2. Human Urine Specimens
The study protocol and consent forms were approved by the Institutional Review Board of the
Hanyang University, and all the participants provided written informed consent to participate in the
study. The eligibility criteria for the study included physically healthy ethnic Korean adult men (19
years of age or older) who signed written informed consent. Participants were excluded if they were
being treated for acute disease or other diseases or who needed treatment, or were receiving any
medication that might affect the metabolism or excretion of caffeine. Urine samples were collected
from 6 volunteers prior to the consumption of a caffeine-containing drink (120 mg of caffeine intake),
and 1 h, 2 h, 4 h, 6 h, 8 h, and 10 h after the drink. Blank urine samples were obtained from healthy
volunteers who had not consumed any methyl xanthine-containing food or beverage for the last 24
h. The urine samples were collected in clear 15-mL centrifuge tubes. All the study procedures were
conducted in compliance with the principles of Declaration of Helsinki and Korean Good Clinical
Practice guidelines (IRB HYG-16-193-2).
2.3. Urine Sample Preparation and Standard Samples
For the LC–MS/MS analysis, 100 μL of urine was added to 10 mL of 0.1% acetic acid with IS. Then,
1 mL of diluted mixture was passed through pre-activated Sep-Pak C18 cartridges (96-well type OASIS
HLB extraction cartridge, Waters). The cartridge was washed with 1 mL of 0.1% formic acid two times,
and then eluted with 1 mL of methanol. The eluate was dried under nitrogen gas. The residue was
resolved in 0.1% acetic acid/acetonitrile (90:10, 100 μL), and a 5-μL aliquot was injected into the HPLC
column for LC-MS/MS analysis. The analyte mixture was dissolved in MeOH at a concentration of 1
mg/mL and diluted to a series of working standard solutions. A 5-μL aliquot of each working standard
solution was spiked to 95 μL of human blank urine. Then, the spiked samples were pretreated as
described above. The concentrations of QC samples for each analyte are provided as supplementary
data (Table S1).
2.4. Method Validation
The developed method was validated according to the US Food and Drug Administration (FDA)
guidelines as mentioned in the “Guidance for Industry, Bioanalytical Method Validation, 2018” [21].
2.4.1. Selectivity, Linearity, and LLOQ
The selectivity of the method was assessed by comparing multiple reaction monitoring (MRM)
chromatograms between a blank sample and a standard spiked mixture. Lower limits of quantitation
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(LLOQs) for each analyte were determined considering the concentration level found in human urine
samples, and evaluated for accuracy and precision. The calibration curves were prepared using the
samples at concentration ranges depending on their LLOQ. The calibration curves were generated
by plotting the peak area ratios of the analytes/IS versus the concentrations in the standard spiked
samples. The linear correlation coefficient (r2) for all the calibration curves should be greater than 0.99.
2.4.2. Precision and Accuracy
To assess the intra-day precision and accuracy, QC samples were analyzed, in triplicate, at different
concentration levels (n = 3) on the same day. In case of inter-day assays, the precision and accuracy were
assessed by determining the QC samples over three consecutive days. The accuracy was measured as
a deviation of the calculated mean value from the nominal mean value, which should be within 15% of
the nominal value except for LLOQ, which should not exceed 20% of the nominal value. The precision
was determined at each concentration level, in terms of percent relative standard deviation (%RSD),
which should not exceed 15% of the nominal concentration, except for the LLOQ, where it should not
deviate by more than 20%.
2.4.3. Matrix Effect and Recovery
The matrix effect was evaluated by comparing the spiked QC samples at low, middle, and high
concentrations in the blank, to the same QC sample in 0.1% acetic acid. The recovery was determined
by comparing the reaction of the extracted sample, to which the analyte is added, and the biological
sample after extraction.
2.4.4. Stability
Stability was evaluated for the QC samples under various conditions such as freeze-and-thaw,
short-term, long-term, and processed sample stability. For the freeze-and-thaw stability test, three
aliquots of the QC samples were stored at −20 ◦C for 24 h and thawed at room temperature. When
completely thawed, the samples were refrozen for 24 h under the same condition, and this was repeated
three times. For short-term stability, the QC samples were maintained at room temperature for 12 h,
and then analyzed. For long-term stability, the QC samples were stored at −20 ◦C for 7 days, and then
analyzed. The post-preparative stability was evaluated by analyzing the QC samples placed in the
autosampler for 24 h at 4 ◦C.
2.5. LC-MS/MS Analysis
The LC-MS/MS system consisted of a Shiseido SP LC SP3202 binary pump HPLC system
(Tokyo, Japan) and TSQ Quantum™ Access MAX Triple Quadrupole Mass Spectrometer (Thermo
Fisher Scientific, Waltham, MA, USA), equipped with an electrospray ionization (ESI) source.
Chromatographic separation was achieved on a Kinetex C18 column (3.0× 100 mm, 2.6μm; Phenomenex,
Torrance, CA, USA) at a temperature of 40 ◦C. The HPLC mobile phases consisted of two solvents: (A)
0.1% acetic acid and (B) acetonitrile in 0.1% acetic acid. A linear gradient program was used with a
flow rate of 0.2 mL/min. The initial mobile phase was set at 15% of solvent B and gradually increased
to 90% in 3 min, kept at 90% for 1 min, and then followed by re-equilibrium for 3 min. Electrospray
ionization (ESI) was performed in both positive and negative ion mode, with nitrogen as the nebulizing
agent, spray voltage, sheath gas pressure, and aux gas pressure at optimal values of 3000, 60, and 20
(arbitrary units), respectively. The capillary temperature was 350 ◦C. Multiple reaction monitoring
(MRM) detection was employed. The precursor–product ion pairs used in MRM mode are provided as
supplementary data (Table S2).
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2.6. Metabolic Ratio Calculation
The urinary caffeine and its metabolite concentrations were measured using the LC-MS/MS
analysis. The resulting data were evaluated using the equations for the metabolic ratio calculation.
The molar urinary ratios specific for each drug-metabolizing enzyme were calculated referring to




Caffeine, 1X, 7X, 17X, 37X, 13U, 17U, 37U, 137U, AAMU, and 1X* were ionized to yield the
protonated molecular ions ([M+H]+) at m/z 195.2, 167.1, 167.0, 181.2, 181.2, 197.2, 197.1, 197.1, 211.2,
199.2, and 174.1, respectively. Additionally, 3X, 13X, 1U, AFMU, and 1U* were ionized to yield the
deprotonated molecular ions ([M−H]−) at m/z 164.9, 179.1, 181.1, 225.1, and 188.1, respectively. Ion
polarity switching was applied for the simultaneous detection of protonated and deprotonated ions.
Water and acetonitrile were used as the mobile phase solutions; to increase the response of 1U, 0.1%
acetic acid was added to both mobile phase solvents. Using the gradient elution, all the analytes were
eluted within 5 min. The representative LC-MS/MS extracted ion chromatograms are provided in the
supplementary data (Figure S1).
3.2. Method Validation
The calibration curves for each analyte were linear over each corresponding, selected concentration
range, with correlation coefficient (r2) values greater than 0.99. The linear ranges for caffeine and its
metabolites are presented in the supplementary data (Table S2). The LLOQ values for all analytes
ranged from 10 ng/mL to 166 ng/mL with an accuracy of approximately 91.4% to 114.0% and a precision
of ≤16.3%.
The intra-day precision was less than 16.4%, while the accuracy (as a percentage of relative error
values) was within the range of ±11.9% at the tested QC concentrations. The inter-day assay also
showed satisfactory accuracy and reproducibility, with a precision of less than 11.4%, and an accuracy
within the range of ±14.0% at the tested QC levels. These results are summarized in Table 1.
The matrix effect was negligible for caffeine and its metabolites, except for 1X, 137U, and AAMU,
which seemed to be affected by it. However, they showed acceptable RSD criteria (within ±15%). For
recovery evaluation, caffeine and all its metabolites were stable and well recovered (%RSD, <10.6)
from samples. The matrix effect and recovery data are provided in the supplementary data (Tables S3
and S4).
In all the tested conditions, caffeine and its metabolites were shown to be stable, with acceptable
recovery (RSD within ±15%), except for the long-term stability of AAMU and AFMU (Table S5). The
accuracy and RSD values were within ±12.4% and ±9.4% for freeze-and-thaw stability, within ±11.6%
and ±9.7% for short-term stability, within ±12.3% and ±10.8% for long-term stability, and within
±12.1% and ±8.2% for processed sample stability. Meanwhile, the long-term stability of AAMU was
323.4%, and that of AFMU was 47.2%. AFMU is known to be spontaneously converted to AAMU,
and the present results may reflect this phenomenon. According to Nyeki et al. [22], the conversion
of AFMU into AAMU is not only subjected to nonenzymatic hydrolysis in urine, but is also NAT2
phenotype-dependent. Nevertheless, it would be better to analyze urine samples immediately after
voiding to minimize errors in calculating the metabolite ratio for enzyme phenotyping.
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3.3. Enzyme Phenotyping Based on Urinary Caffeine Metabolite Ratio
The urinary caffeine metabolite levels in the six subjects are as shown in Figure 2. When the six
urine samples were analyzed, the targeted caffeine metabolites were successfully detected in most
of the samples. The urinary concentration ranges of each metabolite were tabulated in Table 2. The
measured metabolite concentrations exhibited large variations among individuals and time points.
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Figure 2. Urinary concentration levels of caffeine and its metabolites in six
subjects. (a) caffeine, (b) 1,3,7-trimethyluric acid (137U), (c) 1,3-dimethylxanthine (13X), (d)
1,7-dimethylxanthine (17X), (e) 3,7-dimethylxanthine (37X), (f) 1,7-dimethyluric acid (17U), (g)
5-acetylamino-6-formylamino-3-methyluracil (AFMU), (h) 5-acetylamino-6-amino-3-methyluracil
(AAMU), (i) 1-methyluric acid (1U), (j) 1,3-dimethyluric acid (13U), (k) 1-methylxanthine (1X), (l)
3-methylxanthine (3X), (m) 3,7-dimethyluric acid (37U), and (n) 7X.
Table 2. Urinary concentration ranges of caffeine and its metabolites.
Metabolite Concentration Range (μM) Metabolite Concentration Range (μM)
137U 13.9–426.3 1U 104.5–5577.5
13X 0–145.9 13U 104.6–1957.9
17X 191.8–1941.3 1X 126.3–4273.4
37X 54.9–569.3 3X 65.2–1362.3
17U 131.6–2127.2 37U 0–357.2
AFMU 76.8–1514.9 7X 154.3–3145.5
AAMU 26.1–735.0 137X (caffeine) 8.7–271.7
Subsequently, enzyme-specific metabolite ratios were calculated based on the urinary concentration
data. Referring to the extant literature, the urinary metabolite concentrations were applied to various
equations to yield enzyme-specific metabolite ratios (Table 3). Figures 3–6 display the plots for each
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enzyme activity in individuals, which is expressed as the metabolite ratio. The metabolite ratio
patterns varied between individuals and time points, depending on the equations applied, even for
identical enzymes.
Table 3. Equations of caffeine metabolic ratios used for enzyme-specific activities.
Enzyme Equation Reference
CYP1A2
(a) (AFMU + 1X + 1U + 17X + 17U)/137X [4,17,18]
(b) (17X + 17U)/137X [4]
(c) 17X/137X [4]
(d) (AAMU + 1X + 1U)/17U [4]
(e) (AFMU + 1X + 1U)/17U [4]
(f) (AFMU + 1X + 1U)/17X [4]
(g) (AAMU + AFMU + 1X + 1U)/17U [4]
CYP2A6
(a) 17U/(AFMU + 1U + 1X + 17X + 17U) [4]
(b) 17X/17U [4]
NAT2
(a) (AAMU + AFMU)/(AAMU + AFMU + 1X + 1U) [4,10,20]
(b) AAMU/(AAMU + 1X + 1U) [4]
(c) AFMU/(AFMU + 1X + 1U) [4]
(d) AFMU/1X [4]
XO
(a) 1U/1X + 1U [4,20]
(b) 1U/1X [4]
 
Figure 3. Plots of metabolite ratio for CYP1A2. The metabolic ratio equations used are as follows: (a)
(AFMU + 1X + 1U + 17X + 17U)/137X, (b) (17X + 17U)/137X, (c) 17X/137X, (d) (AAMU + 1X + 1U)/17U,
(e) (AFMU + 1X + 1U)/17U, (f) (AFMU+1X+1U)/17X, (g) (AAMU+AFMU+1X+1U)/17U.
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Figure 4. Plots of metabolite ratio for CYP2A6. The metabolic ratio equations used are as follows: (a)
17U/(AFMU + 1U + 1X + 17X + 17U), (b) 17X/17U.
Figure 5. Plots of metabolite ratio for NAT2. The metabolic ratio equations used are as follows: (a)
(AAMU+AFMU)/(AAMU+AFMU+1X+1U), (b) AAMU/(AAMU+1X+1U), (c) AFMU/(AFMU+1X+1U),
(d) AFMU/1X.
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Figure 6. Plots of metabolite ratio for XO. The metabolic ratio equations used are as follows: (a) 1U/1X
+ 1U, (b) 1U/1X.
To investigate the CYP1A2 phenotypes, seven equations were tested. The resulting metabolic
ratio plots are shown in Figure 3. Figure 3a–c exhibited a considerable difference between pre-dose (0
h) and post-dose data. The metabolic ratio patterns of Subject #6 were generally different from those of
other subjects.
To investigate the CYP2A6 phenotypes, two equations were tested (Figure 4). Figure 4a generally
showed constant metabolite ratio patterns within individuals (except for Subject #5) over all of the time
points. However, Figure 4b showed a larger variation according to time. The order of the metabolite
ratio values for all six subjects (i.e., the relative metabolic activity) was not consistent between two plots.
NAT2 activity was tested with four different equations. Three equations (Figure 5a–c) generated
similar metabolite ratio patterns, whereas the other (Figure 5d) showed a large variation between
individuals and time points.
The XO activity was evaluated using two equations. The metabolite ratio plots are shown in
Figure 6. The resultant patterns were generally similar between the two plots, but the variation was
larger in plot (b).
4. Discussion
This study measured the urinary concentrations of caffeine and its 13 metabolites for 8 h, including
a pre-dose time point, using LC-MS/MS. The metabolic ratios for phenotyping the drug metabolizing
enzymes were calculated based on the various equations previously reported. Subsequently, the
resulting metabolic ratios or patterns were compared, and their validity and feasibility were investigated.
The resulting urinary caffeine concentration data showed a relatively obvious increase and
decrease pattern across time, which indicated the absorption and elimination of caffeine after oral
intake. Meanwhile, the changes in caffeine metabolite concentration levels, according to time points,
were not as evident as those of caffeine. However, caffeine metabolites also showed a weak pattern of
slow increase after caffeine intake, on excluding the data at pre-dose. Most metabolites showed the
highest concentrations at pre-dose, which was presumably due to the urine concentration. Thus, the
urine was diluted in post-dose samples, as the urine was frequently collected (i.e., at 2-h intervals) after
caffeine intake; meanwhile, at pre-dose, the caffeine metabolites, which resulted from usual dietary
caffeine intake, could be detected at higher concentrations in relatively concentrated urine.
The most diverse equations have been suggested to determine the enzyme activity of CYP1A2 in
previous research. This study applied seven equations to yield the metabolite ratio. Among them,
three equations (Figure 3a–c) showed a significant difference between pre-dose (0 h) and post-dose
data, and the within-individual variation was large according to the time points. Meanwhile, the other
four plots showed a more constant ratio pattern within individuals. The caffeine (137X) concentration
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was included in the former three equations (Table 3: Equations CYP1A2-(a), (b), and (c)). Accordingly,
the activity showed a large difference in the results between pre-dose and post-dose. However, the
other equations showed relatively constant results over time, even between pre-dose and post-dose
measurements, as those equations did not involve caffeine concentration. Generally, the CYP1A2
activity of Subject #6 appeared to be higher than that of the other subjects, but plot F (Figure 2f) did not
exhibit this tendency. These findings suggest that Equations CYP1A2-(d), (e), and (g) (Table 3) may be
more appropriate for determining the CYP1A2 phenotype.
Acetylation is a primary route for the biotransformation of many hydrazine drugs, which is
mediated by NAT [4]. The polymorphism of NAT (in particular, NAT2) is responsible for the
inter-individual variability in the acetylation of drugs. Thus, the population can be categorized into
rapid acetylators and slow acetylators, according to their NAT2 phenotypes [6]. Such acetylation
polymorphism is reported to vary among ethnic groups [6]. It is known that rapid acetylators are
dominant in the Korean population [23]. In the present study, when the metabolite ratios were
calculated by the equation (AFMU +AAMU)/(AFMU +AAMU + 1X + 1U) (corresponding to Figure 4a)
and evaluated by the criteria reported by Jetter et al. [10,20], the six subjects tested in this study were
determined to be rapid acetylators. This seems to be reasonable based on the generally recognized facts
on acetylation polymorphism in Koreans. However, when evaluated by the criteria based on other
equations, such as AFMU/(AFMU + 1U + 1X) or AAMU/(AAMU + 1U + 1X) [7,13,24], these six subjects
were shown to be slow acetylators. Therefore, to determine the phenotypes exactly, comprehensive
genotyping data is necessary.
Meanwhile, the time point for sample collection may affect the metabolic ratio results, as the
rate of metabolic reaction may be different depending on each metabolic pathway. Jetter et al. (2009)
reported that the timing of urine collection can affect XO phenotyping results [20]. However, this
study’s data, generated from the same equation [1U/(1U + 1X)] (Figure 5a), did not show a significant
variation according to the urine collection time, except in Subject #5. This suggests the possibility that
spot urine samples, under normal dietary conditions, can be used for XO phenotyping.
Recently, research on polymorphism and personalized medicine has been extensive. Genotyping
and phenotyping for drug metabolizing enzymes are vital strategies for characterizing the
polymorphism of drug-metabolizing enzymes in individuals for personalized medicine. However,
evaluating the phenotype is more critical than evaluating the genotype in some enzymes. For example,
XO is a form of xanthine oxidoreductase, which is a type of enzyme that generates reactive oxygen
species [25]. These enzymes catalyze the oxidation of hypoxanthine to xanthine and can further
catalyze the oxidation of xanthine to uric acid. Xanthine oxidase plays a crucial role in many drug
metabolic processes, such as thiopurine drugs, containing 6-mercaptopurine, allopurinol, and uric acid,
etc. [26–29]. Xanthine oxidase is important in gout patients, because XO produces uric acid, which is a
crucial factor in gout. In addition, xanthine oxidase is involved in the catabolism of xenobiotics; for
example, it converts a prodrug (mercaptopurine) into the active form 6-thioinosine-5′triphosphate [30].
About 20 genetic variants are reported, and each XO variant may differ in its enzymatic activity [20];
however, decreased enzyme activity is shown only in 4% or fewer volunteers [31]. Thus, it would be
difficult to explain the cause of the variations in XO activity on the basis of genetic polymorphisms
alone [20]. Therefore, it is meaningful to establish an optimized method for assessing the activity of
the drug-metabolizing enzymes, including XO, for phenotyping.
Meanwhile, it has been recognized that differences in the activity of enzymes involved in
nicotine metabolism are partly responsible for inter-individual variation in lung cancer risk among
smokers [32–35]. CYP2A6 is a principal enzyme in nicotine metabolism, and CYP2A6-mediated
C-oxidase activity has been reported to correlate with exposure to carcinogens by smoking [32–35].
Many reports have demonstrated that CYP2A6 variants that exert reduced enzymatic activity are
associated with lower lung cancer risk [32–35]. However, these genetic polymorphisms are reported
to account for only a portion of the variation in CYP2A6 activity [4]. Therefore, the phenotyping
of CYP2A6 activity could be more appropriate for estimating lung cancer risk related to nicotine
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metabolism. In this context, the urinary caffeine metabolite ratio is a useful biomarker for predicting
the risk of lung cancer.
The limitations of this study are its small sample size, the lack of genotyping data, and that this
data was obtained from a single set of experiments. Nevertheless, this study enables the evaluation
of phenotyping results by demonstrating the caffeine metabolite ratio plots generated from different
phenotyping equations. In addition, the data obtained at different time points, including the pre-dose
and post-dose suggests the possibility that the enzyme phenotyping for CYP1A2, CYP2A6, NAT2, and
XO can be conducted as a routine urine test, without the administration of drugs.
5. Conclusions
Caffeine is popularly present in a wide variety of foods and beverages, and is extensively consumed
via the daily diet. By measuring the exposure to caffeine in biological samples, such as the urine, the
extent of caffeine consumption could be directly indicated. However, caffeine can be also used as
a biomarker to indicate the activities of drug-metabolizing enzymes. This study demonstrated the
possibility that enzyme phenotyping based on urinary caffeine metabolite ratios can be routinely used
under general dietary conditions. This suggests a possibility for urinary caffeine metabolite analysis
as a routine clinical examination. Urinary caffeine and its metabolite analysis would be useful in
evaluating drug metabolic phenotypes for personalized medicine.
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Abstract: The consumption of high levels of dietary caffeine has increased in children and adolescents.
Human and animal studies have shown that chronic intake of high doses of caffeine affects serum
glucocorticoid levels. Given that glucocorticoids play a role in peripubertal organ growth and
development, chronic high doses of caffeine during puberty might impair maturation of the adrenal
glands. To evaluate any effects of caffeine exposure on growing adrenal glands, 22-day-old male
(n = 30) and female Sprague Dawley rats (n = 30) were divided into three groups (n= 10/group); group
1 received tap water (control) and groups 2 and 3 received water containing 120 and 180 mg/kg/day
caffeine, respectively, via gavage for 4 weeks. At the end of the experiment, adrenal glands were
weighed and processed for histological analysis. Relative adrenal weights increased in both groups
of caffeine-fed males and females, whereas absolute weights were decreased in the females. In the
female caffeine-fed groups the adrenal cortical areas resembled irregularly arranged cords and the
medullary area was significantly increased, whereas no such effects were seen in the male rats.
Our results indicate that the harmful effects of caffeine on the adrenal glands of immature rats
differ between females and males. Although female rats seemed to be more susceptible to damage
based on the changes in the microarchitecture of the adrenal glands, caffeine affected corticosterone
production in both female and male rats. In addition, increased basal adrenocorticotropic hormone
levels in caffeine-fed groups may reflect decreased cortical function. Therefore, caffeine may induce
an endocrine imbalance that disturbs the establishment of the hypothalamo–pituitary adrenal axis
during puberty, thereby leading to abnormal stress responses.
Keywords: adrenal gland; caffeine; corticosterone; puberty; rat; sex-difference
1. Introduction
Energy drinks have become a popular source of caffeine, and most of them contain between three
and five times the amount of caffeine found in other soft drinks [1]. Caffeine intake has been increasing
rapidly in children and adolescents due to regular consumption of energy drinks [2,3], but the majority
of studies on caffeine effects have been conducted in adults.
It is known that chronic stress alters the thickness of the cortical and medullary areas and
the secretory response to adrenocorticotropic hormone (ACTH) in rats [4]. In addition, a number
of xenobiotics produce hypertrophic or atrophic changes in the cortex or medulla [5]. Moreover,
caffeine has also been viewed as causing stress [6,7]. This suggests that it could induce morphological
changes in the adrenal glands. Clinical and experimental studies suggest that caffeine affects the
function and morphology of the adrenal glands. For instance, prenatal exposure of rats to caffeine
inhibits glucocorticoid production and reduces the size of the adrenal cortical zone in male offspring;
it also leads to a disorganized arrangement of cells and cellular swelling [8,9]. In contrast, in adult
humans and animals, high doses of caffeine elevate glucocorticoid levels in a stress-like pattern of
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endocrine responses [6,7]. Most studies have focused on prenatal exposure, because the adrenal
gland plays a pivotal role in the regulation of intrauterine homeostasis and fetal development [10].
Since children have immature adrenal glands with cortical and medullary areas of significantly
increased thickness [11,12], their responses to stressors may differ from those at other stages of life.
However, it is not known whether caffeine consumption affects the morphometric characteristics of the
adrenal glands during puberty.
Data on the effects of caffeine on the adrenal gland during puberty are sparse and conflicting [6,13].
Because puberty is a critical period for the completion of adrenal zonation and the establishment of
pituitary responsiveness to corticotrophin-releasing hormone [11,12], its vulnerability to insults seems
to be greater than that of adults. In addition, corticosterone release in response to stress is more delayed
in immature animals than in adults, but more prolonged [14]. Therefore, the responses of children and
adolescents to caffeine exposure might differ from those of adults. Although glucocorticoid secretion
under stress is a beneficial response, constant prolonged secretion due to chronic stressful episodes may
lead to dysregulation of the hypothalamic–pituitary–adrenal axis and cause pathologic conditions [15].
There is much concern about the impact on human health of environmental chemicals that are
able to interfere with the endocrine system, particularly those that affect steroidogenesis. Previously,
we showed that caffeine acts as an endocrine disruptor of the reproductive system in both immature
male and female rats owing to its effects on sex hormone levels [16,17]. In addition, some of the effects
of caffeine on gonadal sex steroid production in immature rats are sex specific [16,17]. In addition,
sex differences in susceptibility to caffeine during both gestation and lactation have been reported
in the offspring of rats [18]. Therefore, the aim of the present study was to investigate the effects of
high doses of caffeine exposure during puberty on the growth and secretory activity of the adrenal
cortex, and to identify sex-specific differences in susceptibility between immature male and female rats.
After exposing the rats to caffeine, their adrenal glands were weighed, and histological analyses were
performed. In addition, serum corticosterone and ACTH levels were analyzed to identify any effects of
caffeine on adrenal cortical hormone production.
2. Materials and Methods
2.1. Animal
Sixty immature male and female Sprague Dawley rats were obtained at 17 days of age along with
their mothers from Samtako Biokorea (Kyunggi, South Korea) and were allowed to acclimate under
controlled humidity (40–50%), temperature (22–24 ◦C), and light conditions (12 h light-dark cycle).
Animal care was consistent with institutional guidelines, and the Hanyang University Animal Care
and Use Committee approved all procedures involving animals (HY-IACUC-2013-0110A). All animals
were housed individually the day after weaning at 21 days of age and were fed standard rat chow ad
libitum. The experiment was started when the rats were 22 days old, as postnatal days (PD) 22–25 are
considered the beginning of sexual maturation in rats [19].
2.2. Experimental Design
Ten animals were assigned to each of three groups based on their mean body weights to obtain
an even distribution. Caffeine (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in distilled water
(10 mL/kg) at concentrations calculated to deliver 120 and 180 mg/kg body weight/day (these caffeine
groups are designated CF1 and CF2, respectively) and administered by gavage to ensure complete
consumption of the established daily dose in the morning (9 to 11 a.m.). The control group (CT)
received distilled water daily for 4 weeks. The choice of dose levels was based on the literature, coupled
with range finding studies to avoid sub-lethal effects at the highest dose [10,16].
Animals were examined for any treatment-related clinical signs and weighed daily. Body weight
was measured to the nearest 0.1 g with an electronic scale (Dretec Corp., Seoul, South Korea) and
recorded from the day before the start of feeding of caffeine for the four weeks of treatment. All the
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animals were killed 24 h after their last treatment, using established protocols and ethical procedures.
Terminal blood samples were collected by heart puncture, and sera were stored at −70 ◦C.
2.3. Weighing the Adrenal Glands
The adrenals were dissected and cleaned of fat and connective tissue. They were then weighed to
the nearest 0.001 g with an electronic scale (Adventurer™ electronic balance, AR1530, OHAUS Corp.,
Parsippany, NJ, USA) and their gross morphology was evaluated. Then, both adrenals were fixed in
10% buffered formalin (pH 7) for histological analysis.
2.4. Histological Analysis of the Adrenal Glands
Immediately after removal, both adrenals from each animal were processed for paraffin embedding
and sectioning. Serial sections of 5 μm thickness were cut from the mid-portion of the adrenals
and stained with hematoxylin and eosin. All histomorphometric evaluations were performed
by the same trained and blinded examiner using an image analysis system (Leica LAS software,
Heidelberg, Germany) coupled to a light microscope (DM4000B, Leica, Heidelberg, Germany) with
final magnifications of 100× or 200×. Ten serial sections were traced for each adrenal gland, and the
areas of the cortex and medulla in the same sections were measured and mean values calculated.
In addition, four serial sections per animal were traced for each adrenal, and numbers of cortical cells,
foamy cells, dilated sinusoids, and cell cords of zona fasciculata were counted within the same defined
region (0.307277 mm2) at 200-fold magnification. For convenience, we considered sinusoids as dilated
when their widths were wider than those of cell cords, and the cell cord was defined as at least six
cells being regularly aligned and spanning the longitudinal diameter of the zone. The mean value of
5 measurements per section was calculated for each adrenal and combined to obtain a mean value per
animal. And then the mean value was calculated for each group.
2.5. Hormone Measurement
Corticosterone and ACTH levels were analyzed in serum samples using commercially available
enzyme-linked immunosorbent assay (ELISA) kits (for corticosterone, KGE009, R&D Systems, Inc.,
Minneapolis, MN, USA) (for ACTH, CSB-E06875r, Cusabio Biotech Co., Ltd., Wuhan, China). The intra-
and inter-assay coefficients of variance for corticosterone and ACTH were less than 15%, and the
limit of detection was 0.1 ng/mL for corticosterone and 1.25 pg/mL for ACTH under the conditions of
our test. Absorbance was read at 450 nm within 15 min against a blanking well in an ELISA Reader
(Bio-Rad, Hercules, CA, USA). All samples were run in duplicate.
2.6. Statistical Analysis
Data for each group are expressed as means with standard deviations (SD). All data were analyzed
using SPSS version 10.0 for Windows (SPSS Inc., Chicago, IL, USA). The distributions of body weight,
adrenal weight and area, hormone levels, and histological data were analyzed for normality using the
Shapiro–Wilk test. Then one-way ANOVA (analysis of variance) or the Kruskal–Wallis test was used
to compare the control and caffeine groups in both male and female rats. Adrenal weights and cortical
or medullary areas were compared in male and female rats by the Mann–Whitney U-test or unpaired
t-tests. In all cases, significant differences were followed by post-hoc analysis (Tukey or Dunnett’s test).
Significance was accepted at p < 0.05.
3. Results
3.1. Body Weight Change
The body weights of the rats were checked at the beginning of the experiment, and no difference
between the groups was observed (CT, 54.86 g; CF1, 54.8 g; CF2, 53.44 g in female rats) (CT, 53.05 g; CF1,
52.7 g; CF2, 52.64 g in male rats). Throughout the experimental period, there were no treatment-related
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undue clinical toxicity indicators such as ungroomed appearance, decreased fecal output, altered fecal
consistency, or excess salivation. The data are summarized in Figure 1. The body weights of all animals
increased continuously during the experiment. After 4 weeks, the body weights of the female and
male rats had increased by approximately 3.7- and 4.6-fold, respectively, whereas in the caffeine-fed
female and male rats, body weights were 0.8-fold of the control. One-way ANOVA revealed that both
caffeine doses reduced body-weight increase in female and male rats, starting from about the first week
of exposure (females, F = 15.1, 24.5, 23.9, and 16.8 for 1st, 2nd, 3rd, and 4th week, p < 0.0001) (post hoc
Tukey analysis, p < 0.0001 vs. CT in females) (males, F = 32.7, 48.4, 65.1, and 67.9, for 1st, 2nd, 3rd, and
4th week, p < 0.0001) (post hoc Tukey analysis, p < 0.0001 vs. CT in males). However, no differential
effect of the different caffeine doses was detected.
Figure 1. Effects of exposure to caffeine on body weight in immature female and male rats. Average
body weights in (A) the female groups and (B) the male groups in each week of the four-week study
period. Both caffeine doses reduced the body-weight changes of the female and male rats, starting from
about the first week of exposure (p < 0.05 vs. CT in females, p < 0.001 vs. CT in males). However, no
differential effect of the different caffeine doses was detected. Values are means ± S.D. (n = 10/group).
Filled circles, CT (control); open circles, CF1, 120 mg caffeine; open squares, CF2 180 mg caffeine.
3.2. Adrenal Gland Weights
The weights of the adrenals of the control rats after four weeks are summarized in Figure 2.
Absolute adrenal weight was analyzed with the Kruskall–Wallis test and one-way ANOVA in female
and male rats, respectively, and there were no differences between the control and caffeine-fed groups
(Figure 2A). Adrenal gland weight relative to body weight was analyzed by one-way ANOVA followed
by the Tukey test. Relative weight increased in a dose-related manner in the caffeine-fed male rats
(F = 33.4, p < 0.0001) (p < 0.0001 vs. CT; 1.3- and 1.4-fold of the controls in the CF1 and CF2, respectively)
(Figure 2B). Relative weight also slightly increased in the caffeine-fed female rats (approximately
1.1- and 1.2-fold of the controls in the CF1 and CF2, respectively), but significance was not attained
(Figure 2B). These results show that the reductions in absolute adrenal weight due to caffeine exposure
were not proportional to body weight in the female rats. On the other hand, male rats had significantly
increased adrenal weight relative to their body weights by caffeine exposure, although absolute weights
were not different between groups. Similar data were obtained from an analysis of individual adrenal
glands. The unpaired t-test was used to compare female and male rats. Both absolute and relative
weights were significantly greater in female rats than in male rats (absolute weights: females- 29.1 ± 1.2,
26.2 ± 1.0, 25.9 ± 4.3 mg; males- 22.5 ± 1.9, 22.5 ± 1.8, 23.9 ± 2.6 mg in CT, CF1, CF2, respectively)
(relative weight: females- 14.3 ± 1.1, 16.1 ± 1.4, 16.7 ± 3.0 mg/100g body weight; males- 9.3 ± 0.8,
12.0 ± 1.1, 13.2 ± 1.5 mg/100 g body weight in CT, CF1, CF2, respectively).
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Figure 2. The effect of caffeine on the weights of the adrenal glands in the control and caffeine-fed
groups at the end of the experiment. (A) Absolute adrenal weights (mg) and (B) adrenal weights
relative to body weight (mg/100 g body weight). In the female rats, absolute adrenal weight was
significantly reduced in CF1 compared to the control, whereas there was no difference between the
control and caffeine-fed groups in the male rats. Relative adrenal weight increased in a dose-related
manner in the caffeine-fed male rats. Values are expressed as means ± S.D. CT, control; CF1, 120 mg
caffeine; CF2, 180 mg caffeine. * p < 0.05 vs. CT, ** p < 0.01 vs. CT.
3.3. Histological Findings
Because caffeine exposure induced changes in the relative weights of adrenal glands, histological
analyses were performed to define whether the weight changes were accompanied by histological
changes. Adrenal cortical and medullary areas were measured from the maximum cross-sectional
area of each animal, and cortex ratios were calculated as the ratios of the cortical area to total area.
Difference between the CT and caffeine-fed groups were analyzed by one-way ANOVA, and between
male and female rats by unpaired t-tests. In the caffeine-fed females, both cortical and medullary areas
increased relative to the controls, but the latter increased more than the former; as a consequence, there
was a significant reduction in the cortical area ratio (post hoc Dunnett’s test, p < 0.01, CT vs. CF1)
(Figure 3A–C). Along with this, a reduced number of cells and cell cords, and increased dilated blood
sinusoids particularly in the zona fasciculata were observed in the caffeine-fed females (Table 1), and
representative sections are shown in Figure 4A (middle and lower panel). These abnormalities were
more obvious as the caffeine dose increased (post hoc Dunnett’s test, p < 0.05, CT vs. CF2 for cortical
cell numbers) (Tukey test, p < 0.001, CF2 vs. CT or CF1 for dilated sinusoids). In addition, foamy
swellings of cortical cells were significantly more common in the caffeine-fed females (Tukey test,
p < 0.05, CT vs. CF2), suggesting that the fatty change results from impaired steroidogenesis rather
than hypertrophic changes (Table 1) (Figure 4A, lower panel). There was no increase in the number of
cell divisions in the image which suggests cell proliferation in the cortex and the medulla in females,
despite the increased areas of the cortex and medulla in the caffeine treated groups. On the other
hand, no treatment-related differences in cortical (One-way ANOVA; F = 1.45, p = 0.25 for cortical area;
F = 0.73, p = 0.49 for cortical ratio) or medulla areas (Kruskall–Wallis test; p = 0.979) were observed in
the male rats (Figure 3). However, histological analysis of the cortical areas revealed a reduced number
of cells (F = 233.3, p < 0.001), disorganized cell cords (F = 8.78, p < 0.01), dilatation of blood sinusoids
(F = 148.3, p < 0.001), and cytoplasmic vacuolation (F = 13.39, p < 0.005), especially in CF2, similar to
the female rat treatment groups (Table 1) (Figure 4B, lower panel). Overall, negative influences of
caffeine on adrenal histology are most likely dependent on dose-level.
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Figure 3. The effect of caffeine on adrenal histology. Whole visual fields in ten consecutive sections
of each adrenal gland were evaluated to measure cortical and medullary areas at 40- and 100-fold
magnification. Adrenal (A) cortical and (B) medullary areas were measured from the maximum
cross-sectional area of each animal, and (C) cortex ratios were calculated as ratios of the cortical area to
total area. In the caffeine-fed females, medullary areas increased significantly more than cortical areas;
as a consequence, the proportion of the cortical area was significantly reduced. No treatment-related
differences in cortical or medulla areas were observed in the male rats. Values represent means ±
S.D. of both adrenal glands in groups of ten rats. CT, control; CF1, 120 mg caffeine-fed; CF2, 180 mg
caffeine-fed. * p < 0.05 vs. CT, ** p < 0.01 vs. CT.
Figure 4. Representative sections of the adrenal glands of control and caffeine-fed rats at the end of
caffeine exposure, stained with hematoxylin and eosin. Sections (40, 100, 200× sequentially from the
left) from (A) the female and (B) male groups. In the caffeine-fed females, a reduced number of cells
and dilated blood sinusoids were observed, particularly in the zona fasciculata. In addition, in CF1 the
cells in the cortex appeared to have foamy swellings. Similarly, a reduced number of cells, disorganized
cell cords, and dilatation of some blood sinusoids were observed in the caffeine-fed males. Arrowheads
and arrows indicate sinusoids and cells with foamy cytoplasm, respectively. CT, control; CF1, 120 mg
caffeine-fed; CF2, 180 mg caffeine-fed.
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Table 1. Histomorphometric findings of the adrenal glands in the control and caffeine-fed groups.
Group
Female Male
CT CF1 CF2 CT CF1 CF2
Cortical cells 522 ± 29 505 ± 23 356 ± 79 ∗ 936 ± 42 480 ± 31 ** 585 ± 19 **’†
Dilated blood sinusoids (ZF) 4 ± 0.3 5 ± 0.8 12 ± 2.1 **’‡ 0.8 ± 1.0 1.3 ± 1.0 12 ± 1.3 **’‡
Foamy swelling of cortical cell 15 ± 7.5 25 ± 5.5 27 ± 5.3 ∗ 35 ± 14.9 76 ± 7.9 ∗ 62 ± 10.8 ∗
Cell cords 24 ± 3.5 15 ± 2.1 ∗ 11 ± 3.7** 56 ± 18.4 25 ± 1.9 43 ± 3.5 †
Values are expressed as mean ± SD of ten rats per group. The data for the number of cells, dilated sinusoids, foamy
cells, or cell cords represent the mean value of 20 measurements from four serial sections per animal counted within
the same defined region (0.307277 mm2) at a 200-fold magnification. * p < 0.05, ** p < 0.001 vs. CT; † p < 0.05,
‡ p < 0.001 vs. CF1. CT, control; CF1, 120 mg caffeine; CF2, 180 mg caffeine; ZF, zona fasciculata.
3.4. Serum Corticosterone and ACTH Concentrations
Serum levels of corticosterone after four weeks of exposure were reduced by approximately 40%
and 60% of the control levels in the caffeine-fed female and male rats, respectively. One-way ANOVA
revealed a substantial effect of caffeine in both female and male rats (females, F = 21.76, p = 0.001;
males, F = 9.31, p = 0.005). Post hoc analysis found that adolescent caffeine consumption significantly
reduced basal corticosterone (females, CT, 43.1 ± 7.6 ng/mL; CF1, 17.4 ± 6.6 ng/mL; CF2, 18.4 ± 2.9
ng/mL) (p < 0.01 vs. CT) (males, CT, 41.4 ± 13.8 ng/mL; CF1, 26.0 ± 10.6 ng/mL; CF2, 27.0 ± 13.7 ng/mL)
(p < 0.05 vs. CT) (T 5A). On the other hand, serum levels of ACTH were significantly different in
the caffeine-fed female and male rats compared to their respective control levels (females, F = 5.021,
p = 0.017; males, F = 3.913, p = 0.032). Although a statistical significance was attained only in the CF2
for female rats (p < 0.01 vs. CT) and the CF1 for male rats (p < 0.05 vs. CT), caffeine consumption
increased ACTH levels compared to the control levels in both female and male rats (females, CT,
2.1 ± 1.5 pg/mL; CF1, 4.6 ± 3.6 pg/mL; CF2, 6.1 ± 2.3 pg/mL) (males, CT, 2.1 ± 0.8 pg/mL; CF1, 3.4 ± 1.2
pg/mL; CF2, 2.9 ± 1.3 pg/mL) (Figure 5B).
Figure 5. The effects of caffeine on serum corticosterone and ACTH levels in the control and caffeine-fed
female and male rats. (A) Serum levels of corticosterone were reduced by approximately 40% and 60%
of the controls, respectively, in the caffeine-fed female and male rats. (B) Serum levels of ACTH were
significantly increased in the caffeine-fed female and male rats compared to the controls. Data are
means ± S.D. of ten rats per group. CT, control; CF1, 120 mg caffeine-fed; CF2, 180 mg caffeine-fed.
* p < 0.05, ** p < 0.01 vs. CT.
4. Discussion
We have shown that chronic high doses of caffeine during puberty have harmful effects on the
adrenal cortex and on corticosterone production, accompanied by the sex-specific histomorphometric
changes. To the best of our knowledge, this study is the first to compare the effects of caffeine on the
adrenal glands in peripubertal female and male rats.
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Increased body size is one of the major physical changes characterizing normal pubertal
development. Most human and animal data support a possible influence of caffeine on body
size, although some discrepancies exist between studies [1,20,21]. Previously, we demonstrated that
peripubertal caffeine exposure reduced body weight gain in immature male and female rats [16,17].
Like others, we observed a significant reduction in body weight gain in the caffeine-fed groups after
only one week, and these reductions persisted throughout the experimental period of four weeks
in both female and male rats (Figure 1). Although food intake was not examined in this study,
our previous reports showed that caffeine exposure decreases food intake in immature rats [16,17]
which might contribute to the body weight reduction.
The adrenal gland is the earliest and fastest-developing organ [22,23] and concentrates caffeine
more than any other organ [24], suggesting that there could be a high risk of caffeine toxicity to this
organ. It has been reported that prenatal exposure to caffeine significantly restricts growth of the
adrenals, particularly of the cortical area [9,10]. As puberty is another crucial phase for neuroendocrine
transformation, including adrenal cortical maturation [25], it could be anticipated that peripubertal
exposure to caffeine would reduce growth of the adrenals. During puberty, mean absolute adrenal
weight increased 1.4-fold, whereas relative adrenal weight declined by half by late puberty because of
the different growth rates of adrenal glands and overall body weight [26]. Therefore, differences in
body weight between rats are not associated with proportional differences in adrenal gland weight
in either sex [27]. In agreement with this, the reduction in absolute weights of the adrenals was not
proportional to the reduction in body weight (Figures 1 and 2A). On the other hand, we observed
a reduction in the absolute weights of the adrenals in the caffeine-fed females, but not in the males
(Figure 2A). Considering that the adrenals of females are heavier than those of males at the same
age [26], the fast growth of the adrenal glands in females may render them more susceptible to insults.
It has also been reported that pubertal caffeine exposure increases the relative weight of adrenals in
immature male rats [13] and we indeed noted dose-dependent increases in relative adrenal weights
following exposure of both male and female rats to caffeine, although the effect was only statistically
significant in the males (Figure 2B). The relative adrenal weights of females were significantly higher
overall than those of males, but caffeine treatment increased the relative adrenal weights in males,
but not in females. Because caffeine exposure did not change the absolute adrenal weight in male rats,
the reduced body weights resulted in increased relative weights, especially in males. Since caffeine
exposure reduced body weight gain in both males and females (Figure 1), the increased relative weights
of the adrenals indicate that a certain amount of adrenal mass may be preserved regardless of any
body weight reduction.
On the other hand, prenatal caffeine exposure has been reported to reduce adrenal cortical area by
half in male rat offspring [9]. However, we observed no difference in adrenal cortical or medullary
area between caffeine-fed and control males (Figure 3), whereas in the caffeine-fed females, cortical
and medullary areas increased in spite of the reduced absolute weights of the adrenals. Sex differences
in adrenal weight clearly appear in the course of adrenal maturation from 50 days of age onward,
due mainly to the marked increase of the zona fasciculata in female rats [28]. Further research is needed
to see whether these sex differences disappear or increase after removal of caffeine.
Considering that absolute adrenal weights reflect the increase in cortical weight during puberty [26],
the increased medullary area may not contribute much to adrenal weight. The decreased adrenal
weights may be related to the histological alterations in the cortex such as the abnormally dilated
intercellular spaces and decreased cellularity. Damage to the adrenal medulla due to various substances
is rare compared to damage to the cortex, and chronic toxic effects in the medulla can lead to hypertrophic
lesions in rats [29]. If medullary hypertrophy is seen as another index of stress, our results suggest that
caffeine-induced stress is more common in female rats than in males. Further study is needed to clarify
sex difference in the caffeine-induced secretory responses of the medulla.
Given that cortical zonation is completed during puberty [11], pubertal caffeine exposure may
cause cellular damage to the changing adrenal glands regardless of the size of the cortical area. The zona
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fasciculata is most frequently affected by noxious compounds [29], and chemically-induced toxicity
causes impaired steroidogenesis, leading to excess steroid precursors and cytoplasmic vacuolation in
the adrenal cortical cells of the zona fasciculata [29]. Similarly, we observed histological distortion
of the adrenal cortex including cloudy swellings and some vacuolation within the cells of the zona
fasciculata, dilation of some blood sinusoids, and more dilated intercellular spaces in the cortex in the
caffeine-fed groups, particularly the females (Figure 4A) (Table 1), consistent with previous data on
caffeine exposure of adult and fetal animals [8–10]. During puberty, there is marked expansion of the
zona fasciculata [26], which constitutes the main bulk of the adrenal cortex. The adrenal cortex (zona
fasciculata) is responsible for the synthesis of glucocorticoids, and their synthesis can be stimulated
by stress in response to multiple environmental factors [22]. Caffeine intake also induces endocrine
alterations similar to those seen in stress responses [30]. Indeed, we observed that peripubertal
caffeine exposure reduced serum corticosterone in both male and female rats regardless of cortical
size (Figure 5A). The adrenal cortex underwent a developmental catch-up after birth in male rats
exposed to caffeine prenatally, but corticosterone secretion remained low [31]. Thus, during puberty,
adrenal cortical thickness may not reflect secretory function. These hormonal changes in the adrenal
cortex may lead to malfunctioning of metabolism, which could adversely affect normal development
in puberty and also affect subsequent mental and physical health [6,13]. In addition, caffeine markedly
increases serum levels of ACTH and corticosterone in adult animals [32]. We also noted increased
ACTH, but not corticosterone in caffeine-fed groups (Figure 5B). Previous studies reported a differential
sensitivity of the adrenal to ACTH in adolescence [30]. Therefore, peripubertal caffeine exposure may
interfere with cortical function by blunting the secretory response to ACTH. In addition, adolescent
caffeine consumption may also change the circadian rhythm in corticosterone secretion, which could
affect the adrenal growth during puberty; this needs to be further clarified. Considering that ACTH
is the principal hormone responsible for the maintenance of adrenal structure and function [33],
caffeine exposure may cause more adverse effects in this period than in adulthood when development
has ceased.
5. Conclusions
In conclusion, we have shown that the harmful effects of caffeine on the adrenal glands of immature
rats differ between females and males. Although, based on the changes in the microarchitecture of the
adrenal glands, female rats seem to be more susceptible to damage, caffeine also affected corticosterone
production in male rats. Therefore, caffeine may induce an endocrine imbalance that disturbs the
establishment of the hypothalamo–pituitary adrenal axis during puberty, thereby leading to abnormal
stress responses. Further studies are needed to identify the cellular/molecular mechanisms by which
caffeine affects adrenal steroidogenesis.
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Abstract: Coffee is a blend of compounds related to gastrointestinal physiology. Given its popularity
and the epidemiology of colorectal cancer, the impact of this beverage on public health could be
considerable. Our aim was to provide an updated synthesis of the relationship between coffee
consumption and the risk of colorectal cancer. We conducted a systematic review and meta-analysis
of 26 prospective studies. Regarding colorectal cancer, no significant relationship was detected.
Stratifying for ethnicity, a protective effect emerged in US subjects. Concerning colon cancer, coffee
proved to exert a protective effect in men and women combined and in men alone. Stratifying for
ethnicity, a significant protective effect was noted in European men only and in Asian women only.
Concerning rectal cancer, no association was found. Decaffeinated coffee exhibited a protective effect
against colorectal cancer in men and women combined. Studies were appraised for their quality by
means of the Newcastle-Ottawa Quality Assessment Scale for Cohort studies. Only one study proved
to be of low quality. Ethnicity could explain the heterogeneity of the studies. However, little is known
about the relationship between the genetic make-up and the risk of colorectal cancer associated with
coffee. Further research is warranted.
Keywords: coffee/caffeine; systematic review and meta-analysis; prospective studies; epidemiology;
cancer prevention; colorectal cancer
1. Introduction
Coffee is a complex blend of bioactive compounds. These are related to gastrointestinal physiology
in various ways and may exert contrasting effects. On the one hand, coffee contains anti-oxidants and
anti-mutagens, which could, as such, reduce exposure of the epithelial cells of the bowel to carcinogenic
chemicals and compounds, and prevent and counteract the effect of potential promoters of intestinal
carcinogenesis. Indeed, coffee seems to enhance bowel motility and functioning, reducing fecal transit
times and increasing stool output. Furthermore, coffee contains lipidic compounds, such as cafestol
and kahweol, which, by finely tuning cholesterol metabolism, reduce the synthesis and release of bile
acids [1]. They act also as reactive oxygen species (ROS) scavengers, activating DNA repair enzymes [2]
and phase-II enzymes involved in carcinogen detoxification. Furthermore, coffee modulates the
microbiome of the gut. Caffeine has anti-apoptotic effects, inducing programmed cell death [3]. Caffeic
acid is involved in several pathways related to inflammation, apoptosis and the cell cycle. Finally,
chlorogenic acid seems to have antioxidant properties. On the other hand, coffee contains mutagens,
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such as glyoxal, methylglyoxal, ethylglyoxal, propylglyoxal, diacetyl, acetol and other dicarbonyls [4–7]
or tannins [8], among others, which could counteract the protective effects of coffee.
Moreover, the quantity of these bioactive compounds varies according to the type of coffee.
For example, unfiltered coffees, such as French press coffee or Turkish/Greek coffee, contain significant
amounts of these compounds, unlike filtered blends, such as dip-brewed coffee. Moreover, filtered
coffee also contains fewer phenols and polyphenols [2,9].
Being cheap and easy to prepare, coffee is a widespread beverage, its worldwide consumption
of two billion cups per day being second only to that of water [2]. Given the popularity of coffee,
its impact on public health could be considerable. Statistics on cancer reveal that colorectal cancer
is the third most common cancer among men, after lung and prostate cancer, and the second most
common cancer among women, after breast cancer; in terms of cancer-related death, it ranks fourth
after lung, liver and stomach cancer [10]. We therefore aimed to provide an updated quantitative
synthesis of the relationship between coffee consumption and the risk of colorectal cancer.
2. Materials and Methods
The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA)
guidelines [11] were used as a guide to ensure that the current standard for meta-analysis methodology
were met (see also Supplementary Materials). We searched PubMed/MEDLINE and Scopus archives
and databases for a combination of keywords such as “coffee” and “colorectal cancer”, using Medical
Subject Headings (MeSH) terms as vocabulary, according to the National Center for Biotechnology
Information (NCBI) nomenclature and guidelines and, where appropriate, a wild-card option.
Inclusion criteria were: (1) articles with relevant quantitative details and information on the
relationship between coffee consumption and the risk of developing colorectal cancer; (2) prospective
studies. Exclusion criteria were: (1) items not directly pertinent to the query string; (2) articles not
containing sufficient information on the relationship between coffee consumption and the risk of
colorectal cancer; (3) articles not meeting the PICOS criteria (P: patients with colorectal cancer; I:
consuming coffee; C: coffee consumption versus non-consumption, and/or comparison between
different kinds of coffee: caffeinated or decaffeinated, etc.; O: risk ratio, RR, of colorectal cancer
associated to coffee consumption; S: prospective study); all such articles were consequently discarded.
No time filter or language filter was applied. For further details of the search strategy, see Table 1.
Table 1. Search strategy adopted in the present systematic review and meta-analysis.
Search Strategy Details
Search string (coffee OR caffeine) AND (tumor OR cancer OR neoplasm) AND(colon OR rectal OR colorectal)
Databases PubMed/MEDLINE, Scopus
Inclusion criteria
P (patients/population): general population/patients suffering from
colorectal cancer
I (intervention/exposure): subjects consuming coffee
C (comparisons/comparators): coffee consumers versus non-consumers;
different kinds of coffee (caffeinated/decaffeinated)
O (outcome): incidence of colorectal cancer
S (study design): prospective study
Exclusion criteria
Experimental studies investigating in vitro or animal models
Study design: editorial, commentaries, expert opinions, letters to editor,
review articles, original non-prospective studies, articles with
insufficient details
Time filter None (from inception)
Language filter None (any language)
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Two of the authors independently screened the literature. Any case of disagreement was solved by
discussion until consensus was reached. After the full text review, the papers included were retained
for data extraction.
Data for the meta-analysis were extracted from the studies included by means of a standardized
documentation form. The parameters extracted were: the surname of the first author, the year and
country of publication, sample size, percentages of females and males, incidence of colorectal cancer
(broken down by clinical site: colon and rectum), and the amount and type of coffee consumed.
RR of developing colorectal cancer on the basis of coffee consumed (i.e., RR of subjects with
colorectal cancer who consumed the greatest amount of coffee versus subjects who did not consume
coffee) were calculated as effect size estimates, with their 95% confidence intervals (CIs). Additional
analyses were performed after stratification by type of coffee, study region, publication period
and gender.
Study quality was appraised by two researchers, working independently, with respect to the
appropriateness of the research questions tested and of the methods employed. For this purpose, the
Newcastle-Ottawa Quality Assessment Scale for Cohort studies (NOS) was used; scores of ≥7 indicated
high-quality and <7 indicated low-quality studies. Any disagreement was solved by consensus.
Statistical heterogeneity was also assessed in our meta-analysis by means of I2 statistics and
chi-square test, heterogeneity being deemed significant if the p value (χ2) was <0.1. In detail, it was
determined that the values of 25%, 50% and 75% in the I2 test corresponded to low, moderate and high
levels of heterogeneity, respectively. In the event of significant (moderate or high) heterogeneity among
the studies, a random-effects model was used for the meta-analysis. The RR of the meta-analyses
were deemed significant when the confidence intervals did not contain the value “1”; indeed, if the
confidence interval contains the value “1”, we cannot exclude the absence of an association between
exposure and disease. A narrower CI than that of the individual studies indicates less imprecision.
Meta-analyses were carried out by means of the STATA SE14R (StataCorp LP, College Station, TX,
USA) software. To identify sources of variation, further stratification was performed with respect to
study quality. In addition, in the sensitivity analyses, the stability of the pooled estimate with respect
to each study was investigated by excluding individual studies from the analysis. Possible publication
bias was visually inspected by means of a funnel plot. If asymmetry was detected by visual assessment,
exploratory analyses using trim and/or fill analysis were performed in order to investigate and adjust
the effect-size estimate. In addition, the probability of publication bias was tested by means of Egger’s
linear regression, a value of p < 0.05 being indicative of publication bias.
3. Results
Concerning the systematic review, our initial query resulted in 390 hits (specifically, 376 articles
from PubMed/MEDLINE and Scopus, and 14 from other sources); after removal of duplicate items,
the resulting list comprised of 270 non-redundant articles. Only 33 studies were retained in the
qualitative synthesis, and 26 were finally considered in our systematic review and meta-analysis
(186 articles were discarded as not being directly pertinent to the topic under investigation and 51 as
not meeting the inclusion criteria). For further details, see Figure 1.
The full list of studies included [12–37] and their main characteristics are shown in Table 2.
The studies examined included 3,308,028 subjects. Eleven studies were performed in European
countries, seven in Asian countries and seven in the USA. Nineteen studies were on colorectal cancer,
19 on colon cancer and 18 on rectal cancer.
With regard to colorectal cancer, from the pooled RR, no significant relationship between coffee
consumption and the risk of developing cancer was detected (Table 3).
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Figure 1. Flowchart of study selection, inclusion and synthesis.
Table 2. Characteristics of studies included.








≥7 cups/d vs. ≤2 cups/d 97 CC—63 RC




≥4 cups/d vs. ≤1 cup/d NA (CRC)
Klatsky (1988) [14] USA All (10,572) Continuous variable(cups/d) 203 CC—66 RC
Stensvold (1994) [15] Sweden F (21,238);M (21,735) ≥7 cups/d vs. ≤2 cups/d
F: 52 CC—38 RC;
M: 78 CC—41 RC
Terry (2001) [16] Sweden F (61,463) ≥4 cups/d vs. <1 cup/d 291 CC—159 RC—460 CRC
Khan (2004) [17] Japan F (1634);M (1524)
Continuous variable
(cups/d) F: 14 CRC; M: 15 CRC










Larsson (2006) [19] Sweden All (106,739) ≥4 cups/d vs. <1 cup/d 843 CC—440 RC—1279 CRC
Mucci (2006) [20] Sweden F (61,467) ≥4 cups/d vs. ≤1 cup/d 504 CC—237 RC—741 CRC
Oba (2006) [21] Japan F (16,327);M (13,894) ≥1 cups/d vs. none F: 102 CC; M: 111 CC
Lee (2007) [22] Japan F (50,139);M (46,023) ≥3 cups/d vs. none
F: 286 CC—151 RC—437 CRC
M: 174 CC—102 RC—276 CRC




≥3 cups/d vs. none
ALL: 281 CC—180 RC—457 CRC
F: 106 CC—68 RC—173 CRC
M: 175 CC—112 RC—284 CRC
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Table 2. Cont.








≥10 cups/d vs. none
ALL: 333 CC—252 RC—538 CRC
F: 167 CC—123 RC—271 CRC
M: 166 CC—129 RC—267 CRC
Nilsson (2010) [25] Sweden All (64,603) ≥4 cups/d vs. <1 cup/d 321 CRC
Simons (2010) [26] Netherlands F (62,573)M (58,279) >6 cups/d vs. ≤2 cups/d
F: 173 RC—939 CRC





All (731,441) High quintile vs. lowquintile 5,604 CC
Sinha (2012) [28] USA All (489,706)
≥6 cups/d vs. none
(all, caffeinated,
decaffeinated)
5,072 CC—2863 Prox CC—1993
Distal CC—1874 RC—6946 CRC
Dominianni (2013) [29] USA All (57,398) ≥4 cups/d vs. none 681 CRC











2691 CC—1242 Prox CC—1202
Distal CC—1543 RC—4234 CRC
Hartmann (2014) [32] Finland M (27,111) >6 cups/d vs. ≤4 cups/d 106 CC—79 RC
Peterson (2014) [33] Singapore All (61,321) ≥2 cups/d vs. <1 cup/d 591 CC—370 RC
Yamada (2014) [34] Japan F (34,614)M (23,607) ≥4 cups/d vs. <1 cup/d
F: 332 CC—112 RC—444 CRC
M: 355 CC—202 RC—557 CRC
Groessl (2016) [35] USA F (83,972) ≥4 cups/d vs. none 1,083 CC—160 RC—12,852 CRC
Lukic (2016) [36] Norway F (79,461) >7 cups/d vs. ≤1 cup/d 1266 CRC
Kashino (2018) [37] Japan F (170,388)M (149,934) ≥3 cups/d vs. <1 cup/d
F: 1963 CC—770 RC—2689 CRC
M: 2619 CC—1402 RC—4022 CRC
Abbreviations: CC (colon cancer); CRC (colorectal cancer); d (day); F (female); M (male); NA (not available); prox
(proximal); RC (rectal cancer); vs. (versus).
Table 3. Risk ratio (RR) and 95% CI for all meta-analyses carried out. Values in bold are
statistically significant.
Tumor and Geographic Provenience of the Studies








All 0.96 [0.88–1.03]: (8) 0.96 [0.88–1.04]; (9) 1.06 [0.97–1.14]; (13)
EU studies only 1.07 [0.96–1.17]; (4) 0.93 [0.80–1.06]; (3) 1.10 [0.98–1.22]; (6)
Asian studies only NA 0.97 [0.87–1.08]; (5) 0.94 [0.78–1.09]; (5)
USA studies only 0.83 [0.72–0.95]; (3) NA 1.14 [0.92–1.36]; (2)
Caffeinated coffee 0.96 [0.77–1.17]; (3) NA NA
Decaffeinated coffee 0.88 [0.78–0.97]; (3) NA NA
CC
All 0.91 [0.83–0.998]; (9) 0.94 [0.89–0.99]; (11) 0.92 [0.80–1.03]; (13)
EU studies only 0.96 [0.84–1.09]; (4) 0.85 [0.72–0.99]; (4) 1.05 [0.93–1.18]; (5)
Asian studies only 0.91 [0.73–1.09]; (2) 0.94 [0.82–1.06]; (5) 0.73 [0.58–0.88]; (5)
USA studies only 0.83 [0.66–1.01]; (2) NA 0.90 [0.38–1.42]; (2)
Caffeinated coffee 0.92 [0.68–1.15]; (3) NA NA
Decaffeinated coffee 0.93 [0.81–1.05]; (3) NA NA
Distal CC
All 0.98 [0.95–1.02]; (5) 0.94 [0.87–1.01]; (5) 1.00 [0.96–1.04]; (6)
EU studies only NA 0.77 [0.57–0.98]; (2) 1.09 [0.82–1.36]; (3)
Asian studies only NA 0.83 [0.60–1.05]; (2) 0.91 [0.56–1.25]; (2)
USA studies only 0.88 [0.65–1.12]; (2) NA NA
Caffeinated coffee 0.99 [0.79–1.91]; (2) NA NA
Decaffeinated coffee 1.05 [0.79–1.32]; (2) NA NA
Proximal CC
All 0.93 [0.73–1.15]; (5) 0.98 [0.92–1.04]; (5) 0.99 [0.96–1.03]; (6)
EU studies only NA 0.90 [0.66–1.14]; (2) 1.17 [0.90–1.44]; (3)
Asian studies only NA 1.08 [0.83–1.32]; (2) 0.85 [0.57–1.13]; (2)
USA studies only 0.92 [0.23–1.60]; (2) NA NA
Caffeinated coffee 0.85 [0.32–1.36]; (2) NA NA
Decaffeinated coffee 0.86 [0.66–1.06]; (2) NA NA
RC
All 1.00 [0.89–1.11]; (9) 1.01 [0.87–1.14]; (9) 1.08 [0.94–1.23]; (11)
EU studies only 1.17 [0.97–1.37]; (4) 0.96 [0.78–1.14]; (5) 1.04 [0.87–1.21]; (6)
Asian studies only 1.04 [0.79–1.29]; (2) 1.07 [0.85–1.29]; (4) 1.28 [0.96–1.60]; (4)
USA studies only 0.88 [0.72–1.04]; (3) NA NA
Caffeinated coffee 1.18 [0.98–1.38]; (3) NA NA
Decaffeinated coffee 0.71 [0.41–1.01]; (3) NA NA
Abbreviations: CC (colon cancer); CRC (colorectal cancer); EU (European countries); NA (not available);
RC (rectal cancer).
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Stratifying for ethnicity, a significant protective effect emerged among US subjects (men and
women), with a RR of 0.83 (95% CI 0.72–0.95). While no statistical significance emerged for caffeinated
coffee, decaffeinated coffee exhibited a protective effect on men and women combined (RR 0.88 (95% CI
0.78–0.97)).
Concerning colon cancer (Table 3), coffee consumption proved to exert a protective effect on men
and women combined (RR 0.91 (95% CI 0.83–0.998)) (Figure 2), and on men only (RR 0.94 (95% CI
0.89–0.99)) (Figure 3).
 
NOTE: Weights are from random effects analysis
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Figure 2. Forest plot of colon cancer in men and women combined.
Stratifying for ethnicity, a statistically significant protective effect was noted in European men
only (RR 0.85 (95% CI 0.72–0.99)), and in Asian women only (RR 0.73 (95% CI 0.58–0.88)) (Figure 4A,B).
 
Figure 3. Forest plot of colon cancer in men.
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(A) 
(B) 
NOTE: Weights are from random effects analysis
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Figure 4. Forest plot of colon cancer in European men (A) and in Asian women (B).
Focusing on distal colon cancer (Table 3), coffee consumption proved protective in European
men only (RR 0.77 (95% CI 0.57–0.98)). With regard to proximal colon cancer (Table 3), no significant
association was found.
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Concerning rectal cancer (Table 3), no significant association could be found.
No significant publication bias was detected. Finally, concerning the assessment of the risk of bias,
no significant biases emerged. Only one study was deemed to be of low quality (Wu: NOS score = 5).
Retaining or removing this study from the meta-analyses did not change the results.
4. Discussion
Performing the meta-analysis of prospective studies, we found a significantly high degree
of heterogeneity.
With specific regard to rectal cancer, no evidence of an association between coffee consumption
and the development of the disease could be found. For colorectal cancer, we found evidence of a
protective effect only in US men and women together. Stratification by type of coffee—caffeinated or
decaffeinated—did not reveal any differences linked to the presence of caffeine, since the types of coffee
appeared to be protective in some studies and non-significant in others. Moreover, the quantity of
caffeine in coffee also depends on the type of mixture used [38], a parameter that was not investigated
in the studies considered. Instead, in the present systematic review and meta-analysis decaffeinated
coffee consumption showed a protective role against colorectal cancer, despite the low number
of investigations.
Regarding colon cancer, evidence of a protective effect of coffee consumption was found, both
considering men and women together and considering men alone.
Stratifying for ethnicity, we found that the pooled RR was significant for European men and for
Asian women. We can speculate that this might be due to the particular type of coffee consumed; for
example, in Asia, coffee is rarely consumed boiled or decaffeinated [22]. Another possible explanation
may lie in the biological make-up of the subjects; this might also explain why coffee drinking proved
protective in a particular gender but not in the other. In this regard, Platt et al. found that cultural,
dietary and lifestyle factors influenced the impact of coffee intake in terms of the risk of developing
metabolic syndrome [39]. Similarly, Kumar et al. found a differential effect of caffeine intake on
the onset of Parkinson’s disease, the effect being mediated by genetic variants [40]. Other biological
events or diseases have been found to be characterized by a complex gene–caffeine interaction, such as
variability in the cardiovascular response to caffeine [41], coffee consumption and the risk of developing
neurodegenerative disorders [42], epithelial ovarian cancer [43], breast cancer [44], or myocardial
infarction [45], among others. These genes include cytochrome P450 1A2 (CYP1A2), adenosine A2a
receptor (ADORA2A), and leucine-rich repeat kinase 2 or dardarin (LRRK2).
As potential mechanisms that may explain the inverse association between coffee consumption
and the development of colon cancer, a review by Higdon [46] hypothesizes the presence of
diterpenes as a factor of protection. Indeed, in vitro studies have reported that this molecule
is able to reduce the formation of DNA adducts by several genotoxic carcinogens, including
2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), a heterocyclic amine implicated in colon
carcinogenesis. Moreover, it would seem that diterpenes can promote the elimination of carcinogens
and improve antioxidant status.
A major limitation of the present meta-analysis lies in the fact that most studies did not specify
whether the coffee blend was caffeinated or decaffeinated, filtered or unfiltered, thus hindering the
possibility of precisely stratifying the pooled RR according to the type of coffee consumed.
A major difficulty in interpreting epidemiological data is that studies often do not clearly indicate
the quantity of coffee consumed (which is usually expressed as cups/day and not in mL); estimates
are therefore “rough”.
Moreover, the considerable variability in the composition of the beverage makes it difficult to
accurately determine the potential quantity of bioactive substances involved in the process.
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5. Conclusions
The development of colorectal carcinoma is a complex, multi-step process characterized by
a series of both genetic and epigenetic changes, which involve different cellular cascades and
pathways, including DNA repair, proliferation, apoptosis, intra- and extracellular signaling, and
adhesion, among others [47]. Ethnicity seems to be an important variable in the relationship between
coffee consumption and the risk of developing colorectal cancer. However, little is known about
the relationship between genetic make-up and the risk of colorectal cancer associated with coffee
consumption. Furthermore, given the above-mentioned limitations, further research in the field
is warranted.
In conclusion, the available studies are not sufficient to define a protective role of coffee against
colorectal cancer.
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